https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/power-system-modernization-and-decarbonization-a-qa-with-judy-chang/2024-01-11T10:36:00+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/expert-testimony-in-investor-state-disputes/2024-01-11T10:36:00+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/regulatory-interventions-and-the-nature-of-competition-in-digital-ecosystems-a-qa-with-eliana-garces/2024-01-11T10:36:00+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/can-patent-infringement-harm-be-truly-irreparable-to-an-economist-a-qa-with-john-jarosz-and-robert-vigil/2024-01-11T10:36:00+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/artificial-intelligence-and-real-world-evidence-in-oncology-research/2024-01-11T10:35:59+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/quantitative-approaches-to-stress-testing-scientific-claims-in-health-care/2024-01-11T10:35:59+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/of-note/2024-01-11T10:36:00+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/distinctive-insights-our-physician-economists/2024-01-11T10:35:59+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/law-economics-symposium-webinar-on-antitrust-in-life-sciences-and-pharmaceuticals/2024-01-11T10:35:59+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/if-you-build-it-will-they-come-indirect-network-effects-and-the-chicken-or-egg-dilemma-in-the-nascent-electric-vehicle-market/2024-01-11T10:36:00+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/venture-debt-and-the-failure-of-silicon-valley-bank-a-qa-with-yael-hochberg-and-sabrina-howell/2024-01-11T10:36:00+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/confusing-funny-just-plain-bad-surveys-and-trademark-litigation-after-jack-daniels/2024-01-11T10:35:58+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/high-power-and-high-stakes-a-qa-on-machine-learning-in-diagnostics/2024-01-11T10:35:58+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/shared-learning-without-waiting-for-shared-data-using-federated-analytics-for-health-care-research-across-multiple-institutions-and-countries/2024-01-11T10:35:59+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/a-new-gold-standard-how-digital-health-technologies-can-be-used-to-monitor-patient-progress/2024-01-11T10:35:59+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/fiduciary-duty-and-esg-a-qa-with-oliver-hart/2024-01-11T10:35:59+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/of-note/2024-01-11T10:35:59+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/a-richer-way-to-work-martha-samuelson-and-andrea-okie-explore-the-topic-of-women-and-diversity-in-antitrust/2023-06-13T17:14:35+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2022-selected-highlights/fulfilling-the-promise-real-world-data-and-real-world-evidence-in-action/2024-01-11T10:35:58+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2022-selected-highlights/untangling-competitive-relationships-in-health-care-mergers/2024-01-11T10:35:58+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2022-selected-highlights/expanding-occupational-licensing-in-health-care-a-qa-with-professor-brian-phelan/2024-01-11T10:35:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2022-selected-highlights/also-on-analysisgroup.com2024-01-11T10:35:58+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/recent-case-highlights/2024-01-11T10:35:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/analysis-group-at-the-2022-aba-antitrust-law-spring-meeting/2024-01-11T10:35:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/esg-reporting-and-greenwashing-a-qa-with-david-w.-richardson2024-01-11T10:35:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/the-business-of-cybersecurity-is-business-kevin-powers-on-managing-the-risks-and-consequences-of-cyberattacks-and-data-breaches/2024-01-11T10:35:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/state-collaboration-could-strengthen-pathways-to-decarbonize-new-englands-electrical-grid/2024-01-11T10:35:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/esg-investments-and-disclosures-in-todays-corporate-world-a-qa-with-christianna-wood/2024-01-11T10:35:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/deceptively-simple-survey-evidence-in-food-and-beverage-false-labeling-class-actions/2024-01-11T10:35:58+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/changing-the-pattern-asthma-inhaler-use-societal-costs-and-health-benefits/2024-01-11T10:35:58+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2022-selected-highlights/pricing-litigation-enforcement-the-2022-law--economics-symposium-in-review/2024-01-11T10:35:58+00:00weekly0.5https://www.analysisgroup.com/about/locations/beijing/cn/epidemiology/2024-01-11T10:35:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/also-on-analysisgroup.com2024-01-11T10:35:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/also-on-analysisgroup.com2024-01-11T10:35:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/also-on-analysisgroup.com2024-01-11T10:35:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/also-on-analysisgroup.com2024-01-11T10:35:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/also-on-analysisgroup.com2024-01-11T10:35:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/also-on-analysisgroup.com2024-01-11T10:35:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/featured-engagements/2024-01-11T10:35:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/also-on-analysisgroup.com2024-01-11T10:35:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/featured-engagements/2024-01-11T10:35:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2013/In-this-Issue/2024-01-11T10:35:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2013/recent-litigation/2024-01-11T10:35:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/featured-engagements/2024-01-11T10:35:46+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/featured-publishing/2024-01-11T10:35:46+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/recent-litigation/2024-01-11T10:35:46+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/also-on-analysisgroup.com2024-01-11T10:35:46+00:00weekly0.5https://www.analysisgroup.com/about/locations/beijing/cn/heor/2024-01-11T10:35:46+00:00weekly0.5https://www.analysisgroup.com/about/locations/beijing/cn/market-access/2024-01-11T10:35:46+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/also-on-analysisgroup.com2024-01-11T10:35:46+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/featured-engagements/2024-01-11T10:35:46+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/biologics-biosimilars-and-generics/biologics-biosimilars-and-generics/2022-01-18T17:01:12+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/behind-the-headlines-in-pharmaceutical-investigations/2021-05-18T12:47:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/using-epidemiology-to-identify-unmet-need/2022-01-18T21:54:10+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/using-canadian-provincial-health-plan-claims/2022-01-18T21:53:36+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/evaluating-international-marketing-access/2022-01-18T19:12:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/global-consequences-of-local-pricing-decisions/2022-01-18T19:17:06+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/big-data-in-health-care/2021-05-18T12:49:35+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/assessing-the-economic-burden-of-alzheimers-disease/2022-01-14T22:46:03+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/monitoring-online-signals--implications-of-internet-data-in-pharmacovigilance/2022-01-18T20:52:07+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/addressing-health-care-demand-and-big-data-in-china/2021-05-18T12:49:20+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/a-look-inside-health-care-big-data/2023-05-09T14:04:54+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/diagnostics-and-next-generation-genetic-sequencing/2022-01-18T17:53:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/improper-promotion-and-kickback-allegations/2022-01-18T19:40:29+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/the-growing-economic-burden-of-depression-in-the-united-states/2018-11-01T15:16:05+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/the-depth-of-provider-data/2022-01-18T21:48:17+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/developments-in-medical-big-data-research---what-makes-data-different-today-/2022-01-18T22:15:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/new-challenges-and-initiatives-in-big-data-processing/2018-11-01T15:16:04+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/the-obesity-epidemic--a-new-look-at-the-urgency-challenges-and-opportunities/2022-01-18T21:50:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/anti-obesity-drug-development-risks-and-expectations/2018-11-01T15:16:02+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/the-biosimilar-revolution-is-just-beginning-in-the-u.s2024-01-11T10:35:41+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/viewing-recent-opioid-regulations-in-context/2024-01-11T10:35:41+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/economic-burden-of-schizophrenia-in-the-u.s.-exceeded-$155-billion-in-20132024-01-11T10:35:41+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/machine-learning-algorithms-in-health-care-litigation/2024-01-11T10:35:41+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/the-myth-of-price-disconnects-in-u.s.-pharma-markets2024-01-11T10:35:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/payments-to-doctors--causal-inferences-require-a-closer-look/2024-01-11T10:35:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/recent-trends-in-affordable-care-act-insurance/2024-01-11T10:35:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/evaluating-real-world-effectiveness-in-prescription-coverages/2024-01-11T10:35:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/new-academic-affiliate--dr.-john-e.-ware-jr.-renowned-pro-expert2024-01-11T10:35:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/the-biosimilar-challenge/the-biosimilar-challenge/2022-01-18T21:47:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/making-the-right-call--som-for-prescription-opioids/2024-01-11T10:35:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/abuse-deterrent-opioids-and-the-economic-costs-of-abuse/2024-01-11T10:35:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/why-biosimilar-introduction-may-be-different/2024-01-11T10:35:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/causation-in-product-liability--taking-a-new-look/2024-01-11T10:35:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/patient-reported-outcomes--emerging-developments-and-innovative-approaches/2024-01-11T10:35:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/biopharma-value-based-pricing--how-to-make-it-work-/2024-01-11T10:35:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/a-new-landscape-for-comparative-effectiveness-research/2024-01-11T10:35:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/spotlight-on-europe/2024-01-11T10:35:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/making-more-precise-health-care-decisions-with-machine-learning/2024-01-11T10:35:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/planting-trees-to-reduce-health-related-costs/2024-01-11T10:35:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/analysis-group-expert-david-dranove-highlighted-in-historic-health-care-merger-review/2024-01-11T10:35:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-spring-2012/enhancing-product-value-propositions-in-the-pipeline/2022-01-18T18:51:35+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-spring-2012/methods-for-indirect-comparisons-in-outcomes-research/2022-01-18T20:48:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/wolf-pack-activism--a-quick-look/2019-12-13T19:33:18+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/assessing-commercial-success-at-the-u.s.-patent-trial-and-appeal-board2019-12-13T19:33:23+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/forecasting-corporate-failure--a-look-at-statistical-and-theoretical-approaches/2020-11-09T17:14:35+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/the-myth-of-divided-antitrust-economics/2019-12-13T19:32:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/a-closer-look-at-the-use-of-consumer-surveys-in-litigation/2019-12-13T19:33:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/statistics-and-sports--deflategate/2019-12-13T19:32:21+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/the-reality-of-u.s.-pharmaceutical-spending2022-01-18T21:52:13+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/assessing-the-epas-clean-power-plan/2022-11-22T22:04:17+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/can-epidemiology-be-applied-to-auto-safety-analysis-/2018-11-01T15:16:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/analyzing-causation-damages-in-data-breaches/2018-11-01T15:16:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/common-threads-in-mortgage-backed-securities-cases/2018-10-12T14:17:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/economic-solutions-to-water-conflicts/2018-11-01T15:16:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/a-look-at-patent-litigation-and-valuation-post-reform/2023-12-14T15:17:38+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/where-policy-economics-intersect/2023-12-14T15:17:38+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/a-new-approach-to-regression-analysis-and-antitrust-litigation/2018-11-01T15:16:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/changes-ahead-for-credit-rating-agencies/2018-11-14T15:32:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/assessing-financial-issues-in-tribal-trust-fund-litigation/2018-11-01T15:16:41+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/customer-behavior-and-class-actions/customer-behavior-and-class-actions/2018-11-05T14:38:36+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/economic-analysis-in-erisa-litigation/economic-analysis-in-erisa-litigation/2018-11-01T15:16:41+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/patent-litigation-and-the-innovation-economy/2021-05-18T12:40:38+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/anticipating-exclusion--upward-pricing-pressure-in-vertical-transactions/2021-05-18T12:40:54+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/consolidation-coordination-and-competition---a-challenging-prescription-for-health-care/2021-05-18T12:41:10+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/what-is-a-prudent-investment--using-simulation-to-evaluate-investment-selections/2021-05-18T12:41:22+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/an-inside-look-at-itcs-expedited-investigations-pilot-program/2021-05-18T12:41:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/international-enforcement-in-a-global-economy/2021-05-18T12:42:09+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/reconsidering-the-hypothetical-negotiation/2021-05-18T12:42:20+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/what-is-water-worth-/2021-05-18T12:42:36+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/the-role-of-clinical-trials-in-mass-torts-and-related-shareholder-suits/2022-01-18T21:52:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/perspectives-on-investment-management-disputes/perspectives-on-investment-management-disputes/2018-11-01T15:16:34+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/presenting-demand-models-in-antitrust-litigation/presenting-demand-models-in-antitrust-litigation/2018-11-01T15:16:34+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/using-machine-learning-in-litigation/2024-01-11T10:35:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/qand-a-with-affiliate-austan-goolsbee/2024-01-11T10:35:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/implications-of-the-tyson-ruling-for-class-certification/2024-01-11T10:35:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/the-biosimilar-revolution-is-just-beginning-in-the-u.s2024-01-11T10:35:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/qand-a-with-affiliate-david-dranove/2024-01-11T10:35:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/affiliate-spotlight--oliver-hart/2024-01-11T10:35:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/will-expanded-eeo-1-data-collection-yield-new-insights-into-discrimination-/2024-01-11T10:35:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/affiliate-roundtable--privacy-and-data-security/2024-01-11T10:35:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/data-corner--resolution-of-federal-privacy-and---data-security-cases--19992016/2024-01-11T10:35:41+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/evaluating-potential-development-of-a-broader-market-for-co2-allowance-trading/2024-01-11T10:35:41+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2013/the-causes-and-consequences-of-currency-wars/2021-05-18T12:43:34+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2013/assessing-the-duration-of-damages-in-food-safety-cases/2021-05-18T12:44:03+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2013/investigating-adverse-effects-using-epidemiology/2022-01-18T19:56:08+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/the-missing-data-challenge/the-missing-data-challenge--using-clinical-trials-results/2018-11-01T15:16:19+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/the-role-of-the-economic-expert-in-class-certification/the-role-of-the-economic-expert-in-class-certification/2018-11-01T15:16:19+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/when-all-natural-may-not-be/2022-11-22T21:28:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/when-price-fixing-is-alleged/2021-05-18T12:44:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/royalty-payments-bundled-goods-and-chicago-style-red-hots/2021-10-12T20:27:12+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/mobile-broadband--competition-spectrum-and-consumers/2021-05-18T12:45:24+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/artificial-intelligence-can-open-the-door-to-better-learning-better-care-and-better-coverage/2024-01-11T10:35:51+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/a-new-way-to-quantify-quality-of-life/2024-01-11T10:35:51+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/protecting-access-encouraging-innovation-a-discussion-about-drug-pricing/2024-01-11T10:35:51+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/a-collaboration-to-advance-hematology-research/2024-01-11T10:35:51+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/also-on-analysisgroup.com2024-01-11T10:35:51+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/interactive-shortcut/2024-01-11T10:35:51+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/learning-from-lehman-lessons-for-today/2024-01-11T10:35:51+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/contracts-and-crisis-nobel-laureate-oliver-hart-on-contract-theory-and-the-world-of-the-pandemic/2024-01-11T10:35:51+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/challenges-of-analyzing-health-care-data-in-the-covid-19-era/2024-01-11T10:35:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/assessing-the-evidence-from-covid-19-deaths-a-qa-with-christopher-knittel/2024-01-11T10:35:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/financial-impacts-for-hospitals-from-covid-19/2024-01-11T10:35:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/innovation-drug-pricing-and-the-pandemic-a-qa-with-craig-garthwaite/2024-01-11T10:35:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/shutdowns-joblessness-and-a-tentative-recovery-jesse-rothstein-on-the-impact-of-the-coronavirus-on-the-us-labor-market/2024-01-11T10:35:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/outlook-for-oil-prices-and-the-industry-in-turbulent-times-a-qa-with-philip-k.-verleger2024-01-11T10:35:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/recent-case-highlights/2024-01-11T10:35:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/contributions-to-recently-published-books/2024-01-11T10:35:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/note-from-martha-s-samuelson/2024-01-11T10:35:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/in-combatting-a-global-pandemic-build-public-confidence-first/2024-01-11T10:35:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/zombie-over-levered-or-shocked-but-sound-pandemic-induced-bankruptcies-and-related-valuation-questions/2024-01-11T10:35:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/will-there-be-another-mortgage-crisis-lessons-from-the-great-recession/2024-01-11T10:35:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/forward-looking-statements-and-transparency-esther-mills-on-accounting-for-pandemic-related-losses/2024-01-11T10:35:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/powering-through--and-beyond--the-crisis/2024-01-11T10:35:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/matthew-grennan-on-concentration-in-medical-supply-markets-considerations-from-the-coronavirus-pandemic/2024-01-11T10:35:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/platforms-competition-and-the-crisis-arun-sundararajan-on-how-restaurants-have-adapted-during-the-pandemic/2024-01-11T10:35:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/staffing-tracking-and-testing-for-covid-19-in-elder-care-facilities-a-qa-with-david-grabowski/2024-01-11T10:35:54+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/accounting-for-the-coronavirus-subjectivity-and-judgment-during-times-of-crisis/2024-01-11T10:35:54+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/seeing-is-not-the-same-thing-as-looking-anupam-b.-jena-m.d.-ph.d.-on-learning-from-natural-experiments2024-01-11T10:35:54+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/covid-19-and-bottom-line-impacts-in-trademark-litigation-a-qa-with-joel-steckel/2024-01-11T10:35:54+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/progress-on-hta-and-pharmacoeconomics-in-asia/2024-01-11T10:35:54+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/meeting-the-burden-the-predominance-requirement-in-pharmaceutical-class-actions/2024-01-11T10:35:54+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/a-real-world-view-of-the-health-care-costs-of-air-pollution/2024-01-11T10:35:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/also-on-analysisgroup.com2024-01-11T10:35:54+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/can-computers-engage-in-anticompetitive-behavior-antitrust-questions-raised-by-algorithmic-pricing/2024-01-11T10:35:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/priming-the-pump-for-economic-recovery-by-investing-in-advanced-energy/2024-01-11T10:35:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/does-acquihiring-lead-to-better-outcomes-in-the-technology-sector/2024-01-11T10:35:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/in-future-editions/2024-01-11T10:35:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/recent-case-highlights/2024-01-11T10:35:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/has-the-covid-19-pandemic-changed-economic-analysis-in-merger-review/2024-01-11T10:35:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/tracking-the-path-of-covid-19--in-haiti/2024-01-11T10:35:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/vaccines-incentives-and-innovation-the-lessons-of-covid-19-for-the-pharmaceutical-industry/2024-01-11T10:35:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/award-winning-research/2024-01-11T10:35:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/value-through-the-product-life-cycle-2021-law--economics-symposium/2024-01-11T10:35:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/the-economic-burden-of-depression-finding-hope-amid-despair/2024-01-11T10:35:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/the-role-of-due-diligence-in-mitigating-spac-litigation-risks/2024-01-11T10:35:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/machine-power-applications-of-natural-language-processing-in-economic-consulting/2024-01-11T10:35:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/defending-a-socially-conscious-brand-a-qa-with-professor-tulin-erdem/2024-01-11T10:35:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/determining-the-price-for-one-when-all-you-have-is-the-price-for-many/2024-01-11T10:35:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/new-bottles-for-old-wine-a-new-focus-on-antitrust-in-labor-markets/2024-01-11T10:35:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/aba-mock-trial-would-a-merger-of-online-platforms-lessen-competition/2024-01-11T10:35:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/aba-panel-the-ongoing-tale-of-two-sided-markets/2024-01-11T10:35:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/also-on-analysisgroup.com2024-01-11T10:35:48+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/new-payment-strategies/2024-01-11T10:35:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/asia-spotlight-beijing-forum/2024-01-11T10:35:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/applying-data-science-to-meet-real-world-health-care-challenges/2024-01-11T10:35:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/synthesizing-evidence-secure-coverage-reimbursement/2024-01-11T10:35:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/expanded-role-real-world-evidence/2024-01-11T10:35:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/recalibrating-predictions-survival-benefits-novel-cancer-therapies/2024-01-11T10:35:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/precision-medicine-to-market/2024-01-11T10:35:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/using-machine-learning-to-estimate-the-prevalence-and-onset-of-a-disease/2024-01-11T10:35:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/the-tyranny-of-market-shares-incorporating-survey-based-evidence-into-merger-analysis/2024-01-11T10:35:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/whats-in-the-record-implications-of-the-asacol-case-for-pharmaceutical-class-actions/2024-01-11T10:35:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/taxing-questions-managing-the-taxation-complexities-of-smart-contracts/2024-01-11T10:35:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/leveraging-cap-and-trades-market-incentives-in-climate-policies/2024-01-11T10:35:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/similar-but-not-the-same-charting-the-course-of-biosimilar-ip-litigation-in-the-us/2024-01-11T10:35:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/how-much-is-enough-applying-the-rule-of-reason-to-data-security/2024-01-11T10:35:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/franchise-no-poach-agreements-face-antitrust-scrutiny/2024-01-11T10:35:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/valuation-in-international-arbitration-a-growing-topic-in-investor-state-disputes/2024-01-11T10:35:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/symposium-examines-critical-economic-issues-in-life-sciences-litigation/2024-01-11T10:35:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/recent-case-highlights/2024-01-11T10:35:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/economic-consulting-in-the-data-science-era/2024-01-11T10:35:46+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/how-data-scientists-can-leverage-online-reviews-in-ip-and-antitrust-disputes/2024-01-11T10:35:46+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/the-ongoing-evolution-of-cryptocurrency-regulation-and-litigation/2024-01-11T10:35:47+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/exclusionary-abuses-and-multi-sided-platforms/2024-01-11T10:35:47+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/will-retail-debt-and-financial-distress-continue-to-grow-/2024-01-11T10:35:47+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/the-outlook-for-resilience-in-electricity-generation-and-distribution/2024-01-11T10:35:47+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/lng-contracts-taking-new-shape-in-europe-and-globally/2024-01-11T10:35:47+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/challenges-and-opportunities--suspicious-order-monitoring-of-prescription-opioids/2024-01-11T10:35:47+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/more-than-dollars-and-cents--prescription-drug-pricing-and-value/2024-01-11T10:35:48+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/building-a-foundation-for-essentiality-in-standard-essential-patents/2024-01-11T10:35:48+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/introducing-surveys-into-evidence--how-to-avoid-bias/2024-01-11T10:35:48+00:00weekly0.5https://www.analysisgroup.com/about/locations/montreal/fr/economie-sante/2018-11-05T13:57:47+00:00weekly0.5https://www.analysisgroup.com/about/locations/montreal/fr/institutions-financieres/2018-11-05T13:58:36+00:00weekly0.5https://www.analysisgroup.com/about/locations/montreal/fr/economie-du-travail/2018-11-05T13:59:36+00:00weekly0.5https://www.analysisgroup.com/about/locations/montreal/fr/energie-environnement-et-ressources-naturelles/2018-11-05T14:01:17+00:00weekly0.5https://www.analysisgroup.com/about/locations/montreal/fr/antitrust-et-concurrence/2018-11-05T14:02:27+00:00weekly0.5https://www.analysisgroup.com/about/locations/montreal/fr/cases/2018-12-11T18:24:04+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/recent-case-highlights/2024-01-11T10:35:48+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/contributions-to-recently-published-books/2024-01-11T10:35:48+00:00weekly0.5https://www.analysisgroup.com/careers/why-analysis-group/our-people/yao/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/rajeev/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/elyse/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/maral/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/energy-technology-and-the-future-a-conversation-with-ferc-commissioner-cheryl-lafleur-and-former-epa-administrator-gina-mccarthy/2024-01-11T10:36:08+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/perspectives-on-the-future-of-the-u.s.-power-grid2024-01-11T10:36:08+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/statistical-approaches-to-pay-equity-issues--a-qand-a-with-affiliate-anthony-losasso/2024-01-11T10:36:08+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/2024-01-11T10:36:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/catherine/2024-03-05T18:27:39+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/elizabeth/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/schuyler/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/the-use-of-reverse-termination-fees-in-merger-reviews/2024-01-11T10:36:06+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/david-g/2024-03-07T22:18:52+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/anshika/2024-01-11T10:36:06+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/taylor/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/mahir/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/upamanyu/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/seth/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/jeanne/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/maxime/2024-01-11T10:36:03+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/dody/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/matthew/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/precious/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/celeste/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/andres/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/cassie/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/selvam/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/riccardo/2024-01-11T10:36:03+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/using-implan-as-a-springboard-for-complex-economic-impact-analysis-a-qa-with-pavel-darling/2024-01-11T10:36:03+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/understanding-algorithms-data-structures-and-technical-systems-in-litigation/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/analyzing-the-dynamics-of-shopping-and-consumption-a-qa-with-professor-edward-j.-fox2024-01-11T10:36:03+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/kale/2024-01-11T10:36:04+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/khalilah/2024-01-11T10:36:04+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/anne-catherine/2024-01-11T10:36:03+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/nisha/2024-01-11T10:36:04+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/amanda/2024-01-11T10:36:04+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/kristin/2024-01-11T10:36:03+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/using-economics-in-policymaking-for-digital-platforms-a-qa-with-jeffrey-t.-prince2024-01-11T10:36:03+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/markets-data-and-the-value-of-high-tech-patents-a-qa-with-christopher-knittel/2024-01-11T10:36:03+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/sam/2024-01-11T10:36:03+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/erica/2024-03-18T19:07:38+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/james/2024-01-11T10:36:04+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/kari/2024-01-11T10:36:05+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/ngoc/2024-01-11T10:36:04+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/peter/2024-01-11T10:36:05+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/lamiya/2024-01-11T10:36:05+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/william/2024-01-11T10:36:04+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/mario/2024-01-11T10:36:04+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/garrett/2024-01-11T10:36:05+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/stefano/2024-01-11T10:36:05+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/managing-information-security-and-data-in-the-modern-business/2020-08-07T17:25:42+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/a-discussion-with-dr.-serena-koenig-about-the-why-when-and-how-of-novel-coronavirus-testing2024-01-11T10:36:05+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/conjoint-surveys-can-lead-to-inflated-values-of-minor-product-features/2024-01-11T10:36:05+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/mayo-setting-the-record-straight/2020-08-07T19:33:11+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-humira-team/humira-case-study-1/2024-01-11T10:36:06+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-humira-team/humira-case-study-2/2024-01-11T10:36:06+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-humira-team/humira-case-study-3/2024-01-11T10:36:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/does_acquihiring_lead_to_better_outcomes/2024-01-11T10:36:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/2024-01-11T10:36:06+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/ishita/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/charles/2024-01-11T10:36:12+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/liz/2024-01-11T10:36:12+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/Natacha/2024-01-11T10:36:12+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/megan/2024-01-11T10:36:12+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/rachel/2024-01-11T15:01:00+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/priyanka/2024-01-11T10:36:12+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/lauren/2022-07-27T20:07:52+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/david/2022-07-27T19:57:43+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/mark/2023-05-09T14:14:00+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/na/2022-07-28T17:43:51+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/rebecca/2022-07-28T17:58:08+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/andrew/2022-07-27T19:44:26+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/martha/2022-07-28T17:31:28+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/patrick/2022-07-28T17:46:17+00:00weekly0.6https://www.analysisgroup.com/about/locations/beijing/cn/2024-01-11T10:36:13+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/lisa/2022-07-27T20:08:06+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/ajay/2023-03-08T15:44:37+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/bruce/2022-07-27T19:46:41+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/deal-metrics/a-quick-look-at-topping-bids/2019-01-02T18:59:35+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/deal-metrics/go-shops-and-topping-bids/2019-01-02T19:31:04+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/the-role-of-the-economic-expert-in-class-certification/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/the-missing-data-challenge/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2013/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/presenting-demand-models-in-antitrust-litigation/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/perspectives-on-investment-management-disputes/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/economic-analysis-in-erisa-litigation/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/customer-behavior-and-class-actions/2018-11-05T14:37:46+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/2021-02-02T18:41:18+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/epidemiology-biostatistics/biostatistical-analysis/2024-01-11T10:36:13+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/epidemiology-biostatistics/epidemiology-capabilities-and-services/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/burden-of-illness-research/2022-01-13T19:26:58+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/comparative-effectiveness-research/2022-01-13T19:27:06+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/patient-reported-outcomes/2022-01-13T19:27:16+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/clinical-research-and-study-design/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/personalized-medicine/2022-01-13T19:27:32+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/rare-disease-and-orphan-drug-research/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/health-care/litigation-services/antitrust-litigation/2022-05-06T16:48:46+00:00weekly0.6https://www.analysisgroup.com/practices/health-care/litigation-services/drug-safety-litigation/2022-05-06T16:49:45+00:00weekly0.6https://www.analysisgroup.com/practices/health-care/litigation-services/government-investigations-and-qui-tam-litigation/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/health-care/litigation-services/intellectual-property-disputes/2022-05-06T16:49:33+00:00weekly0.6https://www.analysisgroup.com/practices/health-care/litigation-services/payer-disputes/2022-07-27T20:28:09+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/modeling-and-analytics/big-data-research/2023-12-14T15:17:43+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/modeling-and-analytics/health-technology-assessment-hta/2022-01-13T19:29:08+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/modeling-and-analytics/machine-learning-in-health-care/2024-01-11T10:36:13+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/market-access-and-commercial-strategy/value-proposition-and-evidence-strategy/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/market-access-and-commercial-strategy/forecasting-and-modeling/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/market-access-and-commercial-strategy/payer-provider-and-other-stakeholder-research/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/market-access-and-commercial-strategy/pricing-contracting-and-reimbursement/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/market-access-and-commercial-strategy/evidence-dossiers-and-communication-tools/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/transformation-of-the-nation-s-electric-infrastructure-and-implications-for-reliability/2024-01-11T10:36:09+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-spring-2012/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/assessing-transmission-for-renewables-projects/2024-01-11T10:36:09+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/performance-and-economic-analyses-to-support-the-siting-approval-of-a-new-natural-gas-peaker-plant/2024-01-11T10:36:09+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/assessing-market-needs-to-evaluate-natural-gas-pipeline-development/2024-01-11T10:36:09+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/capacity-market-impacts-of-future-resources-scenarios-in-the-iso-ne-system/2024-01-11T10:36:10+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/the-economics-of-different-ownership-structures-for-water-utilities/2024-01-11T10:36:10+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/revisiting-the-debate-over-natural-gas-pipeline-certifications/2024-01-11T10:36:10+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/cap-and-trade-and-allowance-allocations/2018-11-01T15:15:44+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/reading-the-tea-leaves-in-mand-a-litigation/2018-11-01T15:15:43+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/reinstatement-and-bankruptcy-litigation/2020-11-09T17:15:58+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/the-real-story-behind-mutual-fund-fees/2021-04-16T14:52:04+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/antitrust-experts-discuss-a-state-of-the-art-merger-tool/2018-11-01T15:15:41+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/a-focus-on-proxy-puts--change-of-control-provisions-in-perspective/2020-11-09T17:07:39+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/is-big-data-a-true-source-of-market-power-/2024-01-11T10:36:10+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/the-impact-of-data-breaches-and-hacking/2024-01-11T10:36:10+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/consumer-class-action-litigation--understanding-consumer-decision-making-can-make-the-difference/2024-01-11T10:36:11+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/privacy-and-cybersecurity--the-corporate-perspective/2024-01-11T10:36:11+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/labor-and-employment-issues-in-the-gig-economy--qand-a-with-professor-paul-oyer/2024-01-11T10:36:11+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/gender-identity-discrimination-in-the-greater-boston-housing-market/2024-01-11T10:36:11+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/examining-key-economic-issues-in-anti-poaching-and-pay-equity-litigation/2024-01-11T10:36:11+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/blockchain-economics-and-litigation/2024-01-11T10:36:11+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/materialization-of-risk-in-securities-event-driven-fraud-class-actions/2024-01-11T10:36:11+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/settlement-in-microsoft-iowa-litigation/settlement-in-microsoft-iowa-litigation--overview/2018-11-01T15:15:37+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/settlement-in-microsoft-iowa-litigation/settlement-in-microsoft-iowa-litigation--working-with-academic-experts/2018-11-01T15:15:37+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/settlement-in-microsoft-iowa-litigation/settlement-in-microsoft-iowa-litigation--key-concepts-in-the-litigation/2018-11-01T15:15:36+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/the-biosimilar-challenge/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/biologics-biosimilars-and-generics/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/energy-and-environment/alleged-market-manipulation-in-energy-markets/2024-01-11T10:36:11+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/energy-and-environment/health-related-cost-impacts-from-pollutant-reductions/2024-01-11T10:36:12+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/energy-and-environment/analyzing-competition-in-the-low-level-radioactive-waste-llrw-market/2024-01-11T10:36:12+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/energy-and-environment/energy-and--environment-litigation-case-examples/2024-01-11T10:36:11+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-lcd-team/direct-purchasers/2024-01-11T10:36:08+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-lcd-team/indirect-purchasers/2024-01-11T10:36:09+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-lcd-team/private-litigation/2024-01-11T10:36:09+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-alliance-team/oversight-and-coordination/2024-01-11T10:36:09+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-alliance-team/securities-issues/2024-01-11T10:36:09+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-alliance-team/corporate-governance/2024-01-11T10:36:09+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-alliance-team/financial-accounting/2024-01-11T10:36:09+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-alliance-team/portfolio-theory/2024-01-11T10:36:09+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-alliance-team/damages-rebuttal/2024-01-11T10:36:09+00:00weekly0.6https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-lcd-team/analyst-insights/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/about/locations/paris/fr/2024-02-01T15:48:33+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/also-on-analysisgroup.com2024-01-11T10:36:08+00:00weekly0.6https://www.analysisgroup.com/about/locations/brussels/fr/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2022-selected-highlights/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/the-role-of-accounting-in-esg-reporting-a-qa-with-d.-scott-showalter2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/sumit/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/2024-01-11T10:36:13+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/landing-page/promouvoir-lexcellence-et-linnovation-dans-la-recherche-en-sante/2024-01-29T19:54:40+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/innovating-finance-to-meet-emissions-reduction-goals-a-qa-with-peter-tufano/2024-01-30T21:22:39+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/lohit/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/talissa/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/careers/career-path/recruiting-events/associate-engagement-series/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/samuel/2024-01-11T15:02:31+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/gleb/2024-01-11T10:36:13+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/etienne/2024-01-11T10:36:00+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/samantha/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/trisha/2024-01-11T10:36:13+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/who-covers-what-untangling-the-intricacies-of-administering-prescription-drug-benefits-with-professor-amanda-starc/2024-01-11T10:36:13+00:00weekly0.6https://www.analysisgroup.com/experts-and-consultants/french/ludmila-rovba/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-ishita-rajani-to-moderate-aba-webinar-on-auto-repair-in-the-age-of-telematics/2023-12-18T16:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/proslide-technology-inc-v-whitewater-west-industries-ltd/2024-01-11T10:43:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/jury-adopts-analysis-group-principal-robert-vigils-damages-assessment-in-patent-dispute/2024-01-11T10:43:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-to-contribute-18-new-outcomes-research-presentations-at-65th-american-society-of-hematology-annual-meeting-and-exposition/2024-01-11T10:43:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-burden-treatment-patterns-and-economic-impact-of-rectovaginal-fistulas-in-patients-with-crohns-disease-findings-from-a-retrospective-observational-longitudinal-study-based-on-us-claims-databases/2024-01-11T10:43:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-healthcare-resource-use-in-medicare-beneficiaries-with-parkinsons-disease/2024-02-07T18:16:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparing-real-world-healthcare-costs-associated-with-single-tablet-regimens-for-hiv-1-the-2-drug-regimen-dolutegravirlamivudine-vs-standard-3-or-4-drug-regimens/2024-01-11T10:43:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/weight-and-bmi-changes-following-initiation-of-emtricitabinetenofovir-alafenamide-co-formulated-with-darunavir-or-co-administered-with-dolutegravir-in-overweight-or-obese-art-naive-people-living-with-hiv-1/2024-01-11T10:43:28+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/maria-mercedes-marimer-guevara/2024-01-11T10:43:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-heor-consultants-present-at-ispor-europe-2023/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/critical-considerations-for-analyses-of-anticompetitive-effects-outlined-by-managing-principal-antoine-chapsal-at-concurrences-conference/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-effectiveness-of-dupilumab-in-patients-with-atopic-dermatitis-results-up-to-3-years-from-the-relieve-ad-study2/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-coauthors-explore-novel-method-for-assessing-real-world-data-on-longitudinal-patient-reported-outcomes/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/amanda-starc/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-lisa-pinheiro-speaks-on-the-role-of-collaboration-in-promoting-esg-goals-at-responsible-investor-usa-2023-conference/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-researchers-evaluated-long-term-patient-experience-with-dupilumab-using-groundbreaking-method-for-generating-real-world-data/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessment-of-class-certification-lawsuit-involving-targeted-advertising-data/2024-01-11T10:43:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-josh-white-hosts-fireside-chat-and-panel-at-gcr-analysis-group-competition-and-sustainability-2023/2024-01-11T10:43:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-comparison-of-first-line-treatment-adherence-between-single-agent-ibrutinib-and-acalabrutinib-in-patients-with-chronic-lymphocytic-leukemia/2024-01-11T10:43:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-adults-with-major-depressive-disorder-in-the-united-states-2019/2024-03-14T19:21:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-costs-for-patients-with-spinal-muscular-atrophy-findings-from-a-retrospective-us-claims-database-analysis/2024-01-26T21:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/unintended-consequences-of-increased-out-of-pocket-costs-during-medicare-coverage-gap-on-anticoagulant-discontinuation-and-stroke/2024-02-15T20:53:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-among-patients-with-alopecia-areata-in-the-usa-a-retrospective-claims-analysis/2024-01-11T10:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-adverse-event-related-hospitalization-among-patients-with-epidermal-growth-factor-receptor-egfr-mutated-metastatic-non-small-cell-lung-cancer-after-treatment-with-egfr-tyrosine-kinase-inhibitor-and-platinum-based-chemotherapy-regi/2024-02-15T20:57:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/persistence-and-dose-escalation-during-maintenance-phase-and-use-of-nonbiologic-medications-among-patients-with-ulcerative-colitis-initiated-on-ustekinumab-in-the-united-states/2024-02-15T20:59:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/enhancement-and-external-validation-of-algorithms-using-diagnosis-codes-to-identify-invasive-escherichia-coli-disease/2024-01-11T10:43:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-evidence-of-eteplirsen-treatment-effects-in-patients-with-duchenne-muscular-dystrophy-in-the-usa/2024-01-11T10:43:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-multicenter-retrospective-chart-review-study-of-treatment-and-disease-patterns-and-clinical-outcomes-of-patients-with-chronic-phase-chronic-myeloid-leukemia-in-third-line-treatment-or-with-t315i-mutation/2024-02-16T15:44:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-of-menopausal-vasomotor-symptom-severity-with-sleep-and-work-impairments-a-us-survey/2024-01-11T10:43:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ischemic-stroke-and-systemic-embolism-among-patients-with-non-valvular-atrial-fibrillation-who-abandon-oral-anticoagulant-therapy/2024-02-16T15:46:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-event-free-survival-and-overall-survival-in-early-stage-triple-negative-breast-cancer/2024-02-16T15:47:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effect-of-fecal-microbiota-live-jslm-rebyota-rbl-on-health-related-quality-of-life-in-patients-with-recurrent-clostridioides-difficile-infection-results-from-the-punch-cd3-clinical-trial/2024-01-11T10:43:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/access-and-real-world-use-patterns-of-esketamine-nasal-spray-among-patients-with-treatment-resistant-depression-covered-by-private-or-public-insurance/2024-02-16T15:53:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/persistence-and-other-treatment-patterns-among-bio-experienced-patients-with-crohns-disease-initiated-on-ustekinumab-or-adalimumab/2024-02-16T15:54:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-sponsors-38th-annual-meeting-of-the-canadian-econometrics-study-group-and-awards-research-prize/2024-01-11T10:43:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-explore-the-convergence-of-antitrust-and-sustainability-at-aba-conference/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-susan-tierney-to-join-panel-at-fercs-2023-annual-reliability-technical-conference/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-womens-treatment-preferences-for-vasomotor-symptoms-due-to-menopause/2024-01-11T10:43:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-persistence-and-other-treatment-patterns-among-bio-naive-patients-with-crohns-disease-treated-with-ustekinumab-or-adalimumab/2024-02-12T21:52:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-and-caregiver-outcomes-after-onasemnogene-abeparvovec-treatment-findings-from-the-cure-sma-2021-membership-survey/2024-01-11T10:43:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-stephen-fink-assesses-pharmaceutical-antitrust-litigation-a-decade-after-us-supreme-courts-actavis-decision/2024-01-11T10:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-incidence-of-adverse-clinical-outcomes-among-people-with-coronary-artery-disease-andor-peripheral-artery-disease-in-relation-to-vascular-risk-in-the-united-states/2024-01-11T10:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-centric-assessment-of-rheumatoid-arthritis-using-a-smartwatch-and-bespoke-mobile-app-in-a-clinical-setting/2024-01-11T10:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-effectiveness-of-cladribine-tablets-in-patients-with-relapsing-forms-of-multiple-sclerosis-in-the-united-states/2024-01-11T10:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/progression-free-survival-of-daratumumab-versus-bortezomib-triplet-combination-with-lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-newly-diagnosed-multiple-myeloma-taurus-chart-review-study/2024-01-11T10:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-journey-before-and-after-a-formal-post-traumatic-stress-disorder-diagnosis-in-adults-in-the-united-states-a-retrospective-claims-study/2024-03-14T19:22:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-health-care-costs-and-resource-utilization-for-commonly-used-proteasome-inhibitor-immunomodulatory-drug-based-triplet-regimens-for-the-management-of-patients-with-relapsedrefractory-multiple-myeloma-in-the-united-states/2024-01-11T10:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-herpes-zoster-among-patients-with-psoriasis-in-the-united-states/2024-01-11T10:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-rifaximin-use-following-an-initial-overt-hepatic-encephalopathy-hospitalization-on-rehospitalization-and-costs/2024-01-11T10:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/nivolumab-plus-chemotherapy-for-advanced-gastric-gastroesophageal-junction-and-esophageal-adenocarcinoma-analysis-of-number-needed-to-treat-and-number-needed-to-harm/2024-01-11T10:43:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/corticosteroid-use-and-adherence-in-patients-treated-with-acthar-gel-for-advanced-sarcoidosis/2024-01-11T10:43:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-among-patients-with-connective-tissue-disorder-related-pulmonary-arterial-hypertension-in-the-united-states-a-retrospective-claims-based-analysis/2024-01-11T10:43:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-burden-of-invasive-escherichia-coli-disease-among-older-adult-patients-treated-in-hospitals-in-the-united-states/2024-01-11T10:43:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-update-chapter-on-economic-analysis-of-merger-remedies-in-the-fifth-edition-of-global-competition-reviews-merger-remedies-guide/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/escherichia-coli-resistance-treatment-patterns-and-clinical-outcomes-among-females-with-uuti-in-germany-a-retrospective-physician-based-chart-review-study/2024-03-07T21:51:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-again-recognized-as-the-top-women-led-consulting-firm-in-massachusetts/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electric-system-reliability-and-epa-regulation-of-ghg-emissions-from-power-plants-2023/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/epas-proposed-emissions-regulation-will-not-threaten-electric-system-reliability-if-risks-are-addressed-appropriately-according-to-senior-advisor-susan-tierney-in-independent-study/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/amit-bhattacharjee/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/yuga-labs-inc-v-ryder-ripps-et-al/2024-01-11T10:43:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/expert-testimony-from-analysis-group-supports-yuga-labs-1-6-million-trial-win-in-nft-trademark-infringement-litigation/2024-01-11T10:43:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-join-panel-at-concurrences-global-antitrust-economics-conference/2024-01-11T10:43:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-marissa-ginn-to-join-cba-and-aba-webinar-on-gender-and-competition/2024-01-11T10:43:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-and-clinical-burden-of-herpes-zoster-among-patients-with-inflammatory-bowel-disease-in-the-united-states/2024-02-12T21:35:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-time-to-discontinuation-of-first-line-venetoclaxobinutuzumab-in-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma/2024-01-11T10:43:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-invasive-escherichia-coli-disease-among-older-adult-patients-treated-in-hospitals-in-the-united-states/2024-01-11T10:43:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-switching-following-moderatesevere-chronic-obstructive-pulmonary-disease-exacerbation-in-patients-with-commercial-or-medicare-insurance-in-the-united-states/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-the-allstate-corporation-securities-litigation/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-client-in-securities-fraud-litigation-reaches-settlement/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/world-trade-center-properties-et-al-v-american-airlines-et-al/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fuel-and-energy-security-in-new-york-state-an-assessment-of-winter-operational-risks-for-a-power-system-in-transition2/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-the-transition-to-a-decarbonized-economy-nyiso-will-need-to-continue-to-closely-monitor-fuel-and-energy-security-during-cold-winter-conditions-according-to-new-study-by-analysis-group-energy-experts/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/at-international-aids-society-ias-conference-gheskio-presents-mobile-app-designed-with-analysis-group-to-monitor-patient-visits/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/federal-energy-regulatory-commissions-reliability-technical-conference-prepared-statement-of-susan-f-tierney-ph-d-senior-advisor-analysis-group/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-addresses-electric-system-reliability-concerns-about-epas-proposed-greenhouse-gas-emissions-regulation-at-ferc-conference/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-announces-senior-level-promotions-and-lateral-hires-and-welcomes-new-affiliates/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-welcomes-new-affiliates-and-announces-senior-level-promotions-and-lateral-hires/2024-01-11T10:43:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ten-years-post-actavis-lessons-learned-and-the-future-of-reverse-payment-antitrust-cases/2024-01-11T10:43:24+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/event-summary-how-far-should-the-scope-of-antitrust-be-extended-innovation-environment-privacy/2024-01-11T10:43:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sec-v-pacific-west-capital-group-et-al/2024-01-11T10:36:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/summary-judgment-granted-to-analysis-group-client-in-sec-ponzi-scheme-litigation/2024-01-11T10:36:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-use-of-conjoint-analysis-in-high-stakes-litigation/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/peter-c-chen/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-rebecca-kirk-fair-discusses-non-competes-on-aba-antitrust-law-section-panel/2024-01-11T10:43:19+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/jonathan-freimark/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-heor-consultants-to-present-at-ispor-europe-2023/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wml-gryphon-fund-llc-et-al-v-wood-hat-silver-llc-et-al/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/paper-on-asthma-therapy-adherence-and-persistence-coauthored-by-analysis-group-researchers-recognized-by-the-journal-of-allergy-and-clinical-immunology-in-practice/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-and-affiliates-contribute-scholarship-to-volume-on-marketing-and-the-law/2024-01-11T10:43:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-cambridge-handbook-of-marketing-and-the-law/2024-01-30T18:06:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/laura-happe/2024-01-11T10:43:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/heor-and-epidemiology-research-from-analysis-group-featured-at-amcp-nexus-meeting/2024-03-14T19:23:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/accelerating-decarbonization-in-the-united-states-technology-policy-and-societal-dimensions/2024-01-11T10:43:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/national-academies-report-on-overcoming-barriers-to-decarbonizing-the-us-coauthored-by-analysis-group-senior-advisor-susan-f-tierney/2024-01-11T10:43:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consent-flows-and-cancellation-processes-how-to-spot-dark-patterns/2024-01-11T10:43:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-webinar-exploring-dark-patterns-summarized-by-analysis-groups-rene-befurt-and-helene-rowland/2024-01-11T10:43:19+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/cynthia-steer/2024-01-11T10:43:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/power-grid-most-important-piece-of-climate-puzzle/2024-01-11T10:43:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/energy-experts-susan-tierney-and-paul-hibbard-contribute-op-ed-on-investment-needed-in-massachusetts-power-grid-to-support-clean-energy-transition/2024-01-11T10:43:28+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/amalia-rebecca-miller/2024-01-11T10:43:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-judy-chang-to-be-guest-speaker-at-boston-economic-club-event/2024-01-11T10:43:29+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/nicholas-blair/2024-01-11T10:43:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/humana-inc-v-celgene-corp/2024-01-11T10:43:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-medical-and-economics-experts-testify-in-celgenes-successful-defense-against-claims-involving-off-label-prescriptions-for-cancer-treatments/2024-01-11T10:43:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-paul-hibbard-to-moderate-panel-at-necbcs-31st-annual-us-canada-executive-energy-conference/2024-01-11T10:43:29+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/peter-c-jones/2024-02-02T14:38:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/judy-chang/2024-02-23T14:54:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-anne-catherine-faye-and-new-managing-principal-judy-chang-to-speak-at-aba-antitrust-law-sections-2023-antitrust-and-sustainability-conference/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-to-join-panel-at-gcr-live-global-merger-control-2023-conference/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/oecd-gender-inclusive-toolkit-may-inform-competition-policy/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-law360-analysis-group-authors-discussed-gender-considerations-in-competition-policy/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/iain-snoddy/2024-01-11T10:43:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/janssen-pharmaceuticals-inc-et-al-v-mylan-laboratories-limited/2024-01-23T17:12:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/david-j-hutchings/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lynne-houserman-v-comtech-telecommunications-corporation-et-al-and-telecommunication-systems-inc-v-lynne-houserman-et-al/2024-01-11T10:43:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/research-from-analysis-groups-heor-epidemiology-market-access-practice-to-be-featured-at-amcp-nexus-meeting/2024-01-11T10:43:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-join-panel-at-the-new-york-state-bar-associations-department-of-justice-criminal-antitrust-enforcement-program/2024-01-11T10:43:13+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/ashley-lee/2024-01-11T10:43:13+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/sean-macknight/2024-01-11T10:43:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-vice-president-anne-catherine-faye-interviewed-on-our-curious-amalgam-american-bar-association-podcast/2024-01-11T10:43:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/george-r-golson-v-provident-life-and-accident-insurance-company-et-al/2024-01-11T10:43:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-class-actions-involving-data-collections/2024-01-11T10:43:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/at-the-crossroads-improving-customer-choice-for-products-in-the-u-s-electricity-sector/2024-01-11T10:43:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/principal-paul-hibbard-publishes-analysis-of-impact-of-retail-choice-in-the-us-electricity-sector/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/twitter-v-elon-musk-et-al/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/nandita-krishnaswamy/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/david-j-hutchings/2024-01-12T14:02:17+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/l-charles-duke-meythaler/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/interview-resources/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/david-j-hutchings-expert-in-economics-and-finance-joins-analysis-group-as-managing-principal/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-todd-schatzki-to-join-panel-at-the-renewable-energy-markets-2023-conference/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/electric-utilities-require-regulatory-innovation-capital-investment-to-enable-massachusetts-to-meet-ghg-emission-reduction-targets-according-to-analysis-group-white-paper/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/massachusetts-energy-transition-innovation-for-electric-utility-regulation/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/gender-considerations-in-the-analysis-of-market-definition-and-competitive-effects-a-practical-framework-and-illustrative-example2/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-research-on-gender-considerations-in-antitrust-analyses-published-in-antitrust-report-and-included-in-oecd-toolkit/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/icpe-2023-featured-presentations-from-analysis-group-consultants/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-lisa-pinheiro-to-join-panel-at-lear-competition-festival-2023/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/elizabeth-serra/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/timothy-j-spittle/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/summer-associate-intern/2024-01-11T10:43:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mergers-and-monopsony-the-anthem-cigna-merger/2024-01-11T10:43:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-contribute-to-competition-policy-book/2024-01-11T10:43:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/arjun-dasgupta/2024-01-11T10:43:14+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/health-care-bulletins/health-care-bulletin-2023/2024-01-26T20:11:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/davis-v-amazon-canada-fulfillment-services-ulc/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-client-amazon-canada-defeats-class-certification-in-an-action-brought-by-delivery-drivers/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/thomas-cornwall/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/irena-v-tsvetkova/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/ferc-accepts-analysis-group-recommendations-for-revisions-of-inventoried-energy-program-parameters/2024-01-11T10:43:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/revisions-to-iso-ne-inventoried-energy-program/2024-01-11T10:43:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principals-rebecca-kirk-fair-and-dov-rothman-to-speak-at-aba-antitrust-law-sections-2023-antitrust-merger-guidelines-workshop/2024-01-11T10:43:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/joseph-vellali-et-al-v-yale-university-et-al/2024-01-23T19:53:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-expert-supports-yale-universitys-successful-retirement-plan-defense-in-rare-erisa-jury-trial/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/study-coauthored-by-analysis-group-authors-explores-impacts-of-californias-surprise-billing-law-on-the-cost-of-anesthesia-care/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-balance-billing-legislation-and-anesthesia-payments-in-california-a-retrospective-analysis/2024-01-11T10:43:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-and-stanford-university-study-details-impact-of-californias-balance-billing-law-on-the-cost-of-anesthesia-care/2024-01-11T10:43:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-testifies-before-senate-committee-on-impacts-of-climate-change-on-energy-infrastructure/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/todd-j-mortier-v-livanova-usa-inc/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/summary-judgment-awarded-to-analysis-group-client-in-breach-of-contract-litigation/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/geographic-market-definition-in-commercial-health-insurer-matters-a-unified-approach-for-merger-review-monopolization-claims-and-monopsonization-claims/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/antitrust-bulletin-publishes-analysis-group-paper-outlining-alternative-methodology-for-geographic-market-definition-in-health-care-markets/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-maria-garibotti-to-join-antitrust-and-sports-panel-at-the-first-women-in-antitrust-annual-event/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/analyst-engagement-series/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-supports-testimony-in-pay-for-delay-hiv-treatment-antitrust-matter/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-hiv-antitrust-litigation/2024-01-26T17:54:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/dr-anupam-b-jena-an-analysis-group-affiliate-provides-testimony-in-gilead-sciences-successful-defense-of-pay-for-delay-allegations-of-hiv-treatments/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/u-s-coal-fired-power-generation-market-fundamentals-as-of-2023-and-transitions-ahead/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/report-by-senior-advisor-susan-tierney-details-changes-in-coal-fired-power-production-in-the-us/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/hope-medical-enterprises-inc-v-fagron-compounding-services-llc-et-al/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regulation-and-competition-in-digital-ecosystems-some-missing-pieces/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-health-care-consultants-to-present-at-icpe-2023/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-network-law-review-senior-advisor-eliana-garces-examines-adequacy-of-current-and-proposed-regulation-of-digital-platform-ecosystems/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-of-america-v-krikor-topouzian/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/affiliate-matthew-grennan-testifies-on-behalf-of-doj-in-criminal-price-gouging-conviction-involving-the-illegal-mark-up-of-n95-respirator-masks/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/preliminary-injunctive-relief-in-patent-cases-repairing-irreparable-harm/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-practical-guide-to-the-implementation-of-the-as-efficient-competitor-aec-test/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/abas-price-point-publishes-article-with-analysis-group-coauthors-offering-a-practical-guide-to-implementing-the-as-efficient-competitor-aec-test/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/yeseul-hyun/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/mickey-ferri/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-webinar-exploring-antitrust-considerations-surrounding-app-distribution-summarized-by-analysis-groups-yeseul-hyun-and-lolo-palacios/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recap-of-distribution-essentials-app-distribution-and-related-antitrust-considerations/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/highlights-regulatory-rwe/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-analysis-of-weight-gain-and-body-mass-index-increase-among-patients-with-hiv-1-using-antiretroviral-regimen-containing-tenofovir-alafenamide-tenofovir-disoproxil-fumarate-or-neither-in-the-united-states/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/weight-change-and-predictors-of-weight-change-among-patients-initiated-on-darunavircobicistatemtricitabinetenofovir-alafenamide-or-bictegraviremtricitabinetenofovir-alafenamide-a-real-world-retrospective-study/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/body-mass-index-increase-and-weight-gain-among-people-living-with-hiv-1-initiated-on-single-tablet-darunavircobicistatemtricitabinetenofovir-alafenamide/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-fremanezumab-in-migraine-patients-initiating-treatment-in-the-united-states-results-from-a-retrospective-chart-study/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/decreased-antibiotic-exposure-using-a-procalcitonin-protocol-for-respiratory-infections-and-sepsis-in-us-community-hospitals-procommunity/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiology-and-economic-burden-of-lewy-body-dementia-in-the-united-states/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/projecting-the-long-term-clinical-value-of-mavacamten-for-the-treatment-of-obstructive-hypertrophic-cardiomyopathy-in-the-united-states-an-assessment-of-net-health-benefit/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-management-of-hyperkalemia-in-the-emergency-department-an-electronic-medical-record-analysis/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/modeling-the-health-and-economic-implications-of-adopting-a-1-dose-9-valent-human-papillomavirus-vaccination-regimen-in-a-high-income-country-setting-an-analysis-in-the-united-kingdom/2024-01-11T10:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-metreleptin-on-patient-outcomes-and-quality-of-life-in-generalized-and-partial-lipodystrophy/2024-02-07T16:41:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/benefit-risk-analysis-of-upadacitinib-compared-with-adalimumab-in-the-treatment-of-patients-with-moderate-to-severe-rheumatoid-arthritis/2024-01-11T10:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/defining-utility-values-for-chorea-health-states-in-patients-with-huntingtons-disease/2024-01-11T10:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-adherence-to-tetrabenazine-or-deutetrabenazine-among-patients-with-huntingtons-disease-a-retrospective-database-analysis/2024-01-11T10:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-among-patients-with-gastroesophageal-reflux-disease-barretts-esophagus-and-barretts-esophagus-related-neoplasia-in-the-united-states/2024-01-11T10:43:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-coauthors-study-on-health-care-resource-utilization-and-costs-in-us-patients-with-gerd-barretts-esophagus-and-barretts-esophagus-related-neoplasia/2024-01-11T10:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-outcomes-and-healthcare-resource-utilization-in-newly-treated-korean-patients-with-asthma-a-retrospective-cohort-study/2024-01-11T10:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-healthcare-resource-utilization-hru-and-costs-of-patients-with-paroxysmal-nocturnal-hemoglobinuria-pnh-receiving-eculizumab-in-a-us-population/2024-01-11T10:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluation-of-treatment-patterns-healthcare-resource-utilization-and-costs-among-patients-receiving-treatment-for-cytomegalovirus-following-allogeneic-hematopoietic-cell-or-solid-organ-transplantation/2024-01-11T10:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-pegcetacoplan-versus-ravulizumab-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-previously-treated-with-eculizumab-a-matching-adjusted-indirect-comparison/2024-01-11T10:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-and-safety-of-rivaroxaban-and-warfarin-among-nonvalvular-atrial-fibrillation-nvaf-patients-with-obesity-and-polypharmacy-in-the-united-states-us/2024-01-11T10:43:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/rosamond-mate/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/heavy-duty-vehicle-electrification-planning-for-and-development-of-needed-power-system-infrastructure/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/report-on-electrification-of-us-heavy-duty-vehicle-fleet-explores-impact-on-electric-utilities-provides-key-takeaways-for-meeting-emission-reduction-goals/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/temporal-trends-of-adverse-events-and-costs-of-nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-and-evaluation-of-a-predictive-algorithm-for-unsatisfactory-response-among-patients-with-pulmonary-arterial-hypertension-using-health-insurance-claims-data/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-the-administration-of-erythropoiesis-stimulating-agents-for-the-treatment-of-anemia-in-patients-with-non-dialysis-dependent-chronic-kidney-disease-a-us-societal-perspective/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/nusinersen-for-spinal-muscular-atrophy-in-the-united-states-findings-from-a-retrospective-claims-database-analysis/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-treatment-comparison-of-larotrectinib-versus-entrectinib-in-treating-patients-with-trk-gene-fusion-cancers/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/excess-healthcare-costs-in-patients-with-autosomal-dominant-polycystic-kidney-disease-by-renal-dysfunction-stage/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-rebecca-kirk-fair-to-join-aba-webinar-on-the-pros-and-cons-of-the-us-federal-trade-commissions-proposed-rule-on-non-compete-clauses/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identification-of-patients-with-metastatic-castration-sensitive-or-metastatic-castration-resistant-prostate-cancer-using-administrative-health-claims-and-laboratory-data/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-agitation-in-long-term-care-residents-with-dementia-in-the-united-states/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/higher-medication-adherence-and-lower-opioid-use-among-individuals-with-autoimmune-disease-enrolled-in-an-adalimumab-patient-support-program-in-the-united-states/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-analysis-of-comprehensive-genomic-profiling-in-patients-with-advanced-non-small-cell-lung-cancer2/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-potential-drug-drug-interactions-with-ritonavir-containing-covid-19-therapy/2024-01-11T10:43:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-tardive-dyskinesia-on-physical-psychological-social-and-professional-domains-of-patient-lives-a-survey-of-patients-in-the-united-states/2024-01-11T10:43:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hypereosinophilic-syndrome-in-europe-retrospective-study-of-treatment-patterns-clinical-manifestations-and-healthcare-resource-utilization/2024-01-11T10:43:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/affiliate-david-c-chan-jr-to-receive-ashecon-medal-at-ashecon-2023/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/hunter-lent/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-to-sponsor-and-participate-in-the-57th-annual-conference-of-the-canadian-economics-association/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-the-preds-score-to-predict-in-hospital-mortality-of-patients-with-ebola-virus-disease-under-advanced-supportive-care-results-from-the-evista-cohort-in-the-democratic-republic-of-the-congo/2024-01-11T10:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiology-and-economic-burden-of-von-hippel-lindau-disease-associated-renal-cell-carcinoma-in-the-united-states/2024-01-11T10:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-healthcare-utilization-and-costs-of-patients-with-treatment-resistant-depression-initiated-on-esketamine-intranasal-spray-and-covered-by-us-commercial-health-plans/2024-01-11T10:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-schizophrenia-in-the-united-states/2024-03-07T21:52:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-per-relapse-avoided-for-ozanimod-versus-other-selected-disease-modifying-therapies-for-relapsing-remitting-multiple-sclerosis-in-the-united-states/2024-01-11T10:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-of-serum-calcium-and-phosphate-with-incident-cardiovascular-disease-in-patients-with-hypoparathyroidism/2024-01-11T10:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-barriers-to-access-and-equity-for-covid-19-vaccination-in-the-us/2024-01-11T10:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-pembrolizumab-as-an-adjuvant-treatment-of-renal-cell-carcinoma-post-nephrectomy-in-the-united-states/2024-01-11T10:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/surgical-treatment-patterns-healthcare-resource-utilization-and-economic-burden-in-patients-with-tenosynovial-giant-cell-tumor-who-underwent-joint-surgery-in-the-united-states2/2024-01-11T10:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-analysis-of-rebyota-fecal-microbiota-live-jslm-fmbl-or-preventing-recurrent-clostridioides-difficile-infection-in-the-us/2024-01-26T21:43:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-rebyota-fecal-microbiota-live-jslm-fmbl-versus-standard-of-care-for-the-prevention-of-recurrent-clostridioides-difficile-infection-in-the-usa/2024-01-26T21:42:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-omadacycline-and-impact-of-unapproved-omadacycline-prescription-claims-among-adult-outpatients-with-community-acquired-bacterial-pneumonia/2024-01-11T10:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-impact-of-open-label-designs-in-patient-reported-outcomes-investigation-in-oncology-clinical-trials/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/attainment-of-early-deep-prostate-specific-antigen-response-in-metastatic-castration-sensitive-prostate-cancer-a-comparison-of-patients-initiated-on-apalutamide-or-enzalutamide/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-assess-clinical-benefits-of-early-initiation-of-long-acting-injectable-antipsychotics-in-patients-with-schizophrenia/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-prostate-specific-antigen-response-in-patients-with-metastatic-castration-sensitive-prostate-cancer-initiated-on-apalutamide-or-abiraterone-acetate-a-retrospective-cohort-study/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/about/diversity-equity-and-inclusion-at-analysis-group/rise-at-ag-externship/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiology-and-patient-journey-of-rett-syndrome-in-the-united-states-a-real-world-evidence-study/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-progression-rates-in-ambulatory-duchenne-muscular-dystrophy-by-steroid-type-patient-age-and-functional-status/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/functional-and-clinical-outcomes-associated-with-steroid-treatment-among-non-ambulatory-patients-with-duchenne-muscular-dystrophy1/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-matching-adjusted-indirect-comparison-of-nivolumab-plus-cabozantinib-versus-pembrolizumab-plus-axitinib-in-patients-with-advanced-renal-cell-carcinoma/2024-01-31T16:36:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-multicenter-chart-review-of-patient-characteristics-treatment-and-outcomes-in-hereditary-angioedema-unmet-need-for-more-effective-long-term-prophylaxis/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-treatment-comparison-itc-of-the-efficacy-of-vutrisiran-and-tafamidis-for-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy/2024-01-31T16:34:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/benefits-of-autoantibody-enrichment-in-early-rheumatoid-arthritis-analysis-of-efficacy-outcomes-in-four-pooled-abatacept-trials/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-of-pediatric-liver-transplantation-among-commercially-and-medicaid-insured-patients-with-cholestasis-in-the-united-states/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/projecting-the-economic-outcomes-of-switching-patients-with-schizophrenia-from-oral-atypical-antipsychotics-to-once-monthly-once-every-3-months-and-once-every-6-months-paliperidone-palmitate/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-comorbidities-and-healthcare-resource-utilization-among-medicaid-enrolled-extremely-premature-infants/2024-01-11T10:43:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ckd-progression-and-economic-burden-in-individuals-with-ckd-associated-with-type-2-diabetes/2024-01-31T16:36:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dmd-genotypes-and-motor-function-in-duchenne-muscular-dystrophy-a-multi-institution-meta-analysis-with-implications-for-clinical-trials/2024-01-11T10:43:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/frequency-and-clinicoeconomic-impact-of-delays-to-definitive-diagnosis-of-obstructive-hypertrophic-cardiomyopathy-in-the-united-states/2024-01-11T10:43:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-results-of-carbidopalevodopa-enteral-suspension-across-the-day-in-advanced-parkinsons-disease-post-hoc-analyses-from-a-large-54-week-trial/2024-01-11T10:43:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/time-and-personnel-costs-associated-with-adverse-event-ae-management-among-patients-with-chronic-lymphocytic-leukemia-cll/2024-02-29T21:32:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indicators-of-suboptimal-treatment-and-associated-healthcare-costs-among-patients-with-crohns-disease-initiated-on-biologic-or-conventional-agents/2024-01-11T10:43:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predicting-clinical-remission-of-chronic-urticaria-using-random-survival-forests-machine-learning-applied-to-real-world-data/2024-01-11T10:43:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-on-hospitalizations-of-long-term-versus-short-term-therapy-with-sodium-zirconium-cyclosilicate-during-routine-outpatient-care-of-patients-with-hyperkalemia-the-recognize-i-study/2024-01-11T10:43:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-experience-of-pediatric-patients-treated-with-peanut-arachis-hypogaea-allergen-powder-dnfp/2024-01-11T10:43:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-cardiometabolic-outcomes-among-people-living-with-hiv-1-initiated-on-integrase-strand-transfer-inhibitor-versus-non-integrase-strand-transfer-inhibitor-antiretroviral-therapies/2024-01-11T10:43:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-recurrent-clostridioides-difficile-infection-in-the-usa-a-systematic-literature-review-and-cost-synthesis/2024-01-11T10:43:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/diagnostic-yield-of-active-case-finding-for-tuberculosis-at-human-immunodeficiency-virus-testing-in-haiti/2024-01-11T10:43:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/superior-outcomes-and-lower-outpatient-costs-with-scale-up-of-antiretroviral-therapy-at-the-gheskio-clinic-in-port-au-prince-haiti/2024-01-11T10:43:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-related-quality-of-life-instruments-for-clinical-trials-in-al-amyloidosis-report-from-the-amyloidosis-forum-hrqol-working-group/2024-01-19T20:22:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-comparative-effectiveness-of-acalabrutinib-and-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia/2024-01-11T10:43:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-among-patients-with-attention-deficithyperactivity-disorder-and-comorbid-anxiety-andor-depression-in-the-united-states-a-retrospective-claims-analysis/2024-03-14T19:18:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reasons-for-treatment-changes-in-children-and-adolescents-with-attention-deficithyperactivity-disorder-a-chart-review-study/2024-01-11T10:43:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prescription-opioid-utilization-patterns-and-associated-outcomes-among-privately-insured-patients-prescribed-opioids-to-manage-pain-associated-with-osteoarthritis/2024-01-11T10:43:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-discontinuation-patterns-for-patients-with-chronic-lymphocytic-leukemia-in-real-world-settings-results-from-a-multi-center-international-study/2024-01-11T10:43:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/safety-differences-across-androgen-receptor-inhibitors-in-nonmetastatic-castration-resistant-prostate-cancer/2024-01-11T10:43:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparison-maic-results-confirmed-by-head-to-head-trials-a-case-study-in-psoriasis/2024-01-11T10:43:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-mepolizumab-in-severe-asthma-and-chronic-rhinosinusitis-in-the-us-impact-of-comorbidity-and-sinus-surgery/2024-01-11T10:43:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-and-risk-of-herpes-zoster-in-patients-with-ulcerative-colitis-and-crohns-disease-in-the-usa/2024-01-11T10:43:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-herpes-zoster-in-patients-with-rheumatoid-arthritis-in-the-united-states-a-retrospective-cohort-study/2024-01-11T10:43:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burden-of-herpes-zoster-in-patients-with-rheumatoid-arthritis-a-retrospective-cohort-study-using-administrative-claims/2024-01-11T10:43:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-illness-and-treatment-patterns-among-patients-with-von-willebrand-disease-in-us-clinical-practice/2024-01-11T10:43:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-and-safety-of-ozanimod-and-ponesimod-for-relapsing-multiple-sclerosis-a-matching-adjusted-indirect-comparison/2024-01-11T10:43:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-clinical-outcomes-health-care-resource-utilization-and-costs-in-older-patients-with-metastatic-castration-resistant-prostate-cancer-in-the-united-states-an-analysis-of-seer-medicare-data/2024-01-11T10:43:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-and-comorbidity-burden-amonpeople-living-with-hiv-a-review-of-systematic-literature-reviews/2024-01-11T10:43:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/chronic-obstructive-pulmonary-disease-is-associated-with-an-increased-risk-of-herpes-zoster-a-retrospective-united-states-claims-database-analysis/2024-01-11T10:43:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-illness-among-patients-with-pulmonary-arterial-hypertension-pah-associated-with-connective-tissue-disorders-ctd/2024-01-11T10:43:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/longitudinal-assessment-of-creatine-kinase-creatinecreatinineratio-and-myostatin-as-monitoring-biomarkers-in-becker-muscular-dystrophy/2024-01-11T10:43:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-in-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer-receiving-first-line-treatment-in-the-united-states-an-insurance-claims-based-descriptive-analysis/2024-01-11T10:43:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/improved-outcomes-with-high-dose-isoniazid-in-multidrug-resistant-tuberculosis-treatment-in-haiti/2024-01-11T10:43:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-overall-survival-of-patients-with-double-class-and-triple-class-refractory-multiple-myeloma-a-us-electronic-health-record-database-study/2024-01-11T10:43:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluation-of-disease-free-survival-as-a-predictor-of-overall-survival-and-assessment-of-real-world-burden-of-disease-recurrence-in-resected-early-stage-non-small-cell-lung-cancer/2024-01-11T10:43:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-outcomes-in-resected-early-stage-non-small-cell-lung-cancer-an-analysis-of-the-seer-medicare-data/2024-01-11T10:43:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-pegcetacoplan-versus-ravulizumab-and-eculizumab-in-complement-inhibitor-naive-patients-with-paroxysmal-nocturnal-hemoglobinuria-a-matching-adjusted-indirect-comparison/2024-01-11T10:43:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-use-and-reimbursement-amount-by-site-of-care-in-patients-with-diffuse-large-b-cell-lymphoma-receiving-chimeric-antigen-receptor-t-cell-car-t-therapy/2024-01-11T10:43:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-therapy-management-on-axitinib-related-adverse-events-in-patients-with-advanced-renal-cell-carcinoma-receiving-first-line-axitinib-checkpoint-inhibitor/2024-02-29T21:29:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-pembrolizumab-as-an-adjuvant-treatment-of-resected-stage-iib-or-iic-melanoma-in-the-united-states/2024-01-11T10:43:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-persistence-among-bio-naive-patients-with-crohns-disease-initiated-on-ustekinumab-or-adalimumab/2024-01-11T10:43:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/esketamine-nasal-spray-for-major-depressive-disorder-with-acute-suicidal-ideation-or-behavior-description-of-treatment-access-utilization-and-claims-based-outcomes-in-the-united-states/2024-01-11T10:43:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-use-of-third-party-surveys-in-litigation/2024-01-11T10:43:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-ipwatchdog-article-analysis-group-consultants-detail-use-of-third-party-surveys-in-litigation/2024-01-11T10:43:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/todor-totev/2024-01-11T10:43:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/jacquelyn-gillette/2024-01-19T18:36:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/irina-pivneva/2024-01-19T19:46:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/financing-building-decarbonization-the-roles-of-government-and-private-sector-investors/2024-01-25T15:21:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/white-paper-coauthored-by-managing-principal-judy-chang-offers-a-strategy-for-funding-building-decarbonization/2024-01-25T15:23:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/wei-song/2024-01-26T21:43:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-heor-research-presented-at-asco-genitourinary-cancers-symposium/2024-01-29T14:38:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/catherine-nguyen/2024-03-05T18:25:52+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/christopher-pratt/2024-03-05T18:24:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-explores-how-to-accelerate-decarbonization-in-the-energy-transition-show-podcast/2024-03-04T14:41:56+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/philipp-tillmann/2024-03-04T15:59:45+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/bill-quirk/2024-03-04T17:01:40+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/anthony-nasr/2024-03-05T20:27:19+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/yanwen-xie/2024-03-12T16:36:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/data-in-the-digital-economy-the-anti-hero-of-antitrust-or-just-bad-reputation/2024-03-06T14:59:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-kristof-zetenyi-and-associate-dheeraj-chaudhary-coauthor-article-on-data-in-the-digital-economy-for-cpi-antitrust-chronicle/2024-03-06T15:01:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-marissa-ginn-to-join-panel-of-judges-at-adam-f-fanaki-competition-law-moot/2024-03-06T16:26:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-to-participate-in-panels-at-2024-aba-antitrust-law-spring-meeting/2024-03-07T15:15:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-to-join-panels-at-aba-antitrust-law-spring-meeting2/2024-03-07T15:19:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/webinar-recap-breaking-news-amazon-and-ftc/2024-03-12T14:37:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-webinar-exploring-ftcs-antitrust-lawsuit-against-amazon-summarized-by-managers-jane-choi-and-hailey-nguyen/2024-03-12T14:36:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/maryaline-catillon/2024-03-07T21:52:36+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/jeffrey-denault/2024-03-05T18:28:40+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/rose-chang/2024-03-18T18:59:32+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-eliana-garces-to-join-digital-ecosystem-mergers-panel-at-gcr-live-telecoms-media-technology-2024/2024-03-11T13:56:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-marissa-ginn-joins-panel-on-gender-and-competition-at-apecs-competition-policy-and-law-group-plenary-meeting/2024-03-11T19:08:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/expert-testimony-from-senior-advisor-keith-ugone-helps-cisco-secure-favorable-settlement-in-antitrust-litigation/2024-03-12T13:09:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dexon-computer-inc-v-cisco-systems-inc-and-cdw-corporation/2024-03-12T13:11:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/hailey-nguyen/2024-03-12T14:38:53+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/alexander-graupner/2024-03-12T16:47:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/energy-harbor-corp-vistra-corp/2024-03-12T17:02:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-energy-harbors-successful-merger-with-vistra/2024-03-12T17:04:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-eliana-garces-to-join-international-bar-associationbusiness-at-oecd-webinar-on-ecosystem-theories-of-harm/2024-03-13T13:52:47+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/jessica-maitland/2024-03-14T19:24:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/catherine-gendron-saulnier/2024-03-18T19:32:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/ceo-and-chairman-martha-samuelson-joins-aba-webinar-on-the-meaning-and-impact-of-brown-shoe/2024-03-05T14:30:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-judy-chang-joins-harvard-kennedy-school-panel-on-the-global-climate-crisis/2023-12-18T18:41:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/affiliated-expert-roberts-brokaw-testifies-for-the-irs-in-a-tax-liability-dispute/2024-03-12T14:38:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ya-global-investments-lp-et-al.-v.-commissioner-of-internal-revenue2024-03-12T14:38:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/david-a-thompson/2024-02-27T22:34:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-eliana-garces-discusses-bookings-blocked-acquisition-of-etraveli-in-aba-podcast/2023-12-19T16:45:38+00:00weekly0.7https://www.analysisgroup.com/careers/why-analysis-group/why-ag/2024-01-23T21:47:03+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-congratulates-authors-of-four-articles-distinguished-with-nominations-for-2024-concurrences-antitrust-writing-awards/2024-01-12T14:03:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/digital-tools-offering-channels-for-success-facilitating-a-small--and-medium-sized-business-renaissance/2024-02-07T16:36:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/small--and-medium-sized-businesses-can-drive-growth-through-use-of-third-party-facilitators-according-to-report-by-analysis-group-experts/2024-02-07T16:34:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-practical-guide-to-using-the-as-efficient-competitor-aec-test-to-manage-and-monitor-antitrust-risk/2023-12-20T21:11:51+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/antitrust-report-article-authored-by-analysis-group-vice-presidents-discusses-the-as-efficient-competitor-aec-test-explores-antitrust-risk-implications-for-us-courts-and-firms/2023-12-20T21:09:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-mergers-and-regulatory-uncertainty2/2023-12-21T20:46:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/article-by-analysis-group-consultants-in-aba-publication-evaluates-merger-review-under-the-biden-administration/2023-12-21T20:46:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/anastasia-bogdanova/2023-12-22T17:42:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/cheryl-xiang/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/shannon-e.-ward2023-12-22T19:24:44+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/matt-infante/2024-01-31T15:38:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/san-jose-neurospine-v.-blue-shield-of-california2024-01-11T10:36:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/california-spine-neurosurgery-institute-v-blue-shield-of-california/2024-01-11T10:36:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-the-debate-about-multi-sided-platform-regulation-is-shaping-merger-enforcement/2024-01-11T10:36:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-gcrs-digital-markets-guide-analysis-group-authors-contribute-chapter-on-merger-enforcement-in-the-context-of-multi-sided-platforms/2024-01-02T14:55:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/german-antitrust-community-debates-how-to-most-effectively-consider-economic-expert-reports-in-follow-on-cartel-damage-proceedings/2024-02-08T10:12:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-vice-president-philipp-tillmann-publishes-aba-article-summarizing-debate-over-the-role-of-economic-expert-reports-in-german-antitrust-proceedings/2024-01-02T16:42:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incorporating-uncertainty-in-trademark-surveys-do-respondents-really-know-what-they-are-talking-about/2024-01-11T10:36:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/academic-affiliate-joel-steckel-coauthors-trademark-reporter-article-on-addressing-uncertainty-in-survey-responses/2024-01-04T18:15:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measuring-the-impact-of-wind-power-and-intermittency/2024-01-11T10:36:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/article-coauthored-by-analysis-group-manager-explores-benefits-and-costs-of-wind-production-in-spanish-electricity-market/2024-01-05T16:04:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-anne-catherine-faye-to-join-panel-at-nysba-antitrust-law-section-annual-meeting/2024-01-08T16:52:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-vice-president-elyse-swallow-elected-to-the-board-of-ispor-boston/2024-01-09T14:57:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/schuyler-m.-livingston2024-03-01T14:52:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/capacity-market-alternatives-for-a-decarbonized-grid-prompt-and-seasonal-markets/2024-01-17T14:26:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-study-evaluates-potential-impacts-of-capacity-market-design-changes-for-evolving-energy-grid-in-new-england-region/2024-01-17T14:28:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-curious-case-of-aspartame-how-the-same-evidence-can-yield-seemingly-different-conclusions/2024-01-17T15:49:04+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-analyze-conflicting-conclusions-on-aspartame-safety-in-fdli-article/2024-01-17T15:59:13+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/wei-jiang/2024-01-17T22:36:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-named-among-most-highly-regarded-thought-leaders-recommended-experts-and-economists-by-whos-who-legal/2024-01-31T21:41:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-and-chief-epidemiologist-dr.-mei-sheng-duh-to-join-panel-at-precision-medicine-world-conference-20242024-01-22T17:36:04+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-anne-catherine-faye-to-speak-at-aba-antitrust-law-sections-2024-next-generation-of-antitrust-data-privacy-and-data-protection-scholars-conference/2024-01-23T14:00:43+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/taiji-wang/2024-01-23T21:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electric-utilities-and-the-iraiija-ensuring-maximum-benefits-for-consumers-from-new-federal-funding-opportunities/2024-01-24T15:38:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-publishes-report-examining-how-vertically-integrated-utilities-could-maximize-return-on-federal-funding-opportunities/2024-01-24T15:40:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/oakland-bulk--oversized-terminal-llc-v.-city-of-oakland2024-01-31T15:34:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/judge-confirms-analysis-group-vice-president-jonathan-borcks-damages-assessment-in-oakland-bulk-oversized-terminal-llc-v-city-of-oakland/2024-01-31T15:38:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/aozhou-wu/2024-01-31T16:36:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/research-by-analysis-group-on-classifying-melanoma-stage-in-a-medicare-population-earns-highest-honor-from-amcp-2024/2024-02-01T18:51:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-data-the-new-oil-non-price-effects-of-mergers-in-data-intensive-industries/2024-02-12T21:09:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/non-price-effects-of-mergers-scrutinized-by-analysis-group-consultants/2024-02-12T21:08:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/ashish-k-jha/2024-02-02T14:55:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-kristof-zetenyi-to-join-nycba-merger-guidelines-webinar/2024-02-02T17:42:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-anne-catherine-faye-to-co-chair-2024-sustainability-and-competition-law-conference/2024-02-05T17:27:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/gcr-antitrust-awards-2024-analysis-group-case-work-and-academic-affiliate-anupam-jena-nominated-for-multiple-competition-awards/2024-02-06T18:00:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-philipp-tillmann-to-moderate-aba-webinar-on-private-enforcement-and-collective-redress-in-europe/2024-02-07T21:00:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/avatrombopag-treatment-response-in-patients-with-immune-thrombocytopenia-the-real-ava-1.0-study2024-02-07T19:01:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/continuity-of-care-among-patients-newly-initiated-on-second-generation-oral-or-long-acting-injectable-antipsychotics-during-a-schizophrenia-related-inpatient-stay/2024-02-16T15:58:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-benralizumab-on-asthma-exacerbation-related-medical-healthcare-resource-utilization-and-medical-costs-results-from-the-zephyr-2-study/2024-02-16T15:59:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pilot-corporation-v-greg-abel-et-al/2024-02-29T20:54:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-affiliate-opines-on-pushdown-accounting-in-support-of-prevailing-plaintiff-in-contract-dispute-in-transportation-industry/2024-02-29T20:55:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/time-to-next-treatment-in-patients-with-chronic-lymphocytic-leukemia-initiating-first-line-ibrutinib-or-acalabrutinib/2024-02-16T16:00:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/persistence-among-patients-with-crohn-disease-previously-treated-with-an-anti-tumor-necrosis-factor-inhibitor-and-switching-or-cycling-to-another-biologic-agent/2024-02-16T16:15:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-provides-recommendations-for-achieving-net-zero-emissions-in-electrify-this-podcast/2024-02-09T15:11:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-biotech-deals-may-help-competition-despite-ftc-view/2024-02-12T19:43:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-apply-a-scientific-and-drug-development-lens-to-evaluating-killer-acquisition-theories-of-harm-in-biotech-deals/2024-02-12T20:04:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-dr.-mei-sheng-duh-invited-to-speak-at-colloquium-seminar-series-at-harvard-t.h.-chan-school-of-public-health2024-02-14T18:29:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-eliana-garces-to-join-biicl-roundtable-on-article-102-of-the-treaty-on-the-functioning-of-the-european-union-tfeu/2024-02-15T15:26:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-lynn-huynh-to-moderate-clinical-trial-panel-at-2024-mit-sloan-healthcare-and-bioinnovations-conference/2024-02-20T16:47:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/chronic-corticosteroid-use-is-associated-with-substantial-clinical-and-economic-burden-in-patients-with-crohns-disease-initiated-on-biologic-or-conventional-therapies-in-the-us-a-retrospective-study/2024-03-08T14:43:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mortality-among-us-veterans-with-a-physician-documented-diagnosis-of-pyruvate-kinase-deficiency/2024-03-15T19:25:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-modeling-of-prostate-specific-membrane-antigen-positron-emission-tomography-with-piflufolastat-f-18-for-the-initial-diagnosis-of-patients-with-prostate-cancer-in-the-united-states/2024-03-15T19:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-burden-and-predictors-associated-with-non-response-to-antihistamine-based-therapy-in-chronic-spontaneous-urticaria/2024-03-15T19:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-factors-associated-with-newly-diagnosed-attention-deficithyperactivity-disorder-in-adults-a-retrospective-case-control-study/2024-03-15T21:24:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-and-physician-preferences-for-acute-myeloid-leukemia-maintenance-treatments-following-hematopoietic-stem-cell-transplantation/2024-03-15T21:25:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-outcomes-on-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-hif-phis-in-anaemia-associated-with-chronic-kidney-disease-network-meta-analyses-in-dialysis-and-non-dialysis-dependent-populations/2024-03-15T21:26:49+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/next-law--economics-symposium-to-convene-on-tools-for-assessing-risk-and-value-in-pharmaceutical-and-biotech-investment/2024-02-20T20:12:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-judy-chang-to-join-panel-at-energy-bar-associations-2024-western-chapter-annual-meeting/2024-02-21T14:34:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/systematic-review-and-network-meta-analysis-comparing-the-efficacy-of-fezolinetant-with-hormone-and-nonhormone-therapies-for-treatment-of-vasomotor-symptoms-due-to-menopause/2024-03-15T21:27:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-costs-among-patients-with-hematologic-malignancies-receiving-allogeneic-transplants-a-us-payer-perspective/2024-03-15T21:28:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/manager-kale-kponee-shovein-to-join-panel-on-addressing-the-double-disease-burden-in-africa-at-harvard-chan-2024-africa-health-conference/2024-02-22T18:43:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-clinical-management-of-individuals-with-rett-syndrome-a-physician-survey/2024-03-15T21:29:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/gastrointestinal-manifestations-in-pediatric-and-adult-patients-with-rett-syndrome-an-analysis-of-us-claims-and-physician-survey-data/2024-03-15T21:30:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-venetoclax-based-combination-therapies-and-other-therapies-in-treatment-naive-patients-with-acute-myeloid-leukemia-ineligible-for-intensive-chemotherapy-a-network-meta-analysis/2024-03-15T21:34:34+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/denis-boyle/2024-02-22T19:09:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-judy-chang-to-join-panel-at-ippsa-30th-annual-conference/2024-02-23T14:54:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/biotech-asset-valuation-methods-a-practitioners-guide/2024-02-23T17:35:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/guide-to-biotech-asset-valuation-methods-coauthored-by-academic-affiliate-amitabh-chandra-and-vice-president-sumon-mazumdar/2024-02-23T17:36:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-of-otx-101-ophthalmic-solution-cyclosporine-ophthalmic-emulsion-and-lifitegrast-ophthalmic-solution-in-patients-with-dry-eye-disease-a-retrospective-analysis/2024-03-15T21:35:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/studies-by-analysis-group-consultants-among-2023s-most-cited-articles-of-the-journal-of-managed-care-specialty-pharmacy/2024-03-05T21:16:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dillon-trust-company-et-al-v-united-states-of-america/2024-02-27T14:32:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-expert-testimony-supports-doj-win-in-tax-shelter-case/2024-02-27T14:35:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-yao-lu-to-chair-session-at-the-21st-annual-international-industrial-organization-conference/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-recognized-by-global-competition-reviews-2023-awards-for-economic-analysis-in-antitrust-litigation/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/sean-mccoy/2024-02-02T14:42:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-abstract-to-be-featured-as-a-lecture-presentation-at-digestive-disease-week/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/phillip-h-ross/2024-01-17T14:28:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/american-academy-of-arts-and-sciences-elects-academic-affiliate-amitabh-chandra/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pharmacyclics-llc-et-al-v-fresenius-kabi-usa-llc-et-al/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-juliette-caminade-testifies-on-competitive-impacts-of-scope-of-work-restrictions-applied-by-licensing-boards/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-and-chief-epidemiologist-dr-mei-sheng-duh-to-join-panel-at-the-annual-milken-institute-global-conference/2024-01-11T10:43:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-apomorphine-sublingual-film-as-an-on-demand-treatment-for-off-episodes-in-patients-with-parkinsons-disease/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-outcomes-in-patients-with-myelodysplastic-syndromes-treated-with-hypomethylating-agents-a-seer-medicare-analysis/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/time-to-first-exacerbation-adherence-and-medical-costs-among-us-patients-receiving-umeclidiniumvilanterol-or-tiotropium-as-initial-maintenance-therapy-for-chronic-obstructive-pulmonary-disease/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overall-survival-in-the-real-world-and-clinical-trials-a-case-study-validating-external-controls-in-advanced-melanoma/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/svb-collapse-reinvigorates-bank-accounting-debate/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-examine-accounting-guidelines-following-the-collapse-of-silicon-valley-bank/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-w-larue/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/jenny-shen/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-recurrence-in-triple-negative-breast-cancer-among-working-age-patients-in-the-united-states/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-overall-survival-of-patients-with-metastatic-castration-resistant-prostate-cancer-in-the-us-prior-to-parp-inhibitors2/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/beyond-frontline-therapy-with-abiraterone-and-enzalutamide-in-metastatic-castration-resistant-prostate-cancer-a-real-world-us-study/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/compliance-with-cannabis-act-regulations-regarding-online-promotion-among-canadian-commercial-cannabis-licensed-firms/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-rene-befurt-to-moderate-webinar-on-litigation-around-dark-patterns-in-consent-and-cancellation-processes/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-affiliates-to-join-aba-panel-on-the-role-of-marketing-experts-in-litigation-moderated-by-manager-kate-schofield-and-organized-by-vice-president-anne-catherine-faye/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/2023-asco-annual-meeting-to-feature-new-outcomes-research-from-analysis-group/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-maria-garibotti-to-join-aba-panel-on-two-sided-platforms/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-eliana-garces-to-join-panel-at-concurrences-digital-antitrust-conference/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-mourns-the-passing-of-vice-president-anne-larue/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/parody-and-tarnishment-how-empirical-methods-can-aid-triers-of-fact/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/scotus-review-provides-analysis-group-authors-opportunity-to-examine-survey-methods-for-assessing-trademark-dilution-in-parody-cases/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-join-panel-on-cartel-enforcement-in-labor-markets-at-gcr-live-cartels-2023/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/michael-bender/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-ishita-rajani-to-join-aba-webinar-on-information-sharing-in-the-current-antitrust-landscape/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/global-issues-in-eus-licensing-plans-for-essential-patents/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/patent-experts-from-analysis-group-examine-proposed-competence-center-for-standard-essential-patents-seps-in-europe/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-thromboembolic-events-and-associated-healthcare-costs-in-patients-with-inflammatory-bowel-disease/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-thromboembolic-events-and-associated-risk-factors-including-treatments-in-patients-with-immune-mediated-diseases/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-thromboembolic-events-among-patients-with-immune-mediated-diseases/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-tisagenlecleucel-and-lisocabtagene-maraleucel-among-adults-with-relapsedrefractory-large-b-cell-lymphomas-an-indirect-treatment-comparison/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-post-traumatic-stress-disorder-in-the-united-states-a-systematic-literature-review/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-attention-deficithyperactivity-disorder-among-adults-in-the-united-states-a-societal-perspective/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-the-covid-19-pandemic-on-adolescent-vaccinations-projected-time-to-reverse-deficits-in-routine-adolescent-vaccination-in-the-united-states/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficiencies-in-the-second-score-auction-model/2024-01-26T17:40:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authored-article-presents-key-considerations-for-merger-review-in-second-score-auctions/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/management-of-patients-with-metastatic-castration-sensitive-prostate-cancer-in-the-real-world-setting-in-the-united-states/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparison-of-isatuximab-plus-carfilzomib-and-dexamethasone-with-daratumumab-plus-lenalidomide-and-dexamethasone-in-relapsed-multiple-myeloma/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consequences-of-insurance-denials-among-u-s-patients-prescribed-repository-corticotropin-injection-acthar-gel-for-nephrotic-syndrome/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-to-speak-at-concurrences-new-frontiers-of-antitrust-conference/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-savings-of-expedited-care-with-upfront-next-generation-sequencing-testing-versus-single-gene-testing-among-patients-with-metastatic-non-small-cell-lung-cancer-based-on-current-canadian-practices/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-collaborates-with-william-osler-health-system-and-janssen-to-estimate-cost-savings-to-the-canadian-health-care-system-of-using-NGS-testing-in-mNSCLC/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-tisagenlecleucel-for-the-treatment-of-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-the-united-states/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-matching-adjusted-indirect-comparison-of-single-arm-trials-in-patients-with-relapsed-or-refractory-follicular-lymphoma-who-received-at-least-two-prior-systemic-treatments/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-analysis-of-adherence-to-hiv-treatment-and-healthcare-utilization-in-a-commercially-insured-population/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-in-medicaid-beneficiaries-with-recently-relapsed-schizophrenia-or-with-uncontrolled-symptoms-of-schizophrenia-not-adherent-to-antipsychotics/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-incidence-and-economic-burden-of-schizophrenia-among-medicaid-beneficiaries/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/honghao-fang/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant-single-agent-pembrolizumab-for-high-risk-early-stage-triple-negative-breast-cancer-in-the-united-states/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/conceptual-framework-and-methodological-challenges-for-modeling-effectiveness-in-oncology-treatment-sequence-models/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-provides-support-in-settlement-reached-with-the-massachusetts-department-of-housing-and-community-department-on-behalf-of-homeless-families/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-pro-bono-team-provides-support-in-settlement-reached-on-behalf-of-homeless-families/2023-09-01T17:43:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-assesses-survey-data-for-report-on-smoking-and-vaping-in-quebec/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/quebec-coalition-for-tobacco-control-data-visualization-of-smoking-and-vaping/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/chelsey-yang/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/concurrences-special-issue-on-no-poach-agreements-features-analysis-group-article-recapping-ftc-panels-on-labor-markets/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-industry-norms-for-security-research-in-a-copyright-infringement-lawsuit/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/class-issues-involving-the-collection-of-biometric-data/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/irish-data-protection-commissions-investigation-of-meta/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-investigation-of-a-financial-services-corporations-regulatory-cybersecurity-practices/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-joshua-white-to-join-a-panel-at-concurrences-fourth-international-mergers-conference/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dynamics-of-improvement-in-health-related-quality-of-life-hrqol-with-long-term-eltrombopag-treatment-in-adults-with-chronic-immune-thrombocytopenia-itp-in-extend/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/multicenter-compact-study-of-complications-in-patients-with-sickle-cell-disease-and-utilization-of-iron-chelation-therapy/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-ten-northeast-and-mid-atlantic-states2/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/rggi-continues-to-deliver-economic-benefits-for-participating-statesand-can-advance-key-equity-priorities-in-ej-communities/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/rggi-program-continues-to-deliver-economic-benefits-for-northeast-and-mid-atlantic-states-while-advancing-environmental-justice-priorities-according-to-latest-analysis-group-study/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/webinar-recap-self-preferencing-is-tech-different-than-brick-and-mortar/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-webinar-exploring-antitrust-concerns-with-digital-self-preferencing-behaviors-summarized-by-analysis-groups-juliette-caminade-and-juan-carvajal/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/primary-hyperoxaluria-type-1-disease-manifestations-and-healthcare-utilization-a-multi-country-online-chart-review-study/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-tisagenlecleucel-for-the-treatment-of-pediatric-and-young-adult-patients-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia-in-japan/2024-03-05T21:18:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-tisagenlecleucel-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-japan/2024-01-11T10:43:46+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/r-harold-schroeder/2024-01-11T10:43:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/report-on-the-implications-of-ubers-paying-the-national-living-wage-on-p1-time/2024-01-11T10:43:46+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/samuel-spare/2024-02-08T17:37:44+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/nathan-shekita/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/arielle-bensimon/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-eliana-garces-to-join-panel-on-digital-markets-and-digital-services-acts/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/michal-k-popiel/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/christopher-m-lako/2024-01-11T10:43:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-samuel-weglein-to-join-aba-webinar-on-app-distribution-and-related-antitrust-considerations/2024-01-11T10:43:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v-philip-r-jacoby-jr-et-al/2024-01-11T10:43:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/supported-by-analysis-group-accounting-expert-sec-obtains-consent-orders-in-securities-fraud-suit-against-osiris-therapeutics/2024-01-11T10:43:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-heor-consultants-to-present-at-ispor-2023/2024-01-11T10:43:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-heor-consultants-to-present-at-ispor-2023/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/devin-reilly/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/dominick-latremouille-viau/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recent-cases-on-green-messaging-in-food-and-beverage-company-advertising/2024-01-30T18:04:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/for-2023-edition-of-top-food-and-drug-cases-analysis-group-authors-explore-greenwashing-class-action-claims-against-food-and-beverage-companies/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-use-short-term-disability-days-and-costs-associated-with-states-of-persistence-on-antidepressant-lines-of-therapy/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/opioid-induced-constipation-cost-impact-of-approved-medications-in-the-emergency-department/2024-03-14T19:20:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/jessica-resch/2024-01-19T15:53:38+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/ayako-yasuda/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-minimization-analysis-comparing-eltrombopag-vs-romiplostim-for-adults-with-chronic-immune-thrombocytopenia/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/trifluridinetipiracil-and-regorafenib-in-patients-with-metastatic-colorectal-cancer-a-retrospective-study-at-a-tertiary-oncology-center/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/-deterioration-of-health-related-quality-of-life-after-withdrawal-of-risankizumab-treatment-in-patients-with-moderate-to-severe-plaque-psoriasis-a-machine-learning-predictive-model/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/cecilia-caliandro/2024-01-11T10:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-gilteritinib-for-relapsedrefractory-flt3mut-acute-myeloid-leukemia/2024-01-11T10:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patterns-of-daily-motor-symptom-control-with-carbidopalevodopa-enteral-suspension-versus-oral-carbidopalevodopa-therapy-in-advanced-parkinsons-disease-clinical-trial-post-hoc-analyses/2024-01-11T10:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-changes-healthcare-resource-utilization-and-costs-among-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-a-claims-database-study/2024-01-11T10:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/value-of-remission-in-patients-with-rheumatoid-arthritis-a-targeted-review/2024-01-31T16:34:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/all-cause-health-care-resource-utilization-and-costs-among-adults-with-alopecia-areata-a-retrospective-claims-database-study-in-the-united-states/2024-01-11T10:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mental-health-and-health-related-quality-of-life-among-nephrology-nurses-a-survey-based-cross-sectional-study/2024-03-14T18:59:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-and-care-partner-burden-in-ckd-patients-with-and-without-anemia-a-us-based-survey/2024-01-11T10:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-associated-with-peanut-allergy-management-under-allergen-avoidance-among-commercially-insured-individuals/2024-01-11T10:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparison-of-tisagenlecleucel-and-historical-treatments-for-relapsedrefractory-diffuse-large-b-cell-lymphoma/2024-01-11T10:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-healthcare-resource-utilization-and-costs-associated-with-tisagenlecleucel-and-axicabtagene-ciloleucel-among-patients-with-diffuse-large-b-cell-lymphoma-an-analysis-of-hospital-data-in-the-united-states/2024-01-11T10:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/steroid-switching-in-dystrophinopathy-treatment-a-us-chart-review-of-patient-characteristics-and-clinical-outcomes/2024-01-11T10:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-and-validation-of-a-healthcare-utilization-based-algorithm-to-identify-acute-exacerbations-of-chronic-obstructive-pulmonary-disease/2024-03-01T21:45:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/benefit-of-prompt-versus-delayed-use-of-single-inhaler-fluticasone-furoateumeclidiniumvilanterol-ffumecvi-following-a-copd-exacerbation/2024-01-11T10:43:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/markets-competition-and-fairness/2024-01-11T10:43:04+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-eliana-garces-coauthors-white-paper-exploring-evolution-of-fairness-principle-in-us-and-eu-competition-regulation/2024-01-11T10:43:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-us-pericarditis-prevalence-using-national-health-encounter-surveillance-databases/2024-02-29T21:33:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-prostate-specific-antigen-response-and-treatment-adherence-of-apalutamide-in-patients-with-non-metastatic-castration-resistant-prostate-cancer/2024-01-11T10:43:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-switching-to-infliximab-biosimilars-on-treatment-patterns-among-us-veterans-receiving-innovator-infliximab/2024-03-01T21:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-tenosynovial-giant-cell-tumors-among-employed-workforce-in-the-united-states/2024-01-11T10:43:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-evidence-of-the-clinical-and-economic-impact-of-long-acting-injectable-versus-oral-antipsychotics-among-patients-with-schizophrenia-in-the-united-states-a-systematic-review-and-meta-analysis/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-and-economic-burden-associated-with-recurrent-pericarditis-in-a-privately-insured-united-states-population/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-central-nervous-system-complications-in-sickle-cell-disease-a-systematic-review-and-meta-analysis/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-risankizumab-on-pasi90-and-dlqi01-duration-in-moderate-to-severe-psoriasis-a-post-hoc-analysis-of-four-phase-3-clinical-trials/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-pasi-response-on-work-productivity-and-the-effect-of-risankizumab-on-indirect-costs-using-machine-learning-in-patients-with-moderate-to-severe-psoriasis/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-rivaroxaban-and-warfarin-among-nonvalvular-atrial-fibrillation-patients-with-obesity-and-polypharmacy/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/literature-review-of-fatigue-scales-and-association-with-clinically-meaningful-improvements-in-outcomes-among-patients-with-and-without-paroxysmal-nocturnal-hemoglobinuria/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/carbon-footprint-and-associated-costs-of-asthma-exacerbation-care-among-uk-adults/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-nephrolithiasis-and-nephrocalcinosis-in-patients-with-chronic-hypoparathyroidism-a-retrospective-cohort-study/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-marianne-cunnington-elected-to-ispe-board/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/gregory-d-weiss/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospitalizations-and-healthcare-costs-associated-with-rifaximin-versus-lactulose-treatment-among-commercially-insured-patients-with-hepatic-encephalopathy-in-the-united-states/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparison-of-tisagenlecleucel-and-blinatumomab-in-pediatric-relapsedrefractory-acute-lymphoblastic-leukemia/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/total-cost-of-testing-for-genomic-alterations-associated-with-next-generation-sequencing-versus-polymerase-chain-reaction-testing-strategies-among-patients-with-metastatic-non-small-cell-lung-cancer/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparison-of-apomorphine-sublingual-film-and-levodopa-inhalation-powder-for-parkinsons-disease-off-episodes/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/our-partners/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-and-validation-of-a-claims-based-model-to-identify-patients-at-risk-of-chronic-thromboembolic-pulmonary-hypertension-following-acute-pulmonary-embolism/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/daratumumab-improves-depth-of-response-and-progression-free-survival-in-transplant-ineligible-high-risk-newly-diagnosed-multiple-myeloma/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burden-of-obstructive-hypertrophic-cardiomyopathy-in-the-united-states/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-acute-otitis-media-in-children-in-the-united-states-before-and-after-the-introduction-of-7-and-13-valent-pneumococcal-conjugate-vaccines-during-1998-2018/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-transition-from-intravenous-to-subcutaneous-delivery-of-rituximab-benefits-for-payers-health-care-professionals-and-patients-with-lymphoma/2024-01-11T10:43:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-announces-senior-level-promotions-and-lateral-hires/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-costs-among-patients-with-macular-oedema-associated-with-non-infectious-uveitis-a-us-commercial-payers-perspective/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-announces-senior-level-promotions-and-lateral-hires/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/continuing-trends-in-u-s-brand-name-and-generic-drug-competition/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-chronic-kidney-disease-and-estimated-glomerular-filtration-rate-decline-in-patients-with-chronic-hypoparathyroidism-a-retrospective-cohort-study/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-cardiovascular-conditions-in-patients-with-chronic-hypoparathyroidism-a-retrospective-cohort-study/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-drivers-of-urban-economic-complexity-and-their-connection-to-economic-performance/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-among-patients-with-mantle-cell-lymphoma-and-comparison-of-healthcare-resource-utilization-and-costs-among-relapsedrefractory-patients/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/increased-health-care-resource-utilization-and-costs-associated-with-herpes-zoster-among-patients-aged-50-years-with-chronic-obstructive-pulmonary-disease-in-the-united-states/2024-01-11T10:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-and-safety-of-rivaroxaban-versus-warfarin-among-non-valvular-atrial-fibrillation-patients-with-obesity-in-a-us-population/2024-01-11T10:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-of-rivaroxaban-versus-warfarin-among-non-valvular-atrial-fibrillation-nvaf-patients-with-obesity-in-a-us-population/2024-01-11T10:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/deceptive-conduct-litigation-related-to-consumer-data/2024-01-11T10:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-political-ad-disclosure-litigation/2024-01-11T10:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/software-license-agreement-litigation/2024-01-11T10:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-healthcare-resource-utilization-and-costs-of-patients-with-hrher2-advanced-breast-cancer-treated-with-ribociclib-versus-other-cdk46-inhibitors/2024-01-11T10:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/defining-utility-values-for-patients-with-tardive-dyskinesia/2024-01-11T10:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-burden-and-treatment-adherence-among-children-and-adolescent-patients-with-asthma/2024-01-11T10:43:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-joshua-white-outlines-critical-considerations-for-pharmaceutical-industry-mergers-at-concurrences-event/2024-01-11T10:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-effectiveness-of-patients-with-multiple-myeloma-initiating-daratumumab-across-different-lines-of-therapy-a-real-world-chart-review-study/2024-01-11T10:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-benefit-risk-profiles-of-treatments-for-moderate-to-severe-plaque-psoriasis-a-network-meta-analysis/2024-01-11T10:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hcv-reinfection-rates-after-cure-or-spontaneous-clearance-among-hiv-infected-and-uninfected-men-who-have-sex-with-men/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-metreleptin-in-patients-with-lipodystrophy-with-and-without-baseline-concomitant-medication-use/2024-02-07T16:46:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/roche-holding-ag-et-al-v-french-competition-authority/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/senior-advisors/tim-giles/2024-01-19T15:53:36+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/maja-glowka/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/daniel-m-fitzpatrick/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/serene-e-warren-v-acova-inc-et-al/2024-01-23T19:42:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/minnesota-state-court-cites-expert-report-and-testimony-of-analysis-group-expert-in-fiduciary-duty-litigation/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/yi-zhong/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-modifications-of-renin-angiotensin-aldosterone-system-inhibitors-in-patients-with-hyperkalemia-initiating-sodium-zirconium-cyclosilicate-therapy-the-optimize-i-study/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ischemic-stroke-and-systemic-embolism-among-one-and-done-direct-oral-anticoagulant-users-with-non-valvular-atrial-fibrillation/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/venous-thromboembolism-recurrence-among-one-and-done-direct-oral-anticoagulant-users-a-retrospective-longitudinal-study/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-study-to-examine-prognostic-value-of-c-reactive-protein-in-patients-with-surgically-resectable-non-small-cell-lung-cancer/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-5-year-retrospective-observational-study-assessing-rheumatoid-arthritis-disease-outcome-measures-to-characterize-systemic-lupus-erythematosus-burden-in-the-usa/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/elucidating-the-real-world-burden-of-chronic-rhinosinusitis-with-nasal-polyps-in-patients-in-the-usa/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/profiling-disease-and-economic-burden-in-crswnp-using-machine-learning/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-progression-and-longitudinal-clinical-outcomes-of-lewy-body-dementia-in-the-nacc-database/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/on-the-double-robustness-and-semiparametric-efficiency-of-matching-adjusted-indirect-comparisons/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-clinical-outcomes-in-patients-with-schizophrenia-following-different-long-acting-injectable-event-driven-initiation-strategies/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/second-annual-blackag-summit-hosted-by-analysis-group/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/respiratory-syncytial-virus-related-complications-and-healthcare-costs-among-a-medicare-insured-population-in-the-united-states/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/network-meta-analysis-of-efficacy-of-ixazomib-lenalidomide-and-dexamethasone-in-relapsedrefractory-multiple-myeloma/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burden-in-patients-with-systemic-lupus-erythematosus-during-the-first-year-after-initiating-oral-corticosteroids-a-retrospective-us-database-study/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-resource-utilization-and-treatment-over-the-disease-course-of-symptomatic-obstructive-hypertrophic-cardiomyopathy-in-the-united-states/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-upper-endoscopy-utilization-patterns-among-patients-with-gastroesophageal-reflux-disease-barrett-esophagus-and-barrett-esophagus-related-esophageal-neoplasia-in-the-united-states/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-economists-again-recognized-as-top-intellectual-property-experts2/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-economists-again-recognized-as-top-intellectual-property-experts/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-weight-changes-in-people-with-hiv-1-at-risk-of-weight-gain-female-black-or-hispanic-switching-from-integrase-strand-transfer-inhibitors/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/same-day-testing-with-initiation-of-antiretroviral-therapy-or-tuberculosis-treatment-versus-standard-care-for-persons-presenting-with-tuberculosis-symptoms-at-hiv-diagnosis-a-randomized-open-label-trial-from-haiti/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-by-patients-with-alagille-syndrome/2024-01-11T10:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-racial-variation-in-treatment-and-outcomes-among-patients-with-peripheral-artery-disease/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-hyperphagia-and-obesity-in-bardet-biedl-syndrome-a-multicountry-survey/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/caregiver-burden-in-bardet-biedl-syndrome-findings-from-the-care-bbs-study/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-characteristics-associated-with-all-cause-healthcare-costs-of-alopecia-areata-in-the-united-states/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-cost-benefits-of-anti-obesity-medication-for-us-veterans-participating-in-the-move-weight-management-program/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/christopher-m-worsham/2024-01-17T15:59:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-treatment-patterns-and-clinical-outcomes-of-chronic-hepatitis-b-across-3-continents-retrospective-database-study/2024-02-29T21:34:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-of-calcium-and-phosphate-levels-with-incident-chronic-kidney-disease-in-patients-with-hypoparathyroidism-a-retrospective-case-control-study/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-free-survival-as-a-predictor-of-overall-survival-in-localized-renal-cell-carcinoma-following-initial-nephrectomy-a-retrospective-analysis-of-surveillance-epidemiology-and-end-results-medicare-data/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparison-of-darolutamide-versus-apalutamide-and-enzalutamide-for-nonmetastatic-castration-resistant-prostate-cancer2/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-associated-with-vonoprazan-based-versus-proton-pump-inhibitor-based-therapy-for-helicobacter-pylori-infection-in-japan/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-non-invasive-all-cause-pneumonia-in-children-in-the-united-states-before-and-after-the-introduction-of-pneumococcal-conjugate-vaccines-a-retrospective-claims-database-analysis/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-acute-otitis-media-pneumonia-and-invasive-pneumococcal-disease-in-children-in-the-united-states-after-the-introduction-of-13-valent-pneumococcal-conjugate-vaccines-during-2014-2018/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prolonged-oral-corticosteroid-treatment-in-patients-with-systemic-lupus-erythematosus-an-evaluation-of-12-month-economic-and-clinical-burden/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/surgical-treatment-patterns-healthcare-resource-utilization-and-economic-burden-in-patients-with-tenosynovial-giant-cell-tumor-who-underwent-joint-surgery-in-the-united-states/2024-01-11T10:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-physician-preferences-for-biologics-in-moderate-to-severe-inflammatory-bowel-disease-retrospective-chart-review-in-europe/2024-01-11T10:43:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-study-estimates-economic-and-environmental-benefits-of-seabrook-nuclear-power-plant/2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-and-environmental-benefits-to-massachusetts-from-the-operation-of-the-seabrook-nuclear-plant/2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/energy-economists-at-analysis-group-release-independent-study-of-economic-and-environmental-benefits-of-seabrook-nuclear-power-plant/2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/darius-palia/2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-authors-win-2023-antitrust-writing-award-for-best-business-article-in-economics/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-win-2023-antitrust-writing-award-for-best-business-article-in-economics/2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/forum-2023/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-groups-eliana-garces-to-join-industry-roundtable-at-the-dynamic-competition-initiatives-first-annual-conference/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/pro-bono-team-helps-measure-impact-of-shannon-trusts-reading-programs-for-incarcerated-people/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-analysis-in-cma-cgm-shipping-matter/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-corsica-linea-pso-france-objet/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/reworld-mediaarnoldo-mondadori-editore-merger-approval/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/natural-resources-agricultural-economics/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/genetically-modified-rice-litigation/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/trends-in-prevalence-and-incidence-of-alopecia-areata-alopecia-totalis-and-alopecia-universalis-among-adults-and-children-in-a-us-employer-sponsored-insured-population/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-coauthors-study-assessing-prevalence-and-incidence-of-alopecia-in-us/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-acute-effects-of-azithromycin-use-on-cardiovascular-mortality-as-compared-with-amoxicillin-clavulanate-in-us-veterans/2024-03-01T21:43:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-combined-prospective-and-retrospective-comparison-of-long-term-functional-outcomes-suggests-delayed-loss-of-ambulation-and-pulmonary-decline-with-long-term-eteplirsen-treatment/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparison-of-the-efficacy-of-loncastuximab-tesirine-versus-treatment-in-the-chemoimmunotherapy-era-for-relapsedrefractory-diffuse-large-b-cell-lymphoma/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-and-economic-burden-of-respiratory-syncytial-virus-among-adults-in-the-united-states-a-retrospective-analysis-using-2-insurance-claims-databases/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-after-initiating-fremanezumab-treatment-in-us-patients-with-episodic-and-chronic-migraine-or-difficult-to-treat-migraine/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-clinical-pathways-on-treatment-patterns-and-outcomes-for-patients-with-non-small-cell-lung-cancer-real-world-evidence-from-a-community-oncology-practice/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-antipsychotic-dose-reduction-on-clinical-outcomes-and-health-care-resource-use-among-medicare-patients-with-schizophrenia/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-associated-with-nasal-polyposis-recurrence-among-commercially-insured-patients-in-the-united-states/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-pre-existing-conditions-relevant-for-adverse-events-and-potential-drug-drug-interactions-associated-with-augmentation-therapies-among-patients-with-treatment-resistant-depression/2024-01-11T10:43:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/gilteritinib-vs-salvage-chemotherapy-in-flt3-mutated-acute-myeloid-leukemia-number-needed-to-treat-for-clinical-outcomes-per-a-secondary-analysis-of-the-admiral-trial/2024-01-11T10:43:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-among-patients-with-metastatic-pancreatic-ductal-adenocarcinoma-treated-with-liposomal-irinotecan/2024-03-01T21:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/difficulty-of-detecting-ai-content-poses-legal-challenges/2024-01-11T10:43:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/challenges-of-detecting-chatgpt-4-discussed-in-law360-article-by-analysis-group-ai-experts/2024-01-11T10:43:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-healthcare-resource-utilization-and-costs-of-patients-diagnosed-with-primary-mediastinal-b-cell-lymphoma-in-the-united-states/2024-01-11T10:43:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-and-treatment-patterns-of-relapsedrefractory-diffuse-large-b-cell-lymphoma-in-patients-receiving-3-therapy-lines-in-post-car-t-era/2024-01-31T16:35:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/luxi-wang/2024-01-11T10:43:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-yellowstone-capital-llc-et-al/2024-01-11T10:43:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-affiliate-consults-to-new-jersey-in-successful-settlement-of-consumer-fraud-case/2024-01-11T10:43:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-trade-commission-v.-meta-platforms-inc.-et-al2024-01-30T17:56:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-successful-defense-of-challenged-meta-within-unlimited-merger/2024-01-11T10:43:39+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/private-equity-venture-capital/2024-01-11T10:43:39+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/alix-duhaime-ross/2024-01-11T10:43:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-health-related-quality-of-life-in-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-eq-5d-based-utilities-in-the-explorer-hcm-trial/2024-01-11T10:43:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/town-of-apple-valley-v.-apple-valley-ranchos-water-corp2024-01-11T10:43:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jeffrey-kinrich-to-join-panel-at-2023-intellectual-property-institute/2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/value-drug-company-v.-takeda-pharmaceuticals-usa-inc.-et-al2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/pharmaceutical-manufacturers-win-multiple-class-certification-rulings-in-federal-antitrust-suit-with-support-from-analysis-group-senior-advisor-bruce-strombom/2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-treatment-sequences-for-chronic-lymphocytic-leukemia-in-the-united-states-a-cost-of-care-and-budget-impact-model-of-venetoclax-plus-obinutuzumab-sequences/2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-to-present-at-aba-antitrust-law-spring-meeting2/2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/carmine-rossi/2024-01-29T14:38:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/two-analysis-group-studies-named-editors-choice-by-the-journal-of-medical-economics-and-journal-of-clinical-pathways/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/webinar-recap-antitrust-questions-in-new-labor-markets/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-webinar-exploring-antitrust-issues-in-the-gig-economy-summarized-by-analysis-groups-nandita-krishnaswamy-and-juliette-thibaud/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/stacie-bosley/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/competitive-analysis-of-canadian-pacifickansas-city-southern-railway-merger/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/delays-in-pulmonary-decline-in-eteplirsen-treated-patients-with-duchenne-muscular-dystrophy/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-pembrolizumab-plus-chemotherapy-as-first-line-treatment-in-pd-l1-positive-metastatic-triple-negative-breast-cancer/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interdisciplinary-model-informed-drug-development-for-extending-duration-of-elagolix-treatment-in-patients-with-uterine-fibroids/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/temporal-trends-in-grade-34-adverse-events-and-associated-costs-of-nivolumab-plus-cabozantinib-versus-sunitinib-for-previously-untreated-advanced-renal-cell-carcinoma/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-venetoclax-in-combination-with-azacitidine-versus-azacitidine-monotherapy-in-patients-with-acute-myeloid-leukemia/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-illness-for-patients-with-cholangiocarcinoma-in-the-united-states-a-retrospective-claims-analysis/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-among-caregivers-of-pediatric-patients-with-neurofibromatosis-type-1-nf1-and-plexiform-neurofibroma-pn-in-the-united-states-a-cross-sectional-study/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-progression-stages-and-burden-in-patients-with-duchenne-muscular-dystrophy-using-administrative-claims-supplemented-by-electronic-medical-records/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comprehensive-genomic-profiling-in-advancedmetastatic-colorectal-cancer-number-needed-to-test-and-budget-impact-of-expanded-first-line-use/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/national-and-regional-description-of-healthcare-measures-among-adult-medicaid-beneficiaries-with-schizophrenia-within-the-united-states/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/contemporary-outpatient-management-of-patients-with-worsening-heart-failure-with-reduced-ejection-fraction-rationale-and-design-of-the-chart-hf-study/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-humanistic-burden-among-pediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibroma-in-the-usa/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-experience-of-a-severe-hypoglycaemic-event-from-the-perspective-of-people-with-diabetes-and-their-caregivers-what-am-i-going-to-do/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-and-understanding-combination-therapy-decision-drivers-for-the-treatment-of-overactive-bladder-in-the-united-states/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/excess-healthcare-resource-utilization-and-healthcare-costs-among-privately-and-publicly-insured-patients-with-major-depressive-disorder-and-acute-suicidal-ideation-or-behavior-in-the-united-states/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reasons-for-treatment-changes-in-adults-with-attention-deficithyperactivity-disorder-a-chart-review-study/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-posttraumatic-stress-disorder-in-the-united-states-from-a-societal-perspective/2024-03-14T18:59:52+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/kimberly-attia/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/bruno-emond/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-eliana-garces-to-join-digital-antitrust-enforcement-panel-at-gcr-live-telecoms-media--technology-2023/2024-01-11T10:42:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/endless-river-technologies-llc-v.-transunion-llc2024-01-11T10:42:53+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/district-court-awards-$0-in-damages-in-trade-secret-and-breach-of-contract-litigation-involving-analysis-group-client-transunion/2024-01-11T10:42:53+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/riccardo-marchingiglio/2024-01-11T10:42:53+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-to-sponsor-energy-bar-associations-western-chapter-annual-meeting/2024-01-11T10:42:53+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/erich-muehlegger/2024-01-11T10:42:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-societal-economic-value-of-covid-19-vaccines-in-the-united-states/2024-01-11T10:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-costs-among-adult-patients-with-hemophilia-a-on-factor-viii-prophylaxis-an-administrative-claims-analysis/2024-02-07T16:48:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-semaglutide-2.4-mg-for-the-treatment-of-adult-patients-with-overweight-and-obesity-in-the-united-states2024-03-05T21:18:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pik3ca-mutation-status-progression-and-survival-in-advanced-hr--her2--breast-cancer-a-meta-analysis-of-published-clinical-trials/2024-01-11T10:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-persistence-and-time-to-next-treatment-with-ibrutinib-in-patients-with-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-including-patients-at-high-risk-for-atrial-fibrillation-or-stroke/2024-01-11T10:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-related-quality-of-life-following-allogeneic-hematopoietic-cell-transplantation-with-omidubicel-versus-umbilical-cord-blood/2024-01-11T10:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-the-relative-effectiveness-of-erenumab-compared-with-onabotulinumtoxina-for-the-prevention-of-chronic-migraine/2024-01-11T10:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/post-transplant-maintenance-therapy-in-patients-with-flt3-mutated-acute-myeloid-leukemia-real-world-treatment-patterns-and-outcomes/2024-01-11T10:42:54+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/studies-by-analysis-group-health-care-researchers-recognized-by-the-journal-of-managed-care--specialty-pharmacy/2024-02-20T14:35:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/advancing-the-development-of-real-world-data-for-healthcare-research-in-china-challenges-and-opportunities/2024-01-11T10:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risk-reduction-of-accidental-exposure-related-systemic-allergic-reactions-extrapolated-based-on-food-challenge-data-after-1-year-of-peanut-oral-immunotherapy/2024-01-11T10:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-eosinophilic-gastritis-and-eosinophilic-enteritis-in-the-united-states/2024-01-11T10:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-migraine-related-healthcare-resource-utilization-and-costs-associated-with-improved-vs.-worsenedstable-migraine-a-panel-based-chart-review-in-france-germany-italy-and-spain2024-01-11T10:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/determinants-of-hyperkalemia-progression-among-patients-with-mild-hyperkalemia/2024-01-11T10:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hemophilia-gene-therapy-value-assessment-methodological-challenges-and-recommendations/2024-01-11T10:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-metabolic-acidosis-among-patients-with-chronic-kidney-disease-and-hyperkalemia/2024-01-11T10:42:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-use-and-costs-associated-with-diabetic-and-idiopathic-gastroparesis-a-claims-analysis-of-the-first-3-years-following-the-diagnosis-of-gastroparesis/2024-01-11T10:42:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/chronic-myeloid-leukemia-part-i-real-world-treatment-patterns-healthcare-resource-utilization-and-associated-costs-in-later-lines-of-therapy-in-the-united-states/2024-01-11T10:42:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-minh-doan-to-join-webinar-discussing-non-competes-and-trade-secrets/2024-01-11T10:42:55+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/analyst-experience-at-analysis-group/2024-02-27T08:27:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-juliette-caminade-and-affiliate-christopher-knittel-to-join-aba-webinar-on-self-preferencing-in-digital-platforms/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/health-care-bulletins/health-care-bulletin-2022-selected-highlights/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-susan-tierney-to-join-panel-at-new-england-electricity-restructuring-roundtable/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/samantha-kappagoda/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/brynna-carswell-smith/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-among-children-and-adolescents-with-attention-deficithyperactivity-disorder-in-the-united-states---a-retrospective-claims-analysis/2024-03-14T19:21:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-attention-deficithyperactivity-disorder-among-children-and-adolescents-in-the-united-states-a-societal-perspective/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risk-of-chronic-kidney-disease-development-in-adult-patients-with-chronic-hypoparathyroidism-treated-with-rhpth1-84-a-retrospective-cohort-study/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-weight-gain-and-the-incidence-of-cardiometabolic-conditions-among-people-living-with-hiv-1-at-high-risk-of-weight-gain-initiated-on-antiretroviral-therapy/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-and-persistence-to-single-inhaler-versus-multiple-inhaler-triple-therapy-for-asthma-management/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-physician-and-administrator-reported-cost-of-drug-utilization-management-to-physician-practices-a-cross-sectional-survey/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/symptom-control-in-patients-with-asthma-using-inhaled-corticosteroidslong-acting-2-agonists-fluticasone-furoatevilanterol-or-budesonideformoterol-in-the-us-a-retrospective-matched-cohort-study/2024-01-11T10:42:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/understanding-the-health-system-conditions-affecting-the-use-of-long-acting-injectable-antipsychotics-in-the-treatment-of-schizophrenia-in-clinical-practice-a-us-healthcare-provider-survey/2024-01-11T10:42:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lower-risk-of-cardiovascular-events-in-adult-patients-with-chronic-hypoparathyroidism-treated-with-rhpth1-84-a-retrospective-cohort-study/2024-01-11T10:42:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-characteristics-treatment-patterns-and-outcomes-among-black-and-white-patients-with-multiple-myeloma-initiating-daratumumab-a-real-world-chart-review-study/2024-01-11T10:42:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-burden-of-respiratory-complications-associated-with-extreme-prematurity-an-analysis-of-us-medicaid-claims/2024-01-11T10:42:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-newly-initiated-systemic-therapy-for-atopic-dermatitis-in-the-united-states-a-claims-database-analysis/2024-01-11T10:42:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/jessica-julien-and-hollywood-smiles-atl-llc-plaintiffs-v.-georgia-board-of-dentistry-et-al.-defendants2024-01-23T19:49:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-steve-allen-to-join-transfer-pricing-controversy--litigation-trends-panel-at-tp-minds-americas-2023/2024-01-11T10:42:58+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/christopher-a.-bail2024-01-11T10:42:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-clients-gsk-and-teva-win-multiple-class-certification-rulings-in-pharmaceutical-suit/2024-01-11T10:42:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-lamictal-direct-purchaser-antitrust-litigation/2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burdens-of-recurrence-following-nephrectomy-for-intermediate-high--or-high-risk-renal-cell-carcinoma-a-retrospective-analysis-of-surveillance-epidemiology-and-end-results-medicare-data/2024-01-11T10:42:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-invasive-pneumococcal-disease-in-children-with-commercial-insurance-or-medicaid-coverage-in-the-united-states-before-and-after/2024-01-11T10:42:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adalimumab-is-associated-with-lower-healthcare-resource-and-steroid-use-versus-vedolizumab-in-biologic-naive-crohns-disease-a-retrospective-claims-database-analysis/2024-01-11T10:42:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/increasing-covid-19-vaccination-in-the-united-states-projected-impact-on-cases-hospitalizations-and-deaths-by-age-and-racial-group/2024-01-11T10:42:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-christopher-llop-to-moderate-digital-innovation-panel-at-the-2023-mit-sloan-healthcare-and-bioinnovations-conference/2024-01-11T10:42:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-provides-valuation-testimony-in-gramercy-funds-managements-successful-claim-in-securities-based-international-arbitration/2024-01-11T10:42:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/valuation-testimony-provided-by-analysis-group-in-gramercy-funds-managements-successful-securities-based-international-arbitration-claim/2024-01-11T10:42:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/gramercy-funds-management-llc-and-gramercy-peru-holdings-llc-v.-republic-of-peru2024-01-26T17:45:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burden-of-tumor-lysis-syndrome-among-patients-with-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-a-real-world-us-retrospective-study/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-utilization-and-outcomes-of-systemic-therapy-among-patients-with-advanced-or-recurrent-endometrial-cancer-in-the-united-states/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-adherence-to-treatment-with-inhaled-corticosteroidslong-acting-agonists-on-asthma-outcomes-in-the-united-states/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-hospitalization-related-costs-of-adverse-events-for-novel-androgen-receptor-inhibitors-in-non-metastatic-castration-resistant-prostate-cancer-an-indirect-comparison/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-per-patient-achieving-remission-with-venetoclax-based-combinations-in-newly-diagnosed-patients-with-acute-myeloid-leukemia-ineligible-for-intensive-induction-chemotherapy/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-the-impact-of-a-meningitisencephalitis-panel-on-hospital-length-of-stay-a-systematic-review-and-meta-analysis/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-utilization-and-costs-among-us-adolescents-with-alopecia-areata/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-real-world-health-resource-use-and-costs-of-misdiagnosing-bipolar-i-disorder/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/avanzalia-solar-sl-et-al.-v.-goldwind-usa-inc2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/federal-judge-grants-analysis-group-clients-motion-for-summary-judgment-in-panama-electrical-grid-litigation/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/chronic-myeloid-leukemia-part-ii-cost-of-care-among-patients-in-advanced-phases-or-later-lines-of-therapy-in-chronic-phase-in-the-united-states-from-a-commercial-perspective/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retail-landscape-changes-may-affect-kroger-albertsons-deal/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-explore-changes-in-grocery-retail-merger-assessment-following-covid-19-pandemic/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-ranked-in-top-10-of-vaults-best-places-to-work/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-provides-expert-testimony-on-secondary-meaning-in-itc-hearing-of-crocs-trademark-infringement-claim/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-michael-schreck-testifies-on-secondary-meaning-in-trademark-infringement-itc-hearing/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-certain-casual-footwear-and-packaging-thereof/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/amcp-2023-conference-to-feature-new-outcomes-research-from-analysis-group/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-k.a.-mordecai2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/paper-on-societal-value-of-covid-19-vaccines-coauthored-by-analysis-group-researchers-earns-top-5-ranking-from-the-journal-of-medical-economics/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/first-2023-law-and-economics-symposium-to-discuss-antitrust-in-life-sciences-and-pharmaceuticals/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/joseph-c.-bamford-et-al.-v.-penfold-lp-et-al2024-01-11T10:42:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/delaware-chancery-court-sides-with-analysis-group-expert-in-fiduciary-duty-ruling/2024-01-11T10:42:34+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/robert-j.-bobby-calzaretta2024-01-11T10:42:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-join-panel-discussing-lessons-from-the-jindal-and-davita-trials/2024-01-11T10:42:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/study-of-covid-19-in-the-us-quantifies-elevated-health-care-costs-associated-with-the-disease/2024-01-11T10:42:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-health-care-costs-associated-with-covid-19-in-the-united-states/2024-01-11T10:42:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/principal-paul-hibbard-discusses-landmark-climate-impact-study-in-nyiso-video-series/2024-01-11T10:42:34+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/lucien-frys/2024-01-11T10:42:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-announces-recent-promotions-and-welcomes-new-consultants-and-affiliates/2024-01-11T10:42:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-announces-recent-promotions-and-welcomes-new-consultants-and-affiliates/2024-01-11T10:42:34+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/marisa-carlos/2024-01-11T10:42:34+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/steven-case/2024-01-11T10:42:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/manager-jia-zhong-to-discuss-real-world-evidence-for-rare-conditions-at-icsa-2022/2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/matthew-d.-cain2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/hitesh-makhija/2024-03-12T13:11:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-affiliate-eileen-kamerick-chosen-as-a-national-association-of-corporate-directors-honoree/2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/dylan-kellachan/2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/sabrina-howell/2024-01-11T10:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/decision-21-d-14-of-french-competition-authority-fca-regarding-karcher-sas/2024-01-11T10:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-intersection-of-self-preferencing-and-pricing-practices-in-the-digital-world/2024-01-11T10:42:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/for-abas-price-point-vice-president-juliette-caminade-affiliate-christopher-knittel-and-coauthor-discuss-self-preferencing-in-the-context-of-digital-platforms-pricing-practices/2024-01-11T10:42:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/prof.-thomas-z.-lys-recognized-by-american-accounting-association-for-distinguished-contributions-to-accounting-literature2024-01-11T10:42:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-mourns-the-loss-of-longtime-academic-affiliate-sharon-oster/2024-01-11T10:42:33+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/jessica-burley/2024-01-11T10:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/brennan-m.-gilmore-plaintiff-v.-alexander-alex-e.-jones-et-al.-defendants-civil-action-no.-318-cv-00017-w.d.-va.-jan.-8-20212024-01-11T10:42:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/pro-bono-team-assists-with-web-analytics-in-defamation-suit-related-to-filming-of-fatality-during-charlottesville-political-rally/2024-01-11T10:42:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-maria-garibotti-to-provide-economists-perspective-on-a-day-in-the-life-of-an-antitrust-practitioner/2024-01-11T10:42:33+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/erik-martino/2024-01-11T10:42:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-pavel-darling-to-join-the-knowledge-group-webcast-on-antitrust-issues-in-the-pharmaceutical-and-life-sciences-industries/2024-01-11T10:42:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-groups-darren-thomason-and-laura-acosta-to-join-aba-webinar-celebrating-pride-month/2024-01-11T10:42:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-president-pierre-cremieux-to-join-no-poach-panel-at-abas-international-cartel-workshop/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/susan-mangiero/2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-utility-dive-vice-president-joe-cavicchi-and-manager-charles-wu-examine-how-fercs-decisions-approving-different-resource-capacity-accreditation-methodologies-may-impact-renewable-energy-development/2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fercs-acceptance-of-2-capacity-accreditation-methods-will-complicate-renewables-development/2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/veoliasuez-merger-approval/2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/sharon-m.-oster---in-memoriam2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/methane-reduction-technology-electricity-and-abatement-costs/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-models-cost-effectiveness-of-methane-emission-reduction-technologies/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/nicolae-done/2024-02-26T16:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/which-problem-to-solve-assessing-the-complexities-of-drug-pricing-in-the-us/2024-01-11T10:42:36+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/susan-ou/2024-01-11T10:42:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/update-on-the-commentary-on-the-doj-bank-merger-guidelines/2024-01-11T10:42:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-maria-garibotti-coauthors-commentary-on-doj-bank-merger-guidelines-in-aba-newsletter/2024-01-11T10:42:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/inaugural-blackag-summit-convened-by-analysis-group/2023-06-13T17:15:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-w.-richardson2024-01-11T10:42:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/nisha-hazra/2024-01-11T10:42:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reading-new-and-old-tea-leaves-u.s.-agencies-request-for-information-may-give-insights-into-the-future-of-merger-review2024-01-11T10:42:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/antitrust-agencies-call-for-update-of-merger-guidelines-analyzed-by-analysis-group-consultants/2024-01-11T10:42:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/moore-v.-trader-joes-co2024-01-11T10:42:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/for-2022-edition-of-top-food-and-drug-cases-analysis-group-authors-examine-the-role-of-contextual-information-in-assessing-reasonable-consumer-interpretations-of-product-labels/2024-01-11T10:42:36+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/zack-campbell/2024-03-12T17:04:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/jason-doran/2024-01-11T10:42:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/affiliate-david-dranove-to-receive-victor-r.-fuchs-award-at-ashecon2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/douglas-oreagan/2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/victory-in-trade-secret-jury-trial-supported-by-analysis-group-expert-testimony/2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/absorption-pharmaceuticals-llc-v.-reckitt-benckiser-llc2024-01-11T10:42:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interim-measures-in-antitrust-investigations-an-economic-discussion-oecd-note/2024-01-11T10:42:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-vice-president-juliette-caminade-analyzes-interim-measures-for-oecd-roundtable/2024-01-11T10:42:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/aolin-wang/2024-01-11T10:42:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/determining-the-price-for-one-when-all-you-have-is-the-price-for-many/2024-01-11T10:42:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/principal-robert-l.-vigil-and-associate-xiao-zhang-summarize-their-research-on-patent-portfolio-valuation-methodologies-in-nacvas-financial-forensics-newsletter2024-01-11T10:42:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-welcomes-antitrust-and-industrial-organization-economics-expert-hitesh-makhija-to-the-firm/2024-01-11T10:42:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/update-on-financial-benchmark-manipulation-litigation/2024-01-11T10:42:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/financial-benchmark-manipulation-litigation-summarized-by-vice-president-kris-comeaux-and-manager-briana-ohaver-in-aba-newsletter/2024-01-11T10:42:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/second-law--economics-symposium-webinar-to-focus-on-false-claims-act-and-drug-pricing-related-cases/2024-01-11T10:42:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-supports-successful-acquittals-in-broiler-chicken-antitrust-criminal-matter/2024-01-11T10:42:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-successful-acquittals-in-broiler-chicken-antitrust-criminal-matter/2024-01-11T10:42:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-v.-penn-et-al2024-01-11T10:42:39+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/marianne-cunnington/2024-01-11T10:42:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/criminal-antitrust-the-discovery-process-and-the-role-of-economic-experts/2024-01-11T10:42:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-discusses-role-of-economic-experts-in-criminal-antitrust-discovery-process-in-american-bar-association-newsletter/2024-01-11T10:42:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-announces-study-using-real-world-evidence-to-support-blueprint-medicines-ayvakyt-avapritinib-label-expansion-for-advanced-systemic-mastocytosis-in-europe/2024-01-11T10:42:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-announces-real-world-evidence-study-supported-blueprint-medicines-label-expansion-of-ayvakyt-avapritinib-to-advanced-systemic-mastocytosis-in-the-eu/2024-01-11T10:42:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-of-avapritinib-versus-best-available-therapy-in-the-treatment-of-advanced-systemic-mastocytosis/2024-01-11T10:42:40+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/xiaoyu-nie/2024-01-11T10:42:40+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/suneal-bedi/2024-01-11T10:42:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/academia-in-court-how-marketing-scholarship-informs-the-law/2024-01-11T10:42:40+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/role-of-academic-marketing-experts-in-high-stakes-litigation-examined-in-article-coauthored-by-analysis-group/2024-01-11T10:42:40+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/leading-epidemiologist-marianne-cunnington-joins-analysis-group-from-the-pharmaceutical-industry/2024-01-11T10:42:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-choice-of-inhalers-for-asthma-care-on-global-carbon-footprint-and-societal-costs-a-long-term-economic-evaluation/2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/the-global-carbon-footprint-of-asthma-inhalers-policy-shifts-can-reduce-emissions-analysis-group-study-finds/2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/marcello-c.-santana2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-susan-f.-tierney-to-moderate-national-academies-of-sciences-engineering-and-medicine-climate-conversations-webinar2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/spacs-market-trends-and-litigation-considerations/2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/hela-romdhani/2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/maria-marta-laurito/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/su-zhang/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prejudgment-interest-w.d.-texas-got-it-right-in-the-vlsi-v.-intel-patent-suit2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-les-nouvelles-article-analysis-group-economists-discuss-prejudgment-interest-awards-in-patent-infringement-cases/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/kai-jye-lou/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/lamiya-sheikh/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/third-law--economics-symposium-webinar-to-focus-on-data-mining-and-the-false-claims-act/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-welcomes-finance-and-labor-market-economics-expert-michael-kwak-to-the-firm/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/finance-and-labor-market-economics-expert-michael-kwak-joins-analysis-group/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/ceo-and-chairman-martha-s.-samuelson-to-join-panel-on-novel-theories-of-harm-at-gcr-conference2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-dov-rothman-named-one-of-two-most-highly-regarded-competition-economists-in-north-america-by-whos-who-legal/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/lou-garrison/2024-03-11T15:50:53+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/analysis-group-and-antitrust/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-and-pfizer-present-interim-data-on-covid-19-vaccine-safety-surveillance-program-showing-no-adverse-safety-signals-among-us-veterans-health-administration-patients/2024-03-01T21:40:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-and-pfizer-present-interim-data-on-covid-19-vaccine-safety-surveillance-program-of-us-veterans-health-administration-patients/2024-03-01T21:38:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/cameron-fowler/2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/roy-roth/2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/michael-kwak/2024-01-11T10:42:40+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/jaclyn-cotton/2024-01-11T10:42:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/molson-coors-llc-v.-anheuser-busch-companies-llc2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/anheuser-busch-wins-super-bowl-ad-dispute-in-lanham-act-case-involving-testimony-from-multiple-analysis-group-experts/2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/emma-xiaoxiao-dong/2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/simon-blanchard/2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-vice-president-emmanuel-frot-to-join-canadian-bar-association-panel-discussion-of-sustainability-issues-in-competition-matters/2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/united-states-platform-economics-and-mergers2/2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/for-gcrs-digital-markets-guide-analysis-group-contributes-chapter-exploring-increased-regulatory-and-legislative-scrutiny-of-digital-platform-mergers/2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/d.-scott-showalter2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/usa-v.-michael-j.-avenatti2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-vice-president-john-drum-provides-accounting-testimony-in-successful-doj-prosecution-of-michael-avenatti-for-wire-fraud/2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-helps-government-follow-the-money-in-successful-prosecution-of-criminal-wire-fraud-charges-against-former-attorney-michael-avenatti/2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-congratulates-dr.-austan-goolsbee-on-his-appointment-as-chicago-fed-president-and-ceo2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/steve-allen/2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/64th-american-society-of-hematology-annual-meeting-and-exposition-to-feature-new-outcomes-research-from-analysis-group/2024-03-14T19:24:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-allergan-plc-securities-litigation/2024-01-11T10:42:51+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/allergan-wins-summary-judgment-in-securities-fraud-class-action-featuring-expert-reports-from-analysis-group-affiliates/2024-01-11T10:42:51+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/katie-williams/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/kevin-wellenius/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-platinum-sponsor-of-nysba-antitrust-law-section-annual-meeting/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-again-recognized-among-the-leading-global-economics-consultancies-by-global-competition-review4/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/global-competition-review-again-recognizes-analysis-group-among-the-leading-global-economics-consultancies/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/senior-advisors/eliana-garces/2024-03-13T13:52:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-mergers-and-regulatory-uncertainty/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perceptions-of-regulatory-uncertainty-in-antitrust-practices/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-survey-gathers-antitrust-practitioner-views-on-us-regulatory-enforcement-trends-in-merger-actions/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/worldline-acquisition-of-ingenico/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/juan-carvajal/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/two-papers-coauthored-by-analysis-group-competition-experts-distinguished-with-nominations-for-2023-concurrences-antitrust-writing-awards/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/recognized-digital-business-models-expert-eliana-garces-joins-as-senior-advisor/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-welcomes-digital-business-models-expert-eliana-garces-to-the-firm/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/janssen-pharma.-inc.-et-al.-v.-teva-pharma.-usa-inc2024-01-23T17:10:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/district-court-denies-plaintiffs-class-certification-motion-in-false-advertising-and-consumer-protection-class-action-involving-analysis-group-client-hp/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/john-cepelak-et-al.-v.-hp-inc2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-jee-yeon-lehmann-discusses-no-poach-litigation-in-aba-podcast/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-john-jarosz-to-co-chair-patent-and-trade-secret-remedies-summit/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/transfer-pricing-expert-steve-allen-joins-analysis-group-as-a-vice-president/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/charles-m.-jones---in-memoriam2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/practices/environmental-social-governance/esg-accounting-finance-governance/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/practices/environmental-social-governance/esg-consumer-behavior/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/practices/environmental-social-governance/climate-change-environmental-sustainability/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/practices/environmental-social-governance/social-impact-business-practices/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/j.-michael-mcwilliams2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-promotes-kris-comeaux-to-managing-principal-eric-korman-to-principal/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-promotes-kris-comeaux-to-managing-principal-eric-korman-to-principal/2024-01-11T10:42:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/crystal-a.-kolden2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pirnik-v.-fiat-chrysler-automobiles-nv-et-al2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/brian-phelan/2024-01-11T10:42:51+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-to-join-panel-at-les-journees-de-leconomie-jeco-2022-conference/2024-01-11T10:42:51+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-sponsoring-2022-neca-power-markets-conference/2024-01-11T10:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-economic-analysis-of-the-self-preferencing-debate/2024-01-11T10:42:51+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/economics-of-self-preferencing-practices-and-regulations-evaluated-by-analysis-group-authors/2024-01-11T10:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fraud-on-the-market-and-the-economics-of-securities-litigation-claims-in-europe/2024-01-31T21:47:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-effectiveness-and-safety-of-dutasteride-versus-finasteride-in-patients-with-male-androgenic-alopecia-in-south-korea-a-multicentre-chart-review-study/2024-01-11T10:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/five-year-estimated-glomerular-filtration-rate-in-adults-with-chronic-hypoparathyroidism-treated-with-rhpth1-84-a-retrospective-cohort-study/2024-01-11T10:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treating-anemic-patients-with-myelofibrosis-in-the-new-janus-kinase-inhibitor-era-current-evidence-and-real-world-implications/2024-01-11T10:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-of-real-world-commercially-insured-patients-with-treatment-resistant-depression-initiated-on-esketamine-nasal-spray-or-conventional-therapies-in-the-united-states/2024-01-11T10:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bial---portela--ca-s.a.-et-al.-v.-torrent-pharmaceuticals-ltd.-et-al2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-hosting-new-york-arbitration-weeks-diversity-equity-and-inclusion-dei-session/2023-06-13T17:13:32+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/final-2022-law--economics-symposium-webinar-to-discuss-economic-loss-arguments-in-pharmaceutical-product-liability-class-actions/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/georgios-zervas/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-welcomes-modeling-and-forecasting-expert-pierre-lissot-to-the-firm/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-examine-geographic-market-definition-in-air-travel/2024-01-11T10:42:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-can-covid-tell-us-about-market-definition-in-air-travel/2024-01-11T10:42:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cll-492-real-world-adherence-to-first-line-ibrutinib-and-acalabrutinib-single-agent-among-patients-with-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cml-475-real-world-treatment-patterns-among-patients-with-chronic-myeloid-leukemia-in-chronic-phase-cml-cp-cycling-through-multiple-tyrosine-kinase-inhibitors-tkis-in-the-united-states-us/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/maralixibat-treatment-response-in-alagille-syndrome-is-associated-with-improved-health-related-quality-of-life/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/symptoms-associated-with-adhdtreatment-related-adverse-side-effects-and-their-impact-on-quality-of-life-and-work-productivity-in-adults-with-adhd/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-dosing-and-discontinuation-patterns-among-patients-treated-with-pegvaliase-for-phenylketonuria-evidence-from-dispensing-data/2024-02-07T16:47:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/physician-perceptions-of-drug-utilization-management-results-of-a-national-survey/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identifying-individuals-with-undiagnosed-post-traumatic-stress-disorder-in-a-large-united-states-civilian-population--a-machine-learning-approach/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/machine-learning-used-to-identify-undiagnosed-ptsd-in-civilian-patients-in-analysis-group-study/2024-01-11T10:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mpn-435-overall-survival-in-patients-with-systemic-mastocytosis-with-associated-hematologic-neoplasm-treated-with-avapritinib-versus-best-available-therapy/2024-01-11T10:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-reported-outcomes-of-upadacitinib-versus-abatacept-in-patients-with-rheumatoid-arthritis-and-an-inadequate-response-to-biologic-disease-modifying-antirheumatic-drugs-12--and-24-week-results-of-a-phase-3-trial/2024-01-11T10:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/early-prostate-specific-antigen-response-among-black-and-non-black-patients-with-advanced-prostate-cancer-treated-with-apalutamide/2024-01-11T10:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/leonid-falberg-v.-the-goldman-sachs-group-inc.-et-al2024-01-11T10:42:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/goldman-sachs-wins-summary-judgment-motion-in-erisa-case-featuring-testimony-by-three-analysis-group-experts/2024-01-11T10:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-achieving-and-maintaining-near-complete-or-complete-skin-clearance-on-patient-quality-of-life-in-moderate-to-severe-psoriasis2/2024-01-11T10:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/nivolumab-versus-placebo-as-adjuvant-therapy-for-resected-stage-iii-melanoma-a-propensity-weighted-indirect-treatment-comparison-and-number-needed-to-treat-analysis-for-recurrence-free-survival-and-overall-survival/2024-01-11T10:42:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/academic-affiliate-lou-garrison-receives-lifetime-achievement-award-for-health-outcomes-research/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/dasha-anosova/2024-01-11T10:42:43+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/carlo-gallimberti/2024-01-11T10:42:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-paul-hibbard-to-moderate-fireside-chat-at-30th-annual-necbc-executive-energy-conference/2024-01-11T10:42:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-ongoing-tale-of-two-sided-markets/2024-01-11T10:42:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-divya-mathur-and-coauthor-explore-the-evolving-debate-around-ohio-v.-amex-and-its-relevance-for-digital-platforms2024-01-11T10:42:43+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/james-t.-jenson2024-01-11T10:42:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/panelists-including-managing-principal-jee-yeon-lehmann-discuss-international-labor-issues-at-concurrences-new-frontiers-of-antitrust-conference/2024-01-11T10:42:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-progression-on-healthcare-resource-utilization-and-costs-among-patients-with-high-grade-non-muscle-invasive-bladder-cancer-after-bacillus-calmette-guerin-therapy-a-retrospective-seer-medicare-analysis/2024-01-11T10:42:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-medication-adherence-on-healthcare-resource-utilization-work-loss-and-associated-costs-in-a-privately-insured-employed-population-treated-with-adalimumab-in-the-united-states/2024-01-11T10:42:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-benefit-from-improvements-in-health-related-quality-of-life-with-upadacitinib-comparisons-with-tofacitinib-and-methotrexate-in-patients-with-rheumatoid-arthritis/2024-01-11T10:42:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/systematic-literature-review-of-clinical-and-economic-evidence-for-spinal-muscular-atrophy/2024-01-11T10:42:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/discontinuation-and-switchback-after-non-medical-switching-from-originator-tumor-necrosis-factor-alpha-tnf-inhibitors-biologics-to-biosimilars-a-meta-analysis-of-real-world-studies-from-2012-to-2018/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-adjuvant-therapy-in-patients-with-resected-melanoma-an-application-of-the-theory-of-planned-behavior/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-join-webinar-on-antitrust-enforcement-in-health-care-labor-markets/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-treatment-effects-of-inotersen-on-health-related-quality-of-life-in-patients-with-hattr-amyloidosis-with-polyneuropathy-analysis-of-the-open-label-extension-of-the-neuro-ttr-trial/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/factors-associated-with-increased-health-related-quality-of-life-benefits-in-hereditary-transthyretin-amyloidosis-polyneuropathy-patients-treated-with-inotersen/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-preferences-for-attributes-of-biologic-treatments-in-moderate-to-severe-asthma-a-discrete-choice-experiment-study/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/analysis-group-highlights-from-our-recent-and-ongoing-heor-work/2024-01-11T10:42:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-heor-consultants-present-at-ispor-europe-2022/2024-01-11T10:42:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-provides-expert-testimony-in-credit-suisse-victory-in-forex-markets-class-action/2024-01-11T10:42:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-provides-expert-testimony-in-credit-suisse-victory-in-forex-markets-class-action/2024-01-11T10:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-foreign-exchange-benchmark-rates-antitrust-litigation/2024-01-26T16:35:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/pierre-lissot/2024-01-11T10:42:45+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/pierre-lissot/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/thomas-polley/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-recognized-as-a-top-women-led-business-in-massachusetts-for-tenth-consecutive-year/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-heor-consultants-present-at-ispor-europe-2022/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/joel-weiss-v.-loomis-sayles--co2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-jee-yeon-lehmann-testifies-in-employment-misclassification-case-won-by-analysis-group-client-loomis-sayles/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-hitesh-makhija-to-join-panel-at-2022-golden-state-antitrust--unfair-competition-law-institute/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-juliette-caminade-to-join-aba-panel-on-antitrust-questions-in-new-labor-markets/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-experts-in-criminal-antitrust-price-fixing-litigation-discovery-and-scope/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authored-article-in-antitrust-report-explores-economic-experts-value-in-criminal-litigation-under-the-per-se-standard/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/analysis-group-veterans-share-their-paths-to-economics-consulting/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/administrative/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/health-care-bulletins/health-care-bulletin-fall-2015/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/health-care-bulletins/health-care-bulletin-fall-2016/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/health-care-bulletins/health-care-bulletin-winter-2018/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/analysis-group-forum-2015-year-in-review/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/analysis-group-forum-spring-2017/2024-01-11T10:40:35+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/energy-infrastructure/2024-01-11T10:40:35+00:00weekly0.7https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-alliance-team/2024-01-11T10:40:35+00:00weekly0.7https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-lcd-team/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/summer-analyst-intern/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/associate/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/analyst/2024-01-11T10:40:35+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/a-diverse-health-care-practice-videos/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2020-03-02T17:50:23+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/susan-tierney---opportunities-and-solutions-in-the-global-energy-market/2024-01-11T10:40:27+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/sarah-cullinan---why-analysis-group/2024-01-11T10:40:27+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/pierre-cremieux---how-we-work/2024-01-11T10:40:27+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/paul-greenberg---pharmaceutical-off-label-promotion/2024-01-11T10:40:27+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/noam-kirson---why-analysis-group/2024-01-11T10:40:27+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/martha-samuelson--yale-school-of-management-leaders-forum-values/2024-01-11T10:40:28+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/martha-samuelson---yale-school-of-management-leaders-forum-developing-talent/2024-01-11T10:40:28+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/martha-samuelson---yale-school-of-management-leaders-forum-culture/2024-01-11T10:40:28+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/martha-samuelson---our-culture-of-collaboration/2024-01-11T10:40:28+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/liz-milsark---why-analysis-group/2024-01-11T10:40:29+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/john-jarosz---delivering-expert-testimony-on-intellectual-property-valuation/2024-01-11T10:40:29+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/jill-linberg---why-analysis-group/2024-01-11T10:40:29+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/eric-davis---why-analysis-group/2024-01-11T10:40:29+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/edward-snyder--pierre-cremieux---the-macro--and-microcommonality-tests/2024-01-11T10:40:29+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/edward-snyder---do-common-issues-predominate/2024-01-11T10:40:29+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/carla-mulhern---patent-litigation-before-the-international-trade-commission-itc/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/bruce-strombom---market-conflicts-leading-to-subprime-mortgage-litigation/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/bruce-deal---the-intersection-of-economic-analysis-and-public-policy/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/brian-gorin---an-innovative-approach-to-strategy/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/settlement-in-microsoft-iowa-litigation/2020-03-02T17:51:17+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/news/2018-10-05T20:23:06+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/q-and-a/2020-03-02T17:51:07+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/internal/2020-03-02T17:50:57+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/infrastructure/2020-03-02T17:50:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/tulin-erdem/2024-02-06T17:56:02+00:00weekly0.7https://www.analysisgroup.com/practices/data-science-and-statistical-modeling/data-visualization-real-time-analyses-and-interactive-platforms/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/practices/data-science-and-statistical-modeling/econometric-modeling/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/practices/data-science-and-statistical-modeling/machine-learning/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/practices/data-science-and-statistical-modeling/natural-language-processing/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/practices/data-science-and-statistical-modeling/predictive-analytics-and-optimization/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/practices/data-science-and-statistical-modeling/statistical-sampling/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jacques-cremer/2024-01-11T10:41:00+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/manager/2024-01-11T10:41:00+00:00weekly0.7https://www.analysisgroup.com/practices/health-care/health-care-policy/2022-05-06T16:50:02+00:00weekly0.7https://www.analysisgroup.com/practices/health-care/controlled-substance-monitoring-and-analytics/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/market-access-and-commercial-strategy/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/modeling-and-analytics/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/health-care/litigation-services/2022-05-06T16:48:35+00:00weekly0.7https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/erisa/company-stock-issues/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/erisa/defined-benefit-plans/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/erisa/erisa-class-actions/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/erisa/excessive-fees-issues/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/erisa/process-of-monitoring-and-selecting-investments/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/practices/government-and-corporate-investigations/antitrust-investigations/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/government-and-corporate-investigations/health-care-investigations/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/government-and-corporate-investigations/securities-investigations/2022-11-08T21:35:22+00:00weekly0.7https://www.analysisgroup.com/practices/government-and-corporate-investigations/tax-and-other-types-of-investigations/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/insurance/claims-handling-and-payment/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/insurance/pricing-coverage-and-management-issues/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/insurance/sales-practices-and-product-performance/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/labor-and-employment/class-certification/2024-01-11T10:36:15+00:00weekly0.7https://www.analysisgroup.com/practices/labor-and-employment/discrimination-and-pay-equity/2024-01-11T10:36:15+00:00weekly0.7https://www.analysisgroup.com/practices/labor-and-employment/labor-market-antitrust/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/practices/labor-and-employment/surveys-experiments-and-other-primary-data-collection-in-labor-and-employment-litigation/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/practices/labor-and-employment/wage-and-hour-litigation/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/practices/labor-and-employment/worker-misclassification/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/practices/media-entertainment-and-communications/copyright-disputes/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/media-entertainment-and-communications/wireless-communications-and-spectrum-valuation/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/media-entertainment-and-communications/cable-and-satellite-distribution/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/investment-suitability/2023-12-14T15:09:04+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/market-microstructure/2022-10-27T15:17:01+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/mutual-funds-and-hedge-funds/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/securities-fraud/2021-07-22T13:04:59+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/structured-finance-and-derivatives/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/strategy-policy-and-analytics/modeling-and-decision-tools/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/strategy-policy-and-analytics/public-policy-and-economic-impact-analysis/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/strategy-policy-and-analytics/analytics/2020-10-15T20:04:01+00:00weekly0.7https://www.analysisgroup.com/practices/surveys-and-experimental-studies/application-and-uses/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/surveys-and-experimental-studies/methods/2021-12-15T18:16:30+00:00weekly0.7https://www.analysisgroup.com/practices/accounting/accounting-liability-issues/2021-04-01T17:02:32+00:00weekly0.7https://www.analysisgroup.com/practices/accounting/damages-and-materiality-analyses/2020-10-26T18:59:38+00:00weekly0.7https://www.analysisgroup.com/practices/technology/hardware/2024-01-11T10:38:42+00:00weekly0.7https://www.analysisgroup.com/practices/technology/policy-and-strategy/2024-01-11T10:38:42+00:00weekly0.7https://www.analysisgroup.com/practices/technology/litigation/2024-01-11T10:38:42+00:00weekly0.7https://www.analysisgroup.com/practices/technology/software/2024-03-12T19:20:12+00:00weekly0.7https://www.analysisgroup.com/practices/technology/coding-analytics-digital-forensics/2024-03-12T19:20:48+00:00weekly0.7https://www.analysisgroup.com/practices/transaction-and-governance-litigation/appraisal/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/transaction-and-governance-litigation/hostile-bids-and-activism/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/transaction-and-governance-litigation/governance-and-contract-disputes/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/transaction-and-governance-litigation/post-merger-disputes/2022-09-16T20:30:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-analysis--proposition-71---california-stem-cell-research-and-cures-initiative/2024-01-11T10:37:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimated-costs-of-prescription-opioid-analgesic-abuse-in-the-united-states-in-2001--a-societal-perspective-/2024-01-11T10:37:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-market-for-follow-on-biologics--how-will-it-evolve-/2024-01-11T10:37:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dosing-patterns-and-costs-of-erythropoietic-agents-in-patients-with-chronic-kidney-disease-not-on-dialysis-in-managed-care-organizations/2024-01-11T10:37:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/relationship-between-hemoglobin-level-and-quality-of-life-in-anemic-patients-with-chronic-kidney-disease-receiving-epoetin-alfa/2024-01-11T10:37:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-benefits-of-once-weekly-epoetin-alfa-in-anemic-patients-with-colorectal-cancer-receiving-chemotherapy/2024-01-11T10:37:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-role-for-u-s--co2-sequestration-/2024-01-11T10:37:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/live-prices-and-stale-quantities--t-1-accounting-and-mutual-fund-mispricing/2024-01-11T10:37:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/off-label-marketing-investigations-in-the-pharmaceutical-industry/2024-01-11T10:37:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dosing-patterns-and-treatment-costs-of-erythropoietic-agents-in-elderly-patients-with-pre-dialysis-chronic-kidney-disease-in-managed-care-organisations/2024-01-11T10:37:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/roundtable-discussion--importance-of-causation-analysis-in-mass-tort-cases/2024-01-11T10:37:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-value-of-antihypertensive-drugs--a-perspective-on-medical-innovation/2024-01-11T10:37:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/policies-can-work-in-strange-ways/2024-01-11T10:37:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-relative-dosing-of-epoetin-alfa-and-darbepoetin-alfa-in-chronic-kidney-disease/2024-01-11T10:37:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dose-conversion-and-cost-effectiveness-of-erythropoietic-therapies-in-chemotherapy-related-anemia--a-canadian-application/2024-01-11T10:37:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/too-good-to-be-true--an-examination-of-three-economic-assessments-of-california-climate-change-policy/2024-01-11T10:37:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/digital-media-patents-for-profit/2024-01-11T10:37:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-clinical-fractures-after-gonadotropin-releasing-hormone-agonist-therapy-for-prostate-cancer/2024-01-11T10:37:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-cost-benefit-analysis-of-the-new-york-independent-system-operator--the-initial-years/2024-01-11T10:37:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/do-authorized-generic-drugs-deter-paragraph-iv-certifications--recent-evidence/2024-01-11T10:37:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pharmaceutical-spending-and-health-outcomes/2024-01-11T10:37:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competition-between-generic-and-branded-drugs/2024-01-11T10:37:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antihypertensive-drugs--a-perspective-on-the-value-of-improved-blood-pressure-control-in-the-usa/2024-01-11T10:37:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lifetime-and-12-month-prevalence-of-bipolar-spectrum-disorder-in-the-national-comorbidity-survey-replication/2024-01-11T10:37:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lost-earnings-of-persons/2024-01-11T10:37:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economics-of-cost-pass-through-and-damages-in-indirect-purchaser-antitrust-cases/2024-01-11T10:37:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tradable-permits--fly-in-the-ointment-/2024-01-11T10:37:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/free-ghg-cuts--too-good-to-be-true-/2024-01-11T10:37:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mapping-fact-p-and-eortc-qlq-c30-to-the-eq-5d-health-utility-in-metastatic-hormone-refractory-prostate-cancer-patients/2024-01-11T10:37:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/short-term-economic-impact-of-body-weight-change-among-patients-with-type-2-diabetes-treated-with-antidiabetic-agents/2024-01-11T10:37:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-of-inhaled-corticosteroids-and-healthcare-costs-in-mild-persistent-asthma/2024-01-11T10:37:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-economic-and-outcomes-analysis-using-international-databases--a-review/2024-01-11T10:37:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimated-prevalence-of-peripheral-neuropathy-and-associated-pain-in-adults-with-diabetes-in-france/2024-01-11T10:37:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-cardiometabolic-risk-factor-clusters-on-health-related-quality-of-life-in-the-us/2024-01-11T10:37:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/annual-prevalence-of-diagnosed-schizophrenia-in-the-usa--a-claims-data-analysis-approach/2024-01-11T10:37:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-a-copd-severity-score/2024-01-11T10:37:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-duloxetine-versus-routine-treatment-for-u-s--patients-with-diabetic-peripheral-neuropathic-pain/2024-01-11T10:37:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lifetime-costs-of-patients-with-clinically-detected-uterine-fibroids--an-employer-s-perspective/2024-01-11T10:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-stroke-on-health-related-quality-of-life-in-the-noninstitutionalized-population-in-the-united-states/2024-01-11T10:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/annual-costs-associated-with-diagnosis-of-uterine-leiomyomata/2024-01-11T10:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-and-work-loss-costs-associated-with-persistent-asthma-patients-in-a-privately-insured-population/2024-01-11T10:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/employees-with-overactive-bladder--work-loss-burden/2024-01-11T10:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/china-s-urban-health-insurance-reform-experiment-in-zhenjiang--cost-and-utilization-analyses/2024-01-11T10:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/was-the-fairness-doctrine-a--chilling-effect---evidence-from-the-postderegulation-radio-market/2024-01-11T10:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regulatory-issues-in-deploying-wireless-voip/2024-01-11T10:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/telecom-antitrust-handbook/2024-01-11T10:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/look-to-markets-for-next-gen-success/2024-01-11T10:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-allowing-local-telephone-companies-to-enter-long-distance-voice-and-data-markets/2024-01-11T10:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-evolving-competitive-landscape-in-wireless-internet-markets/2024-01-11T10:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/-chilling--the-internet--lessons-from-fcc-regulation-of-radio-broadcasting/2024-01-11T10:37:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effect-on-federal-spending-of-legislation-creating-a-regulatory-framework-for-follow-on-biologics--key-issues-and-assumptions/2024-01-11T10:37:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-is-the-future-of-u-s--coal-/2024-01-11T10:37:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/misconceptions-about-h2o-pricing/2024-01-11T10:37:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-national-perspective-on-allocating-the-costs-of-new-transmission-investment--practice-and-principles/2024-01-11T10:37:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tips-from-the-experts--getting-the-most-out-of-your-experts/2024-01-11T10:37:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-sensible-way-to-cut-co2-emissions/2024-01-11T10:37:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-u-s--cap-and-trade-system-to-address-global-climate-change/2024-01-11T10:37:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-epidemiology-in-drug-safety-litigations/2024-01-11T10:37:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cap-and-trade-or-a-carbon-tax-/2024-01-11T10:37:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-analytic-model-to-determine-the-least-costly-inpatient-erythropoiesis-stimulating-therapy-regimen/2024-01-11T10:37:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/psychometric-validation-of-the-patient-symptom-assessment-in-lung-cancer-instrument-for-small-cell-lung-cancer/2024-01-11T10:37:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dose-and-cost-comparison-of-erythropoietic-agents-in-the-inpatient-hospital-setting/2024-01-11T10:37:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-direct-and-indirect-cost-burden-of-atopic-dermatitis--an-employer-payer-perspective/2024-01-11T10:37:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/linking-a-u-s--cap-and-trade-system-for-greenhouse-gas-emissions/2024-01-11T10:37:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/free-greenhouse-gas-cuts--too-good-to-be-true-/2024-01-11T10:37:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/drug-utilization-and-costs-of-erythropoietic-stimulating-agents-in-chronic-kidney-disease-patients-not-receiving-dialysis/2024-01-11T10:37:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-there-a-difference-in-the-cost-effectiveness-of-erythropoietic-therapies-for-the-treatment-of-anemia-in-patients-receiving-hcv-combination-therapy-/2024-01-11T10:37:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-epoetin-alfa-therapy-on-delaying-time-to-dialysis-in-elderly-patients-with-chronic-kidney-disease/2024-01-11T10:37:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-intravenous-chemotherapy-administration-in-patients-with-small-cell-lung-cancer--a-retrospective-claims-database-analysis/2024-01-11T10:37:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/linking-tradable-permit-systems/2024-01-11T10:37:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/intangible-assets--valuation-and-economic-benefit/2024-01-11T10:37:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/where-does-it-go--spending-by-the-financially-constrained/2024-01-11T10:37:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/drug-safety-and-risk-management-practice--what-drug-companies-can-do/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/enviro-justice-and-cap-and-trade/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/winning-initiative-campaigns-with-economic-analysis/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/csr-through-an-economic-lens/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-consequences-of-generic-substitution-for-antiepileptic-drugs-in-a-public-payer-setting--the-case-of-lamotrigine/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-consequences-of-generic-substitution-of-lamotrigine-for-patients-with-epilepsy/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-generic-substitution-of-lamotrigine--projected-costs-in-the-united-states-using-findings-in-a-canadian-setting/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competitive-procurement-of-retail-electricity-supply--recent-trends-in-state-policies-and-utility-practices/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-study-on-the-economic-impact-of-bariatric-surgery/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/valuation-of-bankrupt-firms/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ongoing-drivers-of-wetlands-depletion/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-psoriasis-on-health-care-costs-and-patient-work-loss/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-importance-of-supply-side-effects-in-antitrust-analyses/2024-01-11T10:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ticofrut-s.a.-v.-e.i.-dupont-de-nemours-and--co.-inc2024-01-11T10:39:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cashmere-and--camel-hair-manufacturers-institute-and-l.w.-packard-and--company-v.-harve-benard2024-01-11T10:39:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/co-options-inc.-v.-news-america-marketing2024-01-11T10:39:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/swan-magnetics-v.-mitsumi-electric-co.-ltd2024-01-11T10:39:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wholesale-market-policy-changes-to-provider-of-last-resort-polr-program-design/2024-01-11T10:39:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-and-costs-of-accidents-among-attention-deficit-hyperactivity-disorder-patients/2024-01-11T10:39:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/whats-so-different-about-anxiety-disorders-such-as-phobias-/2024-01-11T10:39:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/money-cant-buy-happiness/2024-01-11T10:39:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/attention-deficit-hyperactivity-disorder--increased-costs-for-patients-and-their-families/2024-01-11T10:39:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-workplace-burden-of-depression--underlying-causes-recent-empirical-findings-and-future-directions/2024-01-11T10:39:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/savings-in-direct-medical-costs-from-the-use-of-tobi-tobramycin-solution-for-inhalation-in-patients-with-cystic-fibrosis/2024-01-11T10:39:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lifetime-medical-costs-for-women--cardiovascular-disease-diabetes-and-stress-urinary-incontinence/2024-01-11T10:39:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/productivity-loss-due-to-irritable-bowel-syndromereply/2024-01-11T10:39:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/l-evolution-du-regime-d-assurance-medicament-changes-in-the-drug-prescription-coverage-in-quebec/2024-01-11T10:39:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/when-can-a-medicare-insured-group-mig-succeed-/2024-01-11T10:39:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/la-performance-des-clsc-au-quebec-local-health-clinic-performance-in-quebec/2024-01-11T10:39:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measuring-hospital-efficiency-in-the-presence-of-quasi-fixed-inputs--an-analysis-of-quebec-hospitals/2024-01-11T10:39:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-unemployment-insurance-on-job-search-productivity-the-reservation-wage-the-probability-of-re-employment-and-the-post-displacement-wage/2024-01-11T10:39:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effect-of-deregulation-on-employee-earnings--pilots-flight-attendants-and-mechanics-1959-1992/2024-01-11T10:39:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-tale-of-two-taxes-a-challenge-to-hill/2024-01-11T10:39:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/using-existing-tools-to-pry-open-transmissiona-new-england-proposal/2024-01-11T10:39:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/needed--broad-perspective-fresh-ideas/2024-01-11T10:39:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-equity-capital-estimation--methodology-measurement-issues-data-and-regression-results/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/power-asset-valuation--real-options-ancillary-services-and-environmental-risks/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/at-the-electricity-resource-bazaar-lessons-from-case-studies-of-integrated-bidding-in-new-york/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/contract-paths-phase-shifters-and-efficient-electricity-trade/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-of-attention-deficit-hyperactivity-disorder-adhd-in-the-us--excess-costs-of-persons-with-adhd-and-their-family-members-in-2000/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-analysis-of-the-diffusion-of-new-antidepressants--variety-quality-and-marketing-efforts/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-conflict-impact-and-common-methods-of-proof-in-intermediate-indirect-purchaser-class-action-litigation/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-prevalence-and-effects-of-adult-attention-deficit-hyperactivity-disorder-on-work-performance-in-a-nationally-representative-sample-of-workers/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-prevalence-and-correlates-of-nonaffective-psychosis-in-the-national-comorbidity-survey-replication-ncs-r/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-antihypertensive-drugs-on-the-number-and-risk-of-death-stroke-and-myocardial-infarction-in-the-united-states/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dosing-patterns-treatment-costs-and-frequency-of-physician-visits-in-adults-with-cancer-receiving-erythropoietic-agents-in-managed-care-organizations/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact--and-treatment-of-anemia-in-the-elderly---clinical-epidemiological-and-economic-perspectives/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/as-reservoirs-fall-prices-should-rise/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/authorized-generic-drugs-price-competition-and-consumers-welfare/2024-01-11T10:39:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-costs-of-adults-treated-for-attention-deficit-hyperactivity-disorder-who-received-alternative-drug-therapies/2024-01-11T10:39:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-retrospective-claims-database-analysis-to-assess-patterns-of-interstitial-cystitis--ic-diagnosis/2024-01-11T10:39:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/decoding-developments-in-todays-electric-industry--ten-points-in-the-prism/2024-01-11T10:39:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hpv-prevalence-e6-sequence-variation-and-physical-state-of-hpv16-isolates-from-patients-with-cervical-cancer-in-sichuan-china/2024-01-11T10:39:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/employees-with-fibromyalgia--medical-comorbidity-healthcare-costs-and-work-loss/2024-01-11T10:39:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/sensation-seeking-overconfidence-and-trading-activity/2024-01-11T10:39:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/linking-tradable-permit-systems-for-greenhouse-gas-emissions--opportunities-implications-and-challenges/2024-01-11T10:39:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-quality-of-life-and-treatment-compliance-associated-with-antibiotic-therapies-in-patients-with-cystic-fibrosis--a-review-of-the-literature/2024-01-11T10:39:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-implications-and-uncertainties-of-obtaining-permanent-injunctive-relief-after-ebay-v.-mercexchange2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-treatment-persistence-hospital-utilization-costs-among-major-depressive-disorder-geriatric-patients-treated-with-escitalopram/2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-chronic-hand-dermatitis-on-quality-of-life-work-productivity-activity-impairment-and-medical-costs/2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-21st-century-interstate-electric-highway-system--connecting-consumers-and-domestic-clean-power-supplies/2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-single-photon-emission-computed-tomography-spect-use-after-acute-myocardial-infarction-ami-on-cardiac-procedure-rates-and-hospital-length-of-stay/2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-referral-patterns-testing-and-surgery-in-aortic-valve-disease--leaving-women-and-elderly-patients-behind-/2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-a-partnership-measurement-model-of-disease-management--improving-cardiovascular-outcomes-in-nova-scotia-icons/2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interstitial-cystitis--cost-treatment-and-co-morbidities-in-an-employed-population/2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/algorithms-to-identify-colonic-ischemia-complications-of-constipation-and-irritable-bowel-syndrome-in-medical-claims-data--development-and-validation/2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-crit-study--anemia-and-blood-transfusion-in-the-critically-ill--current-clinical-practice-in-the-united-states/2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-osteoporosis-breast-cancer-and-cardiovascular-disease-among-postmenopausal-women-in-an-employed-population/2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identification-of-a-claims-data-signature-and-economic-consequences-for-treatment-resistant-depression/2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/switching-costs-price-sensitivity-and-health-plan-choice/2024-01-11T10:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/levaluation-de-lefficience-budgetaire-des-clsc-au-quebec-a-partir-de-la-methode-dea/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-quality-adjusted-life-years-and-supportive-care.-recombinant-human-erythropoietin-as-a-treatment-of-cancer-associated-anemia2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/une-analyse-du-contexte-budgetaire-de-lactivite-medicale-au-quebec-an-analysis-of-the-budgetary-context-of-medical-activity-in-quebec/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/etude-dimpact-du-projet-de-loi-sur-le-tabac-impact-report-on-the-proposed-tobacco-law/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/implementing-communitybased-longterm-care--experience-of-the-longterm-home-health-care-program/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-does-the-nursing-home-sector-behave--a-multiequation-model-of-nursing-home-behavior/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/angel-finance--the-other-venture-capital-in-companion-to-venture-capital/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/discount-rate-risk-and--economic-damages--practical-considerations/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-the-immigrant-investor-program-in-canada-english/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-the-immigrant-investor-program-in-canada-francais/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-hospitalization-risk-and-associated-costs-among-patients-receiving-sargramostim-filgrastim-and-pegfilgrastim-for-chemotherapy-induced-neutropenia/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/modeling-for-health-care-and-other-policy-decisions--uses-roles-and-validity/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/employer-burden-of-mild-moderate-and-severe-major-depressive-disorder--mental-health-services-utilization-and-costs-and-work-performance/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/angiogenesis-inhibitor-therapies-for-metastatic-renal-cell-carcinoma--effectiveness-safety-and-treatment-patterns-in-clinical-practice-based-on-medical-chart-review/2024-01-11T10:40:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ensuring-a-clean-modern-electric-generating-fleet-while-maintaining-electric-system-reliability/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perceptions-and-prescribing-considerations-among-us-psychiatrists-regarding-drugdrug-interactions-associated-with-oral-atypical-antipsychotics/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-real-world-comparison-of-medical-visits-costs-and-adherence-between-nilotinib-and-dasatinib-in-chronic-myeloid-leukemia/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tolerability-efficacy-and-safety-of-pegylated-liposomal-doxorubicin-in-combination-with-carboplatin-vs-gemcitabine-carboplatin-for-the-treatment-of-platinum-sensitive-recurrent-ovarian-cancer--review/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-proposals-on-biosimilars-pay-for-delay-spark-controversy/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-consequence-of-switching-to-citalopram-after-its-generic-entry-for-adult-patients-with-major-depressive-disorder-mdd-treated-with-escitalopram/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparing-healthcare-costs-of-medicaid-patients-with-postherpetic-neuralgia-phn-treated-with-lidocaine-patch-5-percent-versus-gabapentin-or-pregabalin/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-of-copd--relationships-between-daily-dosing-frequency-adherence-resource-use-and-costs/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/seventh-circuit-creates-uncertainty-about-401k-provider-rfps/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/societal-costs-of-prescription-opioid-abuse-dependence-and-misuse-in-the-united-states/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/copayment-level-treatment-persistence-and-health-care-utilization-in-hypertension-patients-treated-with-single-pill-combination-therapy/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiologic-evaluation-of-cardiovascular-risk-in-patients-receiving-milnacipran-venlafaxine-or-amitriptyline--evidence-from-french-health-data/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/compliance-persistence-healthcare-resource-use-and-treatment-costs-associated-with-aliskiren-plus-arb-versus-ace-inhibitor-plus-arb-combination-therapy/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-choice-trial--adalimumab-demonstrates-safety-fistula-healing-improved-quality-of-life-and-increased-work-productivity-in-patients-w-crohn-s/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/computerized-algorithms-for-the-identification-of-irritable-bowel-syndrome-colonic-ischemia-and-complications-of-constipation/2024-01-11T10:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-persistence-healthcare-utilization-and-costs-in-adult-patients-with-major-depressive-disorder--a-comparison-between-escitalopram/2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comorbidity-burden-healthcare-resource-utilization-and-costs-in-chronic-gout-patients-refractory-to-conventional-urate-lowering-therapy/2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/average-wholesale-price--efficient-benchmark-or-conspiratorial-instrument-/2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ensuring-a-clean-modern-electric-generating-fleet-while-maintaining-electric-system-reliability--summer-2011-update/2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ensuring-a-clean-modern-electric-generating-fleet-while-maintaining-electric-system-reliability--fall-2011-update/2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/solar-development-incentives--status-of-colorados-solar-pv-program-practices-in-other-states-and-suggestions-for-next-steps/2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/exact-and-efficient-inference-procedure-for-meta-analysis-and-its-application-to-the-analysis-of-independent-2--2-tables/2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/americas-bright-future--cleaner-air-and-affordable-reliable-electricity/2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/all-cause-and-potentially-disease-related-health-care-costs-associated-with-venous-thromboembolism-in-commercial-medicare-and-medicaid-beneficiaries/2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-analysis-of-everolimus-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-advanced-breast-cancer/2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-dermatologic-adverse-drug-reactions-in-the-treatment-of-colorectal-non-small-cell-lung-and-head-and-neck-cancers/2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/demand-response-in-capacity-markets--reliability-dispatch-and-emission-outcomes/2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/re--stopeck-a-rader-m-henry-d-et-al.-cost-effectiveness-of-denosumab-vs.-zoledronic-acid-for-prevention-of-skeletal-related-events2024-01-11T10:40:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-medication-adherence-to-disease-modifying-drugs-on-severe-relapse-and-direct-and-indirect-costs-among-employees-with-multiple-sclerosis-in-u.s2024-01-11T10:40:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-practice-patterns-health-care-utilization-and-costs-in-patients-with-low-back-pain--the-long-road-to-guideline-concordant-care/2024-01-11T10:40:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disjunctions-of-conjunctions-cognitive-simplicity-and-consideration-sets/2024-01-11T10:40:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recent-average-price-trends-for-implantable-medical-devices-2007-2011/2024-01-11T10:40:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-incremental-net-health-benet-of-requirements-for-cardiovascular-risk-evaluation-for-diabetes-therapies/2024-01-11T10:40:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-of-pasireotide-for-the-treatment-of-cushing-s-disease-a-rare-endocrine-disorder-associated-with-considerable-comorbidities/2024-01-11T10:40:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-quality-of-life-and-costs-associated-with-implantation-of-vagus-nerve-stimulation-therapy/2024-01-11T10:40:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/advanced-diagnostics--innovation-reimbursement-and-coverage-challenges/2024-01-11T10:40:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-completing-chronic-hepatitis-c-chc-treatment-on-post-therapy-healthcare-cost/2024-01-30T17:42:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-adults-with-major-depressive-disorder-in-the-united-states-2005-and-2010/2024-01-11T10:40:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-implementing-a-multiple-inflammatory-biomarker-based-approach-to-identify-treat-and-reduce-cardiovascular-risk/2024-01-11T10:40:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-use-and-costs-of-privately-insured-patients-who-switch-discontinue-or-persist-on-anti-muscarinic-therapy-for-overactive-bladder/2024-01-11T10:40:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-the-utility-of-existing-patient-reported-outcome-scales-in-novel-patient-populations-with-pancreatic-cancer-lung-cancer-and-myeloproliferative-neoplasms-using-medicare-current-beneficiary/2024-01-11T10:40:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-model-to-identify-patients-at-risk-for-prescription-opioid-abuse-dependence-and-misuse/2024-01-11T10:40:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-resource-use-and-economic-outcomes-associated-with-atypical-antipsychotic-prescriptions-in-children-and-adolescents-with-attention-deficit-hyperactivity-disorder-in-quebec/2024-01-11T10:40:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-outcomes-of-everolimus-temsirolimus-and-sorafenib-as-second-targeted-therapies-for-metastatic-renal-cell-carcinoma--a-us-medical-record-review/2024-01-11T10:40:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-analysis-of-everolimus-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-her2--advanced-breast-cancer-in-the-united-states/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/sleep-quality-and-other-patient-reported-outcomes-improve-after-patients-with-psoriasis-with-suboptimal-response-to-other-systemic-therapies-are-switched-to-adalimumab--results-from-progress-an-open-/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hypoglycemia-treatment-discontinuation-and-costs-in-patients-with-type-2-diabetes-mellitus-on-oral-antidiabetic-drugs/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/deutsche-bahn-files-suit-in-german-court-seeking-1.8-billion-in-damages2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-time-to-clinical-response-a-proxy-for-discharge-readiness-among-hospitalized-patients-with-community-acquired-pneumonia-who-received-either-ceftaroline-fosamil-or-ceftriaxone-in-two-ph/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-validity-responsiveness-and-meaningfulness-of-the-hidradenitis-suppurativa-clinical-response-hiscr-as-the-clinical-endpoint-for-hidradenitis-suppurativa-treatment/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-the-efficacy-of-sequential-biologic-therapies-for-rheumatoid-arthritis-patients-with-an-inadequate-response-to-tumor-necrosis-factor--inhibitors/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/validation-of-the-headache-impact-test-hit-6-across-episodic-and-chronic-migraine/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measuring-the-health-status-burden-in-hemodialysis-patients-using-the-sf-36-health-survey/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-evaluation-of-the-effects-of-an-angiotensin-receptor-blocker-on-health-related-quality-of-life-in-patients-with-high-normal-blood-pressure-prehypertension-in-the-trial-of-preventing-hypertension/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-prescribing-decision-drivers-and-predictors-of-complete-response-following-disease-recurrence-in-gastrointestinal-stromal-tumor-patients-a-chart-extract-based-approach/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-patterns-of-endocrine-therapy-for-metastatic-hormone-receptor-positive-hrhuman-epidermal-growth-factor-receptor-2-negative-her2--breast-cancer-patients-in-the-united-states--2002-2012/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-gastrointestinal-stromal-tumor-gist-recurrence-in-patients-who-have-received-adjuvant-imatinib-therapy/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/confound-it-revisiting-the-special-case-of---overdisclosure---in-the-context-of-halliburtons-price-impact-test/2024-01-11T10:40:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-health-care-resource-utilization-and-costs-in-u.s.-patients-diagnosed-with-chronic-hepatitis-c-infection-who-received-telaprevir-or-boceprevir2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-economics-outcomes-epidemiology-published-research-and-presentations/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economists-perspective-on-the-efficiency-defense-in-provider-consolidations--what-works-what-doesnt-work-and-what-we-still-dont-know/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-index-of-intergenerational-equity--2016/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-private-damages-actions-in-the-united-states-canada-and-the-european-union/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-healthcare-costs-and-dose-escalation-in-psoriasis-patients-initiated-on-ustekinumab-versus-adalimumab--a-retrospective-claim-study/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-ceritinib-in-patients-previously-treated-with-crizotinib-in-anaplastic-lymphoma-kinase-positive-alk-non-small-cell-lung-cancer-in-canada/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rotavirus-vaccination-in-a-medicaid-infant-population-from-four-us-states--compliance-vaccination-completion-rate-and-predictors-of-compliance/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-overall-survival-healthcare-resource-use-and-costs-in-elderly-medicare-beneficiaries-with-chronic-myeloid-leukemia-using-second-generation-tyrosine-kinase-inhibitors-as-second-lin/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-illness-among-patients-with-fragile-x-syndrome-fxs--a-medicaid-perspective/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-ocular-complications-in-patients-with-noninfectious-intermediate-uveitis-posterior-uveitis-or-panuveitis/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-glycemic-blood-pressure-and-weight-control-in-patients-with-type-2-diabetes-mellitus-treated-with-canagliflozin-an-electronic-health-record-based-study/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-expanded-use-of-biologic-therapy-for-the-treatment-of-rheumatoid-arthritis-and-crohn-s-disease-in-argentina-brazil-colombia-and-mexico/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/asas40-and-asdas-clinical-responses-in-the-ability-1-clinical-trial-translate-to-meaningful-improvements-in-physical-function-health-related-quality-of-life-and-work-productivity-in-patients-with-non/2024-01-11T10:40:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/care-pathways-in-us-healthcare-settings--current-successes-and-limitations-and-future-challenges/2024-01-11T10:40:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-treatment-patterns-and-survival-among-alk-non-small-cell-lung-cancer-nsclc-patients-treated-with-crizotinib--a-chart-review-study/2024-01-11T10:40:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/basal-insulin-persistence-associated-factors-and-outcomes-after-treatment-initiation-among-people-with-type-2-diabetes-mellitus-in-the-us/2024-01-11T10:40:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-analysis-model-of-colonoscopy-preparation-using-split-dose-reduced-volume-oral-sulfate-solution-oss-and-polyethylene-glycol-with-electrolytes-solution-peg-els/2024-01-11T10:40:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-indirect-comparison-and-cost-per-responder-analysis-of-adalimumab-methotrexate-and-apremilast-in-the-treatment-of-methotrexate-naive-patients-with-psoriatic-arthritis/2024-01-11T10:40:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-outcomes-health-care-resource-utilization-and-costs-of-bortezomib-and-dexamethasone-with-cyclophosphamide-or-lenalidomide-in-newly-diagnosed-multiple-myeloma/2024-01-11T10:40:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-and-associated-incremental-costs-of-treatment-with-enzalutamide-versus-abiraterone-acetate-plus-prednisone-in-chemotherapy-naive-patients-with-metastatic-castration-resistant-pr2/2024-01-11T10:40:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/individualized-prediction-of-changes-in-6-minute-walk-distance-for-patients-with-duchenne-muscular-d1/2024-01-11T10:40:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/asas40-and-asdas-clinical-responses-in-the-ability-1-clinical-trial-translate-to-meaningful-improvem1/2024-01-11T10:40:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-comparison-of-damage-theories-in-price-fixing-cases-in-the-united-states-canada-and-the-european-union/2024-01-11T10:40:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-clinical-and-economic-burden-of-mucormycosis-related-hospitalizations-in-the-united-states--a-retrospective-study/2024-01-11T10:40:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/calculating-damages-in-price-fixing-cases-in-the-united-states-canada-and-the-european-union/2024-01-11T10:40:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-of-statistical-sampling-in-litigation1/2024-01-11T10:40:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-cost-of-capital1/2024-01-11T10:40:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electricity-markets-reliability-and-the-evolving-u.s.-power-system2024-01-11T10:40:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-research--a-pharmaceutical-industry-perspective-on-outlook-dilemmas-and-controversies/2024-01-11T10:40:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/decision-making-with-machine-learning-in-our-modern-data-rich-health-care-industry/2024-01-11T10:40:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hedge-funds--the-good-the-bad-and-the-lucky/2024-01-11T10:40:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-weight-change-among-patients-treated-with-glucagon-like-peptide-1-receptor-agonist-dipeptidyl-peptidase-4-inhibitor-and-sulfonylureas/2024-01-11T10:40:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-healthcare-resource-utilization-and-costs-following-first-line-antidepressant-treatment-in-major-depressive-disorder--a-retrospective-us-claims-database-analysis/2024-01-11T10:40:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/basal-insulin-persistence-associated-factors-and-outcomes-after-treatment-initiation--a-retrospective-database-study-among-people-with-type-2-diabetes-mellitus-in-japan/2024-01-11T10:40:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-isavuconazole-vs.-voriconazole-as-first-line-treatment-for-invasive-a12024-01-11T10:40:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-reduction-from-resolutionimprovement-of-carcinoid-syndrome-symptoms-following-treatment-with-a1/2024-01-11T10:40:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-and-safety-of-attention-deficithyperactivity-disorder-pharmacotherapies-including-guanfacine-extended-release--a-mixed-treatment-comparison/2024-01-11T10:40:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-common-adverse-events-associated-with-metastatic-colorectal-cancer-treatment-1/2024-01-11T10:40:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-healthcare-costs-among-newly-diagnosed-patients-with-chronic-myeloid-leukemia1/2024-01-11T10:40:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-systemic-glucocorticoid-related-complications-in-severe-asthma1/2024-01-11T10:40:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-biologic-disease-modifying-antirheumatic-drugs-for-the-treatment-of-rheumatoid-arthritis-after-etanercept-discontinuation-in-the-united-kingdom-france-and-germany/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antibiotic-treatment-patterns-costs-and-resource-utilization-among-patients-with-community-acquired-pneumonia--a-us-cohort-study/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-retrospective-study-to-assess-clinical-characteristics-and-time-to-initiation-of-open-triple-therapy-among-patients-with-chronic-obstructive-pulmonary-disease-newly-established-on-longacting-mono-/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-persistence-and-inpatient-utilization-among-adult-schizophrenia-patients-using-once-monthly-versus-twice-monthly-long-acting-atypical-antipsychotics/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-real-world-central-nervous-system-events-in-patients-with-advanced-prostate-cancer-using-abiraterone-acetate-bicalutamide-enzalutamide-or-chemotherapy/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-health-care-resource-utilization-and-spending-in-medicaid-beneficiaries-initiating-second-generation-long-acting-injectable-agents-versus-oral-atypical-antipsychotics/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-of-everolimus-for-the-treatment-of-progressive-well-differentiated-non-functional-neuroendocrine-tumors-of-gastrointestinal-or-lung-origin-that-are-advanced-or-metastatic/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effect-of-adalimumab-on-visual-functioning-in-patients-with-noninfectious-intermediate-uveitis-posterior-uveitis-and-panuveitis-in-the-visual-1-and-visual-2-trials/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/corticosteroid-related-adverse-events-systematically-increase-with-corticosteroid-dose-in-noninfectious-intermediate-posterior-or-panuveitis--post-hoc-analyses-from-the-visual-1-and-visual-2-trials/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-complications-and-health-care-utilization-among-endometriosis-patients-undergoing-a-laparoscopy-or-a-hysterectomy--a-retrospective-claims-analysis/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patterns-of-disease-monitoring-and-treatment-among-patients-with-tuberous-sclerosis-complex-related-1/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-healthcare-costs-and-dose-escalation-in-psoriasis-patients-initiated-on-ustekinumab-versus-adalimumab--a-retrospective-claim-study2/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-ocrelizumab-versus-subcutaneous-interferon-beta-1a-for-the-treatment-1/2024-01-11T10:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/projecting-the-cost-utilization-and-patient-care-impact-of-prescribing-extended-release-non-abuse-deterrent-opioids-to-chronic-pain-patients/2024-01-11T10:40:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-use-costs-and-disease-progression-associated-with-diabetic-nephropathy-in-adults-with-type-2-diabetes--a-retrospective-observational-study/2024-01-11T10:40:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lost-profits-damages--principles-methods-and-applications/2024-01-11T10:40:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comment-on-the-flaws-in-using-the-hypothetical-monopolist-test-from-the-payor-perspective-in-health-care-merger-cases-by-field-fisher-and-coglianese/2024-01-11T10:40:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/joint-ventures-group-boycotts-and-volume-discounts/2024-01-11T10:40:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/united-states-v.-energy-solutionsperspectives-on-litigating-antitrust-merger-challenges2024-01-11T10:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survey-evidence-to-evaluate-a-marketing-claim--skye-astiana-plaintiff-v.-ben-and--jerry-s-homemade-inc.-defendant2024-01-11T10:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/government-takeovers-of-water-systems-are-costly-dont-deliver-results/2024-01-11T10:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-nine-northeast-and-mid-atlantic-states--review-of-rggis-third-three-year-compliance-period-2015-2017/2024-01-11T10:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/back-to-school--a-primer-on-university-403b-plan-litigation/2024-01-11T10:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-healthcare-resource-utilization-and-costs-in-patients-with-acute-myeloid-leukemia-in-commercially-insured-and-medicare-populations/2024-01-11T10:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-evaluation-of-hba1c-blood-pressure-and-weight-loss-among-patients-with-type-2-diabetes-mellitus-treated-with-canagliflozin/2024-01-11T10:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/factors-associated-with-the-number-and-size-of-renal-angiomyolipomas-in-sporadic-angiomyolipoma-saml--a-study-of-adult-patients-with-saml-managed-in-a-dutch-tertiary-referral-center/2024-01-11T10:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/asthma-control-lung-function-symptoms-and-corticosteroid-sparing-after-omalizumab-initiation-in-patients-with-allergic-asthma/2024-01-11T10:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-trajectories-healthcare-resource-use-and-costs-of-diabetic-nephropathy-among-patients-with-type-2-diabetes--a-latent-class-analysis/2024-01-11T10:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reimbursement-landscape-for-molecular-testing-in-non-small-cell-lung-cancer-nsclc/2024-01-11T10:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-additional-costs-per-month-of-progression-free-survival-and-overall-survival--an-economic-model-comparing-everolimus-with-cabozantinib-nivolumab-and-axitinib-for-second-line-treatment-of-metasta/2024-01-11T10:40:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reliability-of-coded-data-to-identify-earliest-indications-of-cognitive-decline-cognitive-evaluation-and-alzheimer-s-disease-diagnosis--a-pilot-study-in-england/2024-01-11T10:40:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-treatment-patterns-and-economic-outcomes-of-patients-initiating-injectable-medications-for-management-of-type-2-diabetes-mellitus-in-japan/2024-01-11T10:40:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluation-of-clinical-outcomes-among-nonvalvular-atrial-fibrillation-patients-treated-with-rivaroxaban-or-warfarin-stratified-by-renal-function/2024-01-11T10:40:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/value-of-transfusion-independence-in-severe-aplastic-anemia-from-patients-perspectives--a-discrete-choice-experiment/2024-01-11T10:40:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-clinical-and-economic-outcomes-of-patients-with-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-receiving-ceritinib--a-retrospective-observational-claims-analysis/2024-01-11T10:40:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risk-of-cardiovascular-events-in-psoriasis-patients-treated-with-tumor-necrosis-factor--inhibitors-versus-phototherapy--an-observational-cohort-study/2024-01-11T10:40:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/singleton-v.-fifth-generation-inc2024-01-11T10:40:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-outcomes-with-subcutaneous-bortezomib-in-patients-with-relapsed-mantle-cell-lymphoma--a-retrospective-observational-study-of-patient-medical-records-from-us-community-oncology/2024-01-11T10:40:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dosing-patterns-and-economic-burden-of-palbociclib-drug-wastage-in-hrher2--metastatic-breast-cancer/2024-01-11T10:40:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/occupational-licensing-in-healthcare-and-beyond--recent-developments-in-case-law-enforcement-legislation-and-research/2024-01-26T17:36:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/clean-water-act-section-316b-engagements/2024-01-11T10:40:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-matter-analysis-of-environmental-contamination-claims/2024-01-11T10:40:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-matter-determination-of-financial-solvency-tests/2024-01-11T10:40:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/enviro-petroleum-inc.-v.-kondur-petroleum-s.a2024-01-11T10:40:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ben-s.-branch-trustee-of-bank-of-new-england-corporation-v.-federal-deposit-insurance-corporation2024-01-11T10:40:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/honeywell-international-inc.-v.-air-products-and-chemicals2024-01-11T10:40:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/study-of-exchange-traded-fund-products-for-american-stock-exchange-nasd-and-american-express/2024-01-11T10:40:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/resonate-inc.-v.-nortel-networks2024-01-11T10:40:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/twister-communications-network-inc.-v.-mci-worldcom-network-services-inc2024-01-11T10:40:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/professional-services-company--performance-rankings/2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/class-action-v.-helping-hands-company-inc2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/valassis-communications-inc.-v.-advo-inc2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/glaxosmithkline-holdings-americas-inc.-v.-commissioner-of-the-irs2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/heuft-systemtechnik-gmbh-v.-industrial-dynamics-co.-ltd2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v.-biopure-corporation-et-al2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/phibro-tech-inc.-v.-osmose-inc2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lee-conrad-v.-eps-solutions-corporation2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cogent-systems-inc.-v.-northrop-grumman-corporation2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/slm-corporation-sallie-mae-v.-j.c.-flowers-ii-l.p2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fdic-v.-bright-first-republic-bank-of-dallas2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/commonwealth-court-building-inc.-v.-criimi-mae-services2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/national-westminster-bank-natwest-v.-us-dept.-of-justice-taxation-division2024-01-11T10:40:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/authorized-generics-competition-and-consumer-prices/2024-01-11T10:40:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/boeing-satellite-systems-international-inc.-v.-ico-global-communications-operations-ltd2024-01-11T10:40:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/louisiana-wholesale-drug-co.-inc.-v.-sanofi-aventis2024-01-11T10:40:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/401k-fee-litigation/2024-01-11T10:40:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/surface-transportation-board--stb-ex-parte-no.-664-sub-no.-12024-01-11T10:40:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bracco-diagnostics-inc.-v.-amersham-health-inc2024-01-11T10:40:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-retek-inc.-securities-litigation2024-01-11T10:40:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lkf-x-investments-lkf-x-capital-corporation-tax-matters-partner-v.-the-commissioner-of-internal-revenue2024-01-11T10:40:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ventas-inc.-v.-hcp-inc2024-01-11T10:40:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/raymond-road-associates-blue-back-square-v.-taubman-centers2024-01-11T10:40:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/palm-canyon-x-investments-llc-ah-investment-holdings-inc.-tax-matters-partner-v.-commissioner-of-internal-revenue-service2024-01-11T10:40:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bavarian-nordic-v.-acambis-plc-inv.-no.-337-ta-5502024-01-11T10:40:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/american-express-v.-visa-and-mastercard-and-related-litigations2024-01-11T10:40:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/playtex-products-inc.-v.-procter-and--gamble-company2024-01-11T10:40:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pbm-products-inc.-v.-mead-johnson2024-01-11T10:40:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/astrazeneca-v.-tap-pharmaceuticals-inc2024-01-11T10:40:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/johnette-c.-alexander-et-al.-v.-kia-motors-america-inc2024-01-11T10:40:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/minuteman-trucks-inc.-v.-hn80-corporation-and-sterling-truck-corp2024-01-11T10:40:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sp-syntax-silver-point-capital-l.p.-v.-ernst-and--young-llp2024-01-11T10:40:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/gallus-et-al.-v.-ameriprise-financial-inc2024-01-11T10:40:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/st.-jude-medical-inc.-v.-access-closure-inc2024-01-11T10:40:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/new-jersey-carpenters-vacation-fund-et-al.-v.-the-royal-bank-of-scotland-group-plc-et-al2024-01-11T10:40:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/air-products-and--chemicals-inc.-v.-airgas-inc2024-01-11T10:40:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cheetah-omni-llc-v.-verizon-services-corporation-et-al2024-01-11T10:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bedrock-computer-technologies-llc-v.-google-inc2024-01-11T10:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/biotechnology-firm-10b-5-matter--phase-iii-testing/2024-01-11T10:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/biotechnology-firm-10b-5-matter--human-testing/2024-01-11T10:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bedrock-computer-technologies-llc-v.-yahoo2024-01-11T10:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/convolve-inc.-v.-dell-inc.-western-digital-corporation-hitachi-global-storage-technologies-inc.-and-hitachi-ltd2024-01-11T10:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/vietnam-telecom-international-v.-eddie-inyang-et-al2024-01-11T10:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/the-citri-lite-company-v.-cott-beverages-inc2024-01-11T10:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fairview-donut-inc.-et-al.-v.-the-tdl-group-tim-hortons2024-01-11T10:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/safeco-insurance-company-of-america-et-al.-v.-aig-et-al2024-01-11T10:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ceats-inc.-v.-continental-airlines-inc.-et-al2024-01-11T10:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fresh-del-monte-produce-inc.-v.-del-monte-foods-co.-et-al2024-01-11T10:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/t.-jeffrey-simpson-et-al.-v.-homestore.com-inc.-et-al2024-01-11T10:40:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bone-care-international-v.-roxane-labs-et-al2024-01-11T10:40:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/peter-claydon-v.-nestle-waters-north-america-inc.-et-al2024-01-11T10:40:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/martin-marietta-materials-inc.-v.-vulcan-materials-company2024-01-11T10:40:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/augustus-et-al.-v.-american-commercial-security-services-inc.-et-al.-abm-security-services-inc2024-01-11T10:40:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fishman-transducers-inc.-v.-stephen-paul-dba-esteban-et-al2024-01-11T10:40:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/galderma-laboratories-et-al.-v.-tolmar-inc2024-01-11T10:40:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ddr-holdings-llc-v.-hotels.com-lp-et-al2024-01-11T10:40:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/adelphia-recovery-trust-v.-bank-of-america-et-al2024-01-11T10:40:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-injunction-ruling-december-20122024-01-11T10:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/tyco-healthcare-group-lp-et-al.-v.-ethicon-endo-surgery-inc2024-01-11T10:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/hitachi-consumer-electronics-co.-ltd.-and-hitachi-advanced-digital-inc.-v.-top-victory-electronics-taiwan-co.-ltd.-et-al2024-01-11T10:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-industry-practices-associated-with-swaps-high-yield-loans/2024-01-11T10:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-optionsxpress-inc.-thomas-e.-stern-and-jonathan-i.-feldman2024-01-11T10:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-the-finances-of-the-city-of-vernon-california/2024-01-11T10:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lake-cherokee-hard-drive-technologies-llc-v.-marvell-semiconductor-inc2024-01-11T10:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re--tft-lcd-flat-panel-antitrust-litigation/2024-01-11T10:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-certain-products-having-laminated-packaging-laminated-packaging-and-components-thereof/2024-01-11T10:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/universal-electronics-inc.-v.-universal-remote-control-inc2024-01-11T10:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/quantifying-energy-savings-and-emission-reductions-under-the-section-111d-carbon-pollution-standard/2024-01-11T10:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fraley-et-al.-v.-facebook-inc.-et-al2024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-certain-integrated-circuit-chips-and-products-containing-the-same-inv.-no.-337-ta-8592024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-injunction-ruling-july-20142024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-trial-may-20142024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-trial-may-2014--professor-judith-chevalier2024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-trial-may-2014--professor-tulin-erdem2024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-trial-may-2014--professor-george-foster2024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-trial-may-2014--professor-david-reibstein2024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/simpleair-v.-google-et-al2024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-of-america-v.-robert-j.-gagalis-et-al2024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/veleron-holding-bv-v.-bnp-paribas-sa-et-al2024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/alfa-gomma-s.p.a.-v.-veyance-technologies-inc2024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/j.c.-van-apeldoorn-and-e.t.-meijer-in-their-capacity-as-trustees-in-bankruptcy-for-kpnqwest-n.v.-et-al.-v.-qwest-communications-international-inc.-qwest-et-al2024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-dole-food-company-inc.-stockholder-litigation2024-01-11T10:40:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lightbourne-v.-cbs-interactive-et-al2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of--certain-footwear-products-investigation-number-337-ta-936/2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/c5-medical-werks-llc-v.-ceramtec-gmbh2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-of-america-v.-energysolutions-inc.-et-al2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/american-tradition-institute-and-rod-lueck-v.-epel-et-al2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/state-of-north-carolina-ex-rel.-roy-cooper-attorney-general-v.-tennessee-valley-authority2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-v.-mark-david-radley-et-al2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mount-olympus-mortgage-company-v.-anderson-et-al2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/noven-pharmaceuticals-inc.-v.-actavis-laboratories-ut-inc2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/morgantown-ol1-llc-et-al.-v.-genon-mid-atlantic-llc-et-al2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cotromano-et-al.-v.-united-technologies-corp.-et-al.-and-adinolfe-et-al.-v.-united-technologies-corp2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/huff-fund-investment-partnership-v.-ckx-inc2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/david-t.-stevenson-et-al.-v.-delaware-department-of-natural-resources-et-al2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/application-of-california-american-water-company-for-authorization-to-modify-conservation-and-rationing-rules-rate-design-and-other-related-issues-for-the-monterey-district/2024-01-11T10:40:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-trade-commission-et-al.-v.-penn-state-hershey-medical-center-et-al2024-01-11T10:40:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/maxell-ltd.-v.-zte-usa-inc2024-01-11T10:40:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ftc-v.-wilhelm-wilhelmsen-et-al2024-01-26T17:35:30+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/wolf-pack-activism--a-deeper-look/2022-08-09T15:11:37+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/analysis-group-insights-featured-in-law360/2024-01-11T10:38:42+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2021-09-17T00:11:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-business-of-economic-consulting/2024-01-11T10:37:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/discussion-of-the-value-relevance-of-intangibles--the-case-of-software-capitalization/2024-01-11T10:37:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fair-value-disclosures-by-bank-holding-companies/2024-01-11T10:37:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-estimation/2024-01-11T10:37:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-baseball-can-teach-policymakers/2024-01-11T10:37:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-clinical-benefits-of-erythropoietic-agents-using-area-under-the-hemoglobin-change-curve/2024-01-11T10:37:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-schizophrenia-in-the-united-states-in-2002/2024-01-11T10:37:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/market-efficiency-versus-behavioral-finance/2024-01-11T10:37:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/energy-and-environmental-policy-in-the-united-states--synergies-and-challenges-in-the-electric-industry/2024-01-11T10:37:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-effects-of-federal-participation-in-terrorism-risk/2024-01-11T10:37:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-importance-of-federal-participation-in-terrorism-risk/2024-01-11T10:37:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/does-econ-analysis-shortchange-future-/2024-01-11T10:37:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/benefits-associated-with-an-early-hemoglobin-response-to-epoetin-alfa-therapy-in-the-treatment-of-chemotherapy-related-anemia/2024-01-11T10:37:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/some-straight-talk-needed-about-csr/2024-01-11T10:37:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-utility-safety-valve-for-cutting-co2/2024-01-11T10:37:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hedge-funds-today--caveat-emptor/2024-01-11T10:37:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-benefit-cost-analysis-helpful-/2024-01-11T10:37:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/application-of-game-theory-to-intellectual-property-royalty-negotiations/2024-01-11T10:37:20+00:00weekly0.7https://www.analysisgroup.com/practices/valuation/financial-instrument-valuation/2020-07-10T17:33:30+00:00weekly0.7https://www.analysisgroup.com/practices/valuation/business-enterprise-valuation/2020-07-10T18:13:36+00:00weekly0.7https://www.analysisgroup.com/practices/valuation/valuation-of-other-assets/2020-07-16T17:12:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pedestrian-and-motor-vehicle-post-stop-data-analysis-report/2024-01-11T10:37:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-cost-benefit-assessment-of-wholesale-electricity-restructuring-and-competition-in-new-england/2024-01-11T10:37:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/calculating-damages-in-broker-raiding-cases/2024-01-11T10:37:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-and-effects-of-mood-disorders-on-work-performance-in-a-nationally-representative-sample-of-u-s--workers/2024-01-11T10:37:20+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/modernization-opportunities-in-new-epa-regulations/2018-11-01T15:16:54+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/sizing-up-the-competition--antitrust-enforcement-and-the-bazaarvoice-ruling/2018-11-01T15:16:54+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/merger-arbitrage-spread---still-shrinking-/2018-11-01T15:16:54+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/the-right-expert-essential-to-bear-stearns-acquittal/2019-03-11T00:07:48+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/academic-perspectives-on-investor-activism/2019-07-23T17:27:29+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/high-frequency-trading-investigations/2022-10-27T15:14:12+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/energy-and-environment/2020-03-02T17:50:29+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/deal-metrics/2020-03-02T17:50:09+00:00weekly0.7https://www.analysisgroup.com/about/locations/boston/2024-01-11T10:36:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/george-kosicki/2024-01-11T10:36:20+00:00weekly0.7https://www.analysisgroup.com/about/locations/montreal/2024-01-11T10:36:19+00:00weekly0.7https://www.analysisgroup.com/about/locations/london/2024-01-11T10:36:19+00:00weekly0.7https://www.analysisgroup.com/about/locations/brussels/2024-01-11T10:36:20+00:00weekly0.7https://www.analysisgroup.com/about/locations/paris/2024-01-11T10:36:20+00:00weekly0.7https://www.analysisgroup.com/careers/why-analysis-group/our-people/2023-12-29T17:25:11+00:00weekly0.7https://www.analysisgroup.com/about/locations/chicago/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/about/locations/dallas/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/about/locations/denver/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/about/locations/los-angeles/2024-01-11T10:36:17+00:00weekly0.7https://www.analysisgroup.com/about/locations/menlo-park/2024-01-11T10:36:17+00:00weekly0.7https://www.analysisgroup.com/about/locations/washington-dc/2024-01-11T10:36:17+00:00weekly0.7https://www.analysisgroup.com/about/locations/new-york/2024-01-11T10:36:17+00:00weekly0.7https://www.analysisgroup.com/about/locations/san-francisco/2024-01-11T10:36:17+00:00weekly0.7https://www.analysisgroup.com/about/locations/beijing/2024-01-11T10:36:17+00:00weekly0.7https://www.analysisgroup.com/globalassets/episerver-forms/experts-and-consultants/principals/2018-08-27T16:12:26+00:00weekly0.6https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-n--mishol/2024-01-11T10:36:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/dave-nellesen/2024-01-11T10:36:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/paul-j--hibbard/2024-01-24T15:40:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/almudena-arcelus/2024-01-11T10:36:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/elizabeth-a--eccher/2024-01-11T10:36:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/robert-l--vigil/2024-01-11T10:36:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/marnie-a--moore/2024-01-11T10:36:19+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/david-w--sosa/2024-01-11T10:36:19+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/antoine-chapsal/2024-02-06T17:56:00+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/laura-boothman-stamm/2024-01-11T10:36:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/robert-s--pindyck/2024-01-11T10:36:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/dennis-j--aigner/2024-01-11T10:36:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/laurence-c--baker/2024-01-11T10:36:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/ray-ball/2024-01-11T10:36:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/edward-p--kahn/2024-01-11T10:36:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/lawrence-m--benveniste/2024-01-11T10:36:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/patricia-chadwick/2024-01-11T10:36:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/judith-a--chevalier/2024-01-11T10:36:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/dwight-b--crane/2024-01-11T10:36:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/michael-r--darby/2024-01-11T10:36:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/francis-x--diebold/2024-01-11T10:36:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/mark-s--grinblatt/2024-01-11T10:36:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/r--glenn-hubbard/2024-01-11T10:36:22+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/philippe-jorion/2024-01-11T10:36:22+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/k--ramesh/2024-01-11T10:36:22+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/meir-statman/2024-01-11T10:36:22+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/peter-tufano/2024-01-11T10:36:22+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/lawrence-p--weiner/2024-01-11T10:36:22+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/susan-e--woodward/2024-01-11T10:36:22+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/karen-hopper-wruck/2024-01-11T10:36:22+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/robert-a--sherwin/2024-01-11T10:36:23+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/arnold-i--barnett/2024-01-11T10:36:23+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/sebastian-edwards/2024-01-11T10:36:23+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/kathleen-m--eisenhardt/2024-01-11T10:36:23+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/steven-d--eppinger/2024-01-11T10:36:23+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/marshall-l--fisher/2024-01-11T10:36:23+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/pierre-fortin/2024-01-11T10:36:23+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/brian-j--hall/2024-01-11T10:36:23+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/john-r--hauser/2024-01-11T10:36:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/luis-m--huete/2024-01-11T10:36:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/ronald-c--kessler/2024-01-11T10:36:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/william-h--lehr/2024-01-11T10:36:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/burton-g--malkiel/2024-01-11T10:36:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/john-w--mayo/2024-01-11T10:36:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/j--f--philip-merrigan/2024-01-11T10:36:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/randolph-bucklin/2024-01-11T10:36:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/george-foster/2024-01-11T10:36:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/robert-e--hall/2024-01-11T10:36:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/barry-m--massarsky/2024-01-11T10:36:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/shmuel-s--oren/2024-01-11T10:36:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/timothy-j--riddiough/2024-01-11T10:36:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/john-a--rizzo/2024-01-11T10:36:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/louis-f--rossiter/2024-01-11T10:36:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/robert-stavins/2024-01-11T10:36:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/ashley-j--stevens/2024-01-11T10:36:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/kerry-dean-vandell/2024-01-11T10:36:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/lawrence-j--white/2024-01-11T10:36:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/john-m--lacey/2024-02-08T17:37:43+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/michael-f--koehn/2024-01-11T10:36:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/nicholas-e--piggott/2024-01-11T10:36:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/a--mitchell-polinsky/2024-01-11T10:36:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/steven-shavell/2024-01-11T10:36:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/lori-pressman/2024-01-11T10:36:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/robert-c--blattberg/2024-01-11T10:36:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/michael-w--maher/2024-01-11T10:36:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/stephen-g--ryan/2024-01-11T10:36:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/walter-n--thurman/2024-01-11T10:36:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/marcel-boyer/2024-01-11T10:36:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/laura-t--starks/2024-01-11T10:36:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/barry-k--goodwin/2024-01-11T10:36:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/henry-g--grabowski/2024-01-11T10:36:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/frank-sloan/2024-01-11T10:36:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/edward-a--snyder/2024-01-11T10:36:28+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/john-chalmers/2024-01-11T10:36:28+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/lucian-a--bebchuk/2024-01-11T10:36:28+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/erik-brynjolfsson/2024-01-11T10:36:28+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/chris-f--kemerer/2024-01-11T10:36:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-rhuepo-in-oncology/2024-01-11T10:36:42+00:00weekly0.7https://www.analysisgroup.com/practices/antitrust-competition/collusion/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/antitrust-competition/mergers-and-acquisitions/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/antitrust-competition/monopolization-and-exclusionary-practices/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/antitrust-competition/vertical-restraints/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/class-certification/types-of-class-actions/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/class-certification/industry-experience/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/commercial-disputes/mass-torts/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/commercial-disputes/breach-of-contract/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/commercial-disputes/false-advertising/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/commercial-disputes/professional-malpractice/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/damages/specialized-expertise/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/damages/industry-experience/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/damages/causes-of-actions/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/energy-and-environment-litigation/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/energy-environmental-climate-policy/2023-04-10T13:33:15+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/infrastructure-valuation-investment-and-siting/2023-04-10T13:33:26+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/utility-ratemaking-and-regulation/2023-04-10T13:33:35+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/power-system-market-design-and-analysis/2023-04-10T13:33:43+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/mergers-and-industry-structure/2023-04-10T13:33:51+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/resource-planning-and-management/2023-12-14T15:09:04+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/chinese/eric-wu/2024-01-11T10:36:28+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/chinese/gordon-liu/2024-01-11T10:36:28+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/chinese/jun-liu/2024-01-11T10:36:28+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/jimmy-royer/2024-01-11T10:36:28+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/lisa-b--pinheiro/2024-01-11T10:36:29+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/patrick-lefebvre/2024-01-11T10:36:29+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/marc-van-audenrode/2024-01-11T10:36:29+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/paul-e--greenberg/2024-01-11T10:36:29+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/pierre-y--cremieux/2024-01-11T10:36:29+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/marissa-ginn/2024-01-11T10:36:29+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/markus-von-wartburg/2024-01-11T10:36:29+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/eric-qiong-wu/2024-01-11T10:36:29+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/richard-m--starfield/2024-01-11T10:36:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/emmanuel-frot/2024-01-11T10:36:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/eric-qiong-wu---paris/2024-01-11T10:36:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/jimmy-royer---brussels/2024-01-11T10:36:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/lisa-b--pinheiro---brussels/2024-01-11T10:36:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/marc-van-audenrode---paris/2024-01-11T10:36:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/pierre-y--cremieux---brussels/2024-01-11T10:36:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/richard-m--starfield---paris/2024-01-11T10:36:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/laura-o-laughlin/2024-01-11T10:36:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/christine-bieri/2024-01-11T10:36:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/ludmila-rovba/2024-01-11T10:36:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/anne-catherine-faye/2024-03-07T15:19:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/rajeev-ayyagari/2024-03-15T21:26:49+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/martin-cloutier/2024-03-15T21:24:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/elyse-swallow/2024-02-26T16:40:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/min-yang/2024-01-26T21:41:46+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/ivan-maryanchyk/2024-01-11T10:36:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/eileen-lu/2024-01-11T10:36:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/jenny-zhou/2024-01-11T10:36:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/shogo-hamasaki/2024-01-11T10:36:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/andrew-clarke/2024-01-11T10:36:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/peter-fabbrucci/2024-01-11T10:36:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/urvi-desai/2024-02-15T20:53:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/stephen-kiebzak/2024-01-31T15:38:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/lynn-huynh/2024-03-15T21:35:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/david-smith/2024-03-12T13:11:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/mark-berberian/2024-01-11T10:36:33+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/kristof-zetenyi/2024-03-07T15:19:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/nathan-trujillo/2024-01-11T10:36:33+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/david-toniatti/2024-01-11T10:36:33+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/yan-song/2024-03-15T21:28:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/jinlin-song/2024-03-15T21:34:34+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/dominic-pilon/2024-03-08T14:43:53+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/elizabeth-milsark/2024-02-16T15:05:19+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/anna-gumen/2024-02-06T17:56:02+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/maral-dersarkissian/2024-01-11T10:36:34+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/tracy-danner/2024-01-11T10:36:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/nick-dadson/2024-01-11T10:36:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/juliette-caminade/2024-03-07T15:19:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/megan-accordino/2024-03-12T17:04:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/federico-mantovanelli/2024-02-12T20:04:00+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/yao-lu/2024-01-11T10:36:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/fan-mu/2024-02-16T15:59:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/catherine-alford/2024-01-11T10:36:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/andrew-j--ungerer/2024-01-11T10:36:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/michael-schreck/2024-01-11T10:36:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/marjolaine-gauthier-loiselle/2024-03-15T21:24:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/thomas-zimmerfaust/2024-01-11T10:36:36+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/joshua-levine/2024-01-11T10:36:36+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/lucia-tiererova/2024-01-11T10:36:36+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/gautam-sajeev/2024-01-11T10:36:36+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/patrick-lefebvre/2024-03-15T21:30:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/michael-holland/2024-01-11T10:36:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/aaron-yeater/2024-03-12T13:11:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/lisa-b--pinheiro/2024-01-12T14:02:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/crystal-pike/2024-01-11T10:36:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/dov-rothman/2024-01-26T17:35:29+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/james-signorovitch/2024-03-15T21:28:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/pierre-y--cremieux/2024-01-19T15:53:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/brian-s--gorin/2024-01-11T10:36:38+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/jeffrey-h--kinrich/2024-01-11T10:36:38+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/john-c--jarosz/2024-01-19T15:53:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/senior-advisors/keith-r--ugone/2024-03-12T13:11:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/marc-van-audenrode/2024-01-11T10:36:39+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/paul-e--greenberg/2024-02-15T20:11:22+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/rebecca-kirk-fair/2024-03-07T15:19:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/bruce-f--deal/2024-01-11T10:36:39+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/r--jeffrey-malinak/2024-02-27T14:35:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/alan-g--white/2024-03-01T21:23:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/senior-advisors/bruce-a--strombom/2024-01-11T10:36:40+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/carla-s--mulhern/2024-01-11T10:36:40+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/t--christopher-borek/2024-01-11T10:36:40+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/edward-tuttle/2024-01-11T10:36:40+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/laurits-r--christensen/2024-01-11T10:36:40+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/d--lee-heavner/2024-01-11T10:36:40+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/mark-h--egland/2024-01-11T10:36:40+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/richard-m--starfield/2024-02-08T17:37:44+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/maureen-m--chakraborty/2024-01-11T10:36:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/nicholas-i--crew/2024-01-11T10:36:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/mei-sheng-duh/2024-03-15T16:43:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/justin-n--mclean/2024-01-11T10:36:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/gaurav-jetley/2024-02-08T17:37:43+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/mark-howrey/2024-01-11T10:36:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/eric-q--wu/2024-02-26T16:40:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/martha-s--samuelson/2024-03-05T14:30:17+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/bruce-e--stangle/2024-01-19T15:53:38+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/adam-decter/2024-02-06T17:56:01+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/andrew-wong/2024-01-11T10:36:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/michael-beauregard/2024-01-11T10:36:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/senior-advisors/anita-j--chawla/2024-01-11T10:36:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/senior-advisors/jeffrey-a--cohen/2024-01-19T15:53:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/coreen-mccool/2024-01-11T10:36:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/senior-advisors/susan-f--tierney/2024-03-04T14:41:56+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/senior-advisors/genia-long/2024-01-11T10:36:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/anemia-related-costs-for-cancer-patients/2024-01-11T10:36:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-costs-of-cancer-to-a-major-employer-in-the-united-states--a-case-control-analysis/2024-01-11T10:36:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/understanding-the-pharmacoeconomic-profile-of-cancer/2024-01-11T10:36:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-outpatient-blood-transfusion-in-cancer-patients/2024-01-11T10:36:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-anemia-and-cancer/2024-01-11T10:36:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/depression-and-fibromyalgia--treatment-and-cost-when-diagnosed-separately-or-concurrently/2024-01-11T10:36:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-implications-of-treatment-resistant-depression-among-employees/2024-01-11T10:36:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-depression-in-the-united-states--how-did-it-change-between-1990-and-2000-/2024-01-11T10:36:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economics-of-women-and-depression--an-employer-perspective/2024-01-11T10:36:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-anxiety-and-stress-disorders/2024-01-11T10:36:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-depression--current-assessment-and-future-directions/2024-01-11T10:36:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-economic-impact-of-psychiatric-disorders--where-to-begin-/2024-01-11T10:36:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/management-of-major-depression-in-the-workplace--impact-on-employee-work-loss/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-antidepressant-use-on-social-functioning--reboxetine-versus-fluoxetine/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-anxiety-disorders-in-the-1990s/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economics-of-clinical-depression/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-of-rheumatoid-arthritis-to-an-employer/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-depression-in-1990/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lower-respiratory-tract-infections--impact-on-the-workplace/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-respiratory-infections-in-an-employed-population/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-of-asthma-to-an-employer/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lack-of-intraocular-pressure-effect-of-budesonide-inhalation-therapy-in-a-mixed-asthmatic-population/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-stress-urinary-incontinence--a-claims-data-analysis/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-consequences-of-irritable-bowel-syndrome--a-us-employer-perspective/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/productivity-and-medical-costs-of-diabetes-in-a-large-employer-population/2024-01-11T10:36:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effects-of-chronic-medical-conditions-on-work-loss-and-work-cutback/2024-01-11T10:36:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/descriptive-epidemiology-of-acute-liver-enzyme-abnormalities-in-the-general-population-of-central-massachusetts/2024-01-11T10:36:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interpretation-of-the-weight-matrix-in-an-artificial-neural-network/2024-01-11T10:36:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/linking-administrative-claims-data-with-archival-productivity-measures-to-inform-employer-decision-making/2024-01-11T10:36:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/administrative-claims-data--a-valuable-tool-in-pharmaceutical-litigation/2024-01-11T10:36:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/using-healthcare-claims-data-for-outcomes-research-and-pharmacoeconomic-analyses/2024-01-11T10:36:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/public-and-private-pharmaceutical-spending-as-determinants-of-health-outcomes-in-canada/2024-01-11T10:36:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-regulatory-perspective-on-productivity-claims--implications-for-future-productivity-research/2024-01-11T10:36:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pharmaceutical-spending-and-health-outcomes-in-the-united-states/2024-01-11T10:36:46+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-j--denis/2024-01-11T10:36:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/diagnosing-the-illness/2024-01-11T10:36:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-spending-as-determinants-of-health-outcomes/2024-01-11T10:36:47+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/michael-k--wohlgenant/2024-01-11T10:36:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tackling-costs-one-disease-at-a-time/2024-01-11T10:36:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pharmacoeconomics-and-health-policy--current-applications-and-prospects-for-the-future/2024-01-11T10:36:47+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/roger-ware/2024-01-11T10:36:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/calculating-return-on-investment-from-reducing-workplace-costs-of-illness/2024-01-11T10:36:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-next-phase-of-managed-care--targeting-investments-in-employee-health/2024-01-11T10:36:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/price-growth-of-prescription-pharmaceutical-preparations--an-update-and-extension-/2024-01-11T10:36:47+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/joel-h--steckel/2024-01-11T10:36:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consolidation-is-a-tonic-for-health-care-providers--trend-toward-managed-care-and-ascent-of-information-technology-fuel-restructuring-of-an-industry/2024-01-11T10:36:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-consequences-of-illness-in-the-workplace/2024-01-11T10:36:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/james-w--hughes/2024-01-11T10:36:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/charlotte-chamberlain/2024-01-11T10:36:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/lorraine-eden/2024-01-11T10:36:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/your-patent-is-about-to-expire--what-now-/2024-01-11T10:36:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-cost-flexibility-in-the-presence-of-many-outputs--a-public-private-comparison/2024-01-11T10:36:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/oliver-hart/2024-01-11T10:36:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/product-liability-in-the-pharmaceutical-industry/2024-01-11T10:36:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/omitted-variable-bias-and-hospital-costs/2024-01-11T10:36:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/atulya-sarin/2024-01-11T10:36:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-cost-function-in-a-non-market-health-care-system/2024-01-11T10:36:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-consolidation--optimal-strategy-for-a-two-hospital-town/2024-01-11T10:36:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/richard-l--smith/2024-01-11T10:36:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-depression--societal-and-patient-perspectives/2024-01-11T10:36:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economics-of-anxiety-disorders/2024-01-11T10:36:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/depression-in-the-workplace--effects-on-short-term-disability/2024-01-11T10:36:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/robin-cooper/2024-01-11T10:36:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-much-does-depression-cost-society-/2024-01-11T10:36:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-cost-and-epidemiological-characteristics-of-patients-with-fibromyalgia-claims/2024-01-11T10:36:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/sanjiv-r--das/2024-01-11T10:36:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/calculating-the-workplace-cost-of-chronic-disease/2024-01-11T10:36:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/thomas-lys/2024-01-11T10:36:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consolidation-and-restructuring--the-next-step-in-managed-care/2024-01-11T10:36:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-value-of-cardiovascular-nuclear-medicine/2024-01-11T10:36:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/valuing-a-business-in-a-litigation-context/2024-01-11T10:36:51+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/william-j--chambers/2024-01-11T10:36:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/options-as-an-alternative-to-cost-sharing/2024-01-11T10:36:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hedging-long-term-commodity-commitments-with-short-dated-futures-contracts/2024-01-11T10:36:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/stock-option-expense-and-cost-sharing--a-comment/2024-01-11T10:36:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/securities-act-violations--estimation-of-damages/2024-01-11T10:36:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hedge-funds--risk-and-return/2024-01-11T10:36:51+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/lee-jen-wei/2024-01-11T10:36:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/unemployment-insurance-and-job-search-productivity/2024-01-11T10:36:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/canada-unemployment-gap-truly-large--a-labor-flow-analysis/2024-01-11T10:36:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mergers-and-bargaining-in-the-us-airline-industry/2024-01-11T10:36:52+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/donna-hitscherich/2024-01-11T10:36:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/why-strike-insurance-is-unilateral--evidence-from-the-airline-industry-s-mutual-aid-pact/2024-01-11T10:36:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-analysis/2024-01-11T10:36:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-analysis-of-intellectual-property/2024-01-11T10:36:52+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/robert-grien/2024-01-11T10:36:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/discounted-cash-flow-analysis-in-patent-infringement-litigation/2024-01-11T10:36:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-damages-in-patent-infringement-cases/2024-01-11T10:36:52+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/james-levinsohn/2024-01-11T10:36:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/damage-measures-in-patent-infringement-actions/2024-01-11T10:36:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/analysis-and-measurement-of-damages-in-patent-infringement-actions/2024-01-11T10:36:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/trademark-misuse/2024-01-11T10:36:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/considering-taxes-in-the-computation-of-lost-business-profits/2024-01-11T10:36:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/taxes-and-lost-profits/2024-01-11T10:36:53+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/thomas-buchmueller/2024-01-11T10:36:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pre-tax-versus-after-tax-patent-damages--do-the-courts-have-it-right-/2024-01-11T10:36:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-cafc-and-its-patent-damages-awards/2024-01-11T10:36:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-panduit-lost-profits-test-after-bic-leisure-v--windsurfing/2024-01-11T10:36:53+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/harold-w--furchtgott-roth/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/damages-in-patent-and-trademark-infringement/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/intellectual-property-valuation-and-hughes-aircraft-v--the-united-states--a-giant-leap-for-mankind-or-lost-in-space-/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-of-the-25-per-cent-rule-in-valuing-ip/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/toby-e--stuart/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/book-review--the-lesi-guide-to-licensing-best-practices--strategic-issues-and-contemporary-realities/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/boards-of-directors--does-independence-matter-/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/preparing-the-financial-expert-or-economist/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/challenges-to-the-admissibility-of-financial-expert-witness-testimony/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/financial-expert-witness-challenges-and-exclusions--results-and-trends-in-federal-and-state-cases-since-kumho-tire/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-s--scharfstein/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-cost-of-capital/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/forensic-accounting-and-litigation-consulting-services/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-myth-of-the-universal-market/2024-01-11T10:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-myth-of-simple-market-solutions/2024-01-11T10:36:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-myths-of-market-prices-and-efficiencies/2024-01-11T10:36:55+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/michael-klausner/2024-01-11T10:36:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-better-climate-change-agreement/2024-01-11T10:36:55+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/michael-s--weisbach/2024-01-11T10:36:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/markets-can-make-fisheries-sustainable/2024-01-11T10:36:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regulating-by-vintage--let-s-put-a-cork-in-it/2024-01-11T10:36:55+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/b--espen-eckbo/2024-01-11T10:36:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/using-market-prices-to-regulate-the-costs-of-a-utility-s-inputs/2024-01-11T10:36:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/datawars--computer-models-in-the-federal-government/2024-01-11T10:36:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-nuclear-waste-controversy/2024-01-11T10:36:55+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/nabil-n--el-hage/2024-01-11T10:36:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/massachusetts--pre-approval-approach-to-prudence-in-massachusetts/2024-01-11T10:36:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/foreword--using-consensus-building-to-improve-utility-regulation/2024-01-11T10:36:56+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/roberto-rigobon/2024-01-11T10:36:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regional-issues-in-restructuring-the-electric-industry/2024-01-11T10:36:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/research-support-for-the-power-industry/2024-01-11T10:36:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-better-co2-rule/2024-01-11T10:36:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/siting-power-plants-in-the-new-electric-industry-structure--lessons-from-california-and-best-practices-for-other-states/2024-01-11T10:36:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-political-economy-of-long-term-generation-adequacy--why-an-icap-mechanism-is-needed-as-part-of-standard-market-design/2024-01-11T10:36:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/uncertainty-and-the-distribution-of-benefits-from-utility-conservation-programs/2024-01-11T10:36:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/designing-purpa-power-purchase-auctions--theory-and-practice/2024-01-11T10:36:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-production-simulation-implementations/2024-01-11T10:36:56+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/steven-m--shugan/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regional-transmission-groups--how-should-they-be-structured-and-what-should-they-do-/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/john-j--richard/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/preparing-for-the-inevitable--the-nationalization-of-the-u-s--nuclear-industry-in-a-competitive-electricity-market/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-efficiency-of-market-coordination--evidence-from-wholesale-electric-power-pools/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/e--han-kim/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competition-and-institutional-change-in-u-s--electric-power-regulation/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/introduction/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/gordon-liu/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/binding-constraints-on-electricity-restructuring--an-inventory/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/walter-torous/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-engineering-economic-approach-to-estimating-the-price-elasticity-of-residential-electricity-demand/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effects-of-conservation-programs-on-electric-utility-earnings--results-of-two-case-studies/2024-01-11T10:36:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-tax-reform-on-renewable-energy-and-cogeneration-projects/2024-01-11T10:36:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/integrated-analysis-of-demand-side-programs/2024-01-11T10:36:58+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/catherine-e--tucker/2024-01-11T10:36:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-integrated-economic-analysis-of-commercial-thermal-energy-storage/2024-01-11T10:36:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/proxy-plant-valuation-methods-for-demand-side-utility-programs/2024-01-11T10:36:58+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/peter-s--fader/2024-01-11T10:36:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-assessment-of-the-demand-side-management-plans-for-four-new-york-utilities/2024-01-11T10:36:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competitive-bidding-for-electric-power--comparing-evaluation-methods/2024-01-11T10:36:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/auctions-for-purpa-purchases--a-simulation-study/2024-01-11T10:36:59+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jun-s--liu/2024-01-11T10:36:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/structural-evolution-in-the-electric-utility-industry/2024-01-11T10:36:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/why-are-vickrey-auctions-rare-/2024-01-11T10:36:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/alternative-approaches-to-competitive-bidding/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/kathleen-m--sutcliffe/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluation-of-front-loading-in-auctions-for-wholesale-power/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/optimization-methods-for-evaluating-competitive-bids-from-private-producers/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/auction-markets-for-dispatchable-power--how-to-score-the-bids/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risks-in-independent-power-contracts--an-empirical-survey/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-dispatchability-features-in-competitive-bidding/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/on-amir/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/integrating-market-processes-into-utility-resource-planning/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/transmission-planning-issues-in-a-competitive-economic-environment/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/coordination-in-the-wholesale-market--where-does-it-work-/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/coal-gasification-in-a-de-integrated-electricity-industry/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/shane-frederick/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reactive-power-is-a-cheap-constraint/2024-01-11T10:37:00+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/kevin-l--keller/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regulation-by-simulation--the-role-of-production-cost-models-in-electricity-planning-and-pricing/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-linear-model-of-voltage-limited-transmission-interface-constraints/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-power-purchases-from-non-utilities-on-the-utility-cost-of-capital/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-electricity-industry-in-spain/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-performance-of-the-u-s--market-for-independent-electricity-generation/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-production-tax-credit-for-wind-turbine-powerplants-is-an-ineffective-incentive/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/market-power-in-california-electricity-markets/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jiwoong-shin/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retail-access-pilot-programs--where-s-the-beef-/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-nuclear-power-become-an-ordinary-commercial-asset-/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/olivier-toubia/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/introducing-competition-to-the-electricity-industry-in-spain--the-role-of-initial-conditions/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/numerical-techniques-for-analyzing-market-power-in-electricity/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/price-forecasting-in-spot-markets--hidden-risks-in-single-part-bidding/2024-01-11T10:37:01+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/michael-a--carrier/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-folklorist-s-guide-to-the-used-power-plant-market/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-quantitative-analysis-of-pricing-behavior-in-california-s-wholesale-electricity-market-during-summer-2000/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/performance-incentives-for-transmission/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/e--scott-peterson/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electric-utility-planning-and-regulation/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/international-comparisons-of-electricity-regulation/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/john-r--minahan/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-damages-using-forecasting-techniques/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dull-witnesses/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/damages-on-the-internet/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/conflicting-rulings-about-conflicts/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/engagement-letters-for-litigation-services--business-valuation-and-forensic---litigation-services-practice-aid-04-1/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/vertical-enclosure--vertical-integration-and-the-reluctance-to-purchase-from-a-competitor/2024-01-11T10:37:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/free-radicals--why-industry-leaders-fail-to-harness-disruptive-technologies/2024-01-11T10:37:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-comprehensive-approach-to-corporate-venturing/2024-01-11T10:37:03+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/matthew-g--nagler/2024-01-11T10:37:03+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/keith-m--schappert/2024-01-11T10:37:03+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/brendan-sheehy/2024-01-11T10:37:04+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/william-mcgivney/2024-01-11T10:37:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-extent-of-the-market/2024-01-11T10:37:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predicting-the-price-effect-of-mergers-with-polynomial-logit-demand/2024-01-11T10:37:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/presenting-economic-expert-testimony-to-a-jury--five-golden-rules/2024-01-11T10:37:04+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/charles-porten/2024-01-11T10:37:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/preparing-for-daubert-challenges-in-antitrust-cases/2024-01-11T10:37:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/network-costs-and-the-regulation-of-wholesale-competition-in-electric-power/2024-01-11T10:37:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hedonic-price-indexes-for-personal-computer-operating-systems-and-productivity-suites/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-j--reibstein/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/red-blood-cell-transfusion-and-ventilator-associated-pneumonia--a-potential-link-/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effectiveness-of-surgery-on-the-treatment-of-acute-spinal-cord-injury-and-its-relationship-with-pharmacological-treatment/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-does-hospice-cost-/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/stephen-j--hoch/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-alternative-in-terminal-care--results-of-the-national-advice-on-hospice-care-for-benefits-design/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/robert-p--navarro/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-alternative-in-terminal-care--results-of-the-national-hospice-study/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/russell-f--peppet/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-costs-of-community-acquired-pneumonia-in-an-employed-population/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/daniel-o--scharfstein/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/roberts-w--brokaw-iii/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/deborah-haas-wilson/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/myron-s--glucksman/2024-01-11T10:37:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/ira-g--kawaller/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/john-j--mcconnell/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/claire-tsai/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/russell-r--wermers/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-gal/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/rangarajan-k--sundaram/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/willy-c--shih/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/paul-b--ginsburg/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/juanjuan-zhang/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/daniel-bauer/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/christopher-r--knittel/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/steven-tadelis/2024-02-06T17:56:04+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/steven-k--gissiner/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/joel-peress/2024-02-01T14:09:33+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/charles-i--plosser/2024-01-11T10:37:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/peter-n--golder/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/michael-siegel/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/nathan-novemsky/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/robert-zeithammer/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/natalie-mizik/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/john-e--ware/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/anja-lambrecht/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/shannon-w--anderson/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/john-contino/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/randal-s--milch/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/paul-oyer/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jesse-rothstein/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/hanming-fang/2024-01-11T10:37:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-dranove/2024-01-11T10:37:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/scott-f--meadow/2024-01-11T10:37:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/sylvia-manning/2024-01-11T10:37:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jonathan-levav/2024-01-11T10:37:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/gary-h--stern/2024-01-11T10:37:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/michael-d--mitzenmacher/2024-01-11T10:37:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/joseph-willett/2024-01-11T10:37:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/alex-edmans/2024-01-11T10:37:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jean-pierre-landau/2024-01-11T10:37:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jura-liaukonyte/2024-01-11T10:37:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/ronald-c--goodstein/2024-01-11T10:37:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/kurt-carlson/2024-01-11T10:37:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jeffrey-t--prince/2024-01-11T10:37:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/scott-bradner/2024-01-11T10:37:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/shlomo-hershkop/2024-01-11T10:37:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/steven-weber/2024-01-11T10:37:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/justin-seitz/2024-01-11T10:37:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/luis-de-la-calle/2024-01-11T10:37:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/francis-a--longstaff/2024-01-11T10:37:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/william-m--mohl/2024-01-11T10:37:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/moshe-buchinsky/2024-01-11T10:37:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/lewis-j--allen/2024-01-11T10:37:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/fabio-savoldelli/2024-01-11T10:37:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/alan-grigoletto/2024-01-11T10:37:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/craig-garthwaite/2024-01-11T10:37:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/christianna-wood/2024-01-11T10:37:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/edward-r--morrison/2024-01-11T10:37:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/anupam-b--jena/2024-02-06T17:56:02+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/senior-advisors/tamar-sisitsky/2024-01-11T10:37:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/senior-advisors/james-rosberg/2024-01-11T10:37:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/mark-a-gustafson/2024-01-11T10:37:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/john-m--browning/2024-02-06T17:56:00+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/na-dawson/2024-01-11T10:37:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/kevin-gold/2024-01-11T10:37:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/peter-hess/2024-01-11T10:37:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/mike-nguyen/2024-01-11T10:37:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/peter-p--simon/2024-01-11T10:37:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/ajay-jyoti/2024-02-27T14:35:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/steven-s--saeger/2024-01-31T15:38:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/michael-cliff/2024-02-27T14:35:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/andrea-okie/2024-01-11T10:37:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/andrew-stichman/2024-01-11T10:37:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/brian-ellman/2024-01-17T15:59:13+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/marissa-ginn/2024-03-11T19:08:28+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/xinyu-ji/2024-02-07T21:36:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/mark-j--lewis/2024-01-11T10:37:12+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/shannon-n--seitz/2024-03-06T17:18:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/divya-mathur/2024-01-11T10:37:12+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/rebeccah-w--filsoof/2024-01-11T10:37:12+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/minh-p--doan/2024-01-11T10:37:12+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/lauren-r--kindler/2024-02-16T15:01:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/kris-comeaux/2024-01-11T10:37:13+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/eric-korman/2024-03-12T17:04:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/mihran-yenikomshian/2024-03-15T21:35:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/peter-finch/2024-01-11T10:37:13+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/stephen-fink/2024-01-11T10:37:13+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/rene-befurt/2024-02-06T17:55:59+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/laura-comstock/2024-01-11T10:37:13+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/brad-rice/2024-01-11T10:37:13+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/ahmer-nabi/2024-01-11T10:37:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/lindsay-greenbaum/2024-01-11T10:37:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/jonathan-borck/2024-01-31T15:38:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/lauren-hunt/2024-01-11T10:37:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/laura-o-laughlin/2024-01-11T10:37:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/eric-b--nguyen/2024-01-11T10:37:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/keith-betts/2024-03-15T21:34:34+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/emily-cotton/2024-02-06T17:56:01+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/pavel-darling/2024-02-06T17:56:01+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/chris-feige/2024-01-11T10:37:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/kenneth-weinstein/2024-01-11T10:37:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/hongbo-yang/2024-03-15T21:25:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/federico-temerlin/2024-01-11T10:37:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/markus-von-wartburg/2024-01-11T10:37:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/kevin-gallagher/2024-01-11T10:37:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/hristina-bojadzieva-bartlett/2024-01-11T10:37:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/john-drum/2024-02-08T17:37:44+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/samir-warty/2024-01-11T10:37:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/maria-garibotti/2024-01-11T10:37:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/carletta-wong/2024-01-11T10:37:17+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/jee-yeon-lehmann/2024-02-20T20:12:33+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/sumon-mazumdar/2024-02-23T17:36:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/joshua-white/2024-01-11T10:37:17+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/emmanuel-frot/2024-02-06T17:56:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/navigating-the-changing-tides-of-managed-care-and-health-reform/2024-01-11T10:37:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-health-care-system-in-canada/2024-01-11T10:37:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-policy/2024-01-11T10:37:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-minimization-analysis-of-once-weekly-versus-thrice-weekly-epoetin-alfa-for-chemotherapy-related-anemia/2024-01-11T10:37:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/exploring-economic-models-using-excel/2024-01-11T10:37:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/proving-damages--issues-to-consider-in-pursuing-and-defending-the-damages-case/2024-01-11T10:37:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/does-generic-substitution-always-make-sense-/2024-01-11T10:37:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ercot-texas-s-competitive-power-experience--a-view-from-the-outside-looking-in/2024-01-11T10:37:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-value-of-formal-quantitative-assessment-of-uncertainty-in-regulatory-analysis/2024-01-11T10:37:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/five-minutes-with----the-economic-impact-of-bariatric-surgery-study-investigators/2024-01-11T10:37:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/data-exclusivity-periods-for-biologics--updating-prior-analyses-and-responding-to-critiques/2024-01-11T10:37:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/land-use-change-and-carbon-sinks/2024-01-11T10:37:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/opportunity-for-a-defining-moment/2024-01-11T10:37:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/anaemia-and-the-risk-of-injurious-falls-in-a-community-dwelling-elderly-population-/2024-01-11T10:37:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-myelodysplastic-syndromes--a-meta-analysis-/2024-01-11T10:37:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/management-of-anaemia--a-critical-and-systematic-review-of-the-cost-effectiveness-of-erythropoiesis-stimulating-agents-/2024-01-11T10:37:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-of-pain-therapy-for-osteoarthritis-in-an-insured-population-in-the-united-states-/2024-01-11T10:37:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-claims-data-analysis-of-dosage-adjustment-patterns-of-tnf-antagonists-among-patients-with-rheumatoid-arthritis-/2024-01-11T10:37:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-and-resource-use-of-mild-persistent-asthma-patients-initiated-on-controller-therapy-/2024-01-11T10:37:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/symptom-assessment-in-relapsed-small-cell-lung-cancer--cross-validation-of-the-patient-symptom-assessment-in-lung-cancer-instrument-/2024-01-11T10:37:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-pre-dialysis-epoetin-alfa-on-health-care-and-work-loss-costs-in-chronic-kidney-disease--an-employer-s-perspective/2024-01-11T10:37:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/loss-of-treatment-response-to-infliximab-maintenance-therapy-in-crohn-s-disease--a-payor-perspective/2024-01-11T10:37:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-costs-of-crohn-s-disease-in-the-united-states-and-other-western-countries--a-systematic-review/2024-01-11T10:37:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-escitalopram-versus-citalopram-for-the-treatment-of-major-depressive-disorder-in-a-geriatric-population/2024-01-11T10:37:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-among-employees-with-diabetic-retinopathy-in-the-united-states/2024-01-11T10:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/beyond-lifecycle-management---optimizing-performance-following-patent-expiry/2024-01-11T10:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-analysis-in-off-label-promotion-cases/2024-01-11T10:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/generic-competition-in-the-u-s--pharmaceutical-industry/2024-01-11T10:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/simulating-electricity-restructuring-in-california--interactions-with-the-regional-market/2024-01-11T10:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/workplace-burden-of-depression--case-study-in-social-functioning-using-employer-claims-data/2024-01-11T10:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/depression-in-the-workplace--an-economic-perspective/2024-01-11T10:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/depression--a-neglected-major-illness/2024-01-11T10:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/institutions-and-individuals/2024-01-11T10:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/challenges-in-rif-analyses/2024-01-11T10:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-related-and-all-cause-health-care-costs-of-elderly-patients-with-gout/2024-01-11T10:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-care-for-patients-with-rheumatoid-arthritis-receiving-tnf-antagonist-therapy-using-claims-data/2024-01-11T10:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mapping-fact-p-and-eortc-qlq-c30-to-patient-health-status-measured-by-eq-5d-in-metastatic-hormone-refractory-prostate-cancer-patients/2024-01-11T10:37:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risk-of-renal-impairment-in-hormone-refractory-prostate-cancer-patients-with-bone-metastases-treated-with-zoledronic-acid/2024-01-11T10:37:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/productivity-costs-associated-with-cardiometabolic-risk-factor-clusters-in-the-united-states/2024-01-11T10:37:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comment-on--the-relative-dosing-of-epoetin-alfa-and-darbepoetin-alfa-in-chronic-kidney-disease/2024-01-11T10:37:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-economic-and-outcomes-analyses-using-non-us-databases--a-review/2024-01-11T10:37:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/considering-the-costs-of-bipolar-depression/2024-01-11T10:37:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/compulsory-generic-switching-of-antiepileptic-drugs--high-switchback-rates-to-branded-compounds-compared-with-other-drug-classes/2024-01-11T10:37:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/do-drugs-reduce-utilisation-of-other-healthcare-resources-/2024-01-11T10:37:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/foundations-of-opioid-risk-management/2024-01-11T10:37:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/actual-versus-predicted-first-year-utilization-patterns-of-teriparatide-in-patients-with-employer-sponsored-health-insurance/2024-01-11T10:37:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medical-costs-of-untreated-anemia-in-elderly-patients-with-predialysis-chronic-kidney-disease/2024-01-11T10:37:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dose-conversion-ratio-for-epoetin-alfa-and-darbepoetin-alfa-in-chemotherapy-patients-with-anemia-and-cancer/2024-01-11T10:37:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-and-workloss-costs-associated-with-patients-with-persistent-asthma-in-a-privately-insured-population/2024-01-11T10:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-cancer-treatment-associated-bone-loss-and-fractures-among-women-with-breast-cancer-receiving-aromatase-inhibitors/2024-01-11T10:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-economic-impact-of-chronic-conditions-in-postmenopausal-women/2024-01-11T10:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-illness-for-employees-with-painful-conditions/2024-01-11T10:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-and-co-morbidities-of-atrial-fibrillation-in-a-privately-insured-population/2024-01-11T10:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-costs-of-opioid-abuse-in-an-insured-population-in-the-united-states/2024-01-11T10:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-depression-in-the-us--societal-and-patient-perspectives/2024-01-11T10:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dose-conversion-and-cost-effectiveness-of-erythropoietic-therapies-in-chemotherapy-related-anaemia--a-meta-analysis/2024-01-11T10:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-cost-effectiveness-of-weekly-epoetin-alfa-relative-to-weekly-darbepoetin-alfa-in-patients-with-chemotherapy-induced-anemia/2024-01-11T10:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-epoetin-alfa-and-darbepoetin-alfa-in-patients-with-chemotherapy-related-anemia/2024-01-11T10:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/alkaline-phosphatase-predicts-survival-in-patients-with-metastatic-neuroendocrine-tumors/2024-01-11T10:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dose-conversion-from-epoetin-alfa-to-darbepoetin-alfa-for-patients-with-chronic-kidney-disease-receiving-hemodialysis/2024-01-11T10:37:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-olanzapine-plus-fluoxetine-combination-therapy-among-patients-treated-for-depression--a-pilot-study/2024-01-11T10:37:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-depression-with-painful-symptoms/2024-01-11T10:37:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-relationship-between-technology-availability-and-health-care-spending/2024-01-11T10:37:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/relationship-between-changes-in-hemoglobin-level-and-quality-of-life-during-chemotherapy-in-anemic-cancer-patients-receiving-epoetin-alfa-therapy/2024-01-11T10:37:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/statistical-explanations-for-a-community-based-study-of-once-weekly-epoetin-alfa-therapy-in-patients-receiving-chemotherapy/2024-01-11T10:37:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-costs-of-cancer--cancer-related-conditions-can-add-dramatically-to-overall-costs-of-care/2024-01-11T10:37:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-technology-in-a-non-market-health-care-system/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-of-statistical-sampling-in-litigation/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-evaluation-of-the-mccullough-research-report-on-new-york-s-wholesale-power-market/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-stimulus-and-green-jobs/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-growing-role-of-economic-analysis-in-off-label-promotion-cases/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risks-and-costs-of-multiple-generic-substitution-of-topiramate/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/proving-patent-damages/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-drug-vintage-on-patient-survival--a-patient-level-analysis-using-quebec-s-provincial-health-plan-data/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/projected-economic-impact-of-clinical-findings-of-generic-entry-of-topiramate-on-g4-european-countries/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/drug-utilization-and-cost-considerations-of-erythropoiesis-stimulating-agents-in-oncology-patients-receiving-chemotherapy/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-all-cause-health-care-costs-associated-with-chronic-kidney-disease-in-patients-with-diabetes-and-hypertension--a-managed-care-perspective/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-limiting-erythropoiesis-stimulating-agent-use-for-chemotherapy-induced-anemia-on-the-united-states-blood-supply-margin/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/erythropoietin-therapy-and-left-ventricular-mass-index-in-ckd-and-esrd-patients--a-meta-analysis/2024-01-11T10:37:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-assessment-of-erythroid-response-to-epoetin-alfa-as-a-single-agent-versus-in-combination-with-granulocyte--or-granulocyte-macrophage-colony-stimulating-factor-in-myelodysplastic-syndromes-using-a-m/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/no-free-lunch-at-the-auto-cafe/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measuring-the-capacity-impacts-of-demand-response/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/determinants-of-direct-cost-differences-among-us-employees-with-major-depressive-disorders-using-antidepressants/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/depression-and-work-productivity--the-comparative-costs-of-treatment-versus-nontreatment/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identification-of-diabetes-patients-using-claims-data--an-economic-analysis/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-illness-and-its-treatment-on-workplace-costs--regulatory-and-measurement-issues/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/actual-and-perceived-impacts-of-tobacco-regulation-on-restaurants-and-firms/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measuring-alzheimer-s-disease-progression-with-transition-probabilities--estimates-from-cerad/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-pneumonia-in-an-employed-population/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-home-infusion-therapy_relative-benefit-index--summary-of-an-analysis-using-insurance-claims-data/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/workplace-performance-effects-from-chronic-depression-and-its-treatment/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiologic-interpretation-of-artificial-neural-networks/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prediction-and-cross-validation-of-neural-networks-versus-logistic-regression--using-hepatic-disorders-as-an-example/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/improvement-in-subjective-work-performance-after-treatment-of-chronic-depression--some-preliminary-results/2024-01-11T10:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effectiveness-of-surgery-on-the-treatment-of-acute-spinal-cord-injury-and-its-relation-to-pharmacological-treatment/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impacts-of-the-new-york-long-term-home-health-care-program/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/home-care-in-hospices/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/managing-programs-for-the-elderly--design-of-a-social-information-system/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-determinants-of-nursing-home-operating-costs-in-new-york-state/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medicare-legislation-for-hospice-care--implications-of-national-hospice-study-data/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/national-hospice-study-analysis-plan/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/why-do-nursing-home-costs-vary--the-determinants-of-nursing-home-costs/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/wonderful-politics-of-cap-and-trade/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/legal-and-economic-perspectives-concerning-u-s--government-investigations-of-alleged-off-label-promotion-by-drug-manufacturers/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effect-of-statutory-indemnity-on-securities-class-action-litigation-settlements--a-first-look/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/aba-pharmaceutical-industry-antitrust-handbook/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/licensing-in-the-presence-of-technology-standards/2024-01-11T10:37:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/addressing-environmental-justice-concerns-in-the-design-of-california-s-climate-policy/2024-01-11T10:37:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evolving-ghg-trading-systems-outside-its-borders--how-should-california-respond--6442447901/2024-01-11T10:37:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/strategic-options-for-investment-in-transmission-in-support-of-offshore-wind-development-in-massachusetts/2024-01-11T10:37:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/worried-about-competitiveness--6442447033/2024-01-11T10:37:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competition-and-title-insurance-rates-in-california/2024-01-11T10:37:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/angel-finance--the-other-venture-capital/2024-01-11T10:37:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-relationship-between-compliance-with-antidepressant-therapy-and-employer-costs-among-employees-in-the-united-states/2024-01-11T10:37:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/combating-stat-abuse/2024-01-11T10:37:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patent-auctions--how-far-have-we-come-/2024-01-11T10:37:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-shrinking-merger-arbitrage-spread--reasons-and-implications/2024-01-11T10:37:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/voluntary-agreements-with-industries--participation-incentives-with-industry-wide-targets/2024-01-11T10:37:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-new-york-independent-system-operator--a-ten-year-review/2024-01-11T10:37:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/next-steps-for-california-climate-policy-ii--moving-ahead-under-uncertain-circumstances/2024-01-11T10:37:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-mutual-fund-industry--competition-and-investor-welfare/2024-01-11T10:37:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/left-behind--latin-america-and-the-false-promise-of-populism/2024-01-11T10:37:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-of-transfusional-iron-overload-in-patients-with-myelodysplastic-syndrome-or-severe-anemia--data-from-multicenter-clinical-practices/2024-01-11T10:37:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-implications-of-iv-versus-oral-anti-angiogenesis-therapies-in-patients-with-advanced-renal-cell-carcinoma--retrospective-claims-database-analysis/2024-01-11T10:37:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-consequences-of-not-recognizing-bipolar-disorder-patients--a-cross-sectional-descriptive-analysis/2024-01-11T10:37:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/proof-of-common-impact-in-antitrust-litigation--the-value-of-regression-analysis/2024-01-11T10:37:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/securities-class-action-doesn-t-suit-us/2024-01-11T10:37:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-exacerbations-of-chronic-obstructive-pulmonary-disease-and-exacerbation-definition--a-review/2024-01-11T10:37:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-proton-pump-inhibitor-compliance-on-health-care-resource-utilization-and-costs-in-patients-with-gastroesophageal-reflux-disease/2024-01-11T10:37:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-new-approach-to-antitrust-class-certification/2024-01-11T10:37:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-cost-of-disability-and-medically-related-absenteeism-among-employees-with-multiple-sclerosis-in-the-us/2024-01-11T10:37:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-compliance-with-proton-pump-inhibitors-on-nsaid-treatment/2024-01-11T10:37:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-a-budget-impact-model-to-quantify-potential-cost-savings-from-prescription-opioids-designed-to-deter-abuse-or-ease-of-extraction/2024-01-11T10:37:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-utility-of-adalimumab-versus-infliximab-maintenance-therapies-in-the-united-states-for-moderately-to-severely-active-crohn-s-disease/2024-01-11T10:37:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-renal-impairment-after-treatment-with-ibandronate-versus-zoledronic-acid--a-retrospective-medical-records-review/2024-01-11T10:37:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/resource-utilization-and-costs-of-schizophrenia-patients-treated-with-olanzapine-versus-quetiapine-in-a-medicaid-population/2024-01-11T10:37:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparing-the-treatment-patterns-of-patients-with-schizophrenia-treated-with-olanzapine-and-quetiapine-in-the-pennsylvania-medicaid-population/2024-01-11T10:37:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/workplace-impacts-of-anti-tnf-therapies-in-rheumatoid-arthritis--review-of-the-literature/2024-01-11T10:37:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antidepressant-treatment-patterns-and-costs-among-us-employees/2024-01-11T10:37:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-nonadherence-to-antiepileptic-drugs-on-health-care-utilization-and-costs--findings-from-the-ransom-study/2024-01-11T10:37:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-multiple-sclerosis-disease-modifying-drugs-in-an-employed-population--direct-and-indirect-costs/2024-01-11T10:37:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-two-adalimumab-treatment-schedule-strategies-for-moderate-to-severe-crohn-s-disease--results-from-the-charm-trial/2024-01-11T10:37:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-health-care-use-and-costs-in-newly-diagnosed-and-established-patients-with-fibromyalgia/2024-01-11T10:37:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-psoriasis-compared-to-the-general-population-and-stratified-by-disease-severity/2024-01-11T10:37:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-associated-with-epileptic-partial-onset-seizures-among-the-privately-insured-in-the-united-states/2024-01-11T10:37:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-utilization-and-costs-incurred-by-patients-with-major-depression-after-being-switched-from-escitalopram-to-another-ssri-for-non-medical-reasons/2024-01-11T10:37:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-adalimumab-on-symptoms-of-psoriatic-arthritis-in-patients-with-moderate-to-severe-psoriasis--a-pooled-analysis-of-randomized-clinical-trials/2024-01-11T10:37:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effect-of-adalimumab-on-reducing-depression-symptoms-in-patients-with-moderate-to-severe-psoriasis--a-randomized-clinical-trial/2024-01-11T10:37:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/coronary-heart-disease-and-stroke-risk-in-patients-with-psoriasis--retrospective-analysis/2024-01-11T10:37:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/high-prevalence-of-potential-drug-drug-interactions-for-psoriasis-patients-prescribed-methotrexate-or-cyclosporine-for-psoriasis/2024-01-11T10:37:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/societal-cost-of-rheumatoid-athritis-patients-in-the-us/2024-01-11T10:37:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-costs-associated-with-initiating-nph-insulin-versus-glargine-in-patients-with-type-2-diabetes--a-retrospective-database-analysis/2024-01-11T10:37:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/inhaled-corticosteroids-or-long-acting-beta-agonists-alone-or-in-fixed-dose-combinations-in-asthma-treatment--a-systematic-review-of-fluticasone-budesonide-and-formoterol-salmeterol/2024-01-11T10:37:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/analytic-models-to-identify-patients-at-risk-for-prescription-opioid-abuse/2024-01-11T10:37:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/age-differences-in-the-prevalence-and-co-morbidity-of-dsm-iv-major-depressive-episodes--results-from-the-who-world-mental-health-survey-initiative/2024-01-11T10:37:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cardiovascular-and-economic-outcomes-after-initiation-of-lipid-lowering-therapy-with-atorvastatin-vs-simvastatin-in-an-employed-population/2024-01-11T10:37:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-adalimumab-for-the-maintenance-of-remission-in-patients-with-crohn-s-disease/2024-01-11T10:37:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/employer-model-of-workplace-impacts-of-anti-tnf-therapy-for-rheumatoid-arthritis/2024-01-11T10:37:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-implications-of-generic-substitution-of-antiepileptic-drugs--a-review-of-recent-evidence/2024-01-11T10:37:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/do-electric-cars-make-economic-sense-for-the-mass-market-/2024-01-11T10:37:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-u-s--electric-car-race--what-do-consumers-really-want-/2024-01-11T10:37:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-uneasy-case-for-product-liability/2024-01-11T10:37:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-angiogenesis-inhibitor-therapies-for-metastatic-renal-cell-carcinoma-in-clinical-practice--results-from-a-medical-chart-review-study/2024-01-11T10:37:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-of-response-to-sequential-sunitinib-and-the-impact-of-prior-vegf-targeted-drug-washout-in-patients-with-metastatic-clear-cell-renal-cell-carcinoma/2024-01-11T10:37:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/renal-toxicity-in-patients-with-multiple-myeloma-receiving-zoledronic-acid-vs--ibandronate--a-retrospective-medical-records-review/2024-01-11T10:37:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-epilepsy-among-the-privately-insured-in-the-us/2024-01-11T10:37:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/taming-a-whale-lurking-in-pension-financing/2024-01-11T10:37:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-we-afford-to-cut-carbon-/2024-01-11T10:37:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-path-forward-for-climate-talks/2024-01-11T10:37:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/two-countries-key-to-progress-in-2010/2024-01-11T10:37:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/state-eyes-on-the-climate-policy-prize/2024-01-11T10:37:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/beware-scorched-earth-strategies/2024-01-11T10:37:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-investors-really-want/2024-01-11T10:37:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-non-adherence-to-imatinib-treatment-in-chronic-myeloid-leukemia-patients/2024-01-11T10:37:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-25-percent-rule-lives-on/2024-01-11T10:37:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-hepatotoxicity-related-hospitalizations-among-patients-treated-with-opioid-acetaminophen-combination-prescription-pain-medications/2024-01-11T10:37:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/introducing-perspectives-on-comparative-effectiveness-research/2024-01-11T10:37:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perspectives-on-comparative-effectiveness-research--views-from-diverse-constituencies/2024-01-11T10:37:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-experts-in-antitrust-class-certification/2024-01-11T10:37:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-the-clinical-benefits-of-bariatric-surgery-in-diabetes-patients-with-bmi-is-great-than-equal-35-kg-per-m2/2024-01-11T10:37:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/generic-antiepileptic-drugs-and-associated-medical-resource-utilization-in-the-united-states/2024-01-11T10:37:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-changing-landscape-for-credit-ratings/2024-01-11T10:37:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-fruits-of-comparative-effectiveness/2024-01-11T10:37:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/in-defense-of-pollution-markets/2024-01-11T10:37:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/wind-integration-studies--optimization-vs--simulation/2024-01-11T10:37:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-price-isn-t-right--event-studies-in-m-a-suits/2024-01-11T10:37:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/data-exclusivity-for-biologics/2024-01-11T10:37:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-effective-way-to-quantify-the-safety-profile-of-a-drug-or-device-when-background-toxicity-rates-are-low/2024-01-11T10:37:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-public-sector-research-in-the-discovery-of-drugs-and-vaccines/2024-01-11T10:37:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fcc-media-ownership-study--5--station-ownership-and-programming-in-radio/2024-01-11T10:37:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-firm-size-in-bilateral-bargaining--a-study-of-the-cable-television-industry/2024-01-11T10:37:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/horizontal-integration-for-bargaining-power--evidence-from-the-cable-television-industry/2024-01-11T10:37:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reading-of-biosimilar-law-could-mean-one-day-or-years-until-competitors-on-market/2024-01-11T10:37:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/president-reignites-biologics-exclusivity-battle-with-proposal-for-seven-years/2024-01-11T10:37:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consumption-inequality-and-intra-household-allocations/2024-01-11T10:37:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pros-and-cons-of-statistical-sampling/2024-01-11T10:37:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-guide-to-economic-and-policy-analysis-of-epa-s-transport-rule/2024-01-11T10:37:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-a-reasonable-royalty-ever-be-zero-/2024-01-11T10:37:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cardiovascular-and-economic-outcomes-after-initiation-of-atorvastatin-versus-simvastatin-in-an-employed-population-stratified-by-cardiovascular-risk/2024-01-11T10:37:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/removal-of-opioid-acetaminophen-combination-prescription-pain-medications--assessing-the-evidence-for-hepatotoxicity-and-consequences-of-removal/2024-01-11T10:37:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/managing-care-and-costs--the-sustained-cost-impact-of-reduced-hospitalizations-in-a-partnership-measurement-model-of-disease-management/2024-01-11T10:37:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-benefit-analysis-of-adalimumab-versus-traditional-non-biologic-therapies-for-patients-with-crohn-s-disease/2024-01-11T10:37:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/methodological-issues-in-a-meta-analysis/2024-01-11T10:37:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-of-employees-with-treatment-resistant-and-non-treatment-resistant-major-depressive-disorder/2024-01-11T10:37:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/descriptive-analysis-of-medicaid-patients-with-postherpetic-neuralgia-treated-with-lidocaine-patch-5-percent/2024-01-11T10:37:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-without-head-to-head-trials--a-method-for-matching-adjusted-indirect-comparisons-applied-to-psoriasis-treatment/2024-01-11T10:37:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluation-of-compliance-and-health-care-utilization-in-patients-treated-with-single-pill-vs--free-combination-antihypertensives/2024-01-11T10:37:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/chart-review-of-patients-on-valsartan-based-single-pill-combinations-vs--arb-based-free-combinations-for-bp-goal-achievement/2024-01-11T10:37:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/benefit-risk-analysis-of-adalimumab-vs-methotrexate-and-placebo-in-the-treatment-of-moderate-to-severe-psoriasis/2024-01-11T10:37:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-bariatric-surgery-on-comorbidities-and-medication-use-among-obese-patients/2024-01-11T10:37:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comment--the-impact-of-methodological-approach-on-cost-findings-in-comparison-of-epoetin-alfa-with-darbepoetin-alfa/2024-01-11T10:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-and-medical-care-costs-among-medicare-beneficiaries-receiving-therapy-for-peripheral-arterial-disease/2024-01-11T10:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/commercial-importation-of-prescription-drugs-in-the-united-states--short-run-implications/2024-01-11T10:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/generation-fleet-turnover-in-new-england--modeling-energy-market-impacts/2024-01-11T10:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retirement-is-coming--preparing-for-new-england-s-capacity-transition/2024-01-11T10:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/resale-price-maintenance-following-leegin--u-s--and-canadian-perspectives/2024-01-11T10:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-initiation-timing-of-ssri-or-snri-on-depressed-adolescent-health-care-utilization-and-costs/2024-01-11T10:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-economic-framework-for-analyzing-covenants-not-to-compete/2024-01-11T10:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/does-the-route-of-administration-for-estrogen-hormone-therapy-impact-the-risk-of-venous-thromboembolism-/2024-01-11T10:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/anemia-and-the-risk-of-injurious-falls-in-a-community-dwelling-elderly-population/2024-01-11T10:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-switching-from-valsartan-to-other-angiotensin-receptor-blockers-in-patients-with-hypertension/2024-01-11T10:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-cardiovascular-events-in-patients-with-hypertension-in-u-s--managed-care-settings/2024-01-11T10:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effects-of-adalimumab-treatment-and-psoriasis-severity-on-self-reported-work-productivity-and-activity-impairment-for-patients-with-moderate-severe-psoriasis/2024-01-11T10:37:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-and-safety-of-adalimumab-among-patients-with-moderate-to-severe-psoriasis-with-co-morbidities/2024-01-11T10:37:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-adalimumab-versus-placebo-on-risk-of-symptom-worsening-in-psoriasis-and-subsequent-impacts-on-health-related-quality-of-life/2024-01-11T10:37:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-comorbidities-in-patients-with-psoriasis-is-substantial/2024-01-11T10:37:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-survey-based-assessment-of-the-prevalence-and-severity-of-chronic-hand-dermatitis-in-a-managed-care-organization/2024-01-11T10:37:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-vildagliptin-and-sitagliptin-in-japanese-patients-with-type-2-diabetes--a-matching-adjusted-indirect-comparison-of-randomized-trials/2024-01-11T10:37:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/achieving-glycemic-goal-with-initial-versus-sequential-combination-therapy-using-metformin-and-pioglitazone-in-type-2-diabetes-mellitus/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/systematic-review--the-costs-of-ulcerative-colitis-in-western-countries/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-adalimumab-therapy-on-incidence-of-hospitalization-and-surgery-in-crohn-s-disease--results-from-the-charm-study/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-outcomes-of-switching-treatment-in-major-depressive-disorder-patients/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/savings-estimate-for-a-medicare-insured-group/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/red-blood-cell-transfusions-and-the-risk-of-ards-among-critically-ill--a-cohort-study/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/remission-of-major-depressive-disorder-without-adverse-events--a-comparison-of-escitalopram-versus-serotonin-norepinephrine-reuptake-inhibitors/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-therapeutic-substitution-of-a-brand-selective-serotonin-reuptake-inhibitor-with-an-alternative-generic-selective-serotonin-reuptake-inhibitor/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-of-antipsychotic-drugs-in-patients-with-alzheimer-s-disease-treated-with-rivastigmine-versus-donepezil/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medical-and-work-loss-burden-of-pre-dialysis-chronic-kidney-disease-and-related-anemia--an-employer-s-perspective/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-risk-of-clinical-fracture-in-men-with-non-metastatic-prostate-cancer-receiving-gonadotropin-releasing-hormone-agonist-therapy/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prediction-and-cross-validation-in-modeling-incident-cases-of-hepatic-disorders-using-automated-medical-data/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-nilotinib-and-dasatinib-in-newly-diagnosed-chronic-myeloid-leukemia--a-matching-adjusted-indirect-comparison-of-randomized-trials/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/safety-and-treatment-patterns-of-multikinase-inhibitors-in-patients-with-metastatic-renal-cell-carcinoma-at-a-tertiary-oncology-center-in-italy/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-benefits-of-timely-intervention-with-zoledronic-acid-in-patients-with-metastatic-prostate-cancer-to-bones--a-retrospective-study-of-us-veterans/2024-01-11T10:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-visits-and-costs-following-outpatient-treatment-of-cap-with-levofloxacin-or-moxifloxacin/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/private-sector-investment-and-employment-impacts-of-reassigning-spectrum-to-mobile-broadband-in-the-united-states/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mortality-and-nonadherence-to-aeds/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/running-the-numbers/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-ten-northeast-and-mid-atlantic-states/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-ten-northeast-and-mid-atlantic-states--appendix/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-ten-northeast-and-mid-atlantic-states--methodological-note/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/early-retirement-and-income-loss-in-patients-with-early-and-advanced-parkinson-s-disease/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/integrated-telehealth-and-care-management-program-for-medicare-beneficiaries-with-chronic-disease-linked-to-savings/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-ten-northeast-and-mid-atlantic-states--fact-sheet/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-evaluation-of-denosumab-compared-with-zoledronic-acid-in-hormone-refractory-prostate-cancer-patients-with-bone-metastases/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-applicability-of-the-epa-market-forces-study-to-the-scrap-metal-recycling-industry/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evolving-brand-name-and-generic-drug-competition-may-warrant-a-revision-of-the-hatch-waxman-act/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/carbon-control-and-the-economy--economic-impacts-of-rggi-s-first-three-years/2024-01-11T10:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/book-review--monopsony-in-law-and-economics/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/why-coal-plants-retire--power-market-fundamentals-as-of-2012/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/did-the-durban-meeting-succeed-/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/labor-costs-and-the-rate-case/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pay-as-bid-vs--uniform-pricing--discriminatory-auctions-promote-strategic-bidding-and-market-manipulation/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/options-for-addressing-leakage-in-california-s-climate-policy/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-hazard-rate-analysis-of-mirant-s-generating-plant-outages-in-california/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/california-s-cap-and-trade-decisions/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/next-steps-for-california-with-federal-cap-and-trade-policy-on-the-horizon/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/implementation-of-the-biosimilar-pathway--economic-and-policy-issues/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recently-released-fda-guidance-and-biosimilar-development--implications-for-the-litigation-environment/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-effects-of-most-favored-nation-clauses/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-great-patent-purchase/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/expert-analysis-of-plan-losses-in-erisa-class-action-litigation/2024-01-11T10:37:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/some-economics-of-royalty-bundling/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-interdependence-of-electricity-and-natural-gas--current-factors-and-future-prospects/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-evolving-standards-for-class-certification-in-antitrust-cases/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prioritizing-safety-versus-budget--fda-and-cms-adopt-different-stances/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-positive-outlook-for-cleaner-air-and-reliable-electric-service/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/persistence-and-compliance-of-deferoxamine-versus-deferasirox-in-medicaid-patients-with-sickle-cell-disease/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/concomitant-asthma-medication-use-in-patients-receiving-omalizumab--results-from-three-large-insurance-claims-databases/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economics-of-the-hematopoietic-growth-factors/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lifetime-costs-to-medicare-of-providing-care-to-patients-with-chronic-lymphocytic-leukemia/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-skeletal-complications-and-treatment-patterns-associated-with-early-vs--delayed-zoledronic-acid-therapy-in-multiple-myeloma/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-related-quality-of-life-in-patients-with-advanced-renal-cell-carcinoma-receiving-pazopanib-or-placebo-in-a-randomised-phase-iii-trial/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/safety-and-treatment-patterns-of-angiogenesis-inhibitors-in-patients-with-metastatic-renal-cell-carcinoma--evidence-from-u-s--community-oncology-clinics/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/increased-risks-of-developing-anxiety-and-depression-in-young-patients-with-crohn-s-disease/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-post-traumatic-stress-disorder-vs-major-depressive-disorder-among-patients-covered-by-medicaid-or-private-insurance/2024-01-11T10:37:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interprofessional-education-about-decision-support-for-patients-across-cultures/2024-01-11T10:37:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-of-patients-treated-with-extended-release-oxymorphone-hcl-or-controlled-release-oxycodone-hcl/2024-01-11T10:37:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-role-of-tricyclic-antidepressants-in-the-treatment-of-fibromyalgia/2024-01-11T10:37:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-costs-and-survival-of-medicare-beneficiaries-with-early-and-advanced-parkinson-s-disease/2024-01-11T10:37:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/utilization-and-cost-comparison-of-erythropoiesis-stimulating-agents-in-inpatient-and-outpatient-hospital-settings/2024-01-11T10:37:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-impact-of-vagus-nerve-stimulation-therapy-in-patients-with-drug-resistant-epilepsy/2024-01-11T10:37:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risks-and-cost-burden-of-venous-thromboembolism-and-bleeding-for-patients-undergoing-total-hip-or-knee-replacement-in-a-managed-care-population/2024-01-11T10:37:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risks-of-developing-psychiatric-disorders-in-pediatric-patients-with-psoriasis/2024-01-11T10:37:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reduced-mortality-in-cystic-fibrosis-patients-treated-with-tobramycin-inhalation-solution/2024-01-11T10:37:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-outcomes-of-multiple-versus-single-long-acting-inhalers-in-copd/2024-01-11T10:37:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/excess-costs-associated-with-patients-with-chronic-thromboembolic-pulmonary-hypertension-in-a-u-s--privately-insured-population/2024-01-11T10:37:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tiotropium-therapy-versus-tiotropium-monotherapy-for-treating-severe-to-very-severe-copd/2024-01-11T10:37:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension-in-the-united-states/2024-01-11T10:37:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/excess-costs-associated-with-patients-with-pulmonary-arterial-hypertension-in-a-u-s--privately-insured-population/2024-01-11T10:37:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/therapy-persistence-and-adherence-in-patients-with-chronic-obstructive-pulmonary-disease--multiple-versus-single-long-acting-maintenance-inhalers/2024-01-11T10:37:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-associated-with-dupuytren-s-contracture/2024-01-11T10:37:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-and-economic-damages--theoretical-and-practical-issues/2024-01-11T10:37:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-single-center-experience-with-low-dose-warfarin-in-patients-undergoing-total-hip-or-knee-replacement-surgery/2024-01-11T10:37:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-metastatic-breast-cancer--a-u-s--managed-care-perspective/2024-01-11T10:37:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-to-use-clinical-trial-data-in-court/2024-01-11T10:37:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/climate-policy--a-breath-of-fresh-air/2024-01-11T10:37:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/shut-up-and-stand-still--understanding-the-role-of-standstill-provisions-in-m-a-disputes/2024-01-11T10:37:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reliability-and-emission-impacts-of-stationary-engine-backed-demand-response-in-regional-power-markets/2024-01-11T10:37:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/promotional-reviews--an-empirical-investigation-of-online-review-manipulation/2024-01-11T10:37:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-options-for-cost-containment-raise-costs-/2024-01-11T10:37:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/implications-of-policy-interactions-for-california-s-climate-policy/2024-01-11T10:37:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/using-the-value-of-allowances-from-california-s-ghg-cap-and-trade-system/2024-01-11T10:37:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/data-exclusivity-periods-and-next-generation-improvements-to-innovator-biologics--key-issues/2024-01-11T10:37:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tools-for-handling-mortgage-based-fca-claims/2024-01-11T10:37:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/terrorism-and-the-electric-power-delivery-system/2024-01-11T10:37:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rising-rates-for-rent-a-bees/2024-01-11T10:37:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lost-in-the-clouds--the-impact-of-copyright-scope-on-investment-in-cloud-computing-ventures/2024-01-11T10:37:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/doj-s-recent-workshop-on-most-favored-nation-clauses/2024-01-11T10:37:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/personalized-medicine--trends-in-clinical-studies-based-on-national-registry-data/2024-01-11T10:37:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/summary-of-quantifiable-benefits-and-costs-related-to-select-targeted-infrastructure-replacement-programs/2024-01-11T10:37:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-direct-and-indirect-costs-among-u-s--privately-insured-employees-with-hypogonadism/2024-01-11T10:37:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/duloxetine-use-in-chronic-low-back-pain--treatment-patterns-and-costs/2024-01-11T10:37:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effect-of-asthma-exacerbations-on-health-care-costs-among-asthmatic-patients-with-moderate-and-severe-persistent-asthma/2024-01-11T10:37:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/physicians--decisions-to-prescribe-antidepressant-therapy-in-older-patients-with-depression-in-a-u-s--managed-care-plan/2024-01-11T10:37:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/asthma-severity-categorization-using-a-claims-based-algorithm-or-pulmonary-function-testing/2024-01-11T10:37:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-inhaled-corticosteroid-use-and-local-adverse-events-in-persistent-asthma/2024-01-11T10:37:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/innovation-in-the-biopharmaceutical-pipeline--a-multidimensional-view/2024-01-11T10:37:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/three-lingering-design-issues-affecting-market-performance-in-california-s-ghg-cap-and-trade-program/2024-01-11T10:37:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hypoglycaemia-and-accident-risk-in-people-with-type-2-diabetes-mellitus-treated-with-non-insulin-antidiabetes-drugs/2024-01-11T10:37:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/food-safety-concerns--impact-on-prices-and-producers/2024-01-11T10:37:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-the-regulatory-environment-on-it-entrepreneurship-in-the-u-s--and-eu/2024-01-11T10:37:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/brief-of-antitrust-economists-as-amici-curiae-in-support-of-respondents/2024-01-11T10:37:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/california-s-advanced-energy-economy--advanced-energy-business-leaders--perspectives-and-recommendations-on-california-s-energy-policies/2024-01-11T10:37:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-it-worth-anything--using-surveys-in-intellectual-property-cases/2024-01-11T10:37:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/caution-required-when-using-managerial-accounting-data-in-court/2024-01-11T10:37:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-regulators-and-grid-operators-in-meeting-natural-gas-and-electric-coordination-challenges/2024-01-11T10:37:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-economic-perspective-on-building-labeling-policies/2024-01-11T10:37:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-economic-model-of-parkinson-s-disease--implications-for-slowing-progression-in-the-united-states/2024-01-11T10:37:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-the-data-protection-regulation-in-the-eu/2024-01-11T10:37:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/on-market-pricing-strategies/2024-01-11T10:37:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reflections-on-a-personal-milestone/2024-01-11T10:37:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/planning-for-offshore-energy-development/2024-01-11T10:37:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/planning-for-offshore-energy-development---summary-and-report/2024-01-11T10:37:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/planning-for-offshore-energy-development---complete/2024-01-11T10:37:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-and-validation-of-a-claims-based-prediction-model-for-copd-severity/2024-01-11T10:37:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-guanfacine-extended-release-as-an-adjunctive-therapy-to-a-stimulant-compared-with-stimulant-monotherapy-for-the-treatment-of-adhd/2024-01-11T10:37:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-the-right-model-for-auto-defect-suits/2024-01-11T10:37:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/vertical-practices-and-the-exclusion-of-rivals-post-eaton/2024-01-11T10:37:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/spectrum-auctions-around-the-world--an-assesment-of-international-experiences-with-auction-restrictions/2024-01-11T10:37:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-hypothetical-negotiation-and-reasonable-royalty-damages--the-tail-wagging-the-dog/2024-01-11T10:37:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/little-guidance-for-lower-courts-in-ftc-v--actavis/2024-01-11T10:37:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-the-impact-of-iso-ne-s-proposed-forward-capacity-market-performance-incentives/2024-01-11T10:37:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/problems-with-hypothesizing-reasonable-royalty-negotiation/2024-01-11T10:37:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/monday-morning-quarterbacking-and-antitrust-damages/2024-01-11T10:37:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/report-of-the-independent-advisory-panel-regarding-integration-of-renewable-energy-into-california-s-electric-system/2024-01-11T10:38:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/beyond-ab-32--post-2020-climate-policy-for-california/2024-01-11T10:38:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-attorneys-should-know-about-fda-s-medwatch-data/2024-01-11T10:38:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/opportunities-for-improving-attainment-of-quality-measures-in-patients-with-type-2-diabetes-mellitus/2024-01-11T10:38:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recent-trends-in-brand-name-and-generic-drug-competition/2024-01-11T10:38:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/project-vigilance--functional-feasibility-study-for-the-installation-of-ambri-energy-storage-batteries-at-joint-base-cape-cod/2024-01-11T10:38:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impacts-of-the-green-communities-act-on-the-massachusetts-economy--a-review-of-the-first-six-years-of-the-act-s-implementation/2024-01-11T10:38:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impacts-of-the-green-communities-act-on-the-massachusetts-economy--a-review-of-the-first-six-years-of-the-act-s-implementation--faq/2024-01-11T10:38:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/greenhouse-gas-emission-reductions-from-existing-power-plants--options-to-ensure-electric-system-reliability--report/2024-01-11T10:38:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/greenhouse-gas-emission-reductions-from-existing-power-plants--options-to-ensure-electric-system-reliability--q-and-a/2024-01-11T10:38:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/presentation-of-econometric-analyses/2024-01-11T10:38:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/applying-econometrics-to-address-class-certification/2024-01-11T10:38:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/crediting-greenhouse-gas-emission-reductions-from-energy-efficiency-investments/2024-01-11T10:38:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epa-s-clean-power-plan---states--tools-for-reducing-costs-and--increasing-benefits-to-consumers/2024-01-11T10:38:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/expert-analysis--using-simulation-to-assist-courts-in-assessing-the-prudence-of-retirement-plan-investment-decisions/2024-01-11T10:38:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/big-data-can-yield-big-insights-on-promotional-practices/2024-01-11T10:38:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/meta-analysis-of-the-efficacy-and-safety-of-bortezomib-re-treatment-in-patients-with-multiple-myeloma/2024-01-11T10:38:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-vancouver-energy-socioeconomic-impacts--primary-economic-impacts/2024-01-11T10:38:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-systematic-review-of-the-economic-and-humanistic-burden-of-illness-in-irritable-bowel-syndrome-and-chronic-constipation/2024-01-11T10:38:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comorbidities-in-patients-with-irritable-bowel-syndrome-with-constipation-or-chronic-idiopathic-constipation/2024-01-11T10:38:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incremental-direct-and-indirect-costs-of-untreated-vasomotor-symptoms/2024-01-11T10:38:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/early-evidence-suggests-gigabit-broadband-drives-gdp/2024-01-11T10:38:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-fallacy-of-inferring-collusion-from-countercyclical-prices/2024-01-11T10:38:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/random-selection-is-best-for-mdl-bellwether-trials/2024-01-11T10:38:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-epa-s-clean-power-plan--evaluation-of-energy-efficiency-program-ramp-rates-and-savings-levels/2024-01-11T10:38:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/gastrointestinal-comorbidities-associated-with-atrial-fibrillation/2024-01-11T10:38:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prasugrel-vs--clopidogrel-in-acute-coronary-syndrome-patients-treated-with-prasugrel/2024-01-30T17:41:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-length-of-stay-of-nonvalvular-atrial-fibrillation/2024-01-30T17:43:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-rivaroxaban-associated-with-lower-inpatient-costs-compared-to-warfarin-among-patients-with-non-valvular-atrial-fibrillation-/2024-01-30T17:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/weekly-risk-of-venous-thromboembolism-recurrence-in-patients-receiving-oral-anticoagulants/2024-01-11T10:38:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-comparative-effectiveness-and-safety-of-rivaroxaban-and-warfarin-in-nonvalvular-atrial-fibrillation-patients/2024-01-11T10:38:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medicaid-spending-on-contraceptive-coverage-and-pregnancy-related-care/2024-01-11T10:38:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-early-versus-late-systemic-lupus-erythematosus-diagnosis-on-clinical-and-economic-outcomes/2024-01-11T10:38:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-length-of-stay--is-rivaroxaban-associated-with-shorter-inpatient-stay-compared-to-warfarin-among-patients-with-non-valvular-atrial-fibrillation-/2024-01-30T17:44:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-factors-associated-with-myocardial-infarction-in-venous-thromboembolism-patients/2024-01-11T10:38:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/all-cause-and-disease-related-health-care-costs-associated-with-recurrent-venous-thromboembolism/2024-01-11T10:38:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-once-daily-versus-twice-daily-dosing-frequency-on-adherence-to-chronic-medications-among-patients-with-venous-thromboembolism/2024-01-11T10:38:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-cost-burden-associated-with-multiple-sclerosis-relapses--excess-costs-of-persons-with-ms-and-their-spouse-caregivers/2024-01-11T10:38:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-potential-of-energy-efficiency--a-resource-potentially-unlocked-by-the-clean-power-plan/2024-01-11T10:38:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/towards-understanding-the-role-of-price-in-residential-electricity-choices--evidence-from-a-natural-experiment/2024-01-11T10:38:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effect-of-patent-litigation-and-patent-assertion-entities-on-entrepreneurial-activity/2024-01-11T10:38:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electric-system-reliability-and-epa-s-clean-power-plan--tools-and-practices/2024-01-11T10:38:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-growing-economic-burden-of-depression-in-the-u-s-/2024-01-11T10:38:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electric-system-reliability-and-epa-s-clean-power-plan--the-case-of-pjm/2024-01-11T10:38:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-outcomes-among-medicare-patients-receiving-bioengineered-cellular-technologies-for-treatment-of-diabetic-foot-ulcers/2024-01-11T10:38:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-epidemiology-of-herpes-zoster-and-its-complications-in-medicare-cancer-patients/2024-01-11T10:38:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tax-shelters-or-efficient-tax-planning--a-theory-of-the-firm-perspective-on-the-economic-substance-doctrine/2024-01-11T10:38:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/nyiso-capacity-market--evaluation-of-options/2024-01-11T10:38:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/forecasting-corporate-failure--understanding-statistical-and-theoretical-approaches-to-bankruptcy-prediction/2024-01-11T10:38:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-note-on-the-economics-of-pass-through-with-two-part-tariff-pricing/2024-01-11T10:38:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/3-questions-to-ask-when-using-surveys-in-litigation/2024-01-11T10:38:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-analysis-of-dose-titration-and-serum-testosterone-level-assessments-in-patients-treated-with-topical-testosterone/2024-01-11T10:38:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/duloxetine-use-in-employees-with-low-back-pain--treatment-patterns-and-direct-and-indirect-costs/2024-01-11T10:38:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-intravenous-cancer-therapy-administration-in-patients-with-metastatic-soft-tissue-sarcoma-in-a-us-population/2024-01-11T10:38:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-prevalence-and-economic-impact-of-prescription-opioid-related-side-effects-among-patients-with-chronic-noncancer-pain/2024-01-11T10:38:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-comparative-analysis-of-medicaid-long-term-care-policies-and-their-effects-on-elderly-dual-enrollees/2024-01-11T10:38:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-burden-of-undiagnosed-opioid-abuse-among-commercially-insured-individuals/2024-01-11T10:38:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-diabetic-foot-ulcers-for-medicare-and-private-insurers/2024-01-11T10:38:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/sources-of-prescription-opioids-among-diagnosed-opioid-abusers/2024-01-11T10:38:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-diagnosed-opioid-abuse-among-commercially-insured-individuals/2024-01-11T10:38:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-costs-of-opioid-abuse-and-dependence-from-an-employer-perspective--a-retrospective-analysis-using-administrative-claims-data/2024-01-11T10:38:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/refractory-hodgkin-lymphoma-post-asct--median-overall-survival-meta-analysis/2024-01-11T10:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/refractory-hodgkin-lymphoma-post-autologous-transplant--meta-analysis-versus-historical-data/2024-01-11T10:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-direct-and-indirect-costs-of-uterine-fibroid-tumors--a-systematic-review-of-the-literature-between-2000-and-2013/2024-01-11T10:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-epidemiology-and-targeted-therapies-for-relapsed-and-refractory-cd30--lymphomas/2024-01-11T10:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-utilization-and-costs-in-women-diagnosed-with-endometriosis-before-and-after-diagnosis--a-longitudinal-analysis-of-claims-databases/2024-01-11T10:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-adverse-events-during-treatment-with-everolimus-plus-exemestane-or-single-agent-chemotherapy-in-patients-with-advanced-breast-cancer-in-western-europe/2024-01-11T10:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-analysis-of-liposomal-amphotericin-b-and-amphotericin-b-lipid-complex-in-the-treatment-of-invasive-fungal-infections-in-the-united-states/2024-01-11T10:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identifying-patient-subgroups-who-benefit-most-from-a-treatment--using-administrative-claims-data-to-uncover-treatment-heterogeneity/2024-01-11T10:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-economic-burden-of-metastatic-and-recurrent-locally-advanced-head-and-neck-cancer-patients/2024-01-11T10:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-costs-associated-with-bevacizumab-and-cetuximab-in-second-line-treatment-of-metastatic-colorectal-cancer/2024-01-11T10:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incremental-third-party-costs-associated-with-copd-exacerbations--a-retrospective-claims-analysis/2024-01-11T10:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-assessment-of-the-economic-and-industry-reasonableness-of-sprint-s-offer-for-clearwire/2024-01-11T10:38:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/new-ec-competition-policy-brief/2024-01-11T10:38:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/exploring-key-european-issues-that-have-significant-ramifications-for-u-s--interests/2024-01-11T10:38:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-the-prospects-for-convergence-in-collective-redress-remedies-in-the-european-union/2024-01-11T10:38:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-comparative-analysis-of-uk--and-eu--proposed-collective-action-regimes/2024-01-11T10:38:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/societal-economic-benefits-associated-with-an-extended-release-opioid-with-abuse-deterrent-technology-in-the-united-states/2024-01-11T10:38:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/outlet-types-and-the-canadian-consumer-price-index/2024-01-11T10:38:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measurement-biases-in-consumer-price-indexes/2024-01-11T10:38:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-healthcare-resource-utilization-and-costs-associated-with-ulcerative-colitis-in-a-privately-insured-employed-population-in-the-us/2024-01-11T10:38:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-effectiveness-of-pasireotide-on-health-related-quality-of-life-in-patients-with-cushing-s-disease/2024-01-11T10:38:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-health-related-quality-of-life-study-comparing-vitala-continence-control-device-versus-traditional-pouch-system-only-in-patients-with-end-colostomy/2024-01-11T10:38:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pain-relief-and-tolerability-balance-of-immediate-release-tapentadol-or-oxycodone-treatment-for-patients-with-moderate-to-severe-osteoarthritis-or-low-back-pain/2024-01-11T10:38:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/validating-migraine-specific-quality-of-life-questionnaire-v2-1-in-episodic-and-chronic-migraine/2024-01-11T10:38:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-qualitative-study-on-feasibility-of-a-web-based-women-s-health-portal-and-information-system/2024-01-11T10:38:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-novel-approach-to-estimate-the-minimally-important-difference-for-the-fatigue-impact-scale-in-multiple-sclerosis-patients/2024-01-11T10:38:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interpreting-premenstrual-symptoms-impact-survey-scores-using-outcomes-in-health-related-quality-of-life-and-sexual-drive-impact/2024-01-11T10:38:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-treatments-for-premenstrual-dysphoric-disorder/2024-01-11T10:38:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interpreting-score-differences-in-the-insomnia-severity-index--using-health-related-outcomes-to-define-the-minimally-important-difference/2024-01-11T10:38:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparability-of-the-asthma-control-test-telephone-interview-administration-format-with-self-administered-mail-out-mail-back-format/2024-01-11T10:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antipsychotic-medication-utilization-trends-among-texas-veterans--1997-2002/2024-01-11T10:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-premenstrual-dysphoric-disorder-on-health-related-quality-of-life/2024-01-11T10:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/factors-related-to-antipsychotic-oversupply-among-central-texas-veterans/2024-01-11T10:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mapping-mos-sleep-scale-scores-to-sf-6d-utility-index/2024-01-11T10:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/frequency-of-new-onset-diabetes-mellitus-and-use-of-antipsychotic-drugs-among-central-texas-veterans/2024-01-11T10:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/provision-of-pharmacy-services-in-community-health-centers-and-migrant-health-centers/2024-01-11T10:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rights-issues-and-creeping-acquisitions-in-india/2024-01-11T10:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/carbon-control-and-competitive-wholesale-electricity-markets--compliance-paths-for-efficient-market-outcomes/2024-01-11T10:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/average-overcharge-models-and-determining-individual-harm-in-collective-actions/2024-01-11T10:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ohio-s-electricity-future--assessment-of-context-and-options/2024-01-11T10:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electric-system-reliability-and-epa-s-clean-power-plan--the-case-of-miso/2024-01-11T10:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/positive-subjective-measures-in-abuse-liability-studies-and-real-world-nonmedical-use/2024-01-11T10:38:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-outcomes-in-braf-v600e-mutant-melanoma-patients-with-brain-metastases-receiving-vemurafenib-in-the-real-world-setting/2024-01-11T10:38:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/alk-rearrangement-testing-and-treatment-patterns-for-patients-with-alk-positive-non-small-cell-lung-cancer/2024-01-11T10:38:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/psoriasis-and-risk-of-diabetes-associated-microvascular-and-macrovascular-complications/2024-01-11T10:38:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-survival-and-hospitalization-rates-between-medicare-patients-with-advanced-nsclc-treated-with-bevacizumab-carboplatin-paclitaxel-and-carboplatin-paclitaxel--a-retrospective-cohort-study/2024-01-11T10:38:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/investigation-of-adverse-event-related-costs-for-patients-with-metastatic-breast-cancer-in-a-real-world-setting/2024-01-11T10:38:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-moderate-to-severe-crohn-s-disease-on-employees--salary-growth/2024-01-11T10:38:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-low-grade-adverse-events-on-health-related-quality-of-life-in-adult-patients-receiving-imatinib-or-nilotinib-for-newly-diagnosed-philadelphia-chromosome-positive-chronic-myelogenous-leukemia/2024-01-11T10:38:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/distribution-and-drivers-of-costs-in-type-2-diabetes-mellitus-treated-with-oral-hypoglycemic-agents--a-retrospective-claims-data-analysis/2024-01-11T10:38:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-developing-colorectal-cancer-and-benign-colorectal-neoplasm-in-patients-with-chronic-constipation/2024-01-11T10:38:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-regular-molecular-monitoring-and-tyrosine-kinase-inhibitor-therapy-adherence-in-chronic-myelogenous-leukemia-in-the-chronic-phase/2024-01-11T10:38:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-benefits-of-adequate-molecular-monitoring-in-patients-with-chronic-myelogenous-leukemia/2024-01-11T10:38:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-molecular-monitoring-and-long-term-outcomes-in-chronic-myelogenous-leukemia-patients-treated-with-first-line-imatinib/2024-01-11T10:38:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-longitudinal-analysis-of-costs-associated-with-change-in-disease-activity-in-systemic-lupus-erythematosus/2024-01-11T10:38:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-the-long-term-risk-of-recurrence-and-other-clinical-outcomes-in-gist-patients-receiving-imatinib-as-adjuvant-therapy--a-retrospective-chart-extract-based-approach/2024-01-11T10:38:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/outcomes-in-atrial-fibrillation-patients-on-combined-warfarin---antiarrhythmic-therapy/2024-01-11T10:38:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-second-line-targeted-therapies-for-metastatic-renal-cell-carcinoma--a-systematic-review-and-meta-analysis-of-real-world-observational-studies/2024-01-11T10:38:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/everolimus-and-sunitinib-for-advanced-pancreatic-neuroendocrine-tumors--a-matching-adjusted-indirect-comparison/2024-01-11T10:38:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-pulmonary-exacerbation-risk-score-among-cystic-fibrosis-patients-not-receiving-recommended-care/2024-01-11T10:38:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-treatment-patterns-and-economic-outcomes-in-metastatic-breast-cancer-patients-initiated-on-trastuzumab-versus-lapatinib--a-retrospective-analysis/2024-01-11T10:38:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hyperactivity-disorder--a-retrospective-analysis-of-patients-initiated-on-lisdexamfetamine-vs-other-medications/2024-01-11T10:38:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-therapy-augmentation-and-deviation-rates-from-the-recommended-once-daily-dosing-regimen-between-ldx-and-commonly-prescribed-long-acting-stimulants-for-the-treatment-of-adhd-in-youth-and/2024-01-11T10:38:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hyperactivity-disorder--a-retrospective-analysis/2024-01-11T10:38:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/net-metering-in-the-commonwealth-of-massachusetts--a-framework-for-evaluation/2024-01-11T10:38:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-analysis-in-fiduciary-monitoring-disputes-following-the-supreme-court-s--tibble--ruling/2024-01-11T10:38:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-and-resource-utilization-associated-with-anemia-and-rash-in-chronic-hepatitis-c-patients-treated-with-direct-acting-antiviral-agents-in-the-united-states/2024-01-11T10:38:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/don-t-let-nuke-plants-go-too-fast/2024-01-11T10:38:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-modified-approach-to-random-selection-of-bellwether-cases/2024-01-11T10:38:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/nomenclature-and-traceability-debate-for-biosimilars--small-molecule-surrogates-lend-support-for-distinguishable-nonproprietary-names/2024-01-11T10:38:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-a-telehealth-and-care-management-program-for-patients-with-chronic-obstructive-pulmonary-disease/2024-01-11T10:38:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-adherence-and-persistence-associated-with-nebivolol-or-hydrochlorothiazide-as-add-on-treatment-for-hypertension/2024-01-11T10:38:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-care-management-and-telehealth--a-longitudinal-analysis-using-medicare-data/2024-01-11T10:38:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/appraisal-arbitrage----is-there-a-delaware-advantage-/2024-01-11T10:38:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rebuttal-it-s-not-an-inappropriate-reasonable-royalty-rule/2024-01-11T10:38:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-commercial-success-at-the-u-s--patent-trial-and-appeal-board/2024-01-11T10:38:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-analysis-of-investment-and-drawdown-strategies-over-a-long-retirement-horizon/2024-01-11T10:38:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-backdating-executive-stock-options-always-costly-to-shareholders-/2024-01-11T10:38:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/power-system-reliability-in-new-england--meeting-electric-resource-needs-in-an-era-of-growing-dependence-on-natural-gas/2024-01-11T10:38:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-redemption-option--discussion-and-valuation-considerations-from-the-abi-commission-s--proposed-chapter-11-reform/2024-01-11T10:38:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-global-economic-impacts-associated-with-virtual-and-augmented-reality/2024-01-11T10:38:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/global-economic-impacts-associated-with-artificial-intelligence/2024-01-11T10:38:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-enforcement-in-two-sided-markets/2024-01-11T10:38:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ferc-revises-market-based-rate-procedures/2024-01-11T10:38:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-paris-agreement-lays-a-good-foundation-for-climate-progress/2024-01-11T10:38:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-liability-in-the-context-of-corporate-misconduct/2024-01-11T10:38:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-schizophrenia-in-the-united-states-in-2013/2024-01-11T10:38:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/4-considerations-for-residential-mass-appraisal-valuation/2024-01-11T10:38:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-the-life-sciences-industry-bank-on-biosimilars-/2024-01-11T10:38:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/correlation-or-cause--brand-name-drug-prescription-rates/2024-01-11T10:38:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/donning-and-doffing-damages--tyson-takeaways-for-antitrust/2024-01-11T10:38:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/machine-learning-algorithms-can-help-health-care-litigation/2024-01-11T10:38:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/response-to-rejoinder--clearing-up-the-confusion/2024-01-11T10:38:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-myth-of--price-disconnects--in-us-pharma-markets/2024-01-11T10:38:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/viewing-recent-opioid-regulations-in-context/2024-01-11T10:38:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-and-abuse--the-myth-of-divided-antitrust-economics/2024-01-11T10:38:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economics-of-pass-through-with-production-constraints/2024-01-11T10:38:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-value-of-der-to-d/2024-01-11T10:38:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rggi-and-co2-emissions-trading-under-the-clean-power-plan--options-for-trading-among-generating-unit/2024-01-11T10:38:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/stock-prices-aren-t-enough-for--rule-of-reason--analysis/2024-01-11T10:38:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pay-for-delay-and-stock-prices---smoking-gun-or-damp-squib/2024-01-11T10:38:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-potential-for-litigation-in-new-era-of-biosimilars/2024-01-11T10:38:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/following-recent-trends-in-affordable-care-act-insurance/2024-02-07T16:29:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/will-expanded-eeo-1-data-collection-yield-new-insights-/2024-01-11T10:38:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-u-s--coal-industry--challenging-transitions-in-the-21st-century/2024-01-11T10:38:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/does-the-clean-power-plan-go-too-far--no-/2024-01-11T10:38:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/practical-uses-for-machine-learning-in-health-care-cases/2024-01-11T10:38:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-evaluation-of-timely-versus-delayed-use-of-tumor-necrosis-factor-inhibitors-for-treatment-of-psoriatic-arthritis-in-the-us/2024-01-11T10:38:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-systemic-glucocorticoid-related-complications-in-severe-asthma/2024-01-11T10:38:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-social-media-data-lead-to-earlier-detection-of-drug-related-adverse-events/2024-01-11T10:38:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-common-adverse-events-associated-with-metastatic-colorectal-cancer-treatment-in-the-united-states/2024-01-11T10:38:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-healthcare-costs-among-newly-diagnosed-patients-with-chronic-myeloid-leukemia-receiving-dasatinib-or-nilotinib-as-first-line-therapy-in-the-united-states/2024-01-11T10:38:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/systematic-literature-review-of-dpp-4-inhibitors-in-patients-with-type-2-diabetes-mellitus-and-renal-impairment/2024-01-11T10:38:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-paliperidone-palmitate-versus-oral-atypical-antipsychotics-on-health-care-resource-use-and-costs-in-veterans-with-schizophrenia/2024-01-11T10:38:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-time-to-progression-and-subsequent-survival-inceritinib-treated-patients-with-advanced-alk-positive-non-small-cell-lung-cancer/2024-01-11T10:38:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/categorizing-natural-history-trajectories-of-ambulatory-function-measured-by-the-6-minute-walk-distance-in-patients-with-duchenne-muscular-dystrophy/2024-01-11T10:38:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/excess-costs-associated-with-possible-misdiagnosis-of-alzheimer-s-disease-among-patients-with-vascular-dementia-in-a-uk-cprd-population/2024-01-11T10:38:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ledipasvir-for-hepatitis-c-genotype-1-in-japanese-patients--an-indirect-comparison/2024-01-11T10:38:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/delay-in-initiation-of-adjuvant-trastuzumab-therapy-leads-to-decreased-overall-survival-and-relapse-free-survival-in-patients-with-her2-positive-non-metastatic-breast-cancer/2024-01-11T10:38:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-and-treatment-patterns-of-cycling-between-conventional-synthetic-disease-modifying-antirheumatic-drugs-among-biologic-treated-patients-with-rheumatoid-arthritis/2024-01-11T10:38:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-brain-metastasis-among-lung-cancer-patients-in-the-united-states/2024-01-11T10:38:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-switching-to-a-non-tumor-necrosis-factor-inhibitor-versus-a-tumor-necrosis-factor-inhibitor-biologic-therapy-among-patients-with-rheumatoid-arthritis/2024-01-11T10:38:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-dosing-and-drug-costs-with-everolimus-or-axitinib-as-second-targeted-therapies-for-advanced-renal-cell-carcinoma--a-retrospective-chart-review-in-the-us/2024-01-11T10:38:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hyperactivity-disorder-treated-with-lisdexamfetamine-dimesylate-or-atomoxetine/2024-01-11T10:38:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-rejection-principle-for-sequential-tests-of-multiple-hypotheses-controlling-familywise-error-rates/2024-01-11T10:38:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-iron-chelation-therapy-and-associated-healthcare-resource-utilization-and-costs-in-medicaid-patients-with-sickle-cell-disease-and-thalassemia/2024-01-11T10:38:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/daclatasvir---sofosbuvir-versus-standard-of-care-for-hepatitis-c-genotype-3--a-matching-adjusted-indirect-comparison/2024-01-11T10:38:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/drug-drug-interaction-associated-with-mold-active-triazoles-among-hospitalized-patients/2024-01-11T10:38:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer-receiving-everolimus-based-therapy-or-chemotherapy/2024-01-11T10:38:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer--a-retrospective-us-claims-study/2024-01-11T10:38:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-and-incremental-cost-per-responder-of-methotrexate-versus-apremilast-for-methotrexate-naive-patients-with-psoriasis/2024-01-11T10:38:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/network-meta-analysis-and-cost-per-responder-of-tumor-necrosis-factor-alpha-and-interleukin-inhibitors-in-the-treatment-of-active-ankylosing-spondylitis/2024-01-11T10:38:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-work-loss-in-dermatomyositis-and-polymyositis-patients-in-a-privately-insured-us-population/2024-01-11T10:38:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-happens-after-a-single-surgical-intervention-for-hidradenitis-suppurativa--a-retrospective-claims-based-analysis/2024-01-11T10:38:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/management-of-epidermal-growth-factor-receptor-inhibitor-associated-rash--a-systematic-review/2024-01-11T10:38:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/daclatasvir-and-sofosbuvir-versus-sofosbuvir-and-ribavirin-in-patients-with-chronic-hepatitis-c-coinfected-with-hiv--a-matching-adjusted-indirect-comparison/2024-01-11T10:38:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer-in-the-united-states--a-physician-survey/2024-01-11T10:38:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/relationship-between-brain-volume-loss-and-cognitive-outcomes-among-patients-with-multiple-sclerosis--a-systematic-literature-review/2024-01-11T10:38:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-evaluation-of-treatment-patterns-and-outcomes-in-elderly-patients-newly-diagnosed-with-acute-myeloid-leukemia--a-retrospective-analysis-of-electronic-medical-records-from-us-community-oncology-prac/2024-01-11T10:38:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/updated-trends-in-us-brand-name-and-generic-drug-competition/2024-01-11T10:38:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/validation-of-a-new-risk-measure-for-chronic-obstructive-pulmonary-disease-exacerbation-using-health-insurance-claims-data/2024-01-11T10:38:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-everolimus-and-axitinib-as-second-targeted-therapies-for-metastatic-renal-cell-carcinoma-in-the-us--a-retrospective-chart-review/2024-01-11T10:38:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-medicaid-spending-in-schizoaffective-patients-treated-with-once-monthly-paliperidone-palmitate-or-oral-atypical-antipsychotics/2024-01-11T10:38:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer-receiving-everolimus-based-therapy-or-chemotherapy--a-retrospective-cla/2024-01-11T10:38:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-and-validation-of-an-algorithm-for-identifying-urinary-retention-in-a-cohort-of-patients-with-epilepsy-in-a-large-us-administrative-claims-database/2024-01-11T10:38:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-direct-and-indirect-costs-associated-with-endometriosis--a-systematic-literature-review/2024-01-11T10:38:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--mbc-patients-with-multiple-metastatic-sites/2024-01-11T10:38:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/venous-thromboembolism-and-cardiovascular-disease-complications-in-menopausal-women-using-transdermal-versus-oral-estrogen-therapy/2024-01-11T10:38:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/human-epidermal-growth-factor-receptor-2-negative-metastatic-breast-cancer--a-retrospective-c/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/changes-in-practice-patterns-of-clopidogrel-in-combination-with-proton-pump-inhibitors-after-an-fda-safety-communication/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparisons-of-efficacy-of-bay-81-8973-vs-two-recombinant-factor-viii-for-the-prophylactic-treatment-of-severe-hemophilia-a/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/public-health-impact-of-complete-and-incomplete-rotavirus-vaccination-among-commercially-and-medicaid-insured-children-in-the-united-states/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-analysis-of-the-impact-of-increasing-access-to-long-acting-reversible-contraceptives-in-a-commercially-insured-population/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ml-compared-with-other-basal-insulin-therapies-in-patients-with-type-2-diabetes-mellitus--a-network-meta-analysis/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survival-in-patients-with-non-metastatic-breast-cancer-treated-with-adjuvant-trastuzumab-in-clinical-practice/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/variation-in-care-for-patients-with-irritable-bowel-syndrome-in-the-united-states/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reliable-analysis-is-key-to-addressing-ascertainability/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-bad-data-analyses-can-sabotage-discrimination-cases/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/millstone-power-station---providing-support-for-achieving-connecticut-s-clean-energy-goals/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/challenges-for-empirical-research-on-rpm/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-benefit-based-conjoint-analysis-benefit-product-design-/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-proposed-northern-pass-transmission-project--assessing-its-impacts-on-new-hampshire/2024-01-11T10:38:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-comparison-of-residential-water-bills--cal-water-oroville-and-south-feather-water---power-agency/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-early-origins-of-birth-order-differences-in-children-s-outcomes-and-parental-behavior/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/racial-discrimination-in-the-labor-market--theory-and-empirics/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-dose-ratio-of-subcutaneous-to-intravenous-immunoglobulin-therapy-among-patients-with-primary-immunodeficiency-disease-switching-to-20--subcutaneous-immunoglobulin-therapy/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/study-to-establish-new-york-electricity-market-icap-demand-curve-parameters/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/murky-markets--a-review-of-ferc-s-determination-of-submarkets-in-wholesale-electric-power-mergers/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/asunaprevir-versus-ifn-based-regimens-in-genotype-1b-hepatitis-c-virus-infection/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-biological-treatments-for-moderate-to-severe-psoriasis--a-network-meta-analysis-adjusting-for-cross-trial-differences-in-reference-arm-response/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/new-technologies-and-obsolete-analyses--internet-search-and-the-analysis-of-market-definition/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-consequences-of-contested-government-takeovers-of-investor-owned-water-utilities/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-consumers-really-think-about-reference-price-labels/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ensuring-validity-and-admissibility-of-consumer-surveys/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patterns-of-disease-monitoring-and-treatment-among-patients-with-tuberous-sclerosis-complex-related-angiomyolipomas/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-lifetimes-of-hydrophobic-amino-acid-pairs-measured-directly-from-molecular-dynamics-simulations/2024-01-11T10:38:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tracing-the-path-to-health-care-investigation-settlements/2024-01-11T10:38:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/proliferation-and-apoptosis-of-smooth-muscle-cells-in-benign-prostate-hyperplasia/2024-01-11T10:38:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/certain-and-progressive-methylation-of-histone-h4-at-lysine-20-during-the-cell-cycle/2024-01-11T10:38:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-risk-score-for-fluconazole-failure-among-patients-with-candidemia/2024-01-11T10:38:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-isavuconazole-vs--voriconazole-as-first-line-treatment-for-invasive-aspergillosis/2024-01-11T10:38:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/domains-of-heterochromatin-protein-1-required-for-drosophila-melanogaster-heterochromatin-spreading/2024-01-11T10:38:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-multiple-facets-of-histone-h4-lysine-20-methylation/2024-01-11T10:38:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/preferential-dimethylation-of-histone-h4-lysine-20-by-suv4-20/2024-01-11T10:38:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/expert-analysis-of-class-certification-issues/2024-01-11T10:38:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-analysis-of-nonpatent-intellectual-property-rights-and-damages-measures/2024-01-11T10:38:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/federal-securities-acts-and-areas-of-expert-analysis/2024-01-11T10:38:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/phase-ii-assessment-of-the-competitive-effects-associated-with-the-new-gtld-program/2024-01-11T10:38:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/enforcement-of-anticollusion-laws-against-domestic-and-foreign-firms/2024-01-11T10:38:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rggi-and-emissions-allowance-trading--options-for-voluntary-cooperation-among-rggi-and-non-rggi-states/2024-01-11T10:38:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-biopharmaceutical-pipeline--innovative-therapies-in-clinical-development/2024-01-11T10:38:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survey-and-real-world-data--a-winning-combination/2024-01-11T10:38:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/enhancing-the-resilience-of-the-nation-s-electricity-system/2024-01-11T10:38:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/over-declaration-of-standard-essential-patents-and-determinants-of-essentiality/2024-01-11T10:38:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/decision-making-in-a-world-of-comparative-effectiveness-research/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/introducing-decision-making-in-a-world-of-comparative-effectiveness-research/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perspectives-of-comparative-effectiveness-research-from-the-world-of-decision-making/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perspectives-on-the-use-of-comparative-effectiveness-research-by-life-sciences-executives--an-interview-with-a-senior-executive-at-an-international-life-science-company/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perspectives-on-the-common-drug-review-process-at-the-canadian-agency-for-drugs-and-technologies-in-health/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-non-pharmaceutical-technologies-at-the-canadian-agency-for-drugs-and-technologies-in-health/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/legal-considerations-in-a-world-of-comparative-effectiveness-research/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/challenges-in-developing-and-assessing-comparative-effectiveness-evidence-for-medical-technology/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparisons--a-brief-history-and-a-practical-look-forward/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perspectives-on-the-use-of-comparative-effectiveness-research-by-life-sciences-executives--an-interview-with-mike-bonney/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/managing-multiple-expert-witnesses--best-practices-and-pitfalls/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-new-standard-for-suspicious-order-monitoring/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-ocrelizumab-versus-subcutaneous-interferon-beta-1a-for-the-treatment-of-relapsing-multiple-sclerosis/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/insights-on-provider-consolidation-and-narrow-networks/2024-01-11T10:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/marijuana-legalization-implications-for-massachusetts/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consider-value-vs--budget-impact-in-mass--drug-prices/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-related-quality-of-life-and-work-productivity-associated-with-hiscr-and-nrs30-response-among-patients-with-moderate-to-severe-hidradenitis-suppurativa/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/natural-gas-pipeline-certification--policy-considerations-for-a-changing-industry/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/united-states--economics/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/capacity-resource-performance-in-nyiso-markets--an-assessment-of-wholesale-market-options/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/apolipoprotein-c-iii-and-high-density-lipoprotein-subspecies-defined-by-apolipoprotein-c-iii-in-relation-to-diabetes-risk/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-early-outcomes-of-alk-positive-non-small-cell-lung-cancer-patients-receiving-ceritinib--a-chart-review-study/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/monitoring-for-and-characterizing-crizotinib-progression--a-chart-review-of-alk-positive-non-small-cell-lung-cancer-patients/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-of-acute-ischemic-stroke-treatment-with-intravenous-recombinant-tissue-plasminogen-activator/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/readmission-risk-in-chronic-obstructive-pulmonary-disease-patients--comparative-study-of-nebulized-beta2-agonists/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/utility-values-associated-with-advanced-or-metastatic-non-small-cell-lung-cancer--data-needs-for-economic-modeling/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-services-utilization-among-fee-for-service-medicare-and-medicaid-patients-under-age-65-with-behavioral-health-illness-at-an-urban-safety-net-hospital/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/achievement-of-glycated-hemoglobin-goals-in-the-us-remains-unchanged-through-2014/2024-01-11T10:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-among-patients-with-advanced-gastric-cancer-in-south-korea/2024-01-11T10:38:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-bipolar-i-disorder-in-the-united-states-in-2015/2024-01-11T10:38:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/importance-of-balancing-follow-up-time-and-impact-of-oral-anticoagulant-users--selection-when-evaluating-medication-adherence-in-atrial-fibrillation-patients-treated-with-rivaroxaban-and-apixaban/2024-01-11T10:38:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/maintenance-of-weight-loss-or-stability-in-subjects-with-obesity--a-retrospective-longitudinal-analysis-of-a-real-world-population/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/functional-limitations-and-health-care-resource-utilization-for-individuals-with-cognitive-impairment-without-dementia--findings-from-a-united-states-population-based-survey/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-long-acting-beta2-agonists-as-monotherapy-for-chronic-obstructive-pulmonary-disease--a-network-meta-analysis/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/age-and-outcomes-of-primary-prevention-implantable-cardioverter-defibrillators-in-patients-with-nonischemic-systolic-heart-failure/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-before-and-after-perampanel-initiation-among-patients-with-epilepsy-in-the-united-states/2024-01-30T17:52:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/access-to-cancer-specialist-care-and-treatment-in-patients-with-advanced-stage-lung-cancer/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/poor-early-response-to-methotrexate-portends-inadequate-long-term-outcomes-in-patients-with-moderate-to-severe-psoriasis--evidence-from-2-phase-3-clinical-trials/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/inpatient-admissions-and-costs-associated-with-persistent-use-of-dalfampridine-extended-release-in-multiple-sclerosis--a-claims-database-analysis/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-in-advanced-pancreatic-neuroendocrine-tumors-in-the-era-of-targeted-therapy--perspectives-from-an-academic-tertiary-center-and-community-oncology-practices/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/benefit-risk-trade-offs-for-treatment-decisions-in-moderate-to-severe-rheumatoid-arthritis--focus-on-the-patient-perspective/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/improvement-of-carcinoid-syndrome-symptoms-following-treatment-with-above-standard-dose-of-octreotide-lar/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-and-costs-per-responder-among-biologic-treatments-for-moderate-to-severe-plaque-psoriasis-in-japan/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-effectiveness-among-patients-with-metastatic-colorectal-cancer-treated-with-ziv-aflibercept-in-community-oncology-practices-in-the-usa/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overall-survival-in-patients-with-glioblastoma-before-and-after-bevacizumab-approval/2024-01-11T10:38:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/baseline-characteristics-and-treatment-patterns-of-patients-with-schizophrenia-initiated-on-once-every-three-months-paliperidone-palmitate-in-a-real-world-setting/2024-01-11T10:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/out-of-pocket-medical-costs-and-third-party-healthcare-costs-for-children-with-down-syndrome/2024-01-11T10:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-for-venous-thromboembolism-recurrence-among-rivaroxaban-treated-patients-who-continued-versus-discontinued-therapy--analyses-among-patients-with-vte/2024-01-11T10:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-opioid-abuse--updated-findings/2024-01-11T10:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/same-day-hiv-testing-with-initiation-of-antiretroviral-therapy-versus-standard-care-for-persons-living-with-hiv--a-randomized-unblinded-trial/2024-01-11T10:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/public-health-impact-of-rotarix-vaccination-among-commercially-insured-children-in-the-united-states/2024-01-11T10:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-costs-in-patients-with-chronic-myeloid-leukemia-with-better-adherence-to-tyrosine-kinase-inhibitors-and-increased-molecular-monitoring-frequency/2024-01-11T10:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-paliperidone-palmitate-versus-oral-atypical-antipsychotics-on-health-care-resource-use-and-costs-in-veterans-with-schizophrenia-and-comorbid-substance-abuse/2024-01-11T10:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/attributes-of-nuclear-imaging-centers-impacting-physician-referrals-for-single-photon-emission-computed-tomography-myocardial-perfusion-imaging-tests/2024-01-11T10:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/nilotinib-versus-dasatinib-as-second-line-therapy-in-patients-with-philadelphia-chromosome-positive-chronic-myeloid-leukemia-in-chronic-phase-who-are-resistant-or-intolerant-to-imatinib--a-cost-effect/2024-01-11T10:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-and-outcomes-of-alk--non-small-cell-lung-cancer-patients-in-korea/2024-01-11T10:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-and-associated-incremental-costs-of-treatment-with-enzalutamide-versus-abiraterone-acetate-plus-prednisone-in-chemotherapy-naive-patients-with-metastatic-castration-resistant-pr/2024-01-11T10:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-following-allogeneic-hematopoietic-stem-cell-transplant-in-patients-with-diffuse-large-b-cell-lymphoma/2024-01-11T10:38:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-symptomatic-skeletal-events-on-health-care-resource-utilization-and-quality-of-life-among-patients-with-castration-resistant-prostate-cancer-and-bone-metastases/2024-01-11T10:38:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-costs-of-ischemic-stroke-by-discharge-status/2024-01-11T10:38:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/outcomes-based-contracting-experience--research-findings-from-u-s--and-european-stakeholders/2024-01-11T10:38:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/stroke-risk-reduction-outweighed-bleeding-risk-increase-from-vitamin-k-antagonist-treatment-among-nonvalvular-atrial-fibrillation-patients-with-high-stroke-risk-and-low-bleeding-risk/2024-01-30T17:53:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overall-survival-with-ponatinib-versus-allogeneic-stem-cell-transplantation-in-philadelphia-chromosome-positive-leukemias-with-the-t315i-mutation/2024-01-11T10:38:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-characteristics-and-overall-survival-in-patients-with-post-docetaxel-metastatic-castration-resistant-prostate-cancer-in-the-community-setting/2024-01-11T10:38:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-characteristics-and-outcomes-of-patients-wth-metastatic-castration-resistant-prostate-cancer-receiving-chemotherapy-versus-androgen-receptor-targeted-therapy-after-failure-of-first-line-and/2024-01-11T10:38:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-survival-outcomes-and-prognostic-factors-among-patients-receiving-first-targeted-therapy-for-advanced-renal-cell-carcinoma--a-seer-medicare-database-analysis/2024-01-11T10:38:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patterns-of-care-among-patients-receiving-sequential-targeted-therapies-for-advanced-renal-cell-carcinoma--a-retrospective-chart-review-in-the-usa/2024-01-11T10:38:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/basal-insulin-initiation-use-and-experience-among-people-with-type-2-diabetes-mellitus-with-different-patterns-of-persistence--results-from-a-multi-national-survey/2024-01-11T10:38:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-persistence-and-hospitalization-rates-among-patients-with-schizophrenia--a-quasi-experiment-to-evaluate-a-patient-information-program/2024-01-30T17:48:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/duration-of-treatment-in-prostate-cancer-patients-treated-with-abiraterone-acetate-or-enzalutamide/2024-01-11T10:38:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-in-medicaid-patients-with-schizophrenia-initiated-on-a-first--or-second-generation-long-acting-injectable-versus-oral-antipsychotic/2024-01-11T10:38:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-treatment-patterns-and-healthcare-costs-associated-with-probable-lennox-gastaut-syndrome/2024-01-11T10:38:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-sarcoidosis-in-a-commercially-insured-population-in-the-united-states/2024-01-11T10:38:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/high-cost-sarcoidosis-patients-in-the-united-states--patient-characteristics-and-patterns-of-health-care-resource-utilization/2024-01-11T10:38:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-burden-of-hepatorenal-syndrome-among-commercially-insured-and-medicare-patients-in-the-united-states/2024-01-11T10:38:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-systemic-corticosteroid-exposure--a-systematic-literature-review/2024-01-11T10:38:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/diagnostic-yield-of-active-case-finding-for-tuberculosis-and-hiv-at-the-household-level-in-slums-in-haiti/2024-01-11T10:38:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/opioid-abuse--a-detailed-examination-of-cost-drivers-over-a-24-month-follow-up-period--journal-of-managed-care-and-specialty-pharmacy/2024-01-11T10:38:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/drivers-of-excess-costs-of-opioid-abuse-among-a-commercially-insured-population/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retreatment-rates-among-endometriosis-patients-undergoing-hysterectomy-or-laparoscopy/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-adalimumab-versus-secukinumab-for-the-treatment-of-psoriatic-arthritis--a-matching-adjusted-indirect-comparison/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-matching-adjusted-indirect-comparison-methods-mitigate-placebo-response-differences-among-patient-populations-in-adjunctive-trials-of-brivaracetam-and-levetiracetam-/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-outcomes-in-elderly-advanced-renal-cell-carcinoma-patients-starting-pazopanib-or-sunitinib-treatment--a-retrospective-medicare-claims-analysis/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-renal-function-on-ischemic-stroke-and-major-bleeding-rates-in-nonvalvular-atrial-fibrillation-patients-treated-with-warfarin-or-rivaroxaban--a-retrospective-cohort-study-using-real-world-evi/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-associated-with-switching-or-discontinuation-from-anti-tnf-inhibitors-for-nonmedical-reasons/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cardiovascular-event-risk-assessment-in-psoriasis-patients-treated-with-tumor-necrosis-factor-alpha-inhibitors-versus-methotrexate/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/quality-measure-and-weight-loss-assessment-in-patients-with-type-2-diabetes-mellitus-treated-with-canagliflozin-or-dipeptidyl-peptidase-4-inhibitors/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/relationship-between-patient-copayments-in-medicare-part-d-and-vaccination-claim-status-for-herpes-zoster-and-tetanus-diphtheria-acellular-pertussis/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effectiveness-and-healthcare-costs-among-stabilised-rheumatoid-arthritis-patients-with-dose-reduction-of-adalimumab-or-etanercept-in-real-world/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--advanced-breast-cancer-/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hyperactivity-disorder-in-a-commercially-insured-population-in-the-united-states/2024-01-11T10:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hyperactivity-disorder-in-the-uk/2024-01-11T10:38:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/introduction-to-lost-profits/2024-01-11T10:38:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/analysis-of-cost-behavior/2024-01-11T10:38:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/using-net-cash-flow-versus-accrual-net-income/2024-01-11T10:38:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-ability-to-achieve-lost-sales-as-a-consideration-in-damages-analyses/2024-01-11T10:38:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fiscal-state-aid--are-us-companies-being-unfairly-targeted-/2024-01-11T10:38:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prejudice-and-racial-matches-in-employment/2024-01-11T10:38:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/avoiding-bias--ensuring-validity-and-admissibility-of-survey-evidence-in-litigations/2024-01-11T10:38:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consumer-surveys-in-trademark-infringement-litigation--fiji-vs--viti-case-study/2024-01-11T10:38:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recent-developments-in-litigation-and-regulation-related-to-no-hire-and-employee-non-compete-agreements--implications-for-franchise-systems/2024-01-11T10:38:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-department-of-justice-and-federal-trade-commission-guidance-for-human-resources-professionals-and-recent-comments-by-enforcement-officials-related-to-no-poaching-agreements/2024-01-11T10:38:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/are-workers-willing-to-pay-to-join-a-better-team-/2024-01-11T10:38:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competition-drives-rapid-growth-in-california-communications-market/2024-01-11T10:38:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/proactive-pay-equity-studies-can-shield-mass--employers/2024-01-11T10:38:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/music-consumption-and-marketing-science--does-spotify-change-users--music-consumption-/2024-01-11T10:38:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-primer-on-bargaining--how-mergers-may-affect-negotiated-prices/2024-01-11T10:38:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/claims-based-risk-model-for-first-severe-copd-exacerbation/2024-01-11T10:38:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/spontaneous-urticaria-in-the-united-states/2024-01-11T10:38:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-characteristics-and-outcomes-associated-with-receiving-an-earlier-versus-later-diagnosis-of-probable-alzheimer-s-disease/2024-01-11T10:38:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-analysis-of-braf-gene-mutation-testing-in-real-world-practice-using-claims-data/2024-01-11T10:38:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/implications-of-stroke-and-bleeding-risk-scores-and-comorbidities-on-episode-based-bundled-payments-for-patients-with-nonvalvular-atrial-fibrillation/2024-01-11T10:38:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-prevalence-of-hyperkalemia-in-the-united-states/2024-01-11T10:38:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-utilization-of-molecular-diagnostic-testing-and-matched-drug-therapies-in-the-treatment-of-metastatic-cancers/2024-01-11T10:38:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-cost-burden-and-change-of-employment-status-in-treatment-resistant-depression--a-matched-cohort-study-using-a-us-commercial-claims-database/2024-01-11T10:38:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-patients-with-inadequate-response-to-targeted-immunomodulators-for-rheumatoid-arthritis/2024-01-11T10:38:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/increased-prevalence-of-cancer-in-adult-patients-with-psoriasis-in-the-united-states--a-claims-based-analysis/2024-01-11T10:38:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-costs-associated-with-adverse-events-in-patients-with-cancer/2024-01-11T10:38:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-psoriasis-in-children-and-adolescents-in-the-united-states--a-claims-based-analysis/2024-01-11T10:38:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer-in-us-community-oncology-practices--an-observational-study/2024-01-11T10:38:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-comparison-of-continued-anticoagulation-with-rivaroxaban-versus-placebo-based-on-the-1-year-einstein-extension-trial-efficacy-and-safety-results/2024-01-11T10:38:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/one-year-effect-of-the-medicare-annual-wellness-visit-on-detection-of-cognitive-impairment--a-cohort-study/2024-01-11T10:38:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hba1c-control-and-cost-effectiveness-in-patients-with-type-2-diabetes-mellitus-initiated-on-canagliflozin-or-a-glucagon-like-peptide-1-receptor-agonist-in-a-real-world-setting/2024-01-11T10:38:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/quality-goal-attainment-and-maintenance-in-patients-with-type-ii-diabetes-mellitus-initiated-on-canagliflozin-or-a-glucagon-like-peptide-1-receptor-agonist-in-an-actual-practice-setting/2024-01-11T10:38:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/insurance-switching-and-mismatch-between-the-costs-and-benefits-of-new-technologies/2024-01-11T10:38:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-ceritinib-in-previously-untreated-anaplastic-lymphoma-kinase-positive-metastatic-non-small-cell-lung-cancer-in-the-united-states/2024-01-11T10:38:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-medicaid-spending-in-comorbid-schizophrenia-populations--once-monthly-paliperidone-palmitate-versus-oral-atypical-antipsychotics/2024-01-11T10:38:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-adalimumab-and-etanercept-for-the-treatment-of-moderate-to-severe-psoriasis--an-indirect-comparison-using-individual-patient-data-from-randomized-trials/2024-01-11T10:38:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-treatment-failure-in-chronic-lymphocytic-leukemia-patients/2024-01-11T10:38:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-iron-chelation-therapy-patients-switched-deferasirox-dispersible-tablets-to-deferasirox-film-coated/2024-01-11T10:38:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/procalcitonin-guidance-in-patients-with-lower-respiratory-tract-infections--a-systematic-review-and-meta-analysis/2024-01-11T10:38:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effectiveness-and-safety-of-anticoagulants-for-the-treatment-of-venous-thromboembolism-in-patients-with-cancer/2024-01-11T10:38:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/severe-adverse-events-impact-overall-survival-and-costs-in-elderly-patients-with-advanced-non-small-cell-lung-cancer-on-second-line-therapy/2024-01-11T10:38:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer--a-network-meta-analysis/2024-01-11T10:38:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-persistence-with-fingolimod-for-the-treatment-of-multiple-sclerosis--a-systematic-review-and-meta-analysis/2024-01-11T10:38:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-and-costs-per-responder-among-biologic-treatments-for-moderate-to-severe-psoriasis--a-network-meta-analysis/2024-01-11T10:38:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer-among-adult-premenopausal-women/2024-01-11T10:38:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-cost-of-hyperkalemia-in-the-united-states/2024-01-11T10:38:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-use-and-cost-associated-with-varying-dosages-of-extended-corticosteroid-exposure-in-a-us-population/2024-01-11T10:38:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/quantitative-characterization-of-the-relationship-between-levels-of-extended-corticosteroid-use-and-related-adverse-events-in-a-us-population/2024-01-11T10:38:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-of-ponatinib-versus-earlier-generation-tyrosine-kinase-inhibitors-for-front-line-treatment-of-newly-diagnosed-philadelphia-positive-acute-lymphoblastic-leukemia/2024-01-11T10:38:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-and-costs-per-responder-among-biologic-treatments-for-moderate-to-severe-psoriasis/2024-01-11T10:38:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/role-of-cost-sharing-subsidies-on-the-initiation-of-and-adherence-to-tyrosine-kinase-inhibitor-therapy-by-medicare-beneficiaries-with-chronic-myeloid-leukemia/2024-01-11T10:38:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/systematic-literature-review-and-meta-analysis-of-tumor-necrosis-factor-alpha-experienced-rheumatoid-arthritis/2024-01-11T10:38:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retention-in-care-among-patients-with-early-hiv-disease-in-haiti/2024-01-11T10:38:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/understanding-the-gap-between-efficacy-in-randomized-controlled-trials-and-effectiveness-in-real-world-use-of-glp-1-ra-and-dpp-4-therapies-in-patients-with-type-2-diabetes/2024-01-11T10:38:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-in-patients-with-advanced-gastric-cancer-in-taiwan/2024-01-11T10:38:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparing-the-cost-of-treatment-with-octreotide-long-acting-release-versus-lanreotide-in-patients-with-metastatic-gastrointestinal-neuroendocrine-tumors/2024-01-11T10:38:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-and-safety-of-procalcitonin-guidance-in-patients-with-suspected-or-confirmed-sepsis--a-systematic-review-and-meta-analysis/2024-01-11T10:38:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/keeping-covenants--getting-debt-ratios-right/2024-01-11T10:38:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/are-payers-ready-to-address-the-financial-challenges-associated-with-gene-therapy-/2024-01-11T10:38:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/vehicle-fuel-economy-and-air-pollution-standards--a-literature-review-of-the-rebound-effect/2024-01-11T10:38:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-expanding-carbon-cap-and-trade-regime--a-decade-of-experience-with-rggi-charts-a-path-forward/2024-01-11T10:38:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-tyranny-of-market-shares--incorporating-survey-based-evidence-into-merger-analysis/2024-01-11T10:38:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/we-need-to-improve-medicare-s-annual-wellness-visit-to-better-detect-early-dementia/2024-01-11T10:38:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/b-vaccination-series-completion-among-us-adults--a-claims-based-analysis/2024-01-11T10:38:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/microsoft-private-litigations/2024-01-11T10:39:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/vitamins-antitrust-litigation/2024-01-11T10:39:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-doj-v--mastercard-international-and-visa/2024-01-11T10:39:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/brand-name-prescription-drug-litigation/2024-01-11T10:39:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/virgin-atlantic-v--british-airways/2024-01-11T10:39:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/carnival-corporation-merger/2024-01-11T10:39:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/class-action-v--allstate-insurance/2024-01-11T10:39:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/colgate-v--procter---gamble-company/2024-01-11T10:39:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-ex-rel--jordan-v--northrop-grumman-corporation/2024-01-11T10:39:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/procter---gamble-co--v--haugen/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evergreen-international-airlines-v--asiana-airlines/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ferc-market-based-rate-applications-for-renewable-energy-power-plants/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/distribution-system-reliability--estimation-using-sampling-and-statistical-analysis/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/option-valuation-of-peaking-capacity/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/industry-restructuring-evaluation/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/modeling-of-bidding-behavior-in-competitive-electricity-markets/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-strategic-bidding-and-withholding/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wholesale-market-design-analysis/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/market-modeling--electricity-pricing-analyses/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pricing-and-retail-contract-analysis/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/valuation-of-a-new-hydroelectric-plant/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/market-monitoring-and-mitigation/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/environmental-economics-and-policy-for-the-electric-and-gas-industries/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/independent-market-monitoring/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/contract-and-regulatory-disputes/2024-01-11T10:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/damages-analysis-regarding-price-risk-management-strategy/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/energy-facility-siting/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/developing-a-technical-computing-framework/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/energizing-a-portfolio-for-the-deregulated-marketplace/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bmi-royalty-rates-analysis/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-haulers-association-v--oneida-herkimer-solid-waste-management-authority/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-and-environmental-impacts-of-energy-infrastructure/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/negotiations-regarding-insurance-coverage-of-environmental-liabilities/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pfizer-asbestos-settlement/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/3250-wilshire-blvd--building-v--metropolitan-life-insurance-company/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sheldon-h--solow-v--w--r--grace---company/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/florida-state-board-of-administration-v--alliance-capital-management/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/richard-duhaime-v--john-hancock-mutual-life-insurance-company/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/csr-v--lloyd-s-underwriters/2024-01-11T10:39:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mortgage-insurance-industry-respa-cases/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/class-action-v--ohio-national-life-insurance-company/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/winstar-damages-litigation/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sumitomo-corporation-v--major-investment-banks/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/corporate-partners-v--coopers---lybrand/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/reinsurance-arbitrations/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/orange-county-bankruptcy/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/risk-characteristics-of-swaps/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/developing-a-comprehensive-product-strategy/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/developing-a-growth-strategy-under-constraints/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/achieving-commercial-results-in-managed-markets/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/emc-corp--v--karwowska/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/boston-symphony-orchestra-compensation-analysis/2024-01-11T10:39:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-nursing-home-compensation/2024-01-11T10:39:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-clarent-corporation-securities-litigation/2024-01-11T10:39:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/california-amplifier-10b-5-litigation/2024-01-11T10:39:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/parnes-v--bally-entertainment-corp-/2024-01-11T10:39:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/emeritus-corporation-v--arv-assisted-living/2024-01-11T10:39:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/westside-cellular-v--new-par/2024-01-11T10:39:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/telecom-excise-tax-challenges/2024-01-11T10:39:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/digital-television-receiver-requirement/2024-01-11T10:39:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-new-product-development/2024-01-11T10:39:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/achieving-higher-levels-of-customer-satisfaction/2024-01-11T10:39:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/private-aerospace-manufacturer/2024-01-11T10:39:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/alkus-v--ods-technologies/2024-01-11T10:39:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-class-action-lawsuits/2024-01-11T10:39:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/optimizing-a-go-to-market-capability/2024-01-11T10:39:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/brokerage-company-class-action/2024-01-11T10:39:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/aerospace-workers-class-action/2024-01-11T10:39:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/overtime-pay-dispute/2024-01-11T10:39:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/media-information-business--growth-strategy/2024-01-11T10:39:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-advertising-effectiveness/2024-01-11T10:39:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/commercializing-new-technologies/2024-01-11T10:39:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/expanding-an-r-d-portfolio/2024-01-11T10:39:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/health-care-economics-and-reimbursement-strategy/2024-01-11T10:39:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/identifying-drivers-of-growth/2024-01-11T10:39:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/modeling-the-economics-of-growth-opportunities/2024-01-11T10:39:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/maintaining-competitive-advantage-in-the-face-of-rapid-commoditization/2024-01-11T10:39:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/rapid-response-to-shifting-industry-structure/2024-01-11T10:39:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/value-of-pharmaceuticals-to-society/2024-01-11T10:39:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/understanding-the-challenges-of-alternative-energy-structures/2024-01-11T10:39:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/moving-from-follower-to-market-leader/2024-01-11T10:39:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/retail-banking-customer-satisfaction/2024-01-11T10:39:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/retail-banking-performance-metrics/2024-01-11T10:39:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/segmentation-and-contracting-strategy/2024-01-11T10:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/venture-capital-firm-v--home-furnishings-company/2024-01-11T10:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mci-worldcom-bankruptcy/2024-01-11T10:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/globalizing-product-development/2024-01-11T10:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-lorazepam---clorazepate-antitrust-litigation/2024-01-11T10:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-impact-of-public-sewer-investments/2024-01-11T10:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lapd-racial-profiling-analysis/2024-01-11T10:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/stranded-cost-measurement/2024-01-11T10:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-unwired-acquisition/2024-01-11T10:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/regents-of-the-university-of-california-v--monsanto-company/2024-01-11T10:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v--henry-yuen/2024-01-11T10:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/steadfast-insurance-company-v--purdue-frederick-company/2024-01-11T10:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-department-of-justice-v--tenet-healthcare-corporation/2024-01-11T10:39:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/energy-infrastructure-development/2024-01-11T10:39:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/auction-design-for-wholesale-power-procurement/2024-01-11T10:39:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cost-benefit-analysis-of-wholesale-competition/2024-01-11T10:39:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/baker-v--american-century-investment-management/2024-01-11T10:39:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/putnam-investment-management/2024-01-11T10:39:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nyse-merger/2024-01-11T10:39:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/proyectos-y-construcciones-procisa-v--continental-tire-of-north-america/2024-01-11T10:39:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/archipelago-merger-litigation/2024-01-11T10:39:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/new-world-tmt-v--prediwave/2024-01-11T10:39:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/microsoft-iowa-settlement/2024-01-11T10:39:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bouygues-telecom-v--tekelec/2024-01-11T10:39:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mutual-fund-excessive-fee-case/2024-01-11T10:39:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lost-earnings-analysis-in-wrongful-termination-case/2024-01-11T10:39:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-loss-analyses-in-wrongful-death-case/2024-01-11T10:39:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/using-cps-data-to-compare-wages-by-race/2024-01-11T10:39:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sargon-enterprises-v--university-of-southern-california/2024-01-11T10:39:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/first-marblehead-corporation-v--gregory-house/2024-01-11T10:39:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/energy-policy-act-section-1813-comments--report-of-the-ute-indian-tribe-of-the-uintah-and-ouray-reservation-for-submission-to-the-us-departments-of-energy-and-interior/2024-01-11T10:39:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/vitascan-v--ge-healthcare/2024-01-11T10:39:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/general-american-liquidation-litigation/2024-01-11T10:39:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/coachella-valley-housing-coalition-v--city-of-moreno-valley/2024-01-11T10:39:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/robins-v--roland/2024-01-11T10:39:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/subprime-automobile-loan-portfolio-analysis/2024-01-11T10:39:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/computer-hard-drive-manufacturer-v--commissioner-of-internal-revenue/2024-01-11T10:39:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/managing-risk-under-new-climate-legislation/2024-01-11T10:39:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/black---decker-corp--v--united-states/2024-01-11T10:39:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/damages-calculation-in-dispute-involving-tax-sharing-agreement/2024-01-11T10:39:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dunkin-donuts-v--michael-panagakos/2024-01-11T10:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/flat-top-insurance-agency-v--us-dept--of-justice-taxation-division/2024-01-11T10:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/otto-candies-v--us-dept--of-justice-taxation-division/2024-01-11T10:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/rogers-v--united-states/2024-01-11T10:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/semiconductor-company-v--commissioner-of-internal-revenue/2024-01-11T10:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluation-of-transfer-pricing-of-intercompany-services-of-a-global-oil-and-gas-company/2024-01-11T10:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/global-transfer-pricing-planning-for-an-automotive-parts-supplier/2024-01-11T10:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/transfer-pricing-for-a-software-company/2024-01-11T10:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/valuing-financial-guarantees/2024-01-11T10:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/allegations-of-bid-rigging-by-major-insurers/2024-01-11T10:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/peoplesoft-v--oracle/2024-01-11T10:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/reducing-a-heavy-carbon-footprint/2024-01-11T10:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-market-impact-of-greenhouse-gas-legislation/2024-01-11T10:39:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/interactivecorp-/2024-01-11T10:39:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/slaughter-v--kohl/2024-01-11T10:39:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/jones-v--harris-associates/2024-01-11T10:39:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/awg-leasing-trust-v--united-states-of-america/2024-01-11T10:39:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nanovation-technologies-v--bearingpoint/2024-01-11T10:39:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/carlyle-realty-partners-v--vweb-corporation/2024-01-11T10:39:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-managed-care-litigation/2024-01-11T10:39:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/compilation-and-analysis-of-plaintiff-medical-records/2024-01-11T10:39:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/extrapolating-from-proposed-payout-matrices-to-assess-overall-exposure/2024-01-11T10:39:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/identification-of-the-timing-of-adverse-events-relative-to-drug-use/2024-01-11T10:39:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-assistance-in-connection-with-class-certification/2024-01-11T10:39:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessment-of-excess-risk-for-causation-analysis/2024-01-11T10:39:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/smithkline-v--revenue-canada/2024-01-11T10:39:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/biotechnology-stock-drop-matter/2024-01-11T10:39:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/development-of-a-framework-for-litigation-decision-making/2024-01-11T10:39:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cost-comparison-of-painful-conditions/2024-01-11T10:39:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-roi-for-bariatric-surgery/2024-01-11T10:39:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/quantifying-the-economic-burden-of-depression/2024-01-11T10:39:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-burden-of-opioid-abuse/2024-01-11T10:39:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/effects-of-depression-relative-to-other-health-problems/2024-01-11T10:39:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/costs-associated-with-adhd-patients-and-families/2024-01-11T10:39:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/comparison-of-escitalopram-and-citalopram/2024-01-11T10:39:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/epidemiology-studies-on-spinal-cord-injury/2024-01-11T10:39:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/epidemiology-studies-on-rare-childhood-cancers/2024-01-11T10:39:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/documenting-the-need-for-care-management-in-elderly-hypertensive-patients/2024-01-11T10:39:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/studies-to-assess-incidence-of-renal-injury-in-cancer-patients-using-bisphosphonates/2024-01-11T10:39:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/study-of-safety-and-efficacy-of-vegf-inhibitors-in-actual-use/2024-01-11T10:39:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/studies-of-adverse-events/2024-01-11T10:39:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/impact-of-aromatase-inhibitors-on-bone-loss-in-breast-cancer-patients/2024-01-11T10:39:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/establishing-a-health-outcomes-organization/2024-01-11T10:39:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/developing-a-new-drug-value-profile-to-inform-clinical-trials/2024-01-11T10:39:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/determining-product-value-proposition/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/using-sensitivity-analysis-to-drive-pricing-strategy/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/priority-customer-segmentation-strategy/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/refining-contracting-strategies-in-the-face-of-competition/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cardiovascular-acquisition-analysis/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/investment-and-acquisition-strategy/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/identifying-and-benchmarking-acquisition-targets/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/payer-billing-disputes/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-v--schiff/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-williams-securities-litigation/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-bear-stearns-litigation/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/major-music-publisher-profitability-analysis/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/warner-brothers-television-international-distribution-v--golden-channels---co-/2024-01-11T10:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/equity-broadcasting-corporation-v--pax-tv/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-report-on-california-proposition-71/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluating-opportunities-to-expand-oncology-franchise/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/go-to-market-strategy-for-a-solar-cell-start-up/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/financial-analysis-of-infrastructure-investments/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/scenario-analysis-of-product-and-franchise-performance/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/strategy-and-analysis-of-investment-options-for-global-pharmaceutical-company/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/financial-risk-management-for-a-chemical-company/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cap-and-trade-system-design/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessment-of-alternative-climate-policies/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/erisa-class-action/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/calpine-corporation-bankruptcy-settlement/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/son-of-boss-matters/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/rohm-and-haas-co--v--the-dow-chemical-co-/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/restructuring-of-american-airlines/2024-01-11T10:39:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/structuring-a-successful-turnaround/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/official-committee-of-asbestos-claimants-v--g-i-holdings/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/global-crossing-bankruptcy-bondholder-suit/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/shopping-center-management-fee-litigation/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-parmalat-securities-litigation/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/at-t-v--united-states-of-america/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-oracle-securities-litigation/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-v--cioffi/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lawrence-e--jaffe-pension-plan-v--household-international-inc-/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-american-funds-fee-litigation/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/microsoft-california-class-action/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/walmart-et-al--v--visa-and-mastercard/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-property-values-amid-allegations-of-contamination/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/an-economic-perspective-on-complex-climate-legislation/2024-01-11T10:39:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mastercard-antitrust-litigations/2024-01-11T10:39:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/innovating-to-reduce-emissions-and-energy-use/2024-01-11T10:39:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sofamor-danek-group-v--spine-tech/2024-01-11T10:39:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mylan-pharmaceuticals-v--procter---gamble-co-/2024-01-11T10:39:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/kwaak-et-al-v--pfizer-inc-/2024-01-11T10:39:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cleaning-appliance-manufacturer-false-superiority-claims/2024-01-11T10:39:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/false-superiority-claims-in-personal-hygiene-products-case/2024-01-11T10:39:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/price-comparison-claims-made-by-big-box-retailer/2024-01-11T10:39:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mtbe-water-contamination-litigations/2024-01-11T10:39:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-wetlands-contamination-case/2024-01-11T10:39:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-case-involving-a-major-oil-company/2024-01-11T10:39:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cost-benefit-analysis-on-behalf-of-brayton-point-station/2024-01-11T10:39:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/central-basin-municipal-water-district-v--metropolitan-water-district-of-southern-california/2024-01-11T10:39:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-agricultural-industries-in-antitrust-litigation/2024-01-11T10:39:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/identifying-high-impact-disruptive-technologies/2024-01-11T10:39:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/new-product-development-strategy-for-international-joint-venture/2024-01-11T10:39:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/kia-safety-class-actions/2024-01-11T10:39:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/developing-an-alternative-propulsion-roadmap/2024-01-11T10:39:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/business-impact-of-ghg-emissions-limits/2024-01-11T10:39:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/air-canada-v--toronto-port-authority-and-porter-airlines/2024-01-11T10:39:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/allegations-of-price-fixing-by-lcd-manufacturers/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evan-weiner-et-al--v--snapple-beverage-corporation/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pharmaceutical-off-label-promotion---kickbacks-settlements/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pre-merger-investigation-of-medtronic-acquisition/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/otsuka-pharmaceuticals-abilify-litigations/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/revenue-decoupling-and-other-ratemaking-approaches-for-utility-energy-efficiency/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/transmission-policy/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/establishing-utility-revenue-requirements/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-california-electricity-markets/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/music-licensing-royalty-rate-analyses/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/personal-audio-llc-v--apple-inc-/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/e-i--du-pont-de-nemours---co--v--kolon-industries-inc-/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-countrywide-financial-corp--mortgage-marketing-and-sales-practices-litigation/2024-01-11T10:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nevada-power-rate-proceeding/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-competitiveness-of-retail-electricity-market-in-pennsylvania/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/consumer-benefits-of-competition-in-the-telecommunications-industry/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-at-t-marketing-practices/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-health-care-patent-infringement-claims/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-adverse-events/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-ongoing-pharmaceutical-mass-tort-matter/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-onstar-contract-litigation/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/procter---gamble-company-v--united-states/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-securities-lending-litigations/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-google-adwords-litigation/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-potential-drug-safety-issues-for-a-major-pharmaceutical-company/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-certain-ground-fault-circuit-interrupters-and-products-containing-same/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analyzing-causation-and-damages-in-data-breach-litigation/2024-01-11T10:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/rabin-v--mony-life-insurance-company/2024-01-11T10:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-government-instrumentality-factors-in-fcpa-prosecution/2024-01-11T10:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/at-t-telecommunications-dispute-over-u-verse-equipment/2024-01-11T10:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-erisa-litigation/2024-01-11T10:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-marsh-erisa-litigation/2024-01-11T10:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/the-board-of-trustees-of-the-southern-california-ibew-neca-defined-contribution-plan-et-al--v--the-bank-of-new-york-mellon-corporation-et-al-/2024-01-11T10:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/multiple-antitrust-litigations-on-behalf-of-large-semiconductor-manufacturer/2024-01-11T10:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-reorganization-plan-for-spectrum-brands/2024-01-11T10:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/morpho-detection-inc--v--smiths-detection-inc-/2024-01-11T10:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/market-research-in-support-of-pricing-strategies/2024-01-11T10:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pharmaceutical-product-development-and-launch/2024-01-11T10:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/false-advertising-claims-in-consumer-beverages-market/2024-01-11T10:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/netscape-v--microsoft/2024-01-11T10:39:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/patent-infringement-matter-related-to-consumer-electronics/2024-01-11T10:39:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/trademark-infringement-related-to-luxury-goods/2024-01-11T10:39:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/alta-bates-and-summit-medical-centers-merger-antitrust-suit/2024-01-11T10:39:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analyzing-design-issues-in-a-product-safety-matter/2024-01-11T10:39:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/patent-valuation-and-food-industry-r-d/2024-01-11T10:39:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/chemtech-royalty-associates-l-p--v--united-states-of-america/2024-01-11T10:39:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/rincon-ev-realty-llc-et-al--v--cp-iii-rincon-towers-inc-/2024-01-11T10:39:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analyzing-safety-preparedness-in-high-risk-work-environments/2024-01-11T10:39:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/justice-department-investigation-into-health-care-fraud/2024-01-11T10:39:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/erisa-class-action-against-provider-of-retirement-plan-services-to-small--and-mid-sized-plans/2024-01-11T10:39:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/erisa-class-action-litigations-involving-plans-that-held-investment-options-affiliated-with-the-plan-sponsor/2024-01-11T10:39:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/consultants-study-ceo-perspectives-and-recommendations-on-california-s-advanced-energy-policies/2024-01-11T10:39:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/conducting-a-review-of-the-regional-greenhouse-gas-initiative-s-impact-on-consumer-electricity-bills/2024-01-11T10:39:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/effingo-wireless-inc--v--motorola-mobility-llc/2024-01-11T10:39:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/washington-state-hospital-association-medicaid-supplemental-payments-matter/2024-01-11T10:39:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/batsheva-ackerman-et-al--v--the-coca-cola-company-and-energy-brands-inc-/2024-01-11T10:39:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/eplus-inc--v--lawson-software-inc-/2024-01-11T10:39:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sean-turnbow-et-al--v--life-partners-inc--et-al-/2024-01-11T10:39:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analyzing-the-performance-of-iso-ne-power-generation-resources/2024-01-11T10:39:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-depth-new-analyses-on-the-use-of-renewable-energy-for-power-system-operations/2024-01-11T10:39:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/newire-inc--v--southwire-company/2024-01-11T10:39:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/saint-alphonsus-medical-center---nampa-et-al--v--st--luke-s-health-system-ltd-/2024-01-11T10:39:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sunset-drive-corporation-v--city-of-redlands/2024-01-11T10:39:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/casino-developments/2024-01-11T10:39:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-and-fiscal-impacts-of-clean-fuels-project-alternative-in-kern-county/2024-01-11T10:39:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ferc-market-based-rate-authorization-and-market-power-analyses-in-wholesale-electric-markets/2024-01-11T10:39:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/toyota-industries-and-cascade-corporation-transaction/2024-01-11T10:39:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nxp-b-v--v--blackberry-limited-and-blackberry-corporation/2024-01-11T10:39:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/levi-jones-et-al--v--conagra-foods-inc-/2024-01-11T10:39:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/corvex-management-et-al--v--commonwealth-reit-et-al-/2024-01-11T10:39:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/demand-study-regarding-a-potential-combination-drug-for-a-major-pharmaceutical-company/2024-01-11T10:39:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/blue-cross-blue-shield-of-minnesota-et-al-v--wells-fargo-bank-n-a-/2024-01-11T10:39:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sec-investigation-into-accounting-and-disclosure-practices/2024-01-11T10:39:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-transmission-for-renewables-projects/2024-01-11T10:39:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/class-action-v--horace-mann-life-insurance-et-al-/2024-01-11T10:39:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/comcast-ip-holdings-i-llc-v--sprint-communications-co--lp-et-al-/2024-01-11T10:39:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pricing-and-positioning-of-complex-consumer-products/2024-01-11T10:39:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/center-partners-ltd--et-al--v--urban-shopping-centers-lp--et-al-/2024-01-11T10:39:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mobile-telecommunications-technologies-llc-v--samsung-telecommunications-america-llc/2024-01-11T10:39:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sec-v--mark-a--jackson-and-james-j--ruehlen/2024-01-11T10:39:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/colgate-softsoap-false-advertising-consumer-class-action/2024-01-11T10:39:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/product-liability-class-action--treated-wood-products/2024-01-11T10:39:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/developing-a-go-to-market-strategy/2024-01-11T10:39:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/postova-banka-as-and-istrokapital-se-v--the-hellenic-republic/2024-01-11T10:39:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wfc-holdings-corporation-v--united-states-of-america/2024-01-11T10:39:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/tax-investigation-analysis/2024-01-11T10:39:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessment-of-alleged-postal-fraud/2024-01-11T10:39:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-investment-performance/2024-01-11T10:39:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/earn-out-dispute-in-acquisition-of-engineering-and-project-management-firm/2024-01-11T10:39:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fox-broadcasting-company-et-al-v--dish-network-llc-et-al/2024-01-11T10:39:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluating-the-economic-impact-of-early-diagnosis-of-alzheimer-s-disease/2024-01-11T10:39:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-economic-benefits-of-diabetic-foot-ulcer-treatment/2024-01-11T10:39:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/miriam-haskins-at-al--v--first-american-title-insurance-company/2024-01-11T10:39:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/st--clair-intellectual-property-consultants-inc--v--toshiba-corp--et-al-/2024-01-11T10:39:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/e-retailer-false-advertising-matter/2024-01-11T10:39:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/crtc-review-of-wholesale-wireline-services-and-associated-policies/2024-01-11T10:39:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bayer-healthcare-pharmaceuticals-inc--v--glenmark-pharmaceuticals-ltd-/2024-01-11T10:39:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-impact-analysis-of-direct-lender-ondeck/2024-01-11T10:39:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/at-t-acquisition-of-directv----survey-of-consumer-preferences/2024-01-11T10:39:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-potential-impacts-of-california-climate-policies/2024-01-11T10:39:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/report-on-the-economic-effects-of-mandatory-energy-labeling-for-buildings/2024-01-11T10:39:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluating-the-epa-s-clean-air-transport-rule/2024-01-11T10:39:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/contentguard-holdings-inc--v--google-inc-/2024-01-11T10:39:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-in-nfl-players-association-deflategate-matter/2024-01-11T10:39:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bittitan-inc-v-skykick-inc/2024-01-11T10:39:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/phigenix-v--immunogen/2024-01-11T10:39:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wisconsin-alumni-research-foundation-v--apple/2024-01-11T10:39:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/medtronic-minimed-v-nova-biomedical/2024-01-11T10:39:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nes-financial-corp--v--jpmorgan-chase-bank/2024-01-11T10:39:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/romag-fasteners-inc--v--fossil-inc--et-al-/2024-01-11T10:39:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/class-action-sales-practices-litigation-surrounding-vanishing-premium-sales/2024-01-11T10:39:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-regulatory-matter-involving-alleged-failure-to-annuitize-variable-annuities/2024-01-11T10:39:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wellbutrin-xl-antitrust-litigation/2024-01-11T10:39:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/controlled-substance-suspicious-order-monitoring-modeling/2024-01-11T10:39:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/controlled-substance-monitoring-and-effective-controls-against-diversion--investigations-and-settlements/2024-01-11T10:39:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/tribunal-de-commerce-francophone-de-bruxelles---patrinvest-v--sa-ageas/2024-01-31T21:40:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bmg-rights-management-et-al-v-cox-communications/2024-01-11T10:39:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-deposit-insurance-corporation-as-receiver-for-vantus-bank-v--officers-and-directors-of-vantus-bank/2024-01-11T10:39:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/solyndra-antitrust-litigation/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/philip-morris-v--uruguay/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/petition-to-the-governor-in-council-concerning-telecom-regulatory-policy-crtc-2015-326/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/daiichi-sankyo-and-ranbaxy-laboratories-damages-arbitration/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/tax-dispute-concerning-charitable-easements/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/innopharma-licensing-inc--et-al--v--senju-pharmaceutical-co--ltd--et-al-/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fresenius-kabi-usa-llc-v-fera-pharmaceuticals-llc-et-al/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-impact-of-rwandan-hospital-on-its-community-is-examined-pro-bono-by-analysis-group-at-request-of-pih/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-group-pro-bono-team-assists-harvard-medical-school-in-tb-genome-machine-learning-project/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-group-team-works-pro-bono-with-gheskio-to-study-characteristics-of-sexual-assault-in-haiti/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-group-team-provides-pro-bono-assistance-to--major-homeless-shelter-initiative-in-massachusetts/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dang-v-san-francisco-forty-niners-ltd-et-al/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sec-v-stifel-nicolaus-co-inc-and-david-w-noack/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/city-of-claremont-v--golden-state-water-company/2024-01-11T10:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-et-al--v--anthem-inc--et-al/2024-01-11T10:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/kenneth-hobbs-v-brother-international-corporation-et-al/2024-01-11T10:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lapd-pedestrian-and-motor-vehicle-stop-data-analyses/2024-01-11T10:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-fedex-ground-package-system-inc-employment-practices-litigation/2024-01-11T10:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/drivers-v-united-parcel-services-inc/2024-01-11T10:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/high-tech-employee-class-action-involving-alleged-no-poaching-agreements/2024-01-11T10:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pat-cason-merenda-et-al-v-detroit-medical-center-et-al/2024-01-11T10:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-group-pro-bono-team-assists-suffolk-law-school-in-examining-gender-identity-discrimination-in-the-metro-boston-rental-housing-market/2024-01-11T10:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/denimafia-inc-v-new-balance-athletic-shoe-inc-et-al-and-new-balance-athletic-shoe-inc-v-denimafia-inc/2024-01-11T10:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/basis-pac-rim-opportunity-fund-index-master-et-al-vs-tcw-asset-management-company/2024-01-11T10:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/overall-survival-with-ponatinib-versus-allogeneic-stem-cell-transplantation-in-philadelphia-chromosome-positive-leukemias-with-the-t315i-mutation/2024-01-11T10:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-appraisal-of-petsmart-inc-2017-bl-177567-del-ch-no-10782/2024-01-11T10:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/adidas-america-inc-et-al-v-skechers-usa-inc/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-appraisal-of-sws-group-inc-ca-no-10554-vcg/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wex-inc-acquisition-of-electronic-funds-source-llc/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cintas-corporation-acquisition-of-gk-services/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-of-america-et-al-ex-rel-brown-v-celgene-corp/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/western---southern-life-insurance-co-et-al-v-bank-of-new-york-mellon/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-william-tirrell-before-the-us-securities-and-exchange-commission/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cftc-v--hunter-and-ferc-v--hunter/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/central-vermont-public-service-corporation-and-green-mountain-power-corporation-v--entergy-nuclear-vermont-yankee/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/market-analysis-in-a-contractual-dispute/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-economic-feasibility-of-proposed-coal-plant/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bankruptcy-filing-in-the-offshore-drilling-industry/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-analysis-in-a-water-rights-dispute/2024-01-11T10:39:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/shareholder-derivative-suit-following-an-operational-incident/2024-01-11T10:39:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-lynn-tilton-et-al-before-the-us-securities-and-exchange-commission/2024-01-11T10:39:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ferc-v-national-fuel-marketing-llc/2024-01-11T10:39:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/btg-international-inc-v-wellstat-therapeutics-corporation/2024-01-11T10:39:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluating-the-capacity-market-consequences-of-alternate-resource-portfolios/2024-01-11T10:39:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/capacity-resource-performance-in-nyiso-markets--an-assessment-of-wholesale-market-options/2024-01-11T10:39:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-appraisal-of-dell-inc/2024-01-11T10:39:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re--alere-abbott-merger-litigation/2024-01-11T10:39:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/argentinian-economic-crisis/2024-01-11T10:39:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/itc-investigation-of-standard-essential-patents/2024-01-11T10:39:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/debt-covenant-litigations-involving-caesars/2024-01-11T10:39:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v--nauman-a--aly/2024-01-11T10:39:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-northeast-and-mid-atlantic-states/2024-01-11T10:39:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-airways-v-british-airways/2024-01-11T10:39:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluation-of-materiality-of-actions-constituting-default-by-an-insurer/2024-01-11T10:39:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/patent-infringement-matter-against-e-commerce-retailer/2024-01-11T10:39:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/allegations-of-insider-trading-against-major-shareholder-of-french-biotech-corporation/2024-01-31T21:35:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluation-of-materiality-of-actions-constituting-default-by-an-insurer-6442449825/2024-01-11T10:39:54+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/david-a.-glick2024-03-07T22:18:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ts-media-inc.-et-al.-v.-public-broadcasting-service2024-01-11T10:41:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/micah-officer/2024-01-11T10:41:19+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/rebecca-burne/2024-01-11T10:41:19+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/bruno-emond/2024-02-16T16:00:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/veronica-huan/2024-03-07T22:23:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/in-all-probability-an-economic-reading-of-damages-under-factory-at-chorzow/2024-01-11T10:41:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/w.-michael-hanemann2024-01-11T10:41:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/amazon-inc.--subsidiaries-v.-commissioner-of-internal-revenue2024-01-11T10:41:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-cost-of-obesity-among-the-privately-insured-in-the-united-states-a-focus-on-the-impact-by-type-of-industry/2024-01-11T10:41:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sony-music-entertainment-et-al-v-cox-communications-inc-et-al/2024-01-11T10:41:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/sueyoung-min/2024-01-11T10:41:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-appraisal-of-panera-bread-company/2024-01-11T10:41:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-group-team-joins-partners-in-health-for-pro-bono-data-analysis-in-lesotho/2024-01-11T10:41:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/u.s.-v.-boustani-et-al2024-01-11T10:41:17+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/health-care-bulletins/health-care-bulletin-winter-2019-2020/2024-01-11T10:41:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fercs-certification-of-new-interstate-natural-gas-facilities-revising-the-1999-policy-statement-for-21st-century-conditions/2024-01-11T10:41:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/employed-for-higher-pay-how-medicare-payment-rules-affect-hospital-employment-of-physicians/2024-01-11T10:41:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-appraisal-of-jarden-corp/2024-01-11T10:41:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fuel-and-energy-security-in-new-york-state-an-assessment-of-winter-operational-risks-for-a-power-system-in-transition/2024-01-11T10:41:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-alibaba-group-holding-limited-securities-litigation/2024-01-11T10:41:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/matthew-gentzkow/2024-01-11T10:41:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/discovery-communications-inc.-acquisition-of-scripps-networks-interactive-inc2024-01-11T10:41:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-recognized-as-a-top-women-led-business-in-massachusetts/2024-01-11T10:41:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/punam-anand-keller/2024-01-11T10:41:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competition-scale-and-hedge-fund-performance-evidence-from-merger-arbitrage/2024-01-11T10:41:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/joshua-wasser-et-al.-v.-all-market-inc2024-01-11T10:41:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-sponsors-and-presents-at-annual-uscanada-energy-conference/2024-01-11T10:41:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-to-sponsor-and-present-at-new-england-energy-summit/2024-01-11T10:41:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/dina-mayzlin/2024-01-11T10:41:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-sears-holdings-corporation-et-al.-chapter-11-bankruptcy-proceedings2024-01-11T10:41:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-nine-west-holdings-inc.-et-al.-chapter-11-bankruptcy-proceedings2024-01-11T10:41:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/scalia-v.-wpn-corp.-et-al2024-01-11T10:41:03+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-helps-client-win-summary-judgment-in-erisa-case/2024-01-11T10:41:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/data-pinpoints-expert-valuation-differences-in-del.-appraisals2024-01-11T10:41:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/categorising-trajectories-individual-item-changes-north-star-ambulatory-assessment/2024-01-11T10:41:13+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/mihir-desai/2024-01-11T10:41:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/time-to-move-away-from-old-precedents-in-ferc-pipeline-reviews/2024-01-11T10:41:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-development-of-health-technology-assessment-in-asia-current-status-and-future-trends/2024-01-11T10:41:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/temporal-and-geographic-variation-in-the-incidence-of-alzheimers-disease-diagnosis-in-the-us-between-2007-and-2014/2024-01-11T10:41:12+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/new-amcp-format-for-formulary-submissions/2024-01-11T10:41:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/analyzing-country-risk-premium-in-icsid-awards/2024-01-11T10:41:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/daniel-snow/2024-01-11T10:41:12+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/gary-m.-lawrence2024-01-11T10:41:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/why-does-the-consumer-welfare-standard-work-matching-methods-to-markets/2024-01-11T10:41:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/antoinette-schoar/2024-01-11T10:41:10+00:00weekly0.7https://www.analysisgroup.com/careers/what-is-economic-consulting/meet-the-humira-team/2024-01-11T10:41:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/jia-zhong/2024-01-11T10:41:19+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/weiguang-xue/2024-02-16T15:47:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/alex-fiore/2024-01-11T10:41:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-societal-economic-burden-of-autosomal-dominant-polycystic-kidney-disease-in-the-united-states/2024-01-11T10:41:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/implications-of-energy-ratings-for-residential-real-estate-markets2/2024-01-11T10:41:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/della-cummings/2024-02-27T14:35:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/carlos-chiapa/2024-03-18T20:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evidence-based-assessment-of-current-and-emerging-bladder-sparing-therapies-for-non-muscle-invasive-bladder-cancer-after-bacillus-calmette-guerin-therapy-a-systematic-review-and-meta-analysis/2024-01-11T10:41:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/bertrand-meyer/2024-02-01T14:09:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/powering-through--and-beyond--the-crisis/2022-01-19T17:50:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lincoln-electric-co.-et-al.-v.-harbor-freight-tools-usa-inc2024-01-11T10:41:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/ishita-rajani/2024-03-07T15:19:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/keri-pearlson/2024-02-09T21:39:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/energy-security-improvements-impact-assessment/2024-01-11T10:41:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-inc.-v.-qualcomm-inc.-antitrust2024-01-11T10:41:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/qualcomm-inc.-v.-apple-inc.-patent-infringement2024-01-11T10:41:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-certain-mobile-electronic-devices-and-radio-frequency-and-processing-components-thereof-inv.-no.-337-ta-10932024-01-11T10:41:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/kerri-holmsten/2024-01-11T10:41:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/angie-graves/2024-01-11T10:41:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/merike-kaeo/2024-01-11T10:41:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/5g-infrastructure-buildout-and-the-economic-impact-of-faster-clearing-of-c-band-spectrum-in-the-united-states/2024-01-11T10:41:20+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/analysis-group-forum-2020/2024-01-11T10:41:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/joseph-maloney/2024-02-27T14:35:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-c.-chan-jr2024-01-11T10:41:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/covid-19s-strain-on-hospitals-may-necessitate-more-relief/2024-01-11T10:41:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/vertical-relationships-horizontal-effects-the-evolving-debate-on-vertical-labor-market-restraints/2024-01-11T10:41:19+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/stuart-madnick/2024-01-11T10:41:19+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-grabowski/2024-01-11T10:41:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/patrick-s-gagnon/2024-03-14T19:22:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/great-recession-holds-mortgage-crisis-lessons-for-today/2024-01-11T10:41:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/masha-zhdanava/2024-03-08T14:43:53+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/mark-deyong/2024-01-11T10:41:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/arun-sundararajan/2024-01-11T10:41:22+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/charles-wu/2024-01-11T10:41:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survey-says-tips-on-getting-over-the-daubert-hurdle/2024-01-11T10:41:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/calif.-pay-for-delay-law-lacks-nuance2024-01-11T10:41:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/suicidal-ideation-and-attempts-in-the-united-states-of-america-among-stimulant-treated-non-stimulant-treated-and-untreated-patients-with-a-diagnosis-of-attention-deficithyperactivity-disorder/2024-01-11T10:41:23+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/aaron-kelley/2024-01-11T10:41:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/carbon-pricing-for-new-england-context-key-factors-and-impacts/2020-06-24T20:10:54+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/alex-robinson/2024-02-16T16:27:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/remember-stacker-another-look-at-killer-acquisitions-in-the-digital-economy/2024-01-31T21:38:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/snmp-research-international-et-al.-v.-nortel-networks-et-al2024-01-11T10:41:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/valuing-firms-in-a-world-of-pandemic-induced-bankruptcies/2024-01-11T10:41:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/rozi-kepes/2024-03-18T19:02:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/qualified-renters-need-not-apply-race-and-voucher-discrimination-in-the-metro-boston-rental-housing-market/2023-06-13T17:22:23+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/phil-hall-partyka/2024-01-11T10:41:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/french/2024-01-11T10:41:23+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/philipp-tillmann/2024-03-04T16:00:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-market-needs-to-evaluate-natural-gas-pipeline-development/2024-01-11T10:41:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-the-environmental-impact-of-the-siting-of-a-natural-gas-power-plant/2024-01-11T10:41:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economics--overview-measurement-error-bias-in-overcharge-calculations-global-competition-review-europe-middle-east-and-africa-antitrust-review-2021-july-2020/2024-01-11T10:41:22+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/hadrien-vasdeboncoeur/2024-03-18T19:09:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-the-application-of-transource-maryland-llc-for-a-certificate-of-public-convenience-and-necessity/2024-01-11T10:41:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/alliance-des-professionnels-et-des-professionnelles-de-la-ville-de-quebec-et-al.-v.-la-procureure-generale-du-quebec2024-01-30T17:57:01+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/christopher-f.-noe2024-01-11T10:41:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/william-r.-kruse-v.-synapse-wireless-inc2021-07-30T00:19:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/utility-energy-efficiency-program-performance-from-a-climate-change-perspective-a-comparison-of-structural-and-behavioral-programs/2024-01-26T17:35:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/accounting-for-the-coronavirus/2024-01-11T10:41:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/expediting-ma-deal-processes-via-negotiations-vs.-auctions2024-01-29T20:04:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-assessment-of-clinical-outcomes-among-first-line-sunitinib-patients-with-clear-cell-metastatic-renal-cell-carcinoma-mrcc-by-the-international-mrcc-database-consortium-risk-group/2024-02-29T21:35:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/new-survey-methods-may-assess-tm-dilution-with-more-detail/2024-01-30T18:05:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/model-of-short--and-long-term-outcomes-of-emicizumab-prophylaxis-treatment-for-persons-with-hemophilia-a/2024-01-11T10:41:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-treatment-resistant-depression-in-privately-insured-u.s.-patients-with-physical-conditions2024-01-11T10:41:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/innovation-competition-assessment-by-competition-authorities/2024-01-11T10:41:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-review-of-two-regulatory-approved-anti-cd19-car-t-cell-therapies-in-diffuse-large-b-cell-lymphoma-why-are-indirect-treatment-comparisons-not-feasible/2024-01-11T10:41:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimation-of-total-costs-in-pediatric-and-young-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-receiving-tisagenlecleucel-from-a-u.s.-hospitals-perspective2024-01-11T10:41:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimation-of-total-costs-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-receiving-tisagenlecleucel-from-a-us-hospitals-perspective/2024-01-11T10:41:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/successful-health-care-provider-strategies-to-overcome-psychological-insulin-resistance-in-united-states-and-canada/2024-01-11T10:41:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-safety-and-efficacy-of-ozanimod-versus-fingolimod-for-relapsing-multiple-sclerosis/2024-01-11T10:41:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-based-analysis-can-be-useful-in-calif.-contract-disputes2024-01-11T10:41:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-heart-failure-management-medications-following-cardiac-resynchronization-therapy/2024-01-11T10:41:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/grading-and-management-of-cytokine-release-syndrome-in-patients-treated-with-tisagenlecleucel-in-the-juliet-trial/2024-01-11T10:41:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluation-of-a-fraud-detection-system/2024-01-11T10:41:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/igor-karagodsky/2024-01-11T10:41:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/weighing-the-benefits-how-much-weight-will-your-survey-have-in-court/2024-03-05T14:12:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/nathaniel-good/2024-01-11T10:41:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-of-long-term-prednisone-and-deflazacort-use-in-patients-with-duchenne-muscular-dystrophy-experience-at-a-single-large-care-center/2024-01-11T10:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-renal-and-cardiovascular-events-among-patients-with-type-2-diabetes-mellitus-and-nephropathy-a-cost-model-based-on-the-credence-clinical-trial/2024-01-11T10:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-crohns-disease-in-the-united-states-long-term-healthcare-and-work-loss-related-costs/2024-01-11T10:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-inflammatory-bowel-disease-among-patients-with-chronic-inflammatory-diseases-a-retrospective-cohort-study/2024-01-11T10:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/in-hospital-therapy-for-heart-failure-with-reduced-ejection-fraction-in-the-united-states/2024-01-11T10:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prognostic-factors-for-changes-in-the-timed-4-stair-climb-in-patients-with-duchenne-muscular-dystrophy-and-implications-for-measuring-drug-efficacy-a-multi-institutional-collaboration/2024-01-11T10:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/suitability-of-external-controls-for-drug-evaluation-in-duchenne-muscular-dystrophy/2024-01-11T10:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-longitudinal-assessment-of-the-impact-of-endometriosis-on-patients-salary-growth-and-risk-of-leaving-the-workforce/2024-01-11T10:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-postpartum-depression-among-commercially-insured-households/2024-02-07T16:45:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/projecting-the-long-term-economic-impact-of-once-monthly-paliperidone-palmitate-versus-oral-atypical-antipsychotics-in-medicaid-patients-with-schizophrenia/2024-01-11T10:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-and-treatment-patterns-among-patients-with-atopic-dermatitis-using-advanced-therapies-in-the-united-states-analysis-of-a-retrospective-claims-database/2024-01-11T10:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-economic-evaluation-of-risankizumab-versus-other-biologic-treatments-of-moderate-to-severe-plaque-psoriasis-in-japan/2024-01-11T10:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-jak-inhibitors-for-moderate-to-severe-rheumatoid-arthritis-a-network-meta-analysis/2024-01-11T10:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-trade-commission-v.-qualcomm-inc2024-01-11T10:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-of-home-health-and-other-healthcare-delivery-pathways-among-privately-insured-patients-with-and-without-treatment-resistant-depression/2024-01-11T10:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-simultaneous-versus-sequential-initiation-of-basal-insulin-and-glucagon-like-peptide-1-receptor-agonists-on-hba1c-in-type-2-diabetes-a-retrospective-observational-study/2024-01-11T10:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-illness-among-patients-with-severe-aplastic-anemia-who-have-had-insufficient-response-to-immunosuppressive-therapy-a-multicenter-retrospective-chart-review-study/2024-01-11T10:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/achieving-western-states-greenhouse-gas-ghg-reduction-objectives--least-cost-compliance-in-a-constantly-evolving-policy-environment/2024-01-11T10:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/erisa-litigation-involving-health-and-welfare-plans/2024-01-11T10:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/back-to-school--three-years-later-an-update-on-university-retirement-plan-litigation/2024-01-11T10:41:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/michal-k.-popiel2024-01-11T10:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-and-economic-burden-of-hyperkalemia-in-the-united-states-medicare-population/2024-01-11T10:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dolby-international-ab-ge-video-compression-llc-and-koninklijke-philips-nv-v.-mas-elektronik-aktiengesellschaft2024-01-11T10:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antiproliferative-effects-of-telotristat-ethyl-in-patients-with-neuroendocrine-tumors-the-teleace-real-world-chart-review-study/2024-01-11T10:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-epipen-erisa-litigation/2024-01-11T10:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-illness-among-commercially-insured-patients-with-systemic-sclerosis-with-interstitial-lung-disease-in-the-usa-a-claims-data-analysis/2024-01-11T10:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-among-commercially-insured-patients-with-systemic-sclerosis-in-the-united-states/2024-01-11T10:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/modeling-the-potential-impact-of-abuse-deterrent-opioids-on-medical-resource-utilization/2024-01-11T10:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-clinical-outcomes-of-pazopanib-immediately-after-discontinuation-of-immunotherapy-for-advanced-renal-cell-carcinoma/2024-01-11T10:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-of-chemoradiotherapy-versus-single-modality-therapy-and-overall-survival-among-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer/2024-01-11T10:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-national-comprehensive-cancer-network-guidelines-for-brca-testing-among-high-risk-breast-cancer-patients-a-retrospective-chart-review-study/2024-01-11T10:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-economic-evaluation-of-pembrolizumab-versus-other-adjuvant-treatment-strategies-for-resected-high-risk-stage-iii-melanoma-in-the-usa/2024-01-11T10:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-pembrolizumab-with-axitinib-as-first-line-treatment-for-advanced-renal-cell-carcinoma/2024-01-11T10:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/individual-contribution-in-team-contests/2024-01-11T10:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/key-strategies-for-overcoming-psychological-insulin-resistance-in-adults-with-type-2-diabetes-the-uk-subgroup-in-the-emotion-study/2024-01-11T10:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-analysis-of-comorbidities-and-treatment-burden-among-patients-with-hiv-infection-in-a-us-medicaid-population/2024-01-11T10:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/financing-drug-innovation-in-the-us-current-framework-and-emerging-challenges/2024-01-11T10:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-potential-cost-effectiveness-of-a-gene-therapy-for-the-treatment-of-hemophilia-a/2024-02-07T16:43:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparison-of-the-efficacy-of-apalutamide-and-enzalutamide-with-adt-in-the-treatment-of-non-metastatic-castration-resistant-prostate-cancer/2024-01-11T10:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-assessment-of-weight-change-associated-with-the-initiation-of-a-protease-or-integrase-strand-transfer-inhibitor-in-patients-with-human-immunodeficiency-virus/2024-01-11T10:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/egfr-mutation-testing-and-treatment-decisions-in-patients-progressing-on-first--or-second-generation-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors/2024-01-11T10:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-utilization-rates-following-antipsychotic-dose-reduction-in-mood-disorders-implications-for-treatment-of-tardive-dyskinesia/2024-01-11T10:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/prevalence-of-pericarditis-for-orphan-drug-designation-application/2024-01-11T10:41:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/corey-lang/2024-01-11T10:41:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-pharma-cos.-can-evaluate-alliance-agreements-validity2024-01-11T10:41:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/which-method-is-for-you-not-all-surveys-are-made-the-same/2020-10-01T15:14:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-investigation-into-the-durability-of-glycemic-control-in-patients-with-type-ii-diabetes-initiated-on-canagliflozin-or-sitagliptin-a-real-world-analysis-of-electronic-medical-records/2024-01-11T10:41:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-commissioners-history-of-cartel-enforcement-in-europe-multidimensional-comparison-of-administrations2/2024-01-11T10:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-among-patients-with-advanced-gastric-cancer-in-russia-a-chart-review-study/2024-01-11T10:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/postdischarge-health-care-costs-and-readmission-in-patients-with-hyperkalemia-related-hospitalizations/2024-01-26T16:28:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/innovation-sciences-llc-v.-amazon.com-inc.-et-al2024-01-11T10:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/validation-of-an-ambient-measurement-system-ams-for-physical-activities-in-a-paediatric-population/2024-01-11T10:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-non-cisplatin-first-line-therapies-for-metastatic-urothelial-carcinoma-phase-2-imvigor210-study-versus-us-patients-treated-in-the-veterans-health-administration/2024-01-11T10:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-and-cost-per-remitter-for-biologic-treatments-of-crohns-disease-in-japan/2024-01-11T10:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-risk-models-for-major-adverse-chronic-renal-outcomes-among-patients-with-type-2-diabetes-mellitus-using-insurance-claims-a-retrospective-observational-study/2024-01-11T10:41:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/transparency-in-health-economic-modeling-options-issues-and-potential-solutions/2024-01-11T10:41:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-work-loss-associated-with-prescription-related-opioid-use-disorder-a-retrospective-analysis-of-claims-data/2024-01-11T10:41:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy/2024-01-11T10:41:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cardiac-arrhythmia-detection-outcomes-among-patients-monitored-with-the-zio-patch-system-a-systematic-literature-review/2024-01-11T10:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burden-of-patients-with-chronic-hepatitis-c-with-versus-without-antiviral-treatment-in-japan-an-observational-cohort-study-using-hospital-claims-data/2024-01-11T10:41:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-patient-preferences-for-treatment-decisions-for-new-direct-acting-antiviral-daa-therapies-for-chronic-hepatitis-c-virus-infections/2024-01-11T10:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-of-first-line-sunitinib-followed-by-immuno-oncology-checkpoint-inhibitors-in-patients-with-metastatic-renal-cell-carcinoma/2024-03-01T21:44:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-healthcare-resource-utilization-related-to-migraine-treatment-failure-a-panel-based-chart-review-in-france-germany-italy-and-spain/2024-01-11T10:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/migraine-related-healthcare-resource-use-in-the-emergency-department-setting-a-panel-based-chart-review-in-france-germany-italy-and-spain/2024-01-11T10:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epilepsy-impaired-functioning-and-quality-of-life-in-patients-with-tuberous-sclerosis-complex/2024-01-11T10:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-a-classifier-to-identify-patients-with-probable-lennox-gastaut-syndrome-in-health-insurance-claims-databases-via-random-forest-methodology/2024-01-11T10:41:45+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/kannan-srinivasan/2024-01-11T10:41:45+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/ella-x.-du2024-02-01T18:51:22+00:00weekly0.7https://www.analysisgroup.com/practices/tax/tax-related-valuation/2024-01-11T10:41:46+00:00weekly0.7https://www.analysisgroup.com/practices/tax/transaction-analysis/2024-01-11T10:41:46+00:00weekly0.7https://www.analysisgroup.com/practices/tax/transfer-pricing/2024-01-11T10:41:46+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/michaela-johnson/2024-01-11T10:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/state-vs.-local-management-of-pension-assets-effects-of-the-massachusetts-chapter-68-public-pension-reform2024-01-11T10:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fantasy-cookie-corporation-et-al.-v.-harold-rothman-et-al2024-01-11T10:41:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-securities-and-exchange-commission-v.-penn-west-petroleum-ltd.-et-al2024-01-11T10:41:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/jeffrey-i.-golden-v.-omelveny--myers-llp-et-al2024-01-11T10:41:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/allowances-for-loan-losses-under-the-transition-to-cecl-during-the-pandemic/2024-03-11T14:11:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/technical-review-of-source-code-in-telephone-consumer-protection-act-tcpa-litigation/2024-01-11T10:41:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/climate-change-impact-and-resilience-study--phase-ii-an-assessment-of-climate-change-impacts-on-power-system-reliability-in-new-york-state/2024-01-11T10:41:47+00:00weekly0.7https://www.analysisgroup.com/careers/why-analysis-group/benefits/2024-01-11T10:41:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-of-metastatic-castration-resistant-prostate-cancer-with-radium-223-a-retrospective-study-at-a-us-tertiary-oncology-center/2024-01-11T10:41:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-skipjack-offshore-energy-llcs-qualified-offshore-wind-projects-compliance-with-conditions-approved-in-2017/2024-01-11T10:41:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regulatory-considerations-for-cost-effective-integration-of-electric-vehicle-charging-infrastructure/2024-01-11T10:41:39+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/renee-richardson-gosline/2024-01-11T10:41:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparisons-of-the-efficacy-and-safety-of-acalabrutinib-versus-other-targeted-therapies-in-relapsedrefractory-mantle-cell-lymphoma/2024-01-11T10:41:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/influence-of-patient-reported-outcomes-on-the-treatment-effect-of-deferasirox-film-coated-and-dispersible-tablet-formulations-in-the-eclipse-trial-a-post-hoc-mediation-analysis/2024-01-11T10:41:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-rate-of-occurrence-healthcare-resource-use-and-costs-of-adverse-events-among-metastatic-non-small-cell-lung-cancer-patients-treated-with-first--and-second-generation-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors/2024-01-11T10:41:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/key-factors-for-overcoming-psychological-insulin-resistance-an-examination-of-patient-perspectives-through-content-analysis/2024-01-11T10:41:39+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/michael-scott-kinch/2024-02-20T20:12:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/when-the-wind-doesnt-blow-the-limits-of-intermittent-resources-and-battery-storage-in-the-decarbonization-of-new-englands-power-system-under-increased-electrification/2024-01-11T10:41:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/paper-trail-working-papers-and-recent-scholarship/2024-02-20T14:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/abbvie-inc.s-acquisition-of-allergan-plc2024-01-11T10:41:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--florida/2024-01-11T10:41:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--arizona/2024-01-11T10:41:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--pennsylvania/2024-01-11T10:41:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--nevada/2024-01-11T10:41:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--illinois/2024-01-11T10:41:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--colorado/2024-01-11T10:41:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/trends-in-health-service-use-and-potentially-avoidable-hospitalizations-before-alzheimers-disease-diagnosis-a-matched-retrospective-study-of-us-medicare-beneficiaries/2024-01-11T10:41:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimated-prevalence-and-incidence-of-dry-eye-disease-based-on-coding-analysis-of-a-large-all-age-united-states-health-care-system/2024-01-11T10:41:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survival-motor-function-and-motor-milestones-comparison-of-avxs-101-relative-to-nusinersen-for-the-treatment-of-infants-with-spinal-muscular-atrophy-type-1/2024-01-11T10:41:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/post-discharge-outcomes-among-hyperkalemic-patients-treated-with-and-without-sodium-polystyrene-sulfonate-in-the-inpatient-setting/2024-01-11T10:41:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-the-real-world-safety-profile-of-vedolizumab-using-the-united-states-food-and-drug-administration-adverse-event-reporting-system/2024-01-11T10:41:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-deep-molecular-response-in-chronic-phase---chronic-myeloid-leukemia-patients-treated-with-second-line-nilotinib-or-dasatinib-a-multi-country-retrospective-chart-review-study/2024-01-11T10:41:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-biochemical-control-and-comorbidities-in-patients-with-acromegaly-an-italian-longitudinal-retrospective-chart-review-study/2024-01-11T10:41:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/institutionalization-risk-and-costs-associated-with-agitation-in-alzheimers-disease/2024-01-11T10:41:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparison-of-health-related-quality-of-life-and-adverse-events-of-apalutamide-versus-enzalutamide-in-non-metastatic-castration-resistant-prostate-cancer/2024-01-11T10:41:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/determinants-of-meningococcal-acwy-vaccination-in-adolescents-in-the-us-completion-and-compliance-with-the-cdc-recommendations/2024-02-29T21:31:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/beyond-multidrug-resistance-leveraging-rare-variants-with-machine-and-statistical-learning-models-in-mycobacterium-tuberculosis-resistance-prediction/2024-01-11T10:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-teduglutide-on-quality-of-life-among-patients-with-short-bowel-syndrome-and-intestinal-failure/2024-01-11T10:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-impact-of-glycated-hemoglobin-reduction-on-treatment-intensification-and-glycated-hemoglobin-goal-attainment-in-type-2-diabetes-mellitus-patients/2024-01-11T10:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dry-eye-disease-ranking-among-common-reasons-for-seeking-eye-care-in-a-large-us-claims-database/2024-01-11T10:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medication-adherence-and-persistence-in-chronic-obstructive-pulmonary-disease-patients-receiving-triple-therapy-in-a-usa-commercially-insured-population/2024-01-30T17:51:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-overall-survival-among-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer/2024-01-11T10:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/calcipotriol-plus-betamethasone-dipropionate-aerosol-foam-vs.-apremilast-methotrexate-acitretin-or-fumaric-acid-esters-for-the-treatment-of-plaque-psoriasis-a-matching-adjusted-indirect-comparison2024-01-11T10:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-and-clinical-benefits-of-early-identification-of-acute-kidney-injury-using-a-urinary-biomarker/2024-01-11T10:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-benefits-of-rapid-antiretroviral-therapy-initiation-in-reducing-medical-and-overall-health-care-costs-among-medicaid-covered-patients-with-human-immunodeficiency-virus/2024-01-11T10:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rapid-initiation-of-antiretroviral-therapy-following-diagnosis-of-human-immunodeficiency-virus-among-patients-with-commercial-insurance-coverage/2024-01-11T10:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rapid-initiation-of-antiretroviral-therapy-following-diagnosis-of-human-immunodeficiency-virus-among-patients-with-commercial-insurance-coverage2/2024-01-11T10:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-pembrolizumab-for-the-adjuvant-treatment-of-resected-high-risk-stage-iii-melanoma-in-the-united-states/2024-01-11T10:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparisons-of-annualized-bleeding-rate-and-utilization-of-bay-94-9027-versus-three-recombinant-factor-viii-agents-for-prophylaxis-in-patients-with-severe-hemophilia-a/2024-01-11T10:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--texas/2024-01-11T10:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--michigan/2024-01-11T10:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-of-antipsychotic-treatment-switching-in-patients-with-schizophrenia-bipolar-and-major-depressive-disorders/2024-01-11T10:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medication-adherence-in-patients-with-asthma-using-once-daily-versus-twice-daily-icslabas/2024-01-30T17:49:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characterizing-real-world-use-of-tiotropium-in-asthma-in-the-usa/2024-01-30T17:54:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dupilumab-versus-cyclosporine-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-adults-indirect-comparison-using-the-eczema-area-and-severity-index/2024-01-11T10:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-budget-impact-analysis-of-the-introduction-of-copanlisib-for-treatment-of-relapsed-follicular-lymphoma-in-the-united-states/2024-01-11T10:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy2/2024-01-11T10:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-severity-and-minimal-clinically-important-differences-in-clinical-outcome-assessments-for-alzheimers-disease-clinical-trials/2024-01-11T10:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-non-infectious-inflammatory-eye-disease-niied-in-a-commercially-insured-population-in-the-united-states/2024-01-11T10:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comorbidities-and-survival-in-patients-with-lipodystrophy-an-international-chart-review-study/2024-01-11T10:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/racial-disparities-in-treatment-patterns-and-outcomes-among-patients-with-multiple-myeloma-a-seer-medicare-analysis/2024-01-11T10:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-offsets-in-the-treatment-journeys-of-patients-with-relapsedrefractory-multiple-myeloma/2024-01-11T10:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-costs-associated-with-premature-mortality-among-those-with-veno-occlusive-diseasesinusoidal-obstruction-syndrome-with-multiorgan-dysfunction-post-hematopoietic-stem-cell-transplant/2024-01-11T10:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adverse-medical-conditions-across-treatment-options-in-patients-with-psoriasis-a-claims-based-analysis/2024-01-11T10:41:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-again-recognized-among-the-leading-global-economics-consultancies-by-global-competition-review2/2024-01-11T10:41:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-again-recognized-among-the-leading-global-economics-consultancies-by-global-competition-review2/2024-01-11T10:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/apportioning-value-in-patent-portfolio-license-and-sale-agreements/2024-01-11T10:41:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/framework-for-patent-valuation-apportionment-in-infringement-cases-proposed-by-analysis-group-consultants/2024-01-11T10:41:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/professor-david-grabowski-of-harvard-medical-school-and-analysis-group-vice-president-brian-ellman-discuss-covid-19-litigation-involving-elder-care-facilities/2024-01-11T10:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-switching-to-different-biologic-therapies-among-tumor-necrosis-factor-inhibitor-experienced-patients-with-psoriatic-arthritis/2024-01-11T10:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparison-of-blinatumomab-vs.-inotuzumab-ozogamicin-for-adults-with-relapsedrefractory-acute-lymphoblastic-leukemia2024-01-11T10:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/validation-of-the-atopic-dermatitis-control-tool-adct-using-a-longitudinal-survey-of-biologic-treated-patients-with-atopic-dermatitis/2024-01-11T10:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-costs-associated-with-corticosteroid-use-in-patients-with-castration-resistant-prostate-cancer-an-administrative-claims-analysis/2024-01-11T10:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adverse-events-associated-with-cumulative-corticosteroid-use-in-patients-with-castration-resistant-prostate-cancer-an-administrative-claims-analysis/2024-01-11T10:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-costs-of-stroke-and-major-bleeding-in-patients-with-atrial-fibrillation-treated-with-non-vitamin-k-antagonist-oral-anticoagulants/2024-01-30T17:47:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effect-of-implantable-cardioverter-defibrillator-in-patients-with-diabetes-and-non-ischaemic-systolic-heart-failure/2024-01-11T10:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tyrosine-kinase-inhibitor-therapy-treatment-and-discontinuation-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-in-the-united-states-a-clinical-practice-perspective/2024-01-11T10:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-absenteeism-and-disability-cost-burden-of-obesity-among-privately-insured-employees-a-comparison-of-healthcare-industry-versus-other-major-industries-in-the-united-states/2024-01-11T10:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-and-tolerability-of-pazopanib-as-first-targeted-therapy-in-metastatic-renal-cell-carcinoma-a-retrospective-chart-review-in-latin-america/2024-01-11T10:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/us-integrated-delivery-networks-perspective-on-economic-burden-of-patients-with-treatment-resistant-depression-a-retrospective-matched-cohort-study/2024-01-11T10:41:53+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/kumar-venkataraman/2024-01-11T10:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-clinician-impression-of-depression-symptom-severity-associated-with-incremental-economic-burden-in-privately-insured-us-patients-with-treatment-resistant-depression/2024-01-11T10:41:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-treatment-resistant-depression-in-medicare-a-retrospective-claims-database-analysis/2024-01-11T10:41:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consideration-of-potential-drug-drug-interactions-in-selection-of-fda-approved-drugs-indicated-for-prostate-cancer/2024-01-11T10:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/are-medicaid-coverage-gaps-associated-with-higher-health-care-resource-utilization-and-costs-in-patients-with-schizophrenia/2024-01-11T10:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-and-health-related-quality-of-life-associated-with-current-treatments-for-anaemia-in-patients-with-ckd-not-on-dialysis-a-systematic-review/2024-01-11T10:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mild-traumatic-brain-injury-in-the-united-states-demographics-brain-imaging-procedures-health-care-utilization-and-costs/2024-01-11T10:41:55+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/charles-h.-grice2024-02-29T22:36:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/systematic-literature-review-of-clinical-trials-of-endocrine-therapies-for-premenopausal-women-with-metastatic-hr-her2--breast-cancer/2024-01-11T10:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-assessment-and-prediction-of-td-incidence-in-psychiatric-patients-taking-concomitant-antipsychotics-a-retrospective-data-analysis/2024-01-11T10:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-analysis-of-switching-patients-with-schizophrenia-from-oral-risperidone-or-oral-paliperidone-to-once-monthly-paliperidone-palmitate/2024-01-11T10:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-adherence-in-patients-with-metastatic-colorectal-cancer-treated-with-trifluridine-plus-tipiracil-or-regorafenib/2024-01-30T17:51:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-of-high-cost-patients-with-noninfectious-inflammatory-eye-diseases/2024-01-11T10:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-burden-of-bronchopulmonary-dysplasia-among-extremely-preterm-infants/2024-01-11T10:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adjuvant-therapy-versus-watch-and-wait-post-surgery-for-stage-iii-melanoma-a-multicountry-retrospective-chart-review/2024-01-11T10:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/modeling-the-impact-of-real-world-adherence-to-once-daily-qd-versus-twice-daily-bid-non-vitamin-k-antagonist-oral-anticoagulants-on-stroke-and-major-bleeding-events-among-non-valvular-atrial-fibrillation-patient/2024-01-30T17:48:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-burden-of-tardive-dyskinesia-secondary-to-antipsychotic-medication-use-among-patients-with-mental-disorders/2024-01-11T10:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/federal-government-interest-patent-disclosures-for-recent-top-selling-drugs/2024-01-11T10:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-non-medical-switching-from-originator-biologics-to-biosimilars-a-systematic-literature-review/2024-01-11T10:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/factors-that-impact-a-patients-experience-when-undergoing-single-photon-emission-computed-tomography-myocardial-perfusion-imaging-spect-mpi-in-the-us-a-survey-of-patients-imaging-center-staff-and-physicians/2024-01-11T10:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-first-line-ceritinib-and-crizotinib-in-advanced-or-metastatic-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-an-adjusted-indirect-comparison-with-external-controls/2024-01-11T10:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effectiveness-of-first-line-treatments-in-metastatic-squamous-non-small-cell-lung-cancer/2024-01-11T10:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-models-for-prediction-of-implantable-cardioverter-defibrillator-benefit-insights-from-the-danish-trial/2024-01-11T10:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-implications-of-anticoagulation-strategies-after-percutaneous-coronary-intervention-among-patients-with-atrial-fibrillation-a-pioneer-af-pci-analysis/2024-01-11T10:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-venous-thromboembolism-recurrence-in-patients-with-cancer/2024-01-11T10:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-study-on-the-association-of-biomarkers-with-real-world-outcomes-of-omalizumab-treated-patients-with-allergic-asthma/2024-01-11T10:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measuring-the-impact-of-air-pollution-on-health-care-costs/2024-01-11T10:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-omalizumab-outcomes-in-chronic-idiopathic-urticaria-a-real-world-study/2024-01-11T10:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-modelling-of-costs-associated-with-outcomes-reported-for-type-2-diabetes-mellitus-t2dm-patients-in-the-canvas-and-empa-reg-cardiovascular-outcomes-trials/2024-01-11T10:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-nocturia-on-the-u.s.-health-care-system-and-society-a-national-health-and-nutrition-examination-survey-analysis2024-01-11T10:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/second-line-rituximab-bendamustine-versus-rituximab-gemcitabine-oxaliplatin-in-diffuse-large-b-cell-lymphoma-in-the-real-world/2024-01-11T10:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/analysis-of-real-world-treatment-patterns-healthcare-resource-utilization-and-costs-between-octreotide-and-lanreotide-among-patients-with-neuroendocrine-tumors/2024-01-11T10:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/insights-into-the-natural-history-of-metachromatic-leukodystrophy-from-interviews-with-caregivers/2024-01-11T10:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-change-in-quality-of-life-carcinoid-syndrome-symptoms-and-healthcare-resource-utilization-in-patients-with-carcinoid-syndrome/2024-01-11T10:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-of-adverse-events-among-patients-with-metastatic-urothelial-cancer-in-usa/2024-01-11T10:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-relapse-after-hematopoietic-stem-cell-transplantation-hsct-in-patients-with-acute-myeloid-leukemia-aml-a-retrospective-claims-based-analysis/2024-02-29T21:34:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/suitability-of-natural-history-data-for-external-controls-in-duchenne-muscular-dystrophy/2024-01-11T10:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-provider-characteristics-on-the-hepatitis-a-and-b-vaccination-status-of-adults-in-the-united-states-during-2007-2015/2024-01-11T10:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-relapserecurrence-in-patients-with-major-depressive-disorder/2024-01-11T10:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-treatment-comparison-of-nivolumab-versus-observation-or-ipilimumab-as-adjuvant-therapy-in-resected-melanoma-using-pooled-clinical-trial-data/2024-01-11T10:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-durability-of-relapse-rate-reduction-in-patients-with-multiple-sclerosis-receiving-fingolimod-for-up-to-3years-a-retrospective-us-claims-database-analysis/2024-01-11T10:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-time-to-next-treatment-health-care-resource-utilization-and-costs-in-patients-with-chronic-lymphocytic-leukemia-initiated-on-front-line-ibrutinib-or-chemoimmunotherapy/2024-01-11T10:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-healthcare-resource-utilization-and-costs-in-medicaid-beneficiaries-with-schizophrenia-transitioning-from-once-monthly-to-once-every-3-months-paliperidone-palmitate/2024-01-11T10:41:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-incidence-of-inflammatory-bowel-disease-among-patients-with-other-chronic-inflammatory-diseases-treated-with-interleukin-17a-or-phosphodiesterase-4-inhibitors/2024-01-11T10:41:59+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jack-chen/2024-01-11T10:41:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/right-ventricular-dysfunction-and-the-effect-of-defibrillator-implantation-in-patients-with-nonischemic-systolic-heart-failure/2024-01-11T10:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/myocardial-fibrosis-and-the-effect-of-primary-prophylactic-defibrillator-implantation-in-patients-with-non-ischemic-systolic-heart-failuredanish-mri/2024-01-11T10:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-venous-thromboembolism-in-cancer-patients-treated-with-anticoagulants/2024-01-11T10:41:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-upadacitinib-on-patient-reported-outcomes-results-from-select-beyond/2024-01-11T10:41:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/upadacitinib-improves-patient-reported-outcomes-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-conventional-synthetic-disease-modifying-antirheumatic-drugs-results-from-select-next/2024-01-11T10:41:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-and-quality-of-life-burden-of-anemia-on-patients-with-ckd-on-dialysis-a-systematic-review/2024-01-11T10:41:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mv3-partners-llc-v.-roku-inc.-et-al2024-01-11T10:41:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/obeslo-et-al.-v.-great-west-capital-management-et-al2024-01-11T10:41:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/covid-19-and-bottom-line-impacts-in-trademark-litigation/2024-01-30T18:04:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-spinal-muscular-atrophy-in-the-united-states-a-contemporary-assessment/2024-01-11T10:42:00+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/amitabh-chandra/2024-02-23T17:36:56+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/dominic-pilon/2024-01-11T10:41:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/research-by-analysis-group-consultants-is-among-the-most-downloaded-articles-in-the-journal-of-comparative-effectiveness-research/2024-01-11T10:41:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/coba-et-al.-v.-ford-motor-company2024-01-11T10:41:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/juliette-caminade/2024-01-11T10:41:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-accounting-finance-and-accounting-experts-testimony-in-sec-financial-disclosure-action/2024-01-11T10:41:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v.-rpm-international-inc2024-01-18T19:25:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-andrew-clarke-to-join-webinar-on-itc-section-337-investigations-during-the-pandemic/2024-01-11T10:41:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/making-the-right-call-in-revenue-recognition/2024-01-11T10:41:38+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/investing-stimulus-dollars-in-advanced-energy-could-boost-post-pandemic-economies/2024-01-11T10:41:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effect-of-risankizumab-on-patient-reported-outcomes-in-moderate-to-severe-psoriasis-the-ultimma-1-and-ultimma-2-randomized-clinical-trials/2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-teams-study-comparing-patient-reported-outcomes-of-psoriasis-therapies-provides-data-critical-to-successful-regulatory-submissions/2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-study-provides-patient-reported-outcomes-in-support-of--labeling-claims-for-plaque-psoriasis-treatment-risankizumab/2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-and-principal-paul-hibbard-assess-how-a-federally-supported-clean-energy-accelerator-could-address-economic-and-climate-crises/2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/accelerating-job-growth-and-an-equitable-low-carbon-energy-transition-the-role-of-the-clean-energy-accelerator/2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/t.-jeffrey-wilks2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-platinum-sponsor-of-nysba-antitrust-sections-annual-meeting/2024-01-11T10:41:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/eileen-a.-kamerick2024-01-11T10:41:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-marissa-ginn-and-associate-johanna-posch-to-present-at-oecds-workshop-on-gender-inclusive-competition-policy/2024-01-11T10:41:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-proposes-market-design-for-zero--and-low-carbon-electricity-grid/2024-01-11T10:41:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/wholesale-power-market-design-in-a-future-low-carbon-electric-system/2024-01-11T10:41:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--minnesota/2024-01-11T10:41:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-potential-drug-drug-interactions-and-pre-existing-conditions-for-adverse-events-in-augmentation-therapies-among-patients-with-treatment-resistant-depression/2024-01-11T10:41:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/treatment-resistant-depression-tied-to-increased-likelihood-of-potential-drug-drug-interactions-and-pre-existing-conditions-for-adverse-events-in-psychopharmacologic-augmentation-therapy/2024-01-11T10:41:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/the-trump-travel-bans-and-the-economic-impact-of-immigration/2024-01-11T10:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-biologics-and-oral-treatments-for-plaque-psoriasis-a-meta-analysis/2024-01-11T10:41:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/research-from-analysis-group-and-ihbdh-furthers-understanding-of-hemophilia-in-china/2024-01-11T10:41:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-overview-of-patients-with-haemophilia-a-in-china-epidemiology-disease-severity-and-treatment-strategies/2024-01-11T10:41:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/realworld-analysis-of-haemophilia-patients-in-china-a-single-centres-experience/2024-01-11T10:41:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/research-from-analysis-group-and-ihbdh-furthers-understanding-of-hemophilia-in-china/2024-01-11T10:41:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interim-measures-in-antitrust-investigations-an-economic-discussion/2024-01-11T10:41:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/research-by-analysis-group-consultants-jee-yeon-lehmann-and-judson-woods-on-boston-housing-discrimination-published-by-georgetown-journal/2024-01-11T10:41:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/accelerating-decarbonization-of-the-u.s.-energy-system2024-01-11T10:41:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/net-zero-carbon-emissions-possible-in-us-by-2050-according-to-national-academy-of-sciences-engineering-and-medicine-report-coauthored-by-analysis-group-senior-advisor-susan-f.-tierney2024-01-11T10:41:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jennifer-blouin/2024-02-27T14:35:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/the-vineyard-house-llc-v.-constellation-brands-u.s.-operations-inc.-and-constellation-brands-u.s.-operations-inc.-v.-the-vineyard-house-llc2024-01-11T10:41:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-works-with-constellation-brands-mondavi-winery-in-trademark-infringement-suit/2024-01-11T10:41:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/yan-wang/2024-03-14T20:30:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-divya-mathur-to-join-antitrust-intellectual-property-and-privacy-panel/2024-01-11T10:41:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-todd-schatzki-to-speak-at-the-energy-bar-association-western-chapters-annual-meeting/2024-01-11T10:41:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-presidents-aaron-fix-and-jee-yeon-lehmann-to-lead-econometrics-in-antitrust-course/2024-01-11T10:41:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/evan-carter/2024-03-14T07:31:12+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-joshua-white-to-share-a-practitioners-perspective-on-newly-proposed-eu-competition-policies/2024-01-11T10:41:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/erin-cook/2024-02-16T15:59:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-coauthors-comprehensive-evaluation-of-the-us-grid-in-a-report-for-the-national-academies-of-sciences-engineering-and-medicine/2024-01-11T10:41:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/luke-benedict/2024-01-11T10:41:32+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-rebecca-kirk-fair-to-speak-on-post-pandemic-merger-review-panel/2024-01-11T10:41:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/chill-et-al.-v.-calamos-advisors-llc2024-01-11T10:41:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/guillaume-germain/2024-03-18T19:30:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/katrina-messina/2024-01-11T10:41:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/jess-marden/2024-03-18T19:04:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consequences-of-insurance-denials-among-u.s.-patients-prescribed-repository-corticotropin-injection-for-acute-exacerbations-of-multiple-sclerosis2024-01-11T10:41:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tyrosine-kinase-inhibitor-therapy-discontinuation-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-in-the-united-states-after-clinical-practice-guideline-updates/2024-01-11T10:41:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/five-year-estimated-glomerular-filtration-rate-in-patients-with-hypoparathyroidism-treated-with-and-without-rhpth1-84/2024-01-11T10:41:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-research-using-matching-adjusted-indirect-comparison-an-application-to-treatment-with-guanfacine-extended-release-or-atomoxetine-in-children-with-attention-deficit/2024-01-11T10:41:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/quality-measure-attainment-in-patients-with-type-2-diabetes-mellitus/2024-01-11T10:41:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/kate-schofield/2024-02-06T17:56:03+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-presidents-joe-cavicchi-and-eric-korman-and-manager-megan-accordino-to-lead-energy-market-regulation-course/2024-01-11T10:41:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/ann-murray/2024-03-07T21:32:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/laszlo-jakab/2024-03-04T16:08:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/drug-utilization-and-cost-for-erythropoiesis-stimulating-agents-in-a-long-term-care-resident-population-with-chronic-kidney-disease/2024-01-11T10:41:33+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/ngoc-pham/2024-02-16T15:25:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-of-survival-healthcare-resource-utilization-and-healthcare-costs-in-veterans-with-non-metastatic-castration-resistant-prostate-cancer/2024-01-11T10:41:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mitigating-antitrust-concerns-when-competitors-share-data-using-blockchain-technology/2024-01-11T10:41:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/mitigating-risks-of-anticompetitive-practices-in-business-applications-of-blockchain-technology-explored-by-analysis-group-experts/2024-01-11T10:41:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-cos.-can-reduce-fca-risk-by-leveraging-data2024-01-11T10:41:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/health-care-companies-can-reduce-their-false-claims-act-risk-by-analyzing-data-according-to-article-coauthored-by-analysis-group-team/2024-01-11T10:41:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/forescout-technologies-inc.-v.-ferrari-group-holdings-lp-et-al2024-01-11T10:41:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-testifies-before-us-house-of-representatives-committee-on-energy-grid-resiliency-in-wake-of-texass-blackouts-from-severe-winter-weather/2024-01-11T10:41:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-groups-susan-tierney-testifies-on-energy-grid-resiliency-before-house-of-representatives-committee/2024-01-11T10:41:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-welcomes-new-affiliates-and-announces-senior-level-promotions3/2024-02-07T16:39:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/upadacitinib-monotherapy-improves-patient-reported-outcomes-in-rheumatoid-arthritis-results-from-select-early-and-select-monotherapy/2024-01-11T10:41:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-of-capmatinib-for-adults-with-metastatic-non-small-cell-lung-cancer-harboring-a-met-exon-14-skipping-mutation-in-the-united-states/2024-01-11T10:41:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-in-patients-with-heart-failure-hospitalized-with-covid-19/2024-01-11T10:41:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-predictors-of-adherence-in-hiv-patients-receiving-single--or-multiple-tablet-darunavir-cobicistat-emtricitabine-and-tenofovir-alafenamide/2024-01-11T10:41:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-of-patients-with-locally-advanced-or-metastatic-epithelioid-sarcoma/2024-01-11T10:41:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-healthcare-resource-utilization-in-patients-with-classical-hodgkin-lymphoma-treated-with-pembrolizumab-and-nivolumab-in-the-usa/2024-01-11T10:41:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/arthur-b.-laby2024-01-11T10:41:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/anne-cai/2024-03-18T18:55:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-recurrent-pericarditis-on-health-related-quality-of-life/2024-01-11T10:41:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-effect-of-elagolix-treatment-for-endometriosis-on-postmenopausal-bone-outcomes-a-model-bridging-phase-iii-trials-to-an-older-real-world-population/2024-01-11T10:41:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-and-health-care-resource-use-associated-with-reslizumab-treatment-in-adults-with-severe-eosinophilic-asthma-in-real-world-practice/2024-01-11T10:41:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-ceritinib-vs.-crizotinib-in-previously-untreated-anaplastic-lymphoma-kinase-alk-positive-non-small-cell-lung-cancer-nsclc-in-hong-kong2024-01-11T10:41:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/new-haven-reads-uses-donation-of-laptops-from-analysis-group-to-support-its-mission-of-improving-childrens-literacy-skills/2024-01-11T10:41:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-hosts-webinar-on-the-health-consequences-of-patient-cost-sharing/2024-01-11T10:41:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-aids-georgias-successful-water-dispute-proceeding-before-the-us-supreme-court/2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-aids-georgias-successful-water-dispute-proceeding-before-the-us-supreme-court/2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/florida-v.-georgia2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-joshua-white-to-join-a-panel-at-concurrences-international-mergers-conference/2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/2021-law--economics-symposium/2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/role-of-economic-evidence-and-the-consumer-welfare-standard-in-the-digital-age-discussed-in-article-by-analysis-group-experts/2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-evidence-and-modern-antitrust/2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-budget-impact-analysis-of-gilteritinib-for-the-treatment-of-relapsed-or-refractory-flt3-mut-acute-myeloid-leukemia-in-a-us-health-plan/2024-01-11T10:41:36+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/yuan-tian/2024-03-18T20:40:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-income-growth-in-patients-with-rheumatoid-arthritis-treated-with-anti-tumor-necrosis-factor-therapy/2024-01-11T10:41:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-peanut-allergy-in-pediatric-patients-with-evidence-of-reactions-to-peanuts-in-the-united-states/2024-01-11T10:41:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/enrico-zanardo/2024-03-15T21:35:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/jessica-lu/2024-01-11T10:41:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/andrea-hugill/2024-03-18T18:48:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/cfo-magazine-publishes-article-on-corporate-payouts-by-analysis-groups-gaurav-jetley-laura-comstock-and-affiliate-david-denis/2024-01-11T10:41:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/shareholder-distributions-vs.-reinvestment-the-gap-grows2024-01-11T10:41:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-to-join-fireside-chat-on-antitrust-and-regulatory-policies-for-startup-investing/2024-01-11T10:41:31+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/pro-bono-work-at-analysis-group/2024-01-11T10:41:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-to-present-paper-on-the-challenges-of-using-return-on-capital-as-an-indicator-of-monopoly-power-at-competition-law-conference/2024-01-11T10:41:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-in-patients-with-myelodysplastic-syndromes-treated-with-hypomethylating-agents-a-seer-medicare-analysis/2024-01-11T10:41:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/network-meta-analysis-of-nivolumab-plus-ipilimumab-in-the-second-line-setting-for-advanced-hepatocellular-carcinoma/2024-01-31T16:33:35+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/kate-hanford/2024-01-11T10:41:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-and-affiliate-provide-expert-assistance-in-landmark-english-high-court-ruling-on-pandemic-related-material-adverse-effect-mae-clause/2024-01-11T10:41:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/travelport-worldwide-limited-et-al.-v.-wex-inc2024-01-11T10:41:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wildman-v.-american-century-services-llc-et-al2024-01-11T10:41:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/brian-thomas/2024-03-14T20:25:51+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/health-care-bulletins/health-care-bulletin--2021/2024-01-11T10:42:00+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/yuxiao-huang/2024-03-18T18:45:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/do-appraisal-challenges-benefit-target-shareholders-through-narrowing-arbitrage-spread/2024-01-29T20:03:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-gaurav-jetley-and-manager-yuxiao-huang-dispute-prior-research-on-the-effects-of-appraisal-litigation-on-arbitrage-spreads/2024-01-11T10:41:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-challenges-of-using-return-on-capital-as-an-indicator-of-monopoly-power/2024-01-18T19:24:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-treatment-comparison-of-the-efficacy-of-patisiran-and-inotersen-for-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy/2024-01-11T10:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-matching-adjusted-indirect-comparison-of-upadacitinib-versus-tofacitinib-in-adults-with-moderate-to-severe-rheumatoid-arthritis/2024-01-11T10:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-chronic-respiratory-morbidity-length-of-stay-inpatient-readmissions-and-costs-among-extremely-preterm-infants-with-bronchopulmonary-dysplasia/2024-01-11T10:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-economic-burden-among-patients-with-and-without-heart-failure-worsening-after-cardiac-resynchronization-therapy/2024-01-11T10:42:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-and-hyman-phelps--mcnamara-p.c.-to-host-webinar-on-controlled-substances-act-issues2024-01-11T10:42:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/pro-bono-work-on-rental-discrimination-wins-hero-award-from-massachusetts-housing-association/2024-01-11T10:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/initiation-of-antidepressant-medication-and-risk-of-incident-stroke-using-the-adult-changes-in-thought-cohort-to-address-time-varying-confounding/2024-01-11T10:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-associated-with-tuberous-sclerosis-complex-in-patients-with-epilepsy/2024-01-11T10:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survival-and-clinical-outcomes-with-telotristat-ethyl-in-patients-with-carcinoid-syndrome/2024-01-11T10:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-first-line-ibrutinib-compared-to-chemoimmunotherapy-treatment-among-medicare-beneficiaries-with-chronic-lymphocytic-leukemia/2024-01-11T10:42:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-treatment-resistant-depression-in-privately-insured-us-patients-with-co-occurring-anxiety-disorder-andor-substance-use-disorder/2024-01-11T10:42:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/independent-consultant-study-to-establish-new-york-icap-demand-curve-parameters-for-the-20212022-through-20242025-capability-years--final-report/2024-01-11T10:42:03+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/ferc-adopts-analysis-group-recommendations-for-new-york-electricity-market-demand-parameters/2024-01-11T10:42:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/us-costeffectiveness-of-polatuzumab-vedotin-bendamustine-and-rituximab-in-diffuse-large-b-cell-lymphoma/2024-01-11T10:42:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/causal-inference-and-adjustment-for-reference-arm-risk-in-indirect-treatment-comparison-meta-analysis/2024-01-11T10:42:03+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-bruce-deal-to-join-panel-on-hot-tub-hearings/2024-01-11T10:42:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pro-bono--aclu-of-la-justice-lab/2024-01-23T23:23:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-pro-bono-team-partners-with-aclu-of-louisiana-justice-lab-on-interactive-police-violence-map/2024-01-23T23:22:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-john-jarosz-to-join-panel-at-iam-patent-transactions-conference/2024-01-11T10:42:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-double-low-dose-budesonide-and-low-dose-budesonide-plus-montelukast-among-pediatric-patients-with-persistent-asthma-receiving-step-3-treatment-in-china/2024-01-11T10:42:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-characteristics-among-patients-with-agitation-and-dementia-in-the-united-states-findings-from-a-large-observational-retrospective-chart-review/2024-01-11T10:42:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-outcomes-of-erythropoiesis-stimulating-agent-hyporesponsiveness-in-the-post-bundling-era/2024-01-11T10:42:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cancer-associated-thrombosis-and-mortality-in-patients-with-cancer-stratified-by-khorana-score-risk-levels/2024-01-11T10:42:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-olaparib-as-a-maintenance-treatment-for-women-with-newly-diagnosed-advanced-ovarian-cancer-and-brca12-mutations-in-the-united-states/2024-01-11T10:42:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/access-to-big-data-as-a-remedy-in-big-tech/2024-01-11T10:42:04+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-competition-law-journal-analysis-group-authors-discuss-whether-data-from-big-tech-is-necessary-for-competition/2024-01-11T10:42:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-cost-effectiveness-of-low-dose-budesonide-as-a-step-2-treatment-for-pediatric-asthma-in-china/2024-01-11T10:42:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/amcps-managed-care--specialty-pharmacy-annual-meeting-to-feature-new-outcomes-research-from-analysis-group/2024-02-07T16:38:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-divya-mathur-to-join-aba-panel-on-antitrust-issues-related-to-mobile-payments/2024-01-11T10:42:01+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/james-bernard/2024-01-11T10:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-severity-at-the-time-of-initial-cognitive-assessment-is-related-to-prior-health-care-resource-use-burden/2024-01-11T10:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/grading-of-neurological-toxicity-in-patients-treated-with-tisagenlecleucel-in-the-juliet-trial/2024-01-11T10:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/deflazacort-versus-prednisone-treatment-for-duchenne-muscular-dystrophy-a-meta-analysis-of-disease-progression-rates-in-recent-multicenter-clinical-trials/2024-01-11T10:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/windstream-holdings-inc.-et-al.-v.-charter-communications-inc.-and-charter-communications-operating-llc2024-01-23T16:38:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/bankruptcy-court-adopts-managing-principal-john-jaroszs-lost-profits-calculation-in-false-advertisingbreach-of-contract-case/2024-01-11T10:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/vaso-occlusive-crises-and-costs-of-sickle-cell-disease-in-patients-with-commercial-medicaid-and-medicare-insurance---the-perspective-of-private-and-public-payers/2024-01-11T10:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/major-depressive-disorders-have-an-enormous-economic-impact/2024-01-11T10:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-adults-with-major-depressive-disorder-in-the-united-states-2010-and-2018/2024-03-08T16:30:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/edward-j.-fox2024-01-11T10:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/accounting-for-adverse-events-in-merger-deals-a-discussion-with-professor-david-j.-denis2024-01-11T10:42:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/depression-cost-the-us-$326-billion-per-year-pre-pandemic-a-38-increase-since-2010/2024-01-11T10:42:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/latest-update-to-30-year-economic-study-reveals-important-shifts-in-the-burden-of-major-depressive-disorder/2024-01-11T10:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/monitoring-and-switching-patterns-of-patients-with-chronic-myeloid-leukemia-treated-with-imatinib-in-community-settings-a-chart-review-analysis/2024-01-11T10:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparing-nilotinib-with-dasatinib-as-second-line-therapies-in-patients-with-chronic-myelogenous-leukemia-resistant-or-intolerant-to-imatinib--a-retrospective-chart-review-analysis/2024-01-11T10:42:00+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/forum-2021/2024-01-11T10:42:00+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/michael-barrett/2024-01-11T10:42:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-is-proud-to-support-the-judges-and-lawyers-breast-cancer-alert-jalbca/2024-01-11T10:42:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/three-analysis-group-articles-nominated-for-the-2021-concurrences-antitrust-writing-awards/2024-01-11T10:42:08+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/michael-carson/2024-03-18T18:39:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-model-to-quantify-potential-medical-events-avoided-and-cost-savings-from-abuse-deterrent-opioids/2024-01-11T10:42:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/energy-bar-association-appoints-vice-president-eric-korman-to-energy-professionals-council/2024-01-11T10:42:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/itay-goldstein/2024-01-11T10:42:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/olga-kozlova-guglielmi/2024-01-11T10:42:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-hristina-bojadzieva-bartlett-to-join-webinar-on-group-health-plan-administration/2024-01-11T10:42:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/ceo-and-chairman-martha-samuelson-to-join-panel-at-concurrences-new-frontiers-of-antitrust-conference/2024-01-11T10:42:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-sponsors-2021-canadian-economics-association-conference/2024-01-11T10:42:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-honored-by-global-competition-review-for-work-on-abbvieallergan-merger/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/2021-asco-annual-meeting-to-feature-new-outcomes-research-from-analysis-group/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/david-proudman/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-growing-burden-of-major-depressive-disorders-mdd-implications-for-researchers-and-policy-makers/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-provide-overview-for-special-edition-of-pharmacoeconomics-dedicated-to-new-research-into-treatment-and-costs-of-major-depressive-disorders-mdds/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/martha-samuelson-and-analysis-group-honored-at-jalbca-event/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cluster-analysis-of-care-pathways-in-adults-with-major-depressive-disorder-with-acute-suicidal-ideation-or-behavior-in-the-usa/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-coauthors-a-study-of-mental-health-care-pathways-for-patients-suffering-from-depression-and-suicidal-thoughts/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/first-analysis-group-data-science-symposium-of-2021-updates-firm-on-recent-applications-of-advanced-analytics-and-machine-learning-tools/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-prevalence-and-national-burden-of-treatment-resistant-depression-and-major-depressive-disorder-in-the-united-states/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-use-novel-bottom-up-approach-to-estimate-prevalence-and-burden-of-treatment-resistant-depression-and-major-depressive-disorder-in-the-us/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-emily-cotton-to-join-webinar-on-consumer-surveys-in-merger-investigations/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/economic-analysis-during-the-pandemic/2024-01-11T10:42:10+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/yael-hochberg/2024-01-11T10:42:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/barbara-e.-kahn2024-01-11T10:42:04+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/amol-navathe/2024-01-11T10:42:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/telehealth-growth-trends-highlight-emerging-risks/2024-01-11T10:42:04+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/telehealth-trends-during-the-pandemic-examined-in-law360-article-coauthored-by-analysis-group-and-dr.-lisa-rotenstein2024-01-11T10:42:04+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/paul-h.-kupiec2024-01-11T10:42:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-patent-and-trademark-office-et-al.-v.-booking.com-b.v2024-01-11T10:42:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/ten-analysis-group-economists-recognized-as-top-intellectual-property-expert-witnesses-in-iam-patent-1000/2024-01-11T10:42:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-economists-again-recognized-as-top-intellectual-property-experts/2024-01-11T10:42:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy-for-america/2024-01-11T10:42:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-finds-stimulus-investment-in-us-advanced-energy-could-add-$3.5-trillion-28-million-new-jobs-to-economy2024-01-11T10:42:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/simon-property-group-inc.-et-al.-v.-taubman-centers-inc.-et-al2024-01-11T10:42:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-kenneth-weinstein-to-discuss-analytical-trends-in-controlled-substances-act-issues/2024-01-11T10:42:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/introduction-to-the-special-issue-of-pharmacoeconomics-on-major-depressive-disorders/2024-01-11T10:42:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/paul-e.-greenberg-and-tammy-sisitsky-serve-as-guest-editors-for-special-edition-of-pharmacoeconomics-dedicated-to-new-research-into-treatment-and-costs-of-major-depressive-disorders-mdds2024-01-11T10:42:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-sponsors-annual-ashecon-conference/2024-01-11T10:42:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/qc-manufacturing-inc.-v.-solatube-international-inc.-et-al2024-01-11T10:42:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/testimony-by-analysis-group-managing-principal-jeffrey-kinrich-aids-arbitration-victory-by-solatube/2024-01-11T10:42:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-aaron-yeater-to-join-gcr-panel-on-market-power-in-social-media-and-digital-advertising/2024-01-11T10:42:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lessons-from-recent-banking-litigation/2024-01-26T16:33:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/use-of-data-science-tools-in-competition-investigations-probed-by-analysis-group-consultants/2024-01-11T10:42:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/comtech-telecommunications-corp.-and-convoy-ltd.-v.-gilat-satellite-networks-ltd2024-01-11T10:42:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/covid-19-impacts-on-aviation-technology-industry-featured-in-merger-dispute-over-a-material-adverse-event-clause/2024-01-11T10:42:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-divya-mathur-to-participate-in-aba-mock-deposition/2024-01-11T10:42:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-timely-switching-from-imatinib-to-a-second-generation-tyrosine-kinase-inhibitor-after-12-month-complete-cytogenetic-response-failure-a-chart-review-analysis/2024-01-11T10:42:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-of-gout-patients-treated-with-colchicine-or-other-common-treatments-for-gout-in-acute-care-settings-a-retrospective-chart-review-study/2024-01-11T10:42:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-critical-appraisal-and-recommendations-for-cost-effectiveness-studies-of-polyadp-ribose-polymerase-inhibitors-in-advanced-ovarian-cancer/2024-01-11T10:42:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/procommunity-procalcitonin-use-in-real-world-us-community-hospital-settings/2024-01-11T10:42:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-effectiveness-of-second-line-sunitinib-following-immuno-oncology-therapy-in-patients-with-metastatic-renal-cell-carcinoma-a-real-world-study/2024-01-11T10:42:08+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/the-intersection-of-law-economics-and-the-environment-in-florida-v.-georgia-a-discussion-with-prof.-robert-stavins2024-01-11T10:42:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-welcomes-new-affiliates-and-announces-senior-level-promotions3/2024-01-11T10:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-sequencing-and-healthcare-costs-among-cllsll-patients-treated-with-venetoclax/2024-01-11T10:42:17+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/jonathan-e-baker/2024-03-18T18:57:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/third-data-science-symposium-of-2021-updates-firm-on-interactive-economic-models-for-enhanced-data-collection-exploration-and-usability/2024-01-11T10:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cigar-association-of-america-et-al.-v.-united-states-food-and-drug-administration-et-al2024-01-11T10:42:12+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/connection-between-warning-labels-and-cigar-smoking-rates-probed-by-analysis-group-consultants/2024-01-11T10:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rolling-disclosure-cap-method-may-lead-to-lower-damages/2024-01-11T10:42:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/securities-experts-from-analysis-group-calculate-impacts-of-alternative-damages-methodologies-in-rule-10b-5-cases/2024-01-11T10:42:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-john-jarosz-to-present-at-2021-intellectual-property-scholars-conference/2024-01-11T10:42:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-welcomes-new-affiliates-and-announces-senior-level-promotions4/2024-01-11T10:42:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-certain-beverage-dispensing-systems-and-components-thereof-itc-inv.-no.-337-ta-11302024-01-23T17:12:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/occ-administrative-actions-against-rohan-ramchandani-former-head-of-european-fx-spot-trading-at-citibank-and-richard-usher-former-head-of-emea-fx-spot-trading-at-jpmorgan-chase/2024-01-26T16:36:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-assists-in-winning-dismissal-of-occ-charges-against-foreign-exchange-traders/2024-01-11T10:42:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-v.-richard-usher-et-al2024-01-11T10:42:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-impact-reporting-for-exelon-corporation/2024-01-11T10:42:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-paul-hibbard-to-discuss-net-zero-carbon-at-the-northeast-public-power-associations-annual-conference/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/christine-tewfik/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-the-new-york-times-analysis-group-affiliate-anupam-jena-discusses-how-the-covid-19-birthday-effect-transcends-political-boundaries/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/jutong-pan/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-a.-savitz2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-again-ranked-as-a-top-international-arbitration-expert-witness-firm-by-global-arbitration-review/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-study-fills-research-gap-on-inpatient-management-of-hyperkalemia-and-subsequent-readmissions/2024-01-11T10:42:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/real-world-study-of-treatment-and-outcomes-for-hyperkalemia-coauthored-by-analysis-group-researchers/2024-01-11T10:42:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/inpatient-management-and-post-discharge-outcomes-of-hyperkalemia/2024-01-11T10:42:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-supports-kona-coffee-farmers-successful-us-appellations-of-origin-matter/2024-01-11T10:42:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-kona-coffee-farmers-successful-us-appellations-of-origin-matter/2024-01-11T10:42:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/kona-coffee-farmers-litigation-settlement/2024-01-11T10:42:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/rongzhang-wang/2024-03-18T18:51:59+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/listening-to-the-voice-of-the-consumer-a-qa-with-peter-golder/2024-01-11T10:42:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-transportation-electrification/2024-01-11T10:42:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/applying-stimulus-funds-to-us-transportation-electrification-could-add-$1.3-trillion-to-gdp-and-create-10.7-million-jobs-according-to-analysis-group-team2024-01-11T10:42:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/second-data-science-symposium-of-2021-updates-firm-on-recent-applications-of-models-and-tools-to-analyze-text-data/2024-01-11T10:42:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-data-based-look-at-covids-commercial-real-estate-impact/2024-01-11T10:42:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/pandemics-effect-on-commercial-real-estate-analyzed-by-analysis-group-consultants-and-affiliate/2024-01-11T10:42:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-testifies-before-us-house-energy-subcommittee-at-hearing-for-energy-resiliency-and-electric-transmission-bills/2024-01-11T10:42:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/study-shows-majority-of-licensed-cannabis-sellers-in-canada-are-violating-cannabis-act-regulations/2024-01-11T10:42:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/residential-mortgage-backed-securities-rmbs-matters/2024-01-11T10:42:06+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/financial-services-banking-practices/2024-03-12T19:26:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-dov-rothman-to-join-nysba-antitrust-law-section-annual-summer-mergers-program/2024-01-11T10:42:06+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/discover-analysis-group/2024-01-11T10:42:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/owen-hearey/2024-03-18T18:43:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-emmanuel-frot-to-join-concurrences-panel-on-anticompetitive-practices-in-distribution-networks/2024-01-11T10:42:12+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-supports-basfs-successful-vehicle-fuel-vapor-canister-antitrust-matter/2024-01-11T10:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ingevity-corp.-et-al.-v.-basf-corp2024-01-11T10:42:12+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-basfs-successful-vehicle-fuel-vapor-canister-antitrust-matter/2024-01-11T10:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/when-it-comes-to-the-price-transparency-rule-not-all-data-is-created-equal/2024-01-11T10:42:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-the-abas-health-esource-newsletter-analysis-group-authors-identify-potential-pitfalls-in-the-use-of-hospital-pricing-data-posted-under-cmss-new-price-transparency-rule/2024-01-11T10:42:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-will-join-a-panel-at-gcr-live-merger-control-2021/2024-01-11T10:42:12+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/maxime-leroux/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lanxess-acquisition-of-emerald-kalama-chemical/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-marissa-ginn-and-associate-johanna-posch-to-present-at-oecd-meeting-on-gender-inclusive-competition-policy/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-paul-hibbard-to-moderate-ceo-panel-at-necbc-conference/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-expert-cited-in-apples-successful-defense-of-high-profile-antitrust-suit-brought-by-epic-games/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/epic-games-inc.-v.-apple-inc2024-01-26T17:42:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lvmh-moet-hennessy-louis-vuitton-se-acquisition-of-tiffany--co/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/amcps-annual-nexus-meeting-to-feature-new-outcomes-research-from-analysis-group/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/amcps-nexus-meeting-to-feature-research-from-analysis-groups-health-care-practice/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-juliette-caminade-to-participate-in-aba-webinar-on-two-sided-platforms/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-ipwatchdog-article-analysis-group-experts-describe-enhancements-to-survey-methodologies-to-test-for-strength-of-beliefs/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/new-survey-methods-address-consumer-uncertainty-in-trademark-law/2024-01-30T18:03:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-groups-real-world-data-study-with-takeda-supports-fdas-recent-exkivitytm-mobocertinib-approval/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-groups-real-world-data-study-supports-fdas-recent-exkivitytm-mobocertinib-approval/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/uniloc-usa-inc.-uniloc-luxembourg-s.a.-uniloc-2017-llc-v.-samsung-electronics-america-inc.-samsung-electronics-co.-ltd2024-01-11T10:42:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-research-featured-in-spotlight-poster-at-icpe-2021/2024-01-11T10:42:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-overall-survival-of-patients-with-metastatic-castration-resistant-prostate-cancer-in-the-us-prior-to-parp-inhibitors/2024-01-11T10:42:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-publishes-study-reviewing-real-world-treatment-patterns-and-survival-of-us-patients-with-metastatic-castration-resistant-prostate-cancer-prior-to-parp-inhibitors/2024-01-11T10:42:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-bridge-over-troubled-waters-the-role-of-due-diligence-in-mitigating-spac-litigation-risks/2024-01-11T10:42:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/abas-business-law-today-publishes-in-depth-exploration-of-spac-process-and-associated-litigation-risks-by-analysis-groups-kevin-gold-and-ahmer-nabi-and-affiliated-expert-gary-m.-lawrence2024-01-11T10:42:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-chronic-kidney-disease-in-adult-patients-with-chronic-hypoparathyroidism-treated-with-rhpth1-84-compared-with-a-historical-control-cohort/2024-01-11T10:42:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-teams-research-comparing-clinical-trial-outcomes-with-real-world-external-controls-in-chronic-kidney-disease-wins-poster-award-at-european-society-of-endocrinology-meeting/2024-01-11T10:42:16+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/the-economic-burden-of-depression-30-year-study/2024-01-11T10:42:16+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/lisa-rotenstein/2024-01-11T10:42:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-sue-tierney-to-join-new-england-electricity-restructuring-roundtable/2024-01-11T10:42:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-and-timing-of-response-to-teduglutide-in-patients-with-short-bowel-syndrome-dependent-on-parenteral-support/2024-01-11T10:42:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/umeclidiniumvilanterol-compared-with-fluticasone-propionatesalmeterol-budesonideformoterol-and-tiotropium-as-initial-maintenance-therapy-in-patients-with-copd-who-have-high-costs-and-comorbidities/2024-01-11T10:42:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-characteristics-treatment-patterns-health-care-resource-use-and-costs-of-patients-with-diffuse-large-b-cell-lymphoma-in-the-u.s2024-01-11T10:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-genetic-testing-patterns-in-metastatic-castration-resistant-prostate-cancer/2024-01-11T10:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-impact-of-antiepileptic-drug-combinations-with-versus-without-perampanel-on-healthcare-resource-utilization-in-patients-with-epilepsy-in-the-united-states/2024-01-11T10:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-profiles-clinical-outcomes-and-healthcare-resource-utilization-of-patients-with-migraine-prescribed-erenumab-a-multicenter-chart-review-study-of-us-headache-centers/2024-01-11T10:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-and-relative-ranking-of-biologics-and-oral-therapies-for-moderate-to-severe-plaque-psoriasis-a-network-meta-analysis/2024-01-11T10:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overcoming-psychological-insulin-resistance-a-practical-guide-for-healthcare-professionals/2024-01-11T10:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-cost-burden-of-hemophilia-b-in-the-united-states/2024-01-11T10:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-utilization-and-safety-of-daratumumab-iv-rapid-infusions-administered-in-a-community-setting-a-retrospective-observational-study/2024-01-11T10:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/outcomes-and-resource-use-of-patients-with-large-hemispheric-infarction-and-cerebral-edema-analysis-of-real-world-data/2024-01-11T10:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/persistence-to-hypomethylating-agents-and-clinical-and-economic-outcomes-among-patients-with-myelodysplastic-syndromes/2024-01-11T10:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/upadacitinib-improves-patient-reported-outcomes-vs-placebo-or-adalimumab-in-patients-with-rheumatoid-arthritis-results-from-select-compare/2024-01-11T10:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medication-patterns-of-abiraterone-acetate-plus-prednisone-or-enzalutamide-and-psa-progression-in-veterans-with-metastatic-castration-resistant-prostate-cancer/2024-01-11T10:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--virginia/2024-01-11T10:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--west-virginia/2024-01-11T10:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--new-mexico/2024-01-11T10:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--ohio/2024-01-11T10:42:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-management-and-outcomes-in-patients-hospitalized-for-acute-heart-failure-in-japan/2024-01-11T10:42:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-safety-and-benefit-risk-profile-of-biologics-and-oral-treatment-for-moderate-to-severe-plaque-psoriasis-a-network-meta-analysis-of-clinical-trial-data/2024-01-11T10:42:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-the-use-of-pharmacological-stress-agents-during-single-photon-emission-computed-tomography-myocardial-perfusion-imaging-tests-after-inadequate-exercise-stress-test/2024-01-11T10:42:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-niaspan-antitrust-litigation/2024-01-26T17:55:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-support-aids-defeat-of-class-certification-in-pharmaceutical-antitrust-suit/2024-01-11T10:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regional-variations-in-prevalence-and-severity-of-autosomal-dominant-polycystic-kidney-disease-in-the-united-states/2024-03-14T19:19:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disruption-of-pharmacotherapy-during-the-transition-from-adolescence-to-early-adulthood-in-patients-with-attention-deficithyperactivity-disorder-a-claims-database-analysis-across-the-usa/2024-01-11T10:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-per-remitter-with-esketamine-nasal-spray-versus-standard-of-care-for-treatment-resistant-depression/2024-01-11T10:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/confirmed-disability-progression-provides-limited-predictive-information-regarding-future-disease-progression-in-multiple-sclerosis/2024-01-11T10:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparison-of-darolutamide-versus-apalutamide-and-enzalutamide-for-nonmetastatic-castration-resistant-prostate-cancer/2024-01-11T10:42:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-of-major-atherothrombotic-vascular-events-among-patients-with-peripheral-artery-disease-after-revascularization/2024-01-11T10:42:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-major-atherothrombotic-vascular-events-among-patients-with-peripheral-artery-disease-after-revascularization/2024-01-11T10:42:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/integrating-real-world-data-and-modeling-to-project-changes-in-femoral-neck-bone-mineral-density-and-fracture-risk-in-premenopausal-women/2024-01-11T10:42:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-among-adults-with-attention-deficithyperactivity-disorder-in-the-united-states-a-retrospective-claims-study/2024-03-14T19:00:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-a-clean-electricity-payment-program/2024-01-11T10:42:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/national-clean-electricity-payment-program-could-contribute-$907-billion-and-7.7-million-jobs-to-us-economy-by-2031-according-to-analysis-group-study2024-01-11T10:42:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/economic-analysis-suggests-that-a-national-clean-electricity-payment-program-could-contribute-$907-billion-to-us-economy-and-support-7.7-million-jobs-by-20312024-01-11T10:42:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/kevin-r.-powers2024-01-11T10:42:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-sue-tierney-to-join-webinar-on-electricity-transmission-siting/2024-01-11T10:42:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/atheendar-venkataramani/2024-01-11T10:42:14+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/matthew-grennan/2024-01-11T10:42:15+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/david-a.-maber2024-02-12T18:03:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-to-join-in-house-counsel-roundtable-at-concurrences-global-antitrust-hot-topics-event/2024-01-11T10:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-recent-case-law-tells-us-about-the-importance-of-consumer-surveys-in-trademark-cases/2024-01-11T10:42:12+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/ipwatchdog.com-publishes-analysis-group-article-on-the-role-of-survey-evidence-in-trademark-and-trade-dress-litigation2024-01-11T10:42:12+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/clinical-cancer-research-publishes-a-systematic-review-of-regulatory-real-world-evidence-in-successful-oncology-product-approvals/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-research-sheds-light-on-regulatory-real-world-evidence-in-successful-oncology-product-approvals/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-evidence-in-support-of-oncology-product-registration-a-systematic-review-of-new-drug-application-and-biologics-license-application-approvals-from-2015-2020/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-maria-garibotti-to-share-an-economists-perspective-on-a-day-in-the-life-of-an-antitrust-practitioner/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/youtubes-violative-view-rate-methodology-a-statistical-assessment/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-academic-affiliate-assesses-youtubes-violative-view-rate/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/filippo-balestrieri/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-analysis-of-merger-remedies/2024-01-26T17:33:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-provide-economic-analysis-of-merger-remedies-in-the-fourth-edition-of-global-competition-reviews-merger-remedies-guide/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-paul-hibbard-to-discuss-the-roles-of-storage-and-green-hydrogen-on-decarbonization-panel/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-marissa-ginn-to-discuss-vertical-restraints-on-aba-webinar/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/gender-considerations-in-the-analysis-of-market-definition-and-competitive-effects-a-practical-framework-and-illustrative-example/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-authors-paper-on-gender-considerations-in-antitrust-analyses/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/academic-affiliate-craig-garthwaite-to-join-aspen-institute-group/2024-01-11T10:42:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/aramark-management-llc-et-al.-v.-steve-borgquist-et-al2024-01-11T10:42:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-jeffrey-h.-kinrich-testifies-on-damages-in-successful-breach-of-contract-case2024-01-11T10:42:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/brendan-rogers/2024-01-11T10:42:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/senior-advisors/daniel-j.-slottje2024-01-11T10:42:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jeffrey-h.-kinrich-to-discuss-concepts-from-new-edition-of-lost-profits-damages2024-01-11T10:42:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/ajay-jyoti/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/haimin-zhang/2024-03-14T20:28:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/united-states-platform-economics-and-mergers/2024-01-11T10:42:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-gcrs-digital-markets-guide-analysis-group-authors-contribute-chapter-exploring-us-platform-economics-and-implications-for-merger-reviews/2024-01-11T10:42:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/american-society-of-hematology-annual-meeting-to-feature-outcomes-research-from-analysis-groups-health-care-practice/2024-01-11T10:42:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/63rd-annual-society-of-hematology-annual-meeting-and-exposition-to-feature-new-outcomes-research-from-analysis-group/2024-02-29T21:27:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/solvejg-wewel/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/algorithmic-pricing-what-every-antititrust-lawyer-needs-to-know/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/procompetitive-and-anticompetitive-effects-of-algorithmic-pricing-compared-in-article-by-analysis-groups-david-smith-and-professor-steven-tadelis/2024-01-11T10:42:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/pro-bono-analysis-group-team-uses-data-driven-approach-to-help-west-london-zone-measure-its-academic-impact/2024-01-11T10:42:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/davis-v.-stadion-money-management-llc2024-01-11T10:42:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-testimony-in-denial-of-class-certification-in-erisa-case/2024-01-11T10:42:22+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/careers-in-antitrust-with-rebecca-kirk-fair/2024-01-11T10:42:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-joshua-white-to-join-technology-mergers-panel-at-gcr-live/2024-01-11T10:42:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-groups-jeffrey-kinrich-co-edits-comprehensive-second-edition-of-leading-book-on-lost-profits-damages/2024-01-11T10:42:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-jeffrey-h.-kinrich-and-damages-expert-everett-p.-harry-iii-co-edit-comprehensive-second-edition-of-leading-book-on-lost-profits-damages2024-01-11T10:42:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lost-profits-damages-principles-methods-and-applications-second-edition/2024-01-30T18:07:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-ability-to-achieve-lost-sales-as-a-consideration-in-damages-analyses2/2024-01-11T10:42:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/industry-and-economic-research/2024-01-11T10:42:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/modifications-to-the-bsm-construct-in-the-nyiso-capacity-market-analysis-of-potential-capacity-market-competitiveness-and-reliability-outcomes/2024-01-11T10:42:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-provides-capacity-market-analysis-supporting-nyisos-proposed-reforms-to-market-pricing-rules/2024-01-11T10:42:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-use-of-surveys-in-lost-profits-analyses/2024-01-30T18:05:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/for-the-second-edition-of-a-comprehensive-lost-profits-damages-compendium-analysis-group-experts-contribute-a-new-chapter-on-using-survey-methodologies-in-litigation/2024-01-11T10:42:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/principal-paul-hibbard-discusses-decarbonization-initiatives-and-policy-in-northeast-gas-associations-energy-conversation/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-again-recognized-among-the-leading-global-economics-consultancies-by-global-competition-review3/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-again-recognized-among-the-leading-global-economics-consultancies-by-global-competition-review3/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/epidemiology-biostatistics/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-financial-and-competition-experts-detail-the-venture-capital-ecosystems-contribution-to-entrepreneurship-and-innovation-in-the-uk-and-elsewhere/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-importance-of-exit-via-acquisition-to-venture-capital-entrepreneurship-and-innovation/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/no-exit-a-threat-to-venture-capital-entrepreneurship-and-innovation/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/why-exit-via-acquisition-is-essential-to-entrepreneurial-investment/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-and-repeat-how-the-venture-capital-ecosystem-drives-entrepreneurship-and-innovation/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-samuel-weglein-to-discuss-challenges-in-labor-cartel-cases-at-nysba-antitrust-law-section-annual-meeting/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-researchers-demonstrate-a-highly-effective-new-real-world-data-generation-method/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-health-care-researchers-pioneer-new-method-for-generating-real-world-data/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-outcomes-associated-with-dupilumab-use-in-patients-with-atopic-dermatitis-1-year-results-from-the-relieve-ad-study/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/itc-section-337-investigations/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/frand-royalty-rates-and-terms/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/commercial-success/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/ip-damages/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/injunctive-relief/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/ip-surveys-and-market-research/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/chanont-big-banternghansa/2024-02-26T21:19:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/charles-tillage-et-al.-v.-comcast-corporation-et-al2024-01-11T10:42:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/ninth-circuit-appeals-court-leaves-in-place-denial-of-class-certification-in-false-advertising-case-featuring-testimony-by-three-analysis-group-experts/2024-01-11T10:42:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sean-rad-et-al.-v.-iacinteractivecorp-et-al2024-01-11T10:42:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/breach-of-contract-litigation-settles-for-analysis-group-client/2024-01-11T10:42:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/jiaxing-super-lighting-electric-appliance-co.-ltd.-et-al.-v.-ch-lighting-technology-co.-ltd.-et-al2024-01-11T10:42:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-lauren-kindler-testifies-in-successful-patent-infringement-case-involving-led-lighting-technology/2024-01-11T10:42:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-recognized-as-a-top-women-led-business-in-massachusetts-for-ninth-consecutive-year/2024-01-11T10:42:23+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/eric-sun/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/five-analysis-group-articles-nominated-for-the-2022-concurrences-antitrust-writing-awards/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-welcomes-respected-economists-daniel-slottje-and-brendan-rogers-to-the-firm/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-welcomes-respected-economists-daniel-slottje-and-brendan-rogers-to-the-firm/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-kristof-zetenyi-to-join-class-action-litigation-webinar/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-and-vice-president-juliette-caminade-to-speak-at-digital-antitrust-conference/2024-01-11T10:42:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/mark-s.-robbins2024-01-11T10:42:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/marguerite-brackley/2024-01-11T10:42:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/george-derpanopoulos/2024-01-11T10:42:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/lynne-kiesling/2024-01-11T10:42:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/robert-conway/2024-01-11T10:42:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/erica-vansant/2024-03-18T19:06:44+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/susan-christoffersen/2024-01-11T10:42:25+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/ilona-mostipan/2024-01-11T10:42:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-kristen-comeaux-to-join-aba-panel-on-financial-benchmark-manipulation-litigation/2024-01-11T10:42:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-teams-provide-comprehensive-economic-and-financial-analyses-for-steinhoff-international-in-successful-global-securities-settlement/2024-01-31T21:44:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/steinhoff-international-holdings-n.v.-shareholder-litigation2024-01-31T21:43:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-jee-yeon-lehmann-to-speak-at-kennedys-webinar-on-data-in-the-life-sciences/2024-01-11T10:42:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-rwe-experts-call-for-actions-regarding-generating-real-world-data-for-health-care-research-in-china/2024-01-11T10:42:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-data-for-healthcare-research-in-china-call-for-actions/2024-01-11T10:42:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dotstrategy-co.-individually-and-on-behalf-of-all-other-similarly-situated--plaintiff-v.-facebook-inc.-defendant2024-01-11T10:42:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-to-present-at-aba-antitrust-law-spring-meeting/2024-01-11T10:42:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-to-join-panels-at-aba-antitrust-law-spring-meeting/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-mihran-yenikomshian-to-moderate-artificial-intelligence-ai-panel-at-mit-sloan-healthcare-and-bioinnovations-conference/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jonathan-r.-macey2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/affiliate-deborah-haas-wilson-reviewed-competitive-impacts-of-the-centenemagellan-merger-in-californias-specialty-health-care-services-markets/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/centenemagellan-merger-review-in-california/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/travelpass-group-llc-et-al.-v.-caesars-entertainment-corp.-et-al2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/amcp-2022-to-feature-new-outcomes-research-from-analysis-group/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/amcp-2022-to-feature-new-outcomes-research-from-analysis-group/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/technicaltechnology-evaluation/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-provides-economic-analyses-in-four-matters-on-the-short-list-for-gcrs-2022-antitrust-awards/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/lola-segura-varo/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-to-interpret-a-contract-ask-those-whod-sign-it/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/marjolaine-gauthier-loiselle/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-and-astrazeneca-researchers-fill-real-world-data-gap-for-providers-treating-severe-asthma-sufferers/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/study-by-analysis-group-and-astrazeneca-researchers-fills-real-world-data-gap-for-providers-treating-severe-asthma-sufferers/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-benralizumab-results-from-the-zephyr-1-study/2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/huntsman-international-llc-v.-albemarle-corporation-et-al2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/supported-by-analysis-group-huntsman-corporation-to-receive-$665-million-in-damages-in-favorable-arbitration-outcome/2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/2022-forbes-survey-ranks-analysis-group-among-the-most-recommended-firms-for-legal-and-litigation-consulting/2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/student-loan-lawsuits-against-navient-corporation/2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/state-attorneys-general-reach-favorable-settlement-in-student-loan-suit-with-support-from-analysis-group/2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ams-sensors-usa-inc.-v.-renesas-electronics-america-inc2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/ams-sensors-awarded-disgorged-profits-and-reasonable-royalty-damages-with-support-from-testimony-by-senior-advisor-keith-r.-ugone-ph.d2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-is-first-to-describe-economic-burden-for-patients-with-acute-suicidal-ideation-tied-to-major-depressive-disorder/2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-commercially-insured-patients-with-major-depressive-disorder-and-acute-suicidal-ideation-or-behavior-in-the-united-states/2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/health-care-resource-utilization-study-coauthored-by-analysis-group-is-first-to-describe-economic-burden-of-mdsi/2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/lolo-palacios/2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/sarah-mantels/2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/jane-choi/2024-03-07T18:14:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/pro-bono-team-develops-fundraising-dashboards-for-humanitarian-aid-organization-alima/2023-06-13T17:19:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-keith-r.-ugone-ph.d.-testifies-on-damages-in-patent-infringement-dispute-involving-spine-surgery-technology2024-01-11T10:42:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nuvasive-inc.-v.-alphatec-holdings-inc.-et-al2024-01-26T21:32:43+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/nick-dadson/2024-01-11T10:42:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/using-real-world-data-to-understand-treatment-patterns-and-outcomes-of-blood-disease-patients-in-china/2024-01-11T10:42:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-research-improves-the-quality-of-real-world-data-for-blood-disease-treatment-in-china/2024-01-11T10:42:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/leah-kitashima/2024-03-07T22:26:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pathways-study-evaluation-of-pathways-to-a-future-grid/2024-01-11T10:42:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-groups-study-of-potential-policy-pathways-to-reduced-ghg-emissions-in-new-england-weighs-environmental-economic-and-implementation-concerns/2024-01-11T10:42:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-v.-davita-inc.-and-kent-thiry2024-01-11T10:42:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-testimony-supports-davitas-successful-defense-in-first-of-its-kind-criminal-antitrust-case-involving-no-poach-agreements/2024-01-11T10:42:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-supports-davitas-successful-defense-in-no-poach-antitrust-criminal-matter/2024-01-11T10:42:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-and-vice-president-joshua-white-to-join-panels-at-concurrences-third-annual-international-mergers-conference/2024-01-11T10:42:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-to-speak-at-luxembourg-arbitration-day/2024-01-11T10:42:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-recognized-for-economic-analysis-in-epic-games-v.-apple-global-competition-reviews-2022-matter-of-the-year2024-01-11T10:42:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/global-competition-reviews-2022-antitrust-awards-recognize-analysis-groups-work-on-litigation-and-merger-matters/2024-01-11T10:42:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-and-affiliate-to-join-aba-panel-on-customer-journey-data-in-advertising-litigation/2024-01-11T10:42:29+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/rachel-bechek/2024-02-09T21:28:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-discuss-economic-analyses-of-labor-effects-in-merger-reviews-in-aba-webinar/2024-01-11T10:42:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-supports-intuits-defeat-of-emergency-motion-in-deceptive-advertising-matter/2024-01-11T10:42:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-expert-submissions-support-defeat-of-emergency-motion-in-turbotax-deceptive-advertising-case/2024-01-11T10:42:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-trade-commission-v.-intuit-inc2024-01-11T10:42:29+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/summer-intern-experience---associates/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/summer-intern-experience---analyst/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/hyun-lee/2024-03-07T22:21:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-todd-schatzki-to-discuss-pathways-to-decarbonization-in-new-england-at-raab-associates-roundtable/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/bruno-martins/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-affiliate-judith-chevalier-and-manager-alex-robinson-to-speak-at-international-industrial-organization-conference/2024-01-11T10:42:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-health-care-consultants-to-present-at-ispor-2022/2024-01-11T10:42:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-health-care-consultants-to-present-at-ispor-2022/2024-01-11T10:42:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/new-report-estimates-the-metaverse-could-contribute-2.8-to-global-gdp-in-its-first-decade2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/the-metaverse-could-provide-2.8-boost-to-global-gdp-in-its-first-decade-after-adoption-begins-analysis-group-study-finds2024-01-11T10:42:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-potential-global-economic-impact-of-the-metaverse/2024-01-26T17:41:28+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/emily-gao/2024-03-15T21:27:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/malden-transportation-company-inc.-et-al.-v.-uber-technologies-inc.-and-rasier-llc2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/diego-a.-focanti2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-join-labor-panel-at-concurrences-new-frontiers-of-antitrust-conference/2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-juliette-caminade-to-discuss-interim-measures-at-oecd-roundtable/2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/labor-markets-and-antitrust-the-role-of-the-economic-expert-in-us-v.-davita-inc.-and-kent-thiry2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/gao-meng/2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/mary-reiser/2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/analysis-group-and-data-science/2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-peter-simon-to-join-aba-webinar-on-class-certification-in-in-re-packaged-seafood-antitrust-litigation/2024-01-11T10:42:38+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/kale-kponee-shovein/2024-03-15T21:30:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/qing-liu/2024-03-15T21:28:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/first-webinar-in-law--economics-symposium-webinar-series-to-focus-on-drug-pricing/2024-01-11T10:42:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-mihran-yenikomshian-and-principal-almudena-arcelus-discuss-the-intersection-of-blockchain-and-antitrust-in-antitrust-matters-podcast/2024-01-11T10:42:36+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/mario-luca/2024-01-11T10:42:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/elmagin-capital-llc-v.-chao-chen-karl-petty-entergrid-llc-and-entergrid-fund-i-llc2024-01-23T19:39:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/jury-in-trade-secret-litigation-returns-favorable-verdict-for-analysis-group-clients/2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-and-affiliates-to-speak-at-usc-global-competition-law-thought-leadership-conference/2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/affiliate-amol-navathe-m.d.-ph.d.-appointed-vice-chair-of-medicare-payment-advisory-commission-medpac2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/forum-2022/2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-juliette-caminade-discusses-antitrust-implications-of-two-sided-digital-platforms-in-a-podcast-for-the-abas-trust-and-trade-series/2024-01-11T10:42:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-delaware-s-antitakeover-statute-unconstitutional--further-analysis-and-a-reply-to-symposium-participants/2024-01-11T10:41:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-delaware-s-antitakeover-statute-unconstitutional--evidence-from-1988-2008/2024-01-11T10:41:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/test/2024-01-11T10:41:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economics-overview-2019/2024-01-11T10:41:09+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/joseph-cavicchi/2024-03-12T17:04:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-john-q.-hammons-fall-2006-llc2024-01-11T10:41:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-group-teams-pro-bono-analysis-of-towing-fees-and-their-economic-impact-on-the-poor/2024-01-11T10:41:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nte-connecticut-llc-application-for-a-certificate-of-environmental-compatibility-and-public-need/2024-01-11T10:41:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fuel-mix-and-greenhouse-gas-emissions-of-municipal-electric-light-plants-in-massachusetts/2024-01-11T10:41:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-securities-and-exchange-commission-vs.-elon-musk2024-01-11T10:41:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/occupational-license-laws-may-hurt-health-care-competition/2024-01-26T17:34:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/toby-schechner-et-al.-v.-whirlpool-corporation2024-01-11T10:41:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/guiding-principles-in-setting-cartel-sanctions/2024-01-11T10:41:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/murray-beach/2024-01-11T10:41:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bayer-cropscience-ag-and-bayer-cropscience-nv-v.-dow-agrosciences-llc-et-al2024-01-11T10:41:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v.-john-t.-place-et-al2024-01-11T10:41:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/alberta-electric-system-operator-proceedings-for-capacity-market-design-and-implementation/2024-01-11T10:41:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/edward-b.-rock2024-01-11T10:41:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/lucia-antras/2024-01-11T10:41:04+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/james-r.-hille2024-01-11T10:41:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/appraisal-challenges-and-benefits-to-target-shareholders-through-narrowing-arbitrage-spread/2024-01-29T20:05:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clean-energy-in-new-york-state-the-role-and-economic-impacts-of-a-carbon-price-in-nyisos-wholesale-electricity-markets/2024-01-11T10:41:04+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/daria-z.-killebrew2024-01-11T10:41:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/gao-report-illuminates-insurer-influence-on-drug-discounts/2024-01-11T10:41:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-purchase-probability-scales-can-shed-light-on-consumer-purchase-intentions/2024-01-11T10:41:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-womens-health-clinic-closures-on-fertility/2024-01-11T10:41:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-certain-magnetic-data-storage-tapes-and-cartridges-containing-the-same-inv.-no.-337-ta-10122024-01-11T10:41:05+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jacob-e.-gersen2024-01-11T10:41:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/summary-of-the-federal-trade-commission-workshop/2024-01-11T10:41:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/christopher-ody/2024-01-11T10:41:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/ted-davis/2024-01-11T10:40:55+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/anne-catherine-faye/2024-01-11T10:40:56+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/todd-schatzki/2024-01-17T14:28:36+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/martin-cloutier/2024-01-11T10:40:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risk-of-recurrent-vte-and-major-bleeding-in-a-commerciallyinsured-population-of-cancer-patients-treated-with-anticoagulation/2024-01-11T10:40:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/online-advertising-and-antitrust-network-effects-switching-costs-and-data-as-an-essential-facility/2024-01-11T10:40:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-reallocating-spectrum-to-5g/2024-01-11T10:40:56+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/charlotte-wright/2024-01-11T10:40:56+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jeff-bodington/2024-01-11T10:40:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/vintage-rodeo-parent-llc-et-al.-v.-rent-a-center-inc2024-01-11T10:40:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/devin-reilly/2024-01-11T10:40:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/scarcity-market-power-and-prices-at-slot-constrained-airports-evidence-from-mexico-city/2024-01-11T10:40:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managers/philippe-thompson-leduc/2024-02-12T21:35:39+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/atang-gilika/2024-01-11T10:40:57+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/catherine-gendron-saulnier/2024-03-18T19:32:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/authors-contribution-effect-of-delayed-treatment-intensification-on-glycemic-control-in-the-real-world/2024-01-11T10:40:58+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/irina-pivneva/2024-03-15T19:39:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/erisa-litigation-involving-target-date-funds/2024-01-11T10:40:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/returning-back-to-school-an-update-on-university-retirement-plan-litigation/2024-01-11T10:40:59+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/wei-gao/2024-02-26T16:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/saab-et-al.-v.-the-republic-of-cyprus2024-01-11T10:40:58+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/viviana-garcia-horton/2024-03-15T21:26:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-and-oncologist-preferences-for-the-treatment-of-adults-with-advanced-soft-tissue-sarcoma/2024-01-11T10:40:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lovepop-inc.-vs.-paper-pop-cards-inc2024-01-11T10:40:53+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/keith-hylton/2024-01-11T10:40:53+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/richard-a--mortimer/2024-02-06T17:56:03+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/debbie-goldschmidt/2024-02-26T16:40:24+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/william-m.-zoffer2024-01-11T10:40:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/challenges-and-pitfalls-in-cartel-fining/2024-01-11T10:40:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-senate-committee-hearing-to-examine-the-electricity-sector-in-a-changing-climate/2024-01-11T10:40:55+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/samuel-weglein/2024-01-11T10:40:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/kt-engcore-corporation-v.-asi-corporation-et-al2024-01-11T10:40:55+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/howard-g--birnbaum/2024-01-11T10:40:55+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/james-trautman/2024-01-11T10:40:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/oil-dri-corporation-of-america-v.-nestle-purina-petcare-company2024-01-11T10:40:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/granite-bridge-environmental-benefits-of-system-expansion/2024-01-26T17:33:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/south-carolina-electric--gas-company-preliminary-injunction-hearing-and-rate-proceeding/2024-01-11T10:40:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-of-patients-with-psoriatic-arthritis-receiving-secukinumab-and-reasons-for-initiation-a-us-retrospective-medical-chart-review/2024-01-11T10:40:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/factors-associated-with-more-frequent-diagnostic-tests-and-procedures-in-patients-with-irritable-bowel-syndrome/2024-01-11T10:40:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-clinical-outcomes-in-advanced-gastrointestinal-neuroendocrine-tumors-gi-net-a-multicenter-retrospective-chart-review-study/2024-01-11T10:40:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characterization-of-patients-with-ankylosing-spondylitis-receiving-secukinumab-and-reasons-for-initiating-treatment-a-us-physician-survey-and-retrospective-medical-chart-review/2024-01-11T10:40:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-post-transition-to-once-every-3-months-paliperidone-palmitate-in-patients-with-schizophrenia-within-us-commercial-plans/2024-01-11T10:40:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-clinical-outcomes-in-advanced-lung-neuroendocrine-tumors-in-real-world-settings-a-multicenter-retrospective-chart-review-study/2024-01-11T10:40:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/observational-study-of-characteristics-and-clinical-outcomes-of-dutch-patients-with-tuberous-sclerosis-complex-and-renal-angiomyolipoma-treated-with-everolimus/2024-01-11T10:40:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-among-adults-with-adhd-receiving-long-acting-therapy/2024-01-11T10:40:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/concomitant-use-of-psychotropic-medication-with-stimulants-for-the-treatment-of-adhd-in-children-and-adolescents-a-retrospective-insurance-claims-study-in-the-united-states/2024-01-11T10:40:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-predictive-risk-models-for-major-adverse-cardiovascular-events-among-patients-with-type-2-diabetes-mellitus-using-health-insurance-claims-data/2024-01-11T10:40:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-catheter-related-complications-among-japanese-patients-with-central-venous-catheters-as-well-as-patients-with-short-bowel-syndrome/2024-01-11T10:40:48+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/robert-w.-platt2024-01-11T10:40:48+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/a-closer-look-at-appraisal-outcomes/2024-01-11T10:40:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-burden-and-treatment-patterns-in-commercially-insured-children-with-chronic-idiopathicspontaneous-urticaria-a-real-world-study-in-the-united-states2/2024-01-11T10:40:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/removal-of-ineligible-outcome-cases-reduces-confounding/2024-01-11T10:40:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-economic-outcomes-during-time-on-treatment-among-patients-who-initiated-sunitinib-or-pazopanib-as-first-targeted-therapy-for-advanced-renal-cell-carcinoma-a-retrospective-analysis-of-medicare-claims-data/2024-01-11T10:40:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-cohort-study-comparing-the-risk-of-severe-hepatotoxicity-in-hospitalized-patients-treated-with-echinocandins-for-invasive-candidiasis-in-the-presence-of-confounding-by-indication/2024-01-11T10:40:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-hidradenitis-suppurativa-on-work-loss-indirect-costs-and-income/2024-01-11T10:40:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/postsurgical-treatment-landscape-and-economic-burden-of-locoregional-and-distant-recurrence-in-patients-with-operable-nonmetastatic-melanoma/2024-01-11T10:40:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/stage-iii-melanoma-incidence-and-impact-of-transitioning-to-the-8th-ajcc-staging-system-a-us-population-based-study/2024-01-11T10:40:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-midostaurin-in-the-treatment-of-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-in-the-united-states/2024-01-11T10:40:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epilepsy-treatment-patterns-among-patients-with-tuberous-sclerosis-complex/2024-01-11T10:40:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-of-antiepileptic-drugs-in-the-adjunctive-treatment-of-refractory-partial-onset-seizures-meta-analysis-of-pivotal-trials/2024-01-11T10:40:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-analysis-of-comprehensive-genomic-profiling-in-patients-with-advanced-non-small-cell-lung-cancer/2024-01-11T10:40:49+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/andrzej-andy-skrzypacz/2024-01-11T10:40:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-infections-among-chronic-myeloid-leukemia-patients-receiving-dasatinib-or-nilotinib/2024-01-11T10:40:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-analysis-of-clinical-progression-in-patients-with-metastatic-castration-resistant-prostate-cancer-in-the-strive-and-terrain-trials/2024-01-11T10:40:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-duration-healthcare-resource-utilization-and-costs-among-chemotherapy-naive-patients/2024-01-11T10:40:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-burden-of-non-infectious-intraocular-inflammatory-eye-diseases-a-systematic-literature-review/2024-01-11T10:40:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-abuse-of-prescription-opioids/2024-01-11T10:40:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-psoriasis-with-high-comorbidity-among-privately-insured-patients-in-the-united-states/2024-01-11T10:40:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/short-term-rehospitalizations-in-young-adults-with-schizophrenia-treated-with-once-monthly-paliperidone-palmitate-or-oral-atypical-antipsychotics-a-retrospective-analysis/2024-01-11T10:40:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-among-patients-with-colorectal-cancer-treated-with-trifluridinetipiracil-and-regorafenib/2024-01-11T10:40:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-disease-associated-with-a-copd-eosinophilic-phenotype/2024-01-30T17:46:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-systemic-corticosteroids-on-blood-eosinophil-counts-in-asthma-real-world-data/2024-01-30T17:45:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-workplace-disparities-may-arise-an-economic-outline/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risk-of-recurrent-vte-and-major-bleeding-in-a-commercially-insured-population-of-cancer-patients-treated-with-anticoagulation/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/changes-health-related-quality-of-life-long-term-eltrombopag-treatment-adults-persistentchronic-immune-thrombocytopenia/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/description-of-baseline-characteristics-of-pediatric-allergic-asthma-patients-including-those-initiated-on-omalizumab/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-and-clinical-outcomes-of-treatment-intensification-in-patients-with-type-2-diabetes-uncontrolled-on-basal-insulin-in-a-real-world-setting/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/genotype-and-lifetime-burden-of-disease-in-hypertrophic-cardiomyopathy-insights-from-the-sarcomeric-human-cardiomyopathy-registry-share/2024-01-11T10:40:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-carcinoid-syndrome-symptoms-and-long-term-use-of-somatostatin-analogs-on-quality-of-life-in-patients-with-carcinoid-syndrome/2024-01-11T10:40:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/monitoring-of-hematologic-cardiac-and-hepatic-function-in-post-menopausal-women-with-hrher2--metastatic-breast-cancer/2024-01-11T10:40:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-healthcare-resource-utilization-in-patients-with-flt3-mutated-and-wild-type-acute-myeloid-leukemia/2024-01-11T10:40:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/short-term-costs-associated-with-non-medical-switching-in-autoimmune-conditions/2024-01-11T10:40:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-in-patients-with-metastatic-melanoma/2024-01-11T10:40:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patterns-of-treatment-and-braf-testing-with-immune-checkpoint-inhibitors-and-targeted-therapy/2024-01-11T10:40:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economics-of-excessive-pricing-an-application-to-the-pharmaceutical-industry/2024-01-11T10:40:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-paul-hibbard-to-join-roundtable-on-electricity-wholesale-market-design/2024-01-11T10:40:52+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/nicholas-van-niel/2024-02-06T17:56:04+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/alix-duhaime-ross/2024-01-11T10:40:53+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/esther-mills/2024-01-11T10:40:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-in-labor-markets-insights-from-the-ftc-hearings-on-competition-and-consumer-protection-in-the-21st-century/2024-01-11T10:40:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/nori-mehta/2024-01-11T10:40:50+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/ben-samuels/2024-01-11T10:40:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-in-patients-with-metastatic-castration-resistant-prostate-cancer/2024-01-11T10:40:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-humanistic-burden-of-postpartum-depression-a-systematic-literature-review/2024-01-11T10:40:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-rivaroxaban-versus-apixaban-among-patients-with-non-valvular-atrial-fibrillation/2024-01-30T17:45:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-long-term-direct-and-indirect-economic-burden-among-parkinsons-disease-caregivers-in-the-united-states/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-characteristics-of-patients-with-asthma-copd-and-asthma-copd-overlap-in-the-nhanes-database/2024-01-30T17:46:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-treatments-for-previously-treated-advanced-or-metastatic-non-small-cell-lung-cancer/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-time-to-progression-associated-with-post-progression-survival-in-previously-treated-metastatic-non-small-cell-lung-cancer-with-braf-v600e-mutation/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-first-line-ceritinib-and-crizotinib-in-advanced-or-metastatic-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cms-hospital-readmission-reduction-program-and-anticoagulants-received-following-a-total-hip-and-knee-arthroplasty-discharge/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-comorbidity-burden-of-hidradenitis-suppurativa-in-the-united-states-/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-nab-paclitaxel-plus-gemcitabine-vs-folfirinox-in-metastatic-pancreatic-cancer/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medicaid-spending-burden-among-beneficiaries-with-treatment-resistant-depression/2024-01-11T10:40:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/causation-and-harm-in-data-breach-litigation/2024-01-11T10:40:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antiepileptic-drug-titration-and-related-health-care-resource-use-and-costs/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-prospective-economic-impact-of-once-monthly-paliperidone-palmitate-versus-oral-atypical-antipsychotics-in-medicaid-patients-with-schizophrenia/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-use-of-omalizumab-in-patients-with-chronic-idiopathicspontaneous-urticaria-in-the-united-states/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-factors-health-care-resource-utilization-and-costs-associated-with-nonadherence-to-antiretrovirals-in-medicaid-insured-patients-with-hiv/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/elotuzumab-plus-lenalidomide-and-dexamethasone-in-relapsedrefractory-multiple-myeloma/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/time-to-treatment-intensification-after-monotherapy-failure-and-its-association-with-subsequent-glycemic-control-among-93515-patients-with-type-2-diabetes/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-costs-associated-with-transitioning-to-3-month-paliperidone-palmitate/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reliability-of-coded-data-to-identify-earliest-indications-of-cognitive-decline-cognitive-evaluation-and-alzheimers-disease-diagnosis/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comorbidities-and-prescribed-medications-in-patients-with-or-without-dry-eye-disease-a-population-based-study/2024-03-15T10:38:50+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/health-care-bulletins/health-care-bulletin-winterspring-2019/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-much-is-data-security-worth/2024-01-11T10:41:02+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/priyanka-bobbili/2024-01-11T10:41:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/combining-the-power-of-artificial-intelligence-with-the-richness-of-healthcare-claims-data-opportunities-and-challenges/2024-01-11T10:41:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-and-monitoring-patterns-among-premenopausal-women-with-hrher2--advanced-breast-cancer/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-analysis-healthcare-costs-relative-risk-hyperprolactinemia-associated-antipsychotic-treatments-united-states/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identifying-subpopulation-higher-likelihoods-early-response-treatment-heterogeneous-rare-disease/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-review-of-long-term-toxicity-of-antiretroviral-treatment-regimens-and-implications-for-an-aging-population/2024-01-11T10:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-of-prolonged-anticoagulation-with-rivaroxaban-after-unprovoked-venous-thromboembolism/2024-01-11T10:41:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-study-tolerability-effectiveness-adjunctive-antihypertensive-drugs-patients-inadequate-response-initial-treatment/2024-01-11T10:41:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/progression-free-survival-with-endocrine-based-therapies-progression-non-steroidal-aromatase-inhibitor/2024-01-11T10:41:02+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/rebecca-scott/2024-01-11T10:41:02+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/oscar-patterson-lomba/2024-03-15T21:27:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/panjing-dongxing-oil-well-measure-service-co.-ltd.-v.-petrochina-inc2024-01-26T16:32:21+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/jonathan-reuter/2024-01-11T10:41:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hilsley-v.-ocean-spray-cranberries-inc2024-01-11T10:41:07+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/dave-nellesen---what-are-dossiers/2024-01-11T10:41:00+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/patrick-lefebvre---the-value-of-real-world-evidence-in-drug-approval-and-marketing-processes/2024-01-11T10:40:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-starz-stockholder-litigation/2024-01-11T10:40:59+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/james-signorovitch---rare-diseases/2024-01-11T10:40:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/up-or-down-the-price-effects-of-mergers-of-intermediaries/2024-01-11T10:41:00+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/analysis-group-forum-spring-2019/2024-01-11T10:41:05+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/recruiting-events/2024-03-05T16:17:02+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/evaluating-the-but-for-world-surveys-experiments-and-market-data/2024-01-11T10:41:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comments-on-certification-of-new-interstate-natural-gas-pipeline-facilities/2024-01-11T10:40:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/resource-adequacy-and-wholesale-market-structure-for-a-future-low-carbon-power-system-in-california/2024-01-11T10:40:31+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/crystal-pike-and-kenneth-weinstein---using-data-in-suspicious-order-monitoring-of-opioids/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/paul-greenberg---a-diverse-health-care-practice/2024-01-11T10:40:37+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/eric-wu-and-min-yang---patient-reported-outcomes/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/noam-kirson---balancing-drug-pricing-with-value/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/online-and-offline-retail-distribution--introduction/2024-01-11T10:40:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-assessment-of-mergers-in-online-and-offline-retail-sales--are-new-tools-needed-for-the-economists-toolbox-/2024-01-11T10:40:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competitive-assessment-of-digital-comparison-platforms--in-search-of-consensus/2024-01-11T10:40:31+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/richard-mortimer---the-competitive-landscape-for-biosimilars/2024-01-11T10:40:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/annie-guerin/2024-03-15T21:24:11+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/dominick-latremouille-viau/2024-01-11T10:40:37+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/annie-guerin/2024-01-11T10:40:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/anthony-t.-losasso2024-01-11T10:40:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/french/marie-helene-lafeuille/2024-01-11T10:40:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/nina-maar/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/david-s.-abrams2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cryptocurrencies-demystified-and-the-secs-regulatory-stance/2024-01-11T10:40:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-rise-of-biosimilars-and-the-future-of-healthcare-intellectual-property/2024-01-11T10:40:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re--appraisal-of-solera-holdings-inc/2024-01-11T10:40:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/collins-et-al.-v.-city-of-milwaukee-et-al2024-01-11T10:40:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/marfin-investment-group-holdings-s.a.-alexandros-bakatselos-and-others-v.-republic-of-cyprus2024-01-11T10:40:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/predicting-the-essentiality-of-standard-essential-patents/2024-01-11T10:40:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/supporting-a-national-coverage-determination-request-for-an-innovative-cancer-treatment/2024-01-11T10:40:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/retrospective-study-of-medication-adherence-among-adults-with-metastatic-colorectal-cancer/2024-01-11T10:40:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economics--overview/2024-01-11T10:40:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economics-of-biosimilar-drugs-and-new-considerations-in-intellectual-property-and-antitrust-litigation/2024-01-11T10:40:31+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/marie-helene-lafeuille/2024-02-16T16:00:07+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/francois-laliberte/2024-02-15T20:53:18+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/andree-anne--fournier/2024-02-15T20:11:23+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/analysis-group-forum-summer-2018/2024-01-11T10:41:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patent-damages-in-us-courts--overview-of-current-state-of-play/2024-01-11T10:40:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/thomas-mcgahee/2024-01-11T10:40:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/michael-melvin/2024-01-11T10:40:41+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/stephanie-lee/2024-01-11T10:40:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sanjiv-goel-md-inc.-v.-blue-shield-of-california2024-01-11T10:40:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/margie-daniel-et-al.-v.-ford-motor-company2024-01-11T10:40:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/paul-b.-butler-v.-porsche-cars-north-america-inc2024-01-11T10:40:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-announces-that-richard-levin-saul-pannell-have-joined-the-firms-board-of-directors/2024-01-11T10:40:38+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/william-p.-rogerson2024-01-11T10:40:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/analysis-group-announces-consultant-promotions-2018/2024-01-11T10:40:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimated-cost-of-anticancer-therapy-directed-by-comprehensive-genomic-profiling-in-a-single-center-study/2024-01-11T10:40:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ghg-cap-and-trade-implications-for-effective-and-efficient-climate-policy-in-oregon/2024-01-11T10:40:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/erisa-health-care-litigation-related-to-deductibles-and-out-of-pocket-expenses/2024-01-11T10:40:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/hospital-erisa-class-action-matter/2024-01-11T10:40:38+00:00weekly0.7https://www.analysisgroup.com/practices/erisa/erisa-health-care-claims/2024-01-11T10:40:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/key-issues-facing-californias-ghg-cap-and-trade-system-for-20212030/2024-01-11T10:40:38+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/finding-true-north-in-recent-delaware-appraisal-cases-is-it-the-market-or-the-model/2024-01-11T10:41:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/smart-contracts-and--their-potential-tax-implications/2024-01-11T10:40:42+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/managing-principals/noam-kirson/2024-03-15T19:38:06+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/principals/jimmy-royer/2024-01-11T10:40:41+00:00weekly0.7https://www.analysisgroup.com/practices/antitrust-competition/classcollective-actions/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/viacom-international-inc.-v.-mga-entertainment-inc2024-01-11T10:40:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-ability-to-achieve-lost-sales-as-a-consideration-in-damages-analyses-under-different-legal-frameworks/2024-01-11T10:40:40+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/catherine-tucker-event-summary/2024-01-11T10:40:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/political-advertising-and-election-results/2024-01-11T10:40:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/webinar--new-landscape-in-ip-damages-discussed-by-vice-president-andrew-clarke/2024-01-11T10:40:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-effect-of-mergers-on-labor-markets/2024-01-11T10:40:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-cost-impact-of-continued-anticoagulation-with-rivaroxaban-vs-aspirin-for-prevention-of-recurrent-symptomatic-vte-in-the-einstein-choice-trial-population/2024-01-11T10:40:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-utility-values-for-treatment-related-health-states-of-acute-myeloid-leukemia-in-the-united-states/2024-01-11T10:40:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-ischemic-stroke-in-patients-newly-diagnosed-with-heart-failure-focus-on-patients-without-atrial-fibrillation/2024-01-30T17:40:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-commodity-futures-trading-commission-v.-donald-r.-wilson-and-drw-investments-llc2024-01-11T10:40:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effectiveness-and-safety-of-anticoagulants-for-the-treatment-of-venous-thromboembolism-in-patients-with-cancer2/2024-01-11T10:40:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/3-aspects-of-value-preservation-for-restructuring-cos/2024-01-11T10:40:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identifying-solutions-to-psychological-insulin-resistance-an-international-study/2024-01-11T10:40:47+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/affiliated-experts/marc-zenner/2024-02-22T20:02:32+00:00weekly0.7https://www.analysisgroup.com/experts-and-consultants/vice-presidents/christopher-llop/2024-02-29T18:18:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/european-union--two-sided-markets-platforms-and-network-effects/2024-01-11T10:40:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/united-states--e-commerce-economics-market-power-and-enforcement-in-vertical-markets/2024-01-11T10:40:46+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/tirole-event-summary---french/2024-01-11T10:40:40+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/tirole-event-summary---english/2024-01-11T10:40:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/merger-of-altagas-ltd.-and-wgl-holdings-inc2024-01-11T10:40:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wellesley-municipal-light-plant-greenhouse-gas-emission-reduction-study/2024-01-11T10:40:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/v.-ross-morrison-v.-her-majesty-the-queen2024-01-11T10:40:39+00:00weekly0.7https://www.analysisgroup.com/emplois/stage-dete-professionnel-de-recherche/2023-05-30T15:38:31+00:00weekly0.8https://www.analysisgroup.com/emplois/redacteur-medical/2023-05-30T15:38:48+00:00weekly0.8https://www.analysisgroup.com/careers/what-is-economic-consulting/2024-01-11T10:43:46+00:00weekly0.8https://www.analysisgroup.com/emplois/stage-professionnel-de-recherche/2023-05-30T15:35:20+00:00weekly0.8https://www.analysisgroup.com/emplois/responsable-de-projets/2023-05-30T15:35:59+00:00weekly0.8https://www.analysisgroup.com/emplois/science-des-donnees/2023-05-30T15:37:16+00:00weekly0.8https://www.analysisgroup.com/emplois/postes-administratifs/2024-01-26T20:30:22+00:00weekly0.8https://www.analysisgroup.com/emplois/professionnel-de-recherche/2023-05-30T15:41:51+00:00weekly0.8https://www.analysisgroup.com/practices/bankruptcy-insolvency/2024-01-11T10:43:46+00:00weekly0.8https://www.analysisgroup.com/practices/tax/2024-01-11T10:43:46+00:00weekly0.8https://www.analysisgroup.com/policy/website-privacy-statement/2024-02-06T23:12:14+00:00weekly0.8https://www.analysisgroup.com/policy/terms-of-use/2024-02-06T23:12:05+00:00weekly0.8https://www.analysisgroup.com/forums-and-bulletins/forum/2024-01-11T10:43:47+00:00weekly0.8https://www.analysisgroup.com/policy/franceclientprivacy/2024-02-06T23:13:02+00:00weekly0.8https://www.analysisgroup.com/Error/bulletin-landing-page/2024-01-11T10:43:47+00:00weekly0.8https://www.analysisgroup.com/forums-and-bulletins/health-care-bulletin/2024-01-11T10:43:47+00:00weekly0.8https://www.analysisgroup.com/about/our-work/2024-01-11T10:43:48+00:00weekly0.8https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/2024-02-07T15:37:54+00:00weekly0.8https://www.analysisgroup.com/practices/energy-climate-natural-resources/2024-02-28T16:18:44+00:00weekly0.8https://www.analysisgroup.com/practices/damages/2022-01-27T15:54:26+00:00weekly0.8https://www.analysisgroup.com/practices/commercial-disputes/2020-10-26T14:16:21+00:00weekly0.8https://www.analysisgroup.com/practices/class-certification/2020-11-19T15:26:57+00:00weekly0.8https://www.analysisgroup.com/careers/why-analysis-group/2024-01-25T21:32:03+00:00weekly0.8https://www.analysisgroup.com/globalassets/episerver-forms/experts-and-consultants/2018-08-27T16:12:07+00:00weekly0.7https://www.analysisgroup.com/about/locations/2023-09-15T15:56:51+00:00weekly0.8https://www.analysisgroup.com/practices/valuation/2022-02-22T16:18:43+00:00weekly0.8https://www.analysisgroup.com/practices/transaction-and-governance-litigation/2023-01-13T12:44:39+00:00weekly0.8https://www.analysisgroup.com/practices/technology/2024-03-12T19:18:36+00:00weekly0.8https://www.analysisgroup.com/practices/accounting/2022-12-21T17:28:50+00:00weekly0.8https://www.analysisgroup.com/practices/surveys-and-experimental-studies/2023-01-13T12:44:39+00:00weekly0.8https://www.analysisgroup.com/practices/strategy-policy-and-analytics/2024-03-12T19:22:27+00:00weekly0.8https://www.analysisgroup.com/practices/privacy-and-data-security/2024-01-11T10:43:49+00:00weekly0.8https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/2023-01-13T12:44:39+00:00weekly0.8https://www.analysisgroup.com/practices/media-entertainment-and-communications/2023-01-13T12:44:39+00:00weekly0.8https://www.analysisgroup.com/practices/intellectual-property/2022-05-02T15:01:48+00:00weekly0.8https://www.analysisgroup.com/practices/international-arbitration/2024-01-11T10:43:49+00:00weekly0.8https://www.analysisgroup.com/practices/labor-and-employment/2024-01-11T10:43:49+00:00weekly0.8https://www.analysisgroup.com/practices/health-care/2024-01-11T10:43:49+00:00weekly0.8https://www.analysisgroup.com/practices/government-and-corporate-investigations/2023-01-13T12:44:39+00:00weekly0.8https://www.analysisgroup.com/practices/antitrust-competition/2021-10-12T15:01:39+00:00weekly0.8https://www.analysisgroup.com/practices/erisa/2022-10-20T17:13:39+00:00weekly0.8https://www.analysisgroup.com/practices/insurance/2023-09-22T19:57:55+00:00weekly0.8https://www.analysisgroup.com/practices/data-science-and-statistical-modeling/2024-01-11T10:43:47+00:00weekly0.8https://www.analysisgroup.com/careers/career-path/2024-01-11T10:43:48+00:00weekly0.8https://www.analysisgroup.com/policy/uk-privacy-policy/2024-02-06T23:07:08+00:00weekly0.8https://www.analysisgroup.com/policy/belgiumclientprivacy/2024-02-06T23:13:11+00:00weekly0.8https://www.analysisgroup.com/careers/faqs/2024-01-11T10:43:47+00:00weekly0.8https://www.analysisgroup.com/contact-us/contact-us-thank-you/2024-02-14T18:45:11+00:00weekly0.8https://www.analysisgroup.com/about/pro-bono/2023-06-13T17:17:35+00:00weekly0.8https://www.analysisgroup.com/about/diversity-equity-and-inclusion-at-analysis-group/2024-01-11T15:08:13+00:00weekly0.8https://www.analysisgroup.com/practices/environmental-social-governance/2024-01-11T10:43:46+00:00weekly0.8https://www.analysisgroup.com/policy/US-privacy-notice/2024-02-06T23:11:55+00:00weekly0.8https://www.analysisgroup.com/policy/privacy-notice-eu-uk-applicants/2024-02-06T23:12:46+00:00weekly0.8https://www.analysisgroup.com/policy/privacy-notice-eu-uk-applicants-french/2024-02-06T23:03:39+00:00weekly0.8https://www.analysisgroup.com/policy/privacy-notice-ca-applicants/2024-02-06T23:12:33+00:00weekly0.8https://www.analysisgroup.com/emplois/responsable-de-projets-economie-de-la-sante/2023-05-30T15:39:25+00:00weekly0.8https://www.analysisgroup.com/emplois/responsable-de-projets-senior-soins-de-sante-economie-de-la-sante/2023-05-30T15:39:51+00:00weekly0.8https://www.analysisgroup.com/ludmila-rovba/2023-12-05T18:14:06+00:00weekly0.9https://www.analysisgroup.com/david-j-hutchings/2023-09-05T19:32:39+00:00weekly0.9https://www.analysisgroup.com/general-terms-and-conditions-for-analysis-group-sas/2024-01-11T10:43:51+00:00weekly0.9https://www.analysisgroup.com/irina-pivneva/2024-01-19T19:52:12+00:00weekly0.9https://www.analysisgroup.com/catherine-gendron-saulnier/2024-03-18T19:33:31+00:00weekly0.9https://www.analysisgroup.com/dominick-latremouille-viau/2023-05-04T16:29:36+00:00weekly0.9https://www.analysisgroup.com/michal-k-popiel/2023-04-19T14:08:01+00:00weekly0.9https://www.analysisgroup.com/alix-duhaime-ross/2023-04-07T15:43:26+00:00weekly0.9https://www.analysisgroup.com/bruno-emond/2023-03-27T19:03:05+00:00weekly0.9https://www.analysisgroup.com/forums-and-bulletins/2024-01-11T10:43:50+00:00weekly0.9https://www.analysisgroup.com/contact-us/2024-01-11T10:43:50+00:00weekly0.9https://www.analysisgroup.com/policy/2024-02-08T09:55:13+00:00weekly0.9https://www.analysisgroup.com/search-results/2024-01-11T10:43:50+00:00weekly0.9https://www.analysisgroup.com/news-and-events/2024-01-11T10:43:50+00:00weekly0.9https://www.analysisgroup.com/experts-and-consultants/2024-01-11T10:43:49+00:00weekly0.9https://www.analysisgroup.com/about/2024-01-11T10:43:49+00:00weekly0.9https://www.analysisgroup.com/Insights/2024-01-11T10:43:49+00:00weekly0.9https://www.analysisgroup.com/careers/2024-01-11T10:43:49+00:00weekly0.9https://www.analysisgroup.com/practices/2024-01-11T10:43:49+00:00weekly0.9https://www.analysisgroup.com/pierre-y.-cremieux2021-05-21T13:24:39+00:00weekly0.9https://www.analysisgroup.com/paul-e.-greenberg2021-05-21T13:24:39+00:00weekly0.9https://www.analysisgroup.com/patrick-lefebvre/2023-05-11T20:33:13+00:00weekly0.9https://www.analysisgroup.com/lisa-b.-pinheiro2023-11-07T19:55:44+00:00weekly0.9https://www.analysisgroup.com/jimmy-royer/2023-05-23T20:23:01+00:00weekly0.9https://www.analysisgroup.com/martin-cloutier/2021-05-21T13:24:39+00:00weekly0.9https://www.analysisgroup.com/marissa-ginn/2022-03-23T18:17:21+00:00weekly0.9https://www.analysisgroup.com/annie-guerin/2021-05-21T13:24:39+00:00weekly0.9https://www.analysisgroup.com/marie-helene-lafeuille/2021-05-21T13:24:39+00:00weekly0.9https://www.analysisgroup.com/laura-olaughlin/2023-10-16T13:52:50+00:00weekly0.9https://www.analysisgroup.com/markus-von-wartburg/2021-05-21T13:24:39+00:00weekly0.9https://www.analysisgroup.com/declaration-de-confidentialite/2023-02-06T16:22:04+00:00weekly0.9https://www.analysisgroup.com/francois-laliberte/2023-10-17T16:42:36+00:00weekly0.9https://www.analysisgroup.com/dominic-pilon/2021-05-21T13:32:08+00:00weekly0.9https://www.analysisgroup.com/mandats/2023-09-05T19:42:34+00:00weekly0.9https://www.analysisgroup.com/emplois/2024-02-12T20:24:10+00:00weekly0.9https://www.analysisgroup.com/analyst-pay/2024-01-11T10:43:51+00:00weekly0.9https://www.analysisgroup.com/associate-pay/2024-01-11T10:43:51+00:00weekly0.9https://www.analysisgroup.com/summer-analyst-pay/2024-01-11T10:43:50+00:00weekly0.9https://www.analysisgroup.com/summer-associate-pay/2024-01-11T10:43:50+00:00weekly0.9https://www.analysisgroup.com/ajay-jyoti/2023-03-08T15:33:54+00:00weekly0.9https://www.analysisgroup.com/nick-dadson/2022-04-14T21:54:31+00:00weekly0.9https://www.analysisgroup.com/marjolaine-gauthier-loiselle/2022-04-01T14:55:01+00:00weekly0.9https://www.analysisgroup.com/error404/2024-01-11T10:43:50+00:00weekly0.9https://www.analysisgroup.com/cases/2021-06-16T13:22:24+00:00weekly0.9https://www.analysisgroup.com/antitrust-concurrence/2023-05-04T20:32:42+00:00weekly0.9https://www.analysisgroup.com/energie-environnement/2023-05-04T20:22:30+00:00weekly0.9https://www.analysisgroup.com/economie-travail/2023-05-04T20:22:04+00:00weekly0.9https://www.analysisgroup.com/institutions-financieres/2023-05-04T20:21:28+00:00weekly0.9https://www.analysisgroup.com/economie-sante/2023-05-04T20:20:37+00:00weekly0.9https://www.analysisgroup.com/sign-up/2024-02-28T07:49:40+00:00weekly0.9https://www.analysisgroup.com/sign-up-thank-you/2024-01-11T10:43:50+00:00weekly0.9https://www.analysisgroup.com/Error/2024-02-06T23:16:09+00:00weekly0.9https://www.analysisgroup.com/2024-03-14T20:21:00+00:00weekly1